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Abstract  
The five-year survival rates of paediatric cancer patients have improved considerably in the 
last 40 years with the implementation of more intensive and progressive treatments. 
Consequently attention is shifting to the reduction of treatment-related sequelae during and 
after the completion of therapy. Malnutrition and vitamin D inadequacy are a major concern 
as they are thought to increase the risk of short- and long-term complications in this 
population. Furthermore, emerging evidence has found a protective role of antioxidants and 
docosahexanoic acid (DHA) and eicosapentaenoic acid (EPA) against chronic conditions, 
including cardiovascular disease and cancer, which are common long-term complications in 
survivors of paediatric cancer. Therefore, this thesis aimed to investigate the nutritional 
status (NS), vitamin D, antioxidants and oxidative stress levels, as well as DHA and EPA 
levels of paediatric cancer patients. Potential factors that may contribute to the development 
of malnutrition in this population were also investigated. 
A prospective cohort-study of SE Scottish children aged <18 years, diagnosed with and 
treated for cancer between Aug 2010-Jan 2014 was performed. Clinical and nutritional data 
were collected at defined periods up to 36 months. NS was assessed using anthropometry, 
bioelectrical impedance analyisis (BIA), plasma micronutrients and dietary intake. DHA, 
EPA, antioxidant capacity and oxidative stress were measured at baseline and 6 months 
between April 2013-Jan 2014. Paediatric cancer was stratified by treatment risk (high, 
medium and low) and by diagnostic criteria. The primary outcome was malnutrition defined 
as body mass index (BMI) according to UK growth chart centiles; underweight (<2.3rd), 
overweight (85-95th) and obese (>95th). Vitamin D status was defined by the Endocrine 
Society Clinical Practice Guidelines (2011); inadequacy (<50nmol/L). 
Eighty-two patients [median(IQR) age 3.9(1.9-8.8) years; 56% males)] were recruited. At 
diagnosis, the prevalence of undernutrition was 13%, overweight 7% and obesity 15%. TSF 
identified the highest prevalence of undernutrition (15%) and the lowest of obesity (1%). 
BMI [p<0.001; 95% CI (1.31-3.47)] and FM (BIA) [p<0.05; 95% CI (0.006-0.08)] 
significantly increased after 3 months of treatment, whilst FFM (BIA) [p<0.05; 95% CI (-
0.78-(-0.01)] significantly decreased during the first three months and these patterns 
remained until the end of the study. High-treatment risk significantly contributed to 
undernutrition during the first three months of treatment [p=0.04; 95% CI (-16.8-(-0.4)] and 
solid tumours had the highest prevalence of undernutrition [BMI (17%)]. Vitamin D 
inadequacy was highly prevalent (64%; 42/65) at both baseline and during treatment (33-
50%) and those children who were not supplemented had the lowest vitamin D levels at 
every stage with median(IQR) levels ranging from 32.0(21.0-46.5)nmol/L to 45.0(28.0-
64.5)nmol/L. Paediatric cancer patients had high levels of oxidative stress and low levels of 
DHA and EPA, especially at baseline. Antioxidant status remained steady at 6 months, 
however antioxidant capacity increased slightly. Finally, antioxidant levels, antioxidant 
capacity, oxidative stress and EPA and DHA did not statistically differ between children 
receiving nutritional support and those who were not.   
Arm anthropometry (or BIA) alongside appropriate nutritional supplementation should be 
implemented in clinical practice due to the high risk of malnutrition (undernutrition and 
obesity), the changes in body composition (increase in fat mass and reduction in lean mass) 
and vitamin D inadequacy, as well as the low levels of EPA and DHA seen in this paediatric 
cancer cohort. 
Key words: paediatric, children, cancer, malnutrition, vitamin D, nutritional status, 
antioxidants, oxidative stress, EPA, DHA.  
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1.1 INTRODUCTION TO PAEDIATRIC CANCER  
1.1.2 Paediatric cancer 
The term paediatrics originates from the Greek words “paedion” (child) and iatriki 
(medicine), which refers to a specialty of medicine that focuses on the care of 
infants, children and adolescents  (Lissauer  and Clayden 2007). However, the age 
range differs from place to place; the countries from the European Union define 
paediatrics as children from birth up to 18 years, whilst in the USA and Canada it is 
from birth up to 21 years. Thus, paediatric oncology in the UK includes those 
children under the age of 18 who are diagnosed with benign tumours or malignant 
neoplasms; also referred to as childhood cancer (Pinkerton, Plowman and Pieters 
2004).    
Neoplasm refers to a large group of diseases characterised by unregulated and often 
rapid cell growth. There are three types of neoplasm: benign tumours, pre-cancer (or 
carcinoma in situ) and malignant neoplasm (or cancer). Benign tumours are 
characterised by being cohesive, expansible and localised. In contrast, malignant 
neoplasms are poorly circumscribed and have the ability to metastasise to both 
nearby and distant parts of the body via the blood system, lymphatic system and/or 
directly from the tumour. Finally, pre-cancer (carcinoma in situ) is an early form of 
localised tumour, which has the potential to become malignant (Boon, et al. 2006). 
Although these definitions apply to both adult and paediatric cancers, the latter 
exhibit a great diversity of histological type and anatomical site, in contrast to 
cancers seen in adults from the western world, which are mainly classified by 
topography only (WHO 2014). Additionally, common adult cancers, apart from 
leukaemia or lymphoma, are extremely rare in children (Stiller 2004).    
For research purposes paediatric cancer is classified according to the International 
Classification of Childhood Cancer (ICCC-3) (Steliarova-Foucher et al. 2005) 
(appendix I). The ICCC-3 is based on morphology of the neoplasms and its aim is to 
standardise international population-based epidemiological studies and cancer 
registries to ensure international data is comparable in the field of paediatric 
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oncology/haematology. There are 12 main diagnostic groups and 47 subgroups. The 
12 main diagnostic groups are: leukaemias, lymphomas, sympathetic nervous system 
tumours, brain and spinal tumours, retinoblastoma, renal tumours, hepatic tumours, 
malignant bone tumours, soft tissue sarcomas, gonadal and germ cell tumours, 
epithelial tumours and unspecified malignant neoplasm (Steliarova-Foucher et al. 
2005). Following on from this classification, the different paediatric cancers may be 
then classified into four larger groups, allowing researchers to perform statistical 
analysis in studies that include smaller sample sizes. The groups are: (i) 
Haematological malignancies; (ii) solid tumours; (iii) brain tumours and, (iv) benign 
tumours.         
(i) Haematological malignancies include all cancers of the blood, lymphatic system 
and bone marrow. Leukaemia, the most prevalent type of haematological malignancy 
(Cancer Research UK 2012b), is a group of malignant disorders that affect the 
haematopoietic stem cell compartment leading to an abnormal increase of immature 
white blood cells that cause damage and death by squeezing and forcing normal cells 
out of the bone marrow and/or by metastasising to other organs (Brooker 1994). 
Acute lymphoblastic leukaemia (ALL). acute myeloid leukaemia (AML) and chronic 
myeloid leukaemia (CML) are the three most common types of leukaemias seen in 
children (Stiller 2004). The main differences between these three types of leukaemia 
lies in the type of white blood cells affected and the speed at which the immature or 
malignant cells are synthesised (Pinkerton, Plowman and Pieters 2004).  
(ii) Solid tumours include a large group of malignant neoplasms located in any part 
of the body apart from the brain (and blood, lymphatics and bone marrow). The most 
common are the following: lymphoma, neuroblastoma and soft tissue sarcoma 
(Stiller 2004, Cancer Research UK 2012b). Although lymphoma, like leukaemia, 
affects white blood cells (lymphoid cells), particularly B-cells and T-cells at different 
stages of differentiation, it starts as a solid tumour of the lymph nodes spreading 
rapidly into the bone marrow. For that reason, it is generally classified as solid 
tumour instead of a haematological malignancy (Pinkerton, Plowman and Pieters 
2004). The most common types of lymphomas in children are Hodgkin and non-
Hodgkin’s lymphoma. Neuroblastoma is a malignant neoplasm that arises from the 
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sympathetic central nervous system (CNS) presenting most frequently in the adrenal 
gland, the paravertebral retroperitoneum, the posterior mediastinum, the pelvis and 
the cervical area (Pearson  and Pinkerton 2004). Finally, soft tissue sarcomas are a 
group of heterogeneous malignant neoplasm, which involve the connective and 
supportive tissues (Carli et al. 2004).  
(iii) Brain tumours are also malignant neoplasms originated in the CNS and located 
in the intra-cranium or spinal canal (Kumar, Abbas & Fausto 2006). This group of 
tumours can affect many parts of the brain including, the cranial nerves, the 
meninges, the skull, the pituitary gland and the pineal gland. They can also spread to 
the lymphatic tissue or the circulatory system (Kumar, Abbas & Fausto 2006). They 
are considered life threatening not only for their metastatic character, but also for the 
limited space in which they grow, obstructing other parts of the brain. In turn, this 
can lead to serious complications such as intracranial hypertension and epileptic 
seizures in the short term and cognitive impairment and death in the long term 
(Colledge, Walker & Ralston 2010). An example of brain tumours includes high 
grade glioma.  
Finally, (iv) benign tumours originate in any part of the body; however, the most 
common site is the brain and the most common type of benign tumour is low grade 
glioma (Hargrave, Messahel & Plowman 2004).  
1.1.2 Epidemiology of paediatric cancer 
Cancer is the most common disease-related cause of childhood death in the Western 
World (Cancer Research UK 2012b). However, most children with cancer live in 
low- and middle-income countries accounting for 94% of all deaths in people aged 0-
14 years (Pritchard-Jones et al. 2013). In the UK, the mean incidence of childhood 
cancers between 2008 and 2010 was 1603 new cases per year. Of these, 55% (883) 
were boys and 45% (720) were girls, whilst in Scotland alone the mean incidence 
was 117 per year; 53% (62) were boys and 47% (55) girls (Cancer Research UK 
2012a).   
Figure 1.1 shows the UK incidence of paediatric cancer according to ICCC-3. The 
four most common types of cancer diagnosed in the UK are Leukaemias, which 
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account for nearly one third (31%) of all cases, followed by brain and central nervous 
system (CNS) tumours (25%). Lymphomas and soft tissue sarcomas are the third and 
fourth most common cancers representing 10% and 7% respectively (Cancer 
Research UK 2012a). 
 
 
Figure 1.1 Incidence of paediatric cancer classified according to ICCC-3 in the UK 
(years 2006-2007) (Cancer Research UK 2012a). 
SNS Tumours: Sympathetic Nervous System Tumours.  
Survival rates have improved considerably in recent years (figure 1.2). In the late 
1960s, only 30% of children survived 5-year post-diagnosis; whilst between the 
years 2005-2007, the incidence improved to 80% (Cancer Research UK 2012b). Ten-
year survival rates are similar to the 5-year, as 73% of childhood cancers survivors 
are expected to survive for 10 years (Cancer Research UK 2012b). Most survivors of 
childhood cancer will be cured; however, this population experience higher mortality 
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rates beyond 25 years from diagnosis than the general population as a result of 
treatment side-effects (Cancer Research UK 2012b) such as the metabolic syndrome, 
cardiac complications and second cancers as well as reduced bone mass density 
(Wallace et al. 2013, Brougham et al. 2002).   
 
 
Figure 1.2 Childhood cancer survival trends of patients diagnosed between 1966 and 
2000 (Cancer Research UK 2012)  
 
1.1.3 Treatment and management of paediatric cancer 
The treatment and management of paediatric cancer is complex, constantly 
developing and being revised (Mycroft 2010). Over the last 30 years, great advances 
have been made not only in the treatment of paediatric cancer, but also in the 
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as well as, the adoption of a more holistic approach to patient care with the 
employment of a multidisciplinary team (Pinkerton, Plowman and Pieters 2004). As 
the earlier epidemiological data shows all of these mean that in most cases remission 
and cure is achieved (Cancer Research UK 2012b, Wallace et al. 2013, Sposto 2004). 
Although, more intensive treatment regimens have improved survival, there is a trade 
off with an associated increase in treatment toxicity, which leads to higher morbidity 
during and after therapy. Thus the new objectives of paediatric cancer treatment are 
to reduce morbidity of treatment while achieving cure.          
The main available cancer treatments at present include chemotherapy, radiotherapy 
and surgery (Boon et al. 2006). The use of both proton therapy and bone marrow 
stem cell transplants have recently become more popular and effective (Pinkerton, 
Plowman and Pieters 2004). Increasingly, treatments are being used in combination 
as part of clinical trials or standard regimes. This is particularly the case when the 
treatment aim is curative and the type of paediatric cancer is prevalent (Boon et al. 
2006, Sposto 2004).  
Clinical trials are designed to treat specific types of paediatric cancer and to assess 
the efficacy of one form of treatment or combinations of different treatments in 
comparison to standard regimes (Pinkerton, Plowman and Pieters 2004). Clinical 
trials are available for the most common type of paediatric cancers and, in Scotland; 
they are conducted through the United Kingdom Children’s Cancer Study Group 
(Sposto 2004). The adjustment of therapy will be determined by many factors 
including; severity of disease, early response to treatment, metastasis (where 
applicable), age and in some cases gender (Sposto 2004, Chan 2007). Patients are 
stratified by risk of treatment failure (low, medium or high risk) if the diagnosis is a 
haematological malignancy or, by severity of disease if the diagnosis includes brain 
or solid tumours (stage 1, 2, 3 and 4) (Sposto 2004). Generally, the patients are 
categorised into groups; low intensity, medium intensity or high intensity and, 
consequently randomised into an arm of the trial. Clinical trials are seldom available 
for rare paediatric tumours, thus oncologists often refer to adult guidelines for the 
treatment of these cancers (Grundy and Plowman 2004).   
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With the recent improvement in survival rates (Cancer Research UK 2012b) and the 
application of more intensive therapies, which leads to higher toxicity levels and, a 
subsequent increase in treatment induced side-effects during and after the completion 
of therapy, attention is shifting to the reduction of treatment related side-effects (Sala 
et al. 2004). In particular, malnutrition is now regarded as a consequence of 
treatment and is a source of major concern since it is thought to increase the risk of 
morbidity (van Eys et al. 1980), mortality (Sala et al. 2004, Lange et al. 2005, Reilly 
et al. 1994, Butturini et al. 2007), early relapse (Viana et al. 1994) and the number of 
complications during the course of treatment 
,
(van Eys 1979a; Anon.1998). 
Additionally, it has recently been highlighted in a SIGN guideline that long term 
survivors of childhood cancer might be at higher risk of developing the metabolic 
syndrome, cardiac complications and have a reduced peak bone mass due to related 
treatment side-effects (Wallace et al. 2013). The later complications may be 
exacerbated by malnutrition, as obesity is an independent risk factor for 
cardiovascular disease (Hubert et al. 1983), whilst long term undernutrition is 
associated with osteoporosis (Rizzoli and Bonjour 1999). 
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1.2 NUTRITIONAL STATUS IN PAEDIATRIC CANCER 
Nutritional status is a term used to describe the body’s state in relation to the 
consumption and utilisation of nutrients (Reilly 2008).  It is assessed by 
comprehensively evaluating the following; anthropometry and body composition, 
biochemical parameters, clinical assessment and dietary intake (Thomas & Bishop 
2009, Agostoni et al. 2005a). In order to understand the epidemiology, aetiology and 
pathophysiology of malnutrition in paediatric cancer patients, it is first essential to 
introduce some concepts that define children’s growth and the nutritional status 
assessment in the general paediatric population. These concepts form the bases of 
this project and will be used throughout the thesis.      
1.2.1 Nutritional status of children  
The human body is divided into several theoretical compartments (figure 1.3). As 
more compartments are identified more comprehensive becomes the level of 
nutritional assessment; however, more advanced equipment is required for these to 
be measured. The simplest levels of nutritional assessment include those that assess 
one (body weight) or two compartments (fat free mass (FFM) and fat mass (FM)). 
FFM encompasses everything but FM and, can be divided into four further large 
compartments: visceral protein, intracellular and extracellular water and bone 
minerals (Norton & Olds 1996, Kyle et al. 2004a). These compartments are not static 
and are also affected by many factors including: growth, age and gender, physical 
activity, energy, micronutrient and fluids intake as well as disease.  
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Figure 1.3 Representation of body composition and theoretical body compartments 
(adapted from Norton and Olds 1996, Kyle et al. 2004a) 
 
The main difference between the nutritional status assessment of adults and children 
is that children grow and, are constantly changing and developing to become adults. 
There are three described physical phases in the growth of a child, which are 
accompanied by changes in body composition too: infancy (birth to up to 2 years of 
age), childhood (2 to 12-13 years of age) and puberty (12-13 to 18-19 years of age) 
(figure 1.4) (Karlberg 1989). Infancy is the shortest period of a human’s life; 
however the rate of growth during this phase is the fastest, as most children will have 
doubled their height by the age of 2 and, linear growth up to this point will account 
for about 45% of the final height (Karlberg 1989). Infancy is also a critical period of 
organ and mental development; thereby severe energy deprivation during this early 
phase is often irreversible and may lead to both impaired physical growth and 
intellectual functioning later in life (Lissauer & Clayden 2007, Stoch & Smythe 
1976, Frisancho et al. 1977). The childhood phase is the longest period of a child’s 
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growth; it is slow and steady and, will account for about 40% of the final height. 
Finally, puberty is a period of rapid growth accounting for about 15% of the final 
height and characterised by changes in the sexual organs. Thus, it is the time when a 
child’s body will change into a mature adult body (Karlberg 1989, Tanner 1990a). As 
children grow, changes in body composition; FFM, FM and bone minerals, also 
occur (Norton & Olds 1996). Subcutaneous fat will start increasing soon after birth 
until the age of 2 years, to progressively decrease to the lowest levels (nadir) between 
the ages of 6 and 8 years. After this stage, called adiposity rebound, subcutaneous fat 
starts to rise again until the time of the growth spurt during puberty (Tanner 1990a, 
Reilly et al. 2001).          
 
Figure 1.4 The infancy-childhood-puberty model of growth (reproduced with 
permission from Karlberg J, 1989) 
 
For a child to grow optimally, dietary intake has to meet total energy expenditure 
(TEE) demands (Shaw and Lawson 2007). In healthy children, this includes resting 
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energy expenditure (REE) and physical activity (PA), which is consistent with the 
child’s normal development. Like adults, REE also accounts for basal metabolic rate 
(BMR) and dietary induced thermogenesis (DIT); but in children, a percentage of the 
REE should be taken into consideration to allow for deposition of tissue at a rate 
consistent with healthy growth (Lissauer & Clayden  2007, Shaw & Lawson 2007, 
Butte et al. 2000).   
The growth of a child can be assessed at the simplest level by using methods that 
provide information about one compartment only. Nevertheless, these measurements 
assess whether a child is growing optimally and thus are essential. Unlike adults, a 
standard measure is lacking (Murphy, White & Davies 2009); however, most 
physicians and researchers rely on national and/or international growth charts 
developed from population-based cross-sectional studies and longitudinal cohort 
studies of healthy children (Cole et al. 1995b). Growth charts illustrate growth (Cole 
et al. 1995b, Cole 2014) and references are expressed in a centile and standard 
deviation fashion. In the UK the following growth charts are available: body mass 
index (BMI), weight for age (WFA), weight for height (WFH), height for age (HFA), 
as well as head circumference (Cole et al. 1995b, de Onis et al. 2007, WHO 2007). 
Generally, the assessment will be based on whether the child is following its 
expected centile (Ahmad et al. 2014). Consequently, a single measurement will have 
limited value, unless centile lines fall below the 0.4th centile or above the 99.6th 
centile (de Onis et al. 2007, WHO 2007).   
To assess whether the body has enough reserves stored in the form of FFM and FM 
(2 compartments), there are other simple methods that can be used, which include 
mid-upper circumference (MUAC), triceps skinfold thickness (TSF) (Norton & Olds, 
1996, Frisancho 1981, Frisancho 1974) and bioelectrical impedance analysis (BIA) 
can be used to assess more than 2 compartments. At present, there are not growth 
charts available for MUAC and only one, which was performed in the 1960s and 
included healthy UK children from the age of one month to 19 years, is available for 
TSF measurements (Tanner & Whitehouse 1975, Oakley et al. 1977). A few authors 
have developed percentile ranges also obtained from populations of healthy children, 
from which the data can be compared against (Frisancho 1981, Frisancho 1974, 
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Ozturk et al. 2009, Mwangome et al. 2012). Upper arm muscle area (UAMA) and fat 
mass muscle area (UAFA) can be calculated from MUAC and TSF; for which, a 
chart (Tanner & Whitehouse 1975) and percentile ranges have also been developed 
(Frisancho 1981).  
BIA estimates TBW, FFM and FM by passing an electric current through the body, 
which is conductive in lean tissue due to its high water and electrolyte content, but it 
is not conductive in the fat tissue (resistance). The number of body compartments 
that the BIA measures depend on the frequency used and the most widely used are 
the single and multi-frequency BIA. Single frequency (SF) BIA operates at 50 kHz 
and measurers 3 compartments; the weighted sum of intracellular and extracellular 
fluid without differentiating between these two compartments, which is defined as 
TBW in simple terms. From this, FFM and FM can be estimated (Kyle et al. 2004). 
As it assumes that the intracellular and extracellular water compartments are 
homogenous, its use has been reported to be more accurate in subjects with normal 
hydration status (Gudivaka et al. 1999). Multi frequency (MF) BIA operates using a 
range of frequencies between 1 and 500 kHz and measures 4 compartments as it 
differentiates between intracellular and extracellular fluid (Kyle et al. 2004). As a 
result its use has been reported to be more accurate in critically ill patients who 
present with shifts in fluid distribution between the intracellular and extracellular 
water compartments (Olde Rikkert et al. 1997). 
The estimation of FFM% and FM% from BIA in adults is considered accurate and 
reliable; however its use in children remains controversial. The reasons for this have 
been attributed to the rapid changes that occur in the body composition of children, 
which have made difficult the development of predictive equations (Mast et al. 2002, 
Rowe et al. 2006, Weinand et al. 2000). Accuracy has also been argued in both 
undernourished (Mast et al. 2002, Weinand et al. 2000) and obese children (Wabitsch 
et al. 1996). Finally some authors claimed that the estimation of FFM and FM in 
children is more accurate when these are calculated from MUAC and TSF 
measurements, which has also been attributed to the rapid changes in body 
composition that occur in children (Mast et al. 2002, Weinand et al. 2000, Hammond 
14 
 
et al. 1994, Schaefer et al. 1994b). Yet, some authors report satisfactory levels of 
accuracy (Schaefer et al. 1994a, Okasora et al. 1999). 
Nutritional status can also be assessed using other superior and more reliable 
methods such as Isotope-dilution, Dual-energy X-ray absorptiometry (DEXA), 
Magnetic Resonance, Computed Tomography, Densitometry and total body 
potassium (Thomas & Bishop 2009, Wabitsch et al. 1996, Barbosa-Cortés et al. 
2007, Frisk et al. 2012, Inaba et al. 2012, Collins et al. 2010, Zhang et al. 2014). 
Nevertheless, their role is generally for research purposes and limited in the clinical 
setting (Brennan 1998, Brennan et al. 1997, Murphy et al. 2009).        
1.2.2 Malnutrition in children 
Malnutrition is defined as a state in nutrition in which an inadequate intake of 
energy, protein or other nutrients causes adverse effects on physiological functions, 
body composition and clinical outcome (Agostoni et al. 2005a, BAPEN 2010). This 
imbalance between energy intake and energy expenditure is expressed as 
undernutrition (negative energy balance) and overnutrition (positive energy balance). 
(Brennan 1998, Anon.2006a, BAPEN 2010). As per definition, the term malnutrition 
will be used to refer to both undernutrition and overnutrition. Whilst undernutrition 
in children is recognised when there is rapid weight loss or failure to gain weight (to 
enable optimal growth), poor linear growth (height) and faltering growth (or failure 
to thrive); overnutrition, like in adults, is recognised by clear cut off values, which 
are grouped into two categories: overweight and obesity.  
Undernutrition in children occurs when there is not sufficient energy intake to 
support an increase in FFM and FM, which allows for both normal body functions 
and growth (Reilly 2008, Agostoni et al. 2005a). Undernutrition has been classified 
as acute and chronic. Acute undernutrition is the first sign of undernutrition and, 
normally, presents as either rapid weight loss or, poor weight gain followed by 
weight loss. In these cases the length or height is not generally affected. Thus, the 
child will have low WFH and low BMI (Agostoni et al. 2005a, Waterlow 1972). 
Reduced energy intake affects body stores and thus body composition, consequently 
an undernourished child may also present with reduced muscle mass (FFM) and 
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adipose stores (FM) (Brinksma et al. 2012, Brinksma et al. 2014). Chronic 
undernutrition is the result of long term energy deprivation, which results in poor 
linear growth (low HFA) (Waterlow 1972) and stunting if catch up growth becomes 
impossible. In infants, it may also affect mental development, which may present as 
a reduced head circumference (Martins et al. 2011, Cornelio-Nieto 2007). The 
muscle mass and adipose tissue will also be reduced if the child has acute on chronic 
undernutrition (Waterlow 1972).  
 
In contrast, overnutrition occurs when energy intake exceeds energy expenditure and 
eventually results in an increase in FM (Brinksma et al. 2014, Anon.2006b). An 
overnourished child will present with high WFH, high BMI and high FM% (Reilly 
2008, Waterlow 1972, Reilly 2006, Reilly, Kelly & Wilson 2010). Reduced muscle 
mass has been defined as protein energy malnutrition (PEM); however protein 
energy malnutrition might be accompanied by low fat mass (undernutrition) or high 
fat mass in children (Brinksma et al. 2014). In adults and the elderly, the combination 
of muscle wasting and high fat mass with or without the presence of a mild 
inflammatory response has been defined as Sarcopenic obesity and has extensively 
been studied (Stenholm et al. 2008, Tsai 2012). Yet, this term, unlike osteopenia 
(loss of bone mass) has never been defined in children.  
 
Worldwide, the prevalence of malnutrition in children differs significantly from low 
(developing countries) and high income countries (developed countries) (Stephenson 
et al. 2000, de Onis et al. 2010, de Onis et al. 2004). Undernutrition in developing 
countries is thought to affect 19% to 30% of children; whilst in developed countries, 
it is estimated to affect only 1.6% (Stephenson et al. 2000, de Onis et al. 2010) and is 
generally associated with acute or chronic conditions (Reilly 2002). In the UK, the 
prevalence of undernutrition in children under 42 months of age has been estimated 
to be 3.3% (Armstrong et al. 2003), whilst no recent data exist from older children. 
In contrast, worldwide prevalence of overnutrition (overweight and obesity) is higher 
in developed countries and in the adolescent population (10-19 years) (de Onis et al. 
2010, Bibiloni et al. 2013). Worldwide, the prevalence of overweight and obesity has 
been explored in preschool children (less than 5 years of age) and adolescents (10-19 
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years) and, data have been reported separately. Overnutrition in preschool children is 
estimated to be 7% with higher prevalence rates reported from developed countries 
(12%) than developing countries (6%) (de Onis et al. 2010). Higher prevalence of 
overweight and obesity have been reported in the adolescent group, whereby 
prevalence ranges from rates as low as 5% in China to as high as 30% in North 
America (de Onis et al. 2010, Bibiloni et al. 2013). The UK appeared to have one of 
the highest prevalence of overnutrition with 33% of boys and 34% of girls being 
overweight or obese. Prevalence of overweight is 15% for both boys and girls and 
obesity is 18% for boys and 19% for girls (Bates et al. 2011).             
1.2.3 Nutritional status of paediatric cancer patients 
The nutritional status of paediatric cancer patients has been studied for a long time 
and malnutrition, in particular undernutrition, in this population has long been 
recognised (van Eys 1979a, Sala et al. 2012, Jaime-Pérez et al. 2008); yet, its 
management remains variable (Sala et al. 2004, Brinksma et al. 2012, Reilly et al. 
1999), with many malnourished children going unrecognised and consequently 
untreated (Antillón et al. 2008). Until now, the exact prevalence of malnutrition has 
not been determined and the point during the natural history of the cancer disease 
(diagnosis, during treatment or after the completion of therapy) when this occurs is 
not known. However, prevalence is known to differ in low and high income countries 
(Sala et al. 2004, Barr et al. 2008, Sala et al. 2005, Sala et al. 2008). The prevalence 
of undernutrition in low income countries may average 50%, whilst prevalence of 
undernutrition in high income countries is thought to be more associated with the 
type of tumour and the severity of the disease. For instance, undernutrition has been 
reported to be more prevalent in children diagnosed with Neuroblastoma, Wilms 
tumour and Ewing’s sarcoma (Sala et al. 2004).  
 
In contrast, the prevalence of obesity of paediatric cancer patients has not been 
studied as extensively, perhaps because this is a relatively new global health issue. 
One study from Mexico reported that 24% of patients diagnosed with ALL were 
either at risk of becoming overweight or were already overweight at diagnosis 
(Jaime-Pérez et al. 2008); whilst more evidence exists in high income countries 
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where prevalence of obesity have been reported in children with ALL (Gofman & 
Ducore 2009, Baillargeon et al. 2005, Baillargeon et al. 2006, Baillargeon et al. 
2007, Odame et al. 1994, Reilly et al. 1999) and in survivors of childhood cancer 
(Oeffinger et al. 2003, Hudson et al. 2003), especially those diagnosed with ALL. 
To date, no prospective study investigating the nutritional status of paediatric cancer 
including patients at different stages of the disease have been performed in Scotland. 
Phase I of this project therefore represents the first data that we have and the results 
have shown a pattern in which children diagnosed with a solid tumour tend to 
become undernourished, whilst those with a haematological malignancy tend to 
become obese. Moreover, the prevalence of undernutrition and overnutrition was 
significantly higher than healthy children from the UK when the data was stratified 
into these two categories only (solid tumours and haematological malignancies) 
(Paciarotti I 2013). Given the small size of the cohort investigated in this study, 
caution needs to be exercised when drawing these initial conclusions.  
At the end of phase I there was data available for 26 patients. Nutritional status had 
been assessed using BMI centiles (primary outcome), MUAC, TSF and BIA at 
diagnosis, baseline and during different phases of treatment (3, 6, 9, 12 and 18 
months). The study classified the cancer diagnosis into two categories; solid tumours 
and haematological malignancies. When BMI was used to assess nutritional status, 
the study revealed that children diagnosed with solid tumours had the highest 
prevalence of undernutrition (27% (3/11) at diagnosis, 25% (4/16) at baseline and 
17% (2/12) at 3 months) whilst no child diagnosed with a haematological 
malignancy was undernourished at any stage. In contrast, children diagnosed with 
haematological malignancies had the highest prevalence of obesity at 3 months (50% 
(4/16)) and 6 months (50% (2/4)). In addition, the study showed that the solid tumour 
group had lower TSF, MUAC, UAMA and UAFA values at diagnosis than the 
haematological malignancy group and this was more exaggerated at 3 months. Thus, 
children diagnosed with solid tumours as well as been more likely to be 
undernourished appeared to have a lower muscle and fat mass. In contrast, children 
diagnosed with haematological malignancies showed fat accumulation and were not 
depleted (low FFM) (Paciarotti I 2013).  
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On the account of findings from phase I, the absence of a published systematic 
review which investigates the worldwide prevalence of undernutrition and 
overnutrition at different stages of the disease and possible associations between 
malnutrition and clinical outcomes, a systematic review which investigates these 
topics was planned at the start of phase II. This will be discussed in chapter II, 
section 2.1.    
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1.3 AETIOLOGY AND PATHOPHYSIOLOGY OF MALNUTRITION IN 
PAEDIATRIC CANCER 
The aetiology and pathophysiology of malnutrition in paediatric cancer is 
multifactorial and complicated. It is characterised by either a reduction or an increase 
in dietary intake along with metabolic and hormonal changes, which at present are 
not entirely understood. The different factors at play in the pathogenesis of 
malnutrition in cancer can be divided into three broad groups: (1) the disease and its 
natural history; (2) the various treatment modalities (surgical and medical) and their 
effects on the individual’s nutritional status and, (3) the social and psychological 
influences of the cancer and its associated treatment on the child and its family.  
1.3.1 Aetiology and pathogenesis of malnutrition: cancer and its natural history 
Cancer induces a common immune response which differs in severity and has wide 
ranging metabolic effects (Seyfried & Shelton 2010). The progression of the cancer 
and its effects on nutritional status is dependent on many factors; most importantly 
the type, stage and location of the tumour, but also the gender, age and genotype of 
the host (Sala et al. 2004, Ross 2007). Although, to date there has been limited 
research into the various factors contributing to the development of malnutrition in 
paediatric cancer patients, numerous studies have been performed in animals and the 
adult population (Sala et al. 2004, Brinksma et al. 2012, Gough et al. 1996). It is now 
understood that this “common inflammatory response” is mediated by the release of 
cytokines, including interleukins, interferon (IFN) and tumour necrosis factor (TNF), 
which is initiated by both host and tumour cells (Bauer et al. 2011). Cytokine 
receptors, which produce metabolic changes when stimulated, have been found in the 
hypothalamus (Bauer et al. 2011), muscle, and adipose tissue (Gough et al. 1996). 
Once activated, these induce anorexia, which in turn leads to a reduction in dietary 
intake, skeletal muscle catabolism and to a lesser extent lipolysis (see figure 1.5).  
Additionally, the synthesis of acute phase proteins, such as CRP and ferritin, in the 
liver is up regulated, muscle protein synthesis is down regulated and muscle 
catabolism is up regulated for use as “quick” energy source (Ritchie et al. 1999).  All 
of these results in weight loss, particularly loss of FFM (Picton 1998). In adults with 
advanced disease, this can lead to cancer cachexia, which is defined as an irreversible 
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hypermetabolic state in which progressive weight loss, muscle atrophy, loss of 
physical function and lethargy occur secondary to malignancy (Fearon et al. 2011). 
However, childhood cancer cachexia has not been defined and, studies reporting 
prevalence of undernutrition in this population do not report cancer cachexia; instead 
prevalence of undernutrition, severe undernutrition and PEM are reported in both 
low and high income countries (Brinksma et al. 2012, Sala et al. 2012, Elhasid et al. 
1999, Israels et al. 2010). 
Data investigating the degree of inflammation at the time of diagnosis and its 
relationship with nutritional status in paediatric cancer patients is limited. The type of 
tumours most commonly associated with undernutrition at diagnosis are 
neuroblastoma, Wilms tumour and Ewing’s sarcoma (Sala et al. 2012, Israels et al. 
2010, Green et al. 2008); however, as reported by a recent systematic review 
(Brinksma et al. 2012), no study has investigated the relationship between 
inflammation and malnutrition in these tumours at the time of diagnosis. Two studies 
have been found to investigate this in children diagnosed with ALL (Siimes et al. 
1991) and unspecified types of leukaemias (Yu et al. 1994). Siimmes et al (1991) 
measured TNF levels in a cohort of 12 children compared to 25 healthy controls and, 
found that although TNF levels were high at diagnosis; this was not correlated with 
muscle and fat mass. Similarly, Yu et al (1994) investigated CRP levels in 25 
children with leukaemia; 6 were newly diagnosed, 3 had relapsed and 16 were in 
remission and on treatment; the type of leukaemia was not specified. CRP levels 
were higher in newly diagnosed and relapsed patients, who were not on treatment, 
than in those who were on remission and on treatment. Again, none of the children 
were undernourished at diagnosis, which was attributed to the early detection of the 
cancer. Of note, both studies included very small sample sizes, which might have 
contributed to their findings.  
A further two studies have solely investigated inflammation in cohorts of paediatric 
cancer at the time of their diagnosis; yet nutritional status was not measured 
(Wieland et al. 2003, Giordano et al. 2010). Giordano et al (2010) found higher 
levels of inflammatory markers (IL-6 and TNF) in newly diagnosed ALL children 
when compared with both healthy controls and those who were receiving treatment. 
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Wieland et al (2003) meanwhile measured CRP levels in 95 children with newly 
diagnosed Hodgkin’s lymphoma and 6 healthy controls. Higher CRP levels 
correlated with disease stage, whereby those children with stage I Hodgkin’s 
lymphoma had the lowest CRP levels.  
In conclusion, the small body of evidence presently available raises the possibility 
that children diagnosed with leukaemia and Hodgkin’s lymphoma have an increased 
inflammatory response at the time of diagnosis. The evidence for an association with 
undernutrition does not yet exist. However, the most important conclusion we can 
draw is that there remains a lot of work to be done investigating the hypothesis that 
an inflammatory response is driving undernutrition as has been demonstrated in 
adults with malignancy. In particular future studies need focus on the malignancies 
most commonly associated with undernutrition. 
In adults, it has been proposed that some individuals have an increased susceptibility 
to developing cachexia due to genetic polymorphisms. Important proteins have been 
identified to be involved in the mediation of the previously described inflammatory 
reaction, but also the regulation of appetite (and therefore energy intake) and the 
metabolism and utilisation of nutrients. It is thus held that the host genotype may also 
contribute to some of the differences seen in the nutritional status of paediatric 
cancer patients at diagnosis (Ross 2007, Picton 1998).  
Many studies performed in adults who have an increased susceptibility to develop 
cancer cachexia have shown that these tend to have genetic polymorphisms of 
specific genes that code for the synthesis of inflammatory markers, thus increasing 
the inflammatory response (Zhang et al. 2007, Solheim et al. 2011, Tan and Fearon 
2010). Equally, many genes have been identified which play a role in the regulation 
of appetite. For example, the expression of the Agouiti-related protein (AGRP) in the 
hypothalamus is thought to stimulate appetite, thereby leading to an increased food 
intake. In normal circumstances, the action of leptin suppresses AGRP expression 
and results in a reduction of food intake. However, in some individuals an 
overexpression of AGRP has been associated with obesity (Rossi et al. 1998, 
Schwartz et al. 1997), whilst under-expression has been associated with anorexia 
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nervosa (Vink et al. 2001). Numerous genes involved in the regulation of TEE have 
been described; with some polymorphisms been shown to reduce TEE, thus making 
individuals more susceptible to becoming obese (Yang et al. 2003, Feldman and 
Hegele 2000), and others been shown to increase the release of energy and 
consequently the TEE, thereby leading to weight loss (Astrup et al. 1999). Finally, 
polymorphism of the TNF alpha-308 G/A promoter, which plays a role in lipolysis 
and lipogenesis, have been found to be associated with excess body fat in women 
(though not in men) (Hoffstedt et al. 2000). Nevertheless, to date, no studies have 
been undertaken in paediatric cancer patients and thus the potential role of host 
genetic polymorphism on nutritional status remains unknown.   
The final factor to consider, which may lead to malnutrition, is some of the innate 
characteristics of the tumour. Already we have seen that tumour type may well prove 
to be associated with risk of malnutrition, but it is already accepted that the location 
and size of the tumour can lead to malnutrition. For example, brain tumours, such as 
craniopharyngioma, are known to have the potential to cause raised intracranial 
pressure. In infants this presents with an increasing head circumference, vomiting 
and poor feeding, leading to failure to thrive (Hargrave, Messahel & Plowman PN 
2004). In older children it can present with progressive characteristic headaches 
(worse in the morning and aggravated by posture) which are associated with 
vomiting, with focal neurological deficits and more acutely with seizures or altered 
conscious levels. Another example, relatively common in children, is Multisystem 
Langerhans cell histiocytosis (LCH), which may present with gastrointestinal 
involvement of the mucosa and submucosa of the small and large intestine. In these 
cases, the child will have severe malabsorption; which if not treated will lead to rapid 
weight loss and eventually failure to thrive and, chronic diarrhoea with protein losing 
enteropathy causing PEM (Gadner & Grois 2004). Obstruction of the gastrointestinal 
tract may occur in cancers affecting the oesophagus, such as in children diagnosed 
with large nasopharyngeal carcinomas (Grundy & Plowman 2004). In this case the 
child will either be in pain when trying to swallow or will not be able to swallow at 
all, thus reducing dietary intake.           
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Figure 1.5 Conceptual framework of causes of undernutrition. Model adapted from 
Evans and co-workers (Evans et al. 2008).  
 
1.3.2 Treatment modalities: effects on nutritional status 
As has been previously mentioned, management protocols designed with curative 
intent are used in the management of childhood cancer and involve the concurrent 
use of a variety of treatment modalities. At present the primary available treatments 
include chemotherapy including immunosuppressants, radiotherapy and surgical 
interventions. Additionally, an increasing number of children are using 
complementary and alternative therapies to help reducing treatment induced-side 
effects (Bishop et al. 2010), which may themselves not be relieved by conventional 
medicine (Spix 2008). Thus patients are exposed to multiple agents and therapies 
UNDERNUTRITION: 
POOR WEIGHT GAIN, WEIGHT LOSS, PROTEIN ENERGY 
MALNUTRITION, FAILURE TO THRIVE, MUSCLE WEAKNESS, 
FATIGUE 
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often acting synergistically which together have wide reaching effects on their 
nutritional status (Boon et al. 2006, Donaldson 1982).  
1.3.2.1 Chemotherapy 
Cytotoxic drugs work by targeting rapidly dividing cells and essentially killing them. 
They have both anti-cancer activity and the potential to cause acute and long term 
damage to normal tissues (BNF 2009). There are four main classes of cytotoxic 
drugs that are used in the treatment of paediatric cancer, which include: alkylating 
drugs, cytotoxic antibiotics, antimetabolites (vinca alkaloids and etoposides) and, 
other antioneoplastic drugs (BNF 2009). Although their mode of actions differ, some 
of their side-effects are common to all drugs and, their effect on the nutritional status 
of children will depend on the following factors: (i) the intensity of the treatment, (ii) 
whether the child is hypermetabolic while receiving treatment and, (iii) the 
individual phenotype’s ability to metabolise and excrete active drug metabolites 
(Buxton & Benet 2011, Lennard 1999). Some of the most common side effects of 
chemotherapy agents associated with malnutrition are presented in table 1.1. 
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Table 1-1 Most common side-effects associated to chemotherapy agents that may 
lead to malnutrition (adapted from Donaldson 1982; BNF 2009) 
Side-effects  Drugs  
Anorexia, nausea, vomiting Adriamycin 
5-Azacytidine 
c/s-Diamminedichloroplatinum 
Cyclophosphamide 
Nitrogen mustard 
Procarbazine 
Mucositis Actinomycin D 
Adriamycin 
Bleomycin 
Daunomycin 
5-Fluorouracil 
Methotrexate 
Vinblastine 
Diarrhoea  Actinomycin D 
5-Azacytidine 
5-Fluorouracil 
Methotrexate 
Constipation and adynamic ileus Vinblastine 
Vincristine 
Taste and smell changes  Allopurinol                      
Carboplatin                        
Doxorubicin                      
Methotraxate 
 
Liver impairment  Asparaginase 
Azaserine 
Methotrexate 
6-Mercaptopurine 
Mithramycin 
Pancreatitis  Asparaginase 
Renal impairment  Retinoic acid                             
Ifosfamide                       
Allopurinol                    
Methotrexate                        
Etoposide 
Peripheral neuropathy  Vincristine                       
Vinblastine                           
Clofarabine                        
Fludarabine Phosphate  
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(i) Intensity of the treatment  
Generally, the more intensive and frequent the treatment the more of the above listed 
side effects the host will have, thus increasing the risk of undernutrition. If patients 
are not adequately treated with nutrition, fluid and electrolytes there is the possibility 
of severe weight loss, dehydration and death (Pinkerton, Plowman & Pieters 2004, 
van Eys 1979a, Donaldson 1982, van Eys 1986, van Eys 1979b). The most common 
side effect is mucositis. This occurs when the epithelial cells, which make up the 
mucosa of the oropharynx and small intestine, are damaged resulting in inflammation 
and ulceration. Clinically this presents with pain and bleeding in the mouth and 
throat and diarrhoea. The latter results in malabsorption of micro and macronutrients, 
fluid and electrolyte imbalances, and together mucositis can cause temporary 
gastrointestinal failure in severe cases (Bauer et al. 2011, Donaldson 1982, Matthay 
et al. 1999).  
A serious problem can arise when liver and or renal impairment is precipitated by the 
use of an intensive regimen and or the use of specific hepatotoxic or nephrotoxic 
agents (Matthay et al. 1999). This is because most of the cytotoxic agents are 
metabolised in the liver and excreted in the urine through the kidneys (Buxton & 
Benet 2011). Thus when impaired, there is a resultant accumulation of these 
cytotoxic agents in the blood stream with the risk of more severe side effects, not to 
mention the other sequelae of renal and hepatic failure; uraemia and elevated 
ammonia levels, which taken together exacerbate the risk of undernutrition 
(Colledge, Walker & Ralston 2010).       
(ii) Is the child hypermetabolic while receiving treatment? 
There is limited data investigating the effects of treatment on inflammatory response, 
macronutrients metabolism and total energy expenditure in paediatric cancer 
patients. An increase in total energy expenditure due to tumour burden, inflammatory 
response and chemotherapy treatment has been reported in adults with advanced 
disease (Solheim et al. 2011, Tisdale 1997). In children the data is contradictory, as 
some studies report an increase in REE (Kien and Camitta 1987, Schmid et al. 2005), 
others report no change (Green et al. 2008, Bond et al. 1992, Delbecque-Boussard et 
al. 1997, den Broeder et al. 2001, Vaisman et al. 1993) and others report a decrease 
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in REE; all studies were performed while the patients were receiving treatment 
(Duggan et al. 2003). Additionally, most studies found that children at diagnosis, 
before any form of treatment was given, had higher metabolic rates than after the 
commencement of treatment (Kien and Camitta 1987, Schmid et al. 2005, den 
Broeder et al. 2001, Stallings et al. 1989), thereby indicating that children at 
diagnosis might be hypermetabolic and that this may gradually reduce with the 
initiation of chemotherapy. This has been attributed to a decrease in FFM (Duggan et 
al. 2003), but also to the inhibition of the inflammatory response originally caused by 
the tumour (Yu et al. 1994). A few cautionary notes must be considered, most studies 
were performed in children with ALL (Kien & Camitta 1987, Schmid et al. 2005, 
Bond et al. 1992, Delbecque-Boussard et al. 1997, Vaisman et al. 1993, Duggan et al. 
2003, Stallings et al. 1989), only two studies investigated children diagnosed with 
other cancers; neuroblastoma (Green et al. 2008) and solid tumours (den Broeder et 
al. 2001) and, one study not only included children with any cancer (ICCC-3), but 
also children diagnosed with aplastic anaemia; all undergoing Haematopoietic stem 
cell transplantation (HSCT) (Duggan et al. 2003). Moreover, all studies were small in 
sample size (n=8-26), probably due to the difficulty in measuring REE in children 
with cancer (Brinksma et al. 2012). Thus, due to these limitations (small sample sizes 
and the heterogeneity of the populations studied), it remains unclear whether children 
at the time of cancer diagnosis are hypermetabolic; nevertheless, it appears that most 
children during cancer treatment are not. Therefore, more research is warranted 
looking at whether children are hypermetabolic at different stages of the disease, in 
order to understand the nutritional status of paediatric cancer patients.           
(iii) Individual phenotype variability  
The author has previously considered the concept of host susceptibility to 
malnutrition following the discovery of multiple genetic polymorphisms involved in 
the regulation of inflammation, metabolism and utilisation of nutrients (Picton 1998; 
Ross 2007). More widely genetic polymorphisms of enzymes and transporters 
involved in drug metabolism, which result in altered protein expression and activity, 
have been well described (Lee et al. 2005, Gervasini and Vagace 2012). As part of 
this expanding field of biomedical research several genetic polymorphism have been 
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identified which play a role in the pharmacokinetics and pharmacodynamics of 
chemotherapy drugs (Lee et al. 2005, Riddick et al. 2005). It has also been observed 
that there are significant genetic differences between different ethnic groups (Lee et 
al. 2005). The key message here is that we are beginning to understand why different 
patients respond so differently to treatment with some experiencing more toxicity 
than others (figure 1.6). This concept also goes some way to explaining the 
variability in nutritional status of children with similar demographic characteristics, 
diagnosed with the same condition and treated with the same protocol.  
 
Figure 1.6 Multiple factors contributing to variations in drug response and the 
consequent risk of undernutrition. Adapted from (Lee et al. 2005) 
 
1.3.2.2 Glucocorticoids 
Glucocorticoids, in particular dexamethasone and prednisolone, alongside cytotoxic 
agents have long been the mainstay of treatment for ALL, Hodgkin’s disease, non-
Hodgkin’s lymphoma, and B-Cell lymphoma (BNF 2009). They are also employed 
for their anti-tumour effects in the treatment of other cancers, to prevent organ 
transplant rejection, such as following HSCT and, to reduce intracranial pressure in 
patients diagnosed with brain tumours. Additionally, they are routinely used in 
smaller doses as an antiemetic. Although, their anti-tumour properties have long been 
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demonstrated to be effective, they are known to have multiple serious side-effects, 
including an increased risk of malnutrition, particularly overnutrition and obesity. 
This is detailed in table 1.2 (Odame et al. 1994, Wallace et al. 2003, Ahmed et al. 
2002, Groot-Loonen et al. 1996).  
Despite the well-known metabolic effects of this group of drugs, there has until now 
been very little work looking into the effects of glucocorticoids on the nutritional 
status of childhood cancer patients during and after treatment. Therefore, this is not 
entirely understood (Reilly et al. 2001). This dearth of research has been attributed to 
a number of factors: (i) the difficulty of studying the effect of a single agent since 
most childhood cancers are treated with multiple agents; (ii) in order to estimate the 
precise prevalence of undernutrition, overnutrition and obesity there is a need for 
large expensive multicentre cohort studies; (iii) The technical challenges involved 
with the necessary mechanistic studies which would allow us to investigate whether 
or not specific childhood cancer patients treated with glucocorticoids have a genetic 
predisposition for malnutrition, especially obesity (Reilly 2009b). (iv) Another 
reported barrier is the difficulty of performing physiological studies that investigate 
the relationship between TEE and energy intake and, the development of 
malnutrition in this population (Reilly 2009b).      
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Table 1-2 Most common side-effects associated to glucocorticoids that may lead to 
malnutrition 
Effects of 
glucocorticoids 
Side effects Malnutrition References 
Immunodeficiency  Increase risk of 
infection  
Undernutrition  (Dejean and 
Richard 2013) 
Appetite stimulant 
(leptin resistance)  
Increase appetite → 
increase food intake 
Obesity  (Davies et al. 
2004) 
Changes in 
macronutrient 
metabolism  
Increased proteolysis  
                                       
Lipolysis and increase 
of fatty acids in 
circulation 
                                  
Insulin resistance and 
increased 
gluconeogenesis 
Muscle breakdown → 
reduced FFM 
 
Ectopic fat distribution 
(liver, muscle, and 
central adipocytes) → 
Obesity  
 
Hyperglycaemia  
(Schakman et al. 
2009) 
 
(Peckett et al. 
2011)  
 
 
 
(McMahon et al. 
1988) 
Salt and water retention Oedema May mask 
undernutrition or PEM 
(Motil 1998)  
 Delay puberty, slow 
growth  
Reduced HFA, stunting  (Motil 1998, 
Dalton et al. 
2003) 
Inhibition of osteoblast, 
stimulation of osteoclast, 
reduced calcium 
absorption, increased 
vitamin D catabolism 
Osteopenia, rickets, 
osteoporosis, 
osteonecrosis 
Reduced bone mass 
density → weakness  
Increase risk of fracture 
 
(Zhou et al. 2006) 
 
1.3.2.3 Radiotherapy 
Radiation therapy is the medical treatment of cancer whereby ionising radiation is 
employed to either kill or control cancerous cells (Boon et al. 2006). Ionising 
radiation either damages DNA directly or indirectly by the generation of free radicals 
OH and H from water and reactive oxygen species from oxygen. Cells with pre-
existing DNA defects like cancerous cells tend to be more sensitive to ionising 
radiation than healthy cells. However, healthy cells will also be affected by radiation 
therapy (O'Donoghue 2004). The acute side-effects of radiotherapy on nutritional 
status are generally well understood and predictable (O'Donoghue 2004). However, 
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evidence on the medium to long term effects of  radiotherapy are scarce, with most 
research focusing on the effects of cranial radiotherapy on nutritional status (Dalton 
et al. 2003, Lustig et al. 2003, Müller et al. 1998, Müller et al. 2001, Armstrong et al. 
2010, Siviero-Miachon et al. 2009a). The acute effects of radiotherapy depend on the 
following factors: the dose of radiation, the duration of treatment and the location 
and size of the tumour treated (O'Donoghue 2004). Patients receiving ionising 
therapy to the brain, head and neck and, abdominal and pelvic region will have an 
increased risk of malnutrition, which at the same time will be exacerbated by higher 
doses of radiation (Donaldson 1982, O'Donoghue 2004, Donaldson et al. 1981). This 
is because of the damage to the mucosa of the digestive tract, which like with 
chemotherapy can lead to mucositis of the oropharynx and small intestine. The 
resultant symptoms often render patients unable to eat and cause malabsorption of 
macro and micronutrients with gastrointestinal failure occurring in severe cases. 
Untreated dehydration, deranged electrolytes and weight loss can all result in death 
(Grundy & Plowman 2004, Donaldson 1982, O'Donoghue 2004). It should be 
remembered though that head and neck cancers as well as tumours of the 
gastrointestinal tract are rare in children (Grundy & Plowman 2004).  
There is a lot of evidence to show that the use of cranial irradiation in children 
treated for ALL and brain tumours may lead to obesity later in life (Dalton et al. 
2003, Lustig et al. 2003, Müller et al. 1998, Müller et al. 2001, Armstrong et al. 
2010, Siviero-Miachon et al. 2009a). Currently, with the introduction of new 
protocols, the use of this form of therapy is limited to some children with refractory 
ALL or with optical nerve infiltration (Sposto 2004); however, alongside surgery it is 
the main form of treatment for craniopharyngioma (Hargrave, Messahel & Plowman 
2004).      
1.3.2.4 Surgery and haematopoietic stem cell transplantation  
Surgery is another common form of treatment that can contribute to the 
pathophysiology of malnutrition. It is well known that surgical trauma causes an 
increase in resting energy expenditure as a result of inflammation, and also to 
support the healing process (Garden et al. 2007). Although anorexia is common 
following surgery, this is generally transient as recovery progresses and the effects 
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on nutritional status tend to be short-term unless complications, such as infections, 
occur. Tumours affecting the gastrointestinal tract are very rare in children (Stiller 
2004, Kliegman 2007), but those affected can potentially be at an increased risk of 
undernutrition due to reduced intake and malabsorption of macronutrients and 
micronutrients, especially fat and, thereby, fat soluble vitamins. This has been 
reported in studies performed in adults (Bae et al. 1998). Studies investigating the 
acute and short-term effects of surgery on the nutritional status of paediatric cancer 
patients are very limited; with only one case report published reporting that an 
adolescent boy aged 15 years underwent gastrectomy due to a rare diagnosis of 
gastrointestinal adenocarcinoma. This patient presented very undernourished, 
required oral feeding and parenteral nutrition (PN) post-surgery and was discharged 
after 13 days. At four months follow-up, the patient was well-nourished (Slotta et al. 
2011). Therefore, paediatric cancer patients undergoing surgery are likely to be at 
risk of undernutrition immediately after surgery. However, little is known about the 
long-term effects of gastrectomy and other surgeries performed in this population.      
Finally, haematopoietic stem cell transplantation (HSCT) involves the transplant of 
haematopoietic stem cells, which derive mainly from matched bone marrow donors; 
however, in recent years there has been an increase in the use of umbilical cord blood 
cells (Veys & Rao 2004). HSCT is less commonly used than the previous forms of 
treatment due to the high mortality risk and numerous complications (Veys & Rao 
2004). Hence, it is mainly restricted to high-risk ALL patients who do not respond to 
standard chemotherapy treatment, early AML relapse or in high-risk infant ALL 
treatment (Veys & Rao 2004). HSCT is preceded by an intensive chemotherapy 
regime aimed at both eradicating all malignant cells and providing 
immunosuppression to avoid rejection of the donor’ stem cells. Thereby, the risk of 
undernutrition starts with chemotherapy induced toxicities, which is then exacerbated 
by the HSCT. Additionally, long term-effects including poor growth and reduced 
HFA have been reported in the literature (Leiper 2002b, Leiper 2002a).   
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1.3.2.5 Complementary and alternative medicine (CAM) 
Despite the overall increase in survival rates as a result of the improvements in 
conventional cancer treatment already described, children still suffer major adverse 
effects, which may themselves not be relieved by conventional medicine (McLean & 
Kemper 2006). For this reason many families seek complementary medicine (Bishop 
et al. 2010). CAM has been defined as “a group of diverse medical health care 
systems, practices and products that are not presently considered to be part of 
conventional medicine” (NCCAM 2009). The most popular CAM worldwide are 
herbal remedies (Fernandez et al. 1998, Genc et al. 2009, Slayton 1997), diets and 
nutrition (Fernandez et al. 1998, Kelly et al. 2000, Leis 2000) and faith healing 
(Slayton 1998, Weyl Ben Arush et al. 2006, Yeh et al. 2000). In the UK however, the 
most popular therapies are; aromatherapy and massage (Cubbin 2004, McCann & 
Newell 2006), followed by high dose multivitamins, diets as well as music therapy 
(Cubbin 2004). In contrast, herbal remedies are not commonly used (Cubbin 2004, 
McCann & Newell 2006). CAM therapy has the potential to significantly improve 
the quality of life of childhood cancer patients and their nutritional status by reducing 
stress and alleviating symptoms (Kelly 2004, 2008, La 1994). However, many 
therapies, especially those from biological origin, can interact with conventional 
cancer treatment increasing their toxicity or reducing the efficacy of the actual 
treatment (Ladas et al. 2004) and in turn have detrimental effects on nutritional 
status.  
Complementary therapy specialists providing CAM are now commonly employed in 
oncology units in the UK, often funded by charitable sources (Cancer Research UK 
2012). A study performed in the paediatric oncology population from SE Scotland 
showed that 51% of patients used CAM and the most common therapies were 
multivitamins followed by massage therapy and fish oils (Revuelta-Iniesta et al. 
2014), which is consistent with findings from other two studies performed in the UK 
(Cubbin 2004, McCann & Newell 2006) and a Finnish study, in which 
multivitamins, massage therapy along with aromatherapy were reported to be the 
most prevalent (Mottonen & Uhari 1997).  Overall, 81% of paediatric cancer patients 
from SE Scotland perceived CAM to be beneficial during the course of treatment 
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(Revuelta-Iniesta et al. 2014); consistent with findings published somewhere else 
(Cubbin 2004, Ladas 2004).  
However, at present there is an absence of evidence demonstrating the safety and 
efficacy of biologically based therapies. Consequently their use remains 
controversial owing to their potential interaction with conventional treatments 
(Cancer Research UK 2012). On the one hand it has been hypothesised that high 
doses of vitamins and minerals with anti-oxidant functions reduce the efficacy of 
cytotoxic therapies. This is because the latter function by generating free radicals and 
oxidative stress, which kill cancer cells; an effect which is counteracted by such 
antioxidants (Ladas et al. 2004). On the other hand individuals with depleted 
antioxidant status might benefit from this after treatment (Ladas et al. 2004). It has 
also been shown that other vitamins and minerals, for example selenium increases 
the toxicity of agents used in chemotherapy (Ciplastin). Meanwhile, high-dose 
vitamin E intake can interact with other treatment modalities as it has been associated 
with an increased in clotting time, which in turn can increase the risk of post-surgery 
bleeding (Kelly 2004). 
Of all the biological agents, most adverse effects have been associated with the use 
of herbal remedies, including Echinacea (Kelly 2004), which has been reported to be 
used by 12% of the CAM users from SE Scotland (Revuelta-Iniesta et al. 2014). 
Echinacea might increase the effect of immunosuppressant drugs, such as 
corticosteroids or cyclosporine and the incidence of hepatotoxicity with agents such 
as Methotrexate (Kelly 2004, Post-White et al. 2006). Although 60% of families 
from this study reported a positive attitude towards the use of this herb (Revuelta-
Iniesta et al. 2014), it was concluded that it is important to discuss potential 
interactions of CAM material with specialist pharmacists to inform families about the 
possible adverse effects and adopt a cautious attitude until more high-quality 
evidence is published. Indeed, due to the paucity of evidence high-quality 
interventional studies, which investigate the effects and possible interactions of 
biological based therapies as well as the efficacy and effectiveness of alternative 
health care therapies on nutritional status, are warranted.  
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Although the usage of CAM in paediatric cancer patients from SE Scotland has been 
investigated as part of the ENRICC project, this will not be presented and discussed 
in this thesis.   
1.2.3 Social and psychological influences of the cancer and its associated 
treatment on the child and its family 
Social and psychological factors play an important role in the aetiology and 
pathophysiology of malnutrition. In particular, studies have focused on learned food 
aversion, physical inactivity and behaviour issues due to the consequences of a long 
lasting treatment. Learned food aversion develops when the child associates specific 
foods with treatment induced side-effects, including nausea and vomiting, which 
often results in avoidance of these specific foods (Scalera 2002). In turn, this may 
limit choices (Bernstein 1978, Bernstein et al. 1982), which in this context can have 
detrimental consequences on long term food choices, affecting the nutritional status 
of childhood cancer survivors. Additionally, numerous reviews have been published 
reporting that habits, such as sedentary behaviour may develop during treatment, 
most possibly as a result of the length and intensity of the treatments (Reilly 2009a, 
Stolley et al. 2010, Winter et al. 2010, San Juan et al. 2011). These habits may 
persist, thus increasing the risk of obesity in later life (Reilly 2009a, Stolley et al. 
2010). Finally, sequelae from the treatment may have long term consequences in 
behaviour. In particular, adopting both a permanent sick role and secondary gain 
have been described in patients and also survivors (Mertens et al. 2001), which may 
lead not only to nutritional issues, but also overall lifestyle problems.   
In conclusion, it can be seen that there are many factors at interplay in the aetiology 
and pathophysiology of malnutrition in paediatric cancer patients with many gaps in 
the literature. In order to understand the mechanisms, it is first essential to elucidate 
the epidemiology of malnutrition in paediatric cancer patients, including the 
prevalence and specific patterns of change over time. Thereby, allowing to identify 
those children who might be at risk of becoming malnourished during and after the 
completion of treatment.    
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1.4 ANTIOXIDANTS, OXIDATIVE STRESS AND POLYUNSATURATED 
FATTY ACID STATUS IN PAEDIATRIC CANCER PATIENTS 
The nutritional profile of paediatric cancer patients assessed by measuring plasma 
antioxidants, oxidative stress and polyunsaturated fatty acids (PUFA) has not been 
previously investigated in Scotland and there are very few comprehensive published 
studies performed elsewhere. In clinical practice, a nutritional profile tends to be 
subjectively assessed from a range of anthropometric measures and routine 
biochemical and haematological blood tests and non-routine plasma vitamin and 
mineral concentration.  The antioxidant capacity of the blood, assessed from 
antioxidant status and markers of oxidative stress, provides a further indicator of both 
the nutrient adequacy as well as functional markers. Abnormal antioxidant and 
plasma fatty acid profiles have previously been described in children and adults 
diagnosed with and treated for cancer (de la Torre Aguilar et al. 2012, 
Kuliszkiewicz-Janus et al. 2008, Gleissman et al. 2011, Ladas et al. 2004).  Although 
little is known about the potential effects of this in paediatric cancer patients, it is fair 
to assume that there may be functional implications (Guerra et al. 2007). In order to 
enhance the nutritional profile of paediatric feeds antioxidants such as carotenoids 
and long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA), primarily 
Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA), have been added. 
As results from phase-I of this project showed, almost half of the Scottish paediatric 
oncology patients required enteral nutrition support, mainly via nasogastric tube 
(NG-tube) (Paciarotti I 2013); however, at present there is no data to indicate any 
impact of these developments and their habitual dietary intake on their nutritional 
status and whether this has implications on clinical outcome.  
1.4.1  Antioxidant and oxidative stress status of paediatric cancer patients  
At present, there is a great deal of interest in the benefits of antioxidants on health. In 
particular, attention has focused on their protective role against cardiovascular 
diseases, neurodegenerative disorders and cancer (Ladas et al. 2004, Obrenovich et 
al. 2011). In order to understand the role of antioxidants and oxidative stress in 
paediatric cancer patients, it is first essential to describe oxidative stress, antioxidant 
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status and antioxidant capacity under normal circumstances and with a diagnosis of 
cancer.               
     
Free radicals (FR) and reactive oxygen species (ROS) are essential for normal body 
functions (Conklin 2000). FR are involved in cell signalling and function as 
bactericidal in response to infection and, ROS are secreted as by-products in 
mitochondrial respiration and play an essential role in homeostasis (Conklin 2000). 
As previously discussed, cancer generates FR and ROS induced by an inflammatory 
response. Additionally, some forms of cancer treatment, including the use of 
alkylating agents, antimetabolites and radiotherapy generate FR to induce cancer-cell 
apoptosis (Ladas et al. 2004). FR are electrically charged molecules. As such, they 
capture electrons from other substances to neutralise themselves. Consequently, this 
leads to chain reactions, which in turn cause cell injury (Granot and Kohen 2004) by 
promoting lipid peroxidation, oxidative mediation of proteins and by damaging 
nuclear and mitochondrial DNA (Ou et al. 2001, Girard-Lalancette et al. 2009). 
Although FR are essential for life, excess production of FR and ROS not only 
damage cancer cells, but also cause injury to healthy cells and organs (Battisti et al. 
2008).  
 
Antioxidants are classified as endogenous and exogenous and function interactively 
and synergistically to neutralise FR. Endogenous antioxidants are produced by the 
human body and can either be enzymes, which catalyse FR quenching reactions or, 
metal binding proteins, which sequester free iron and copper ions that are capable of 
catalysing oxidative reactions. Exogenous antioxidants, such as vitamin C or 
selenium, are diet derived and function by neutralising FR and enhancing 
endogenous antioxidant activity (Ladas et al. 2004). Therefore, exogenous 
antioxidant status can be defined as static micronutrient markers, whilst antioxidant 
capacity is a measure of functional enzymes and micronutrient markers. Static 
markers refer to the concentration of vitamins and minerals in the blood, with 
potential antioxidant capacity, at a single point in time, which are then compared to 
reference data (Department of Health 1991). Such measures may not indicate 
whether nutrition metabolism is optimal or whether there are any functional 
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abnormalities (Clayton and Rounds 1994). It is functional markers that measure 
nutrients’ activity in the body, such as the strength of the antioxidants against 
oxidation (Clayton and Rounds 1994).   
 
Despite the potential protective role of antioxidants against cancer, there is 
discrepancy regarding their protective role during cancer therapy with few evidence 
published examining antioxidants status and their role during cancer treatment 
(Battisti et al. 2008, Mazor et al. 2008, Lamson and Brignall 1999). It has been 
suggested that the failure of dietary antioxidants to prevent further progression of 
cancer cells might be due to their inability to scavenge ROS at the site of production 
(Chandel and Tuveson 2014). Furthermore animal and in-vitro studies postulate that 
dietary antioxidants may stimulate oncogenic proteins, which otherwise would be 
attenuated by ROS, and inactivate some tumour suppressor proteins, such as P53, 
which are normally activated by ROS (Chandel & Tuveson 2014). Antioxidants may 
also promote the survival of detached cancer cells by preventing oxidative injuries to 
DNA (Saeidnia & Abdollahi 2013) and may reduce treatment efficacy (Salganik 
2001, Labriola and Livingston 1999, Ray et al. 2000, Pathak et al. 2005). 
 
On the other hand a systematic review (Ladas et al. 2004) and numerous narratives 
reviews have been published reporting that the effects of antioxidants are unlikely to 
be harmful; however, their role regarding their benefits on clinical outcomes is still 
in dispute (Ladas et al. 2004, Block 2004, Prasad 2004, Prasad et al. 1999, Prasad 
2005, Prasad 2003, Prasad et al. 2003). Two mechanisms by which antioxidants may 
be of benefit against cancer cells have been proposed: (i) the direct effect of 
antioxidants on tumour cells and (ii) the effects of antioxidants in combination with 
chemotherapy and radiotherapy. (i) In vitro and animal studies have shown that some 
antioxidants induce cell differentiation and inhibit the growth of several tumour cells, 
thus reducing the growth of certain types of tumour cells (Labriola and Livingston 
1999, Prasad et al. 1999, Agus et al. 1999); (ii) in vitro and very few in vivo studies 
have proposed that some antioxidants, including vitamin A (and β-carotene) (Teicher 
et al. 1994, Rutz and Little 1989), vitamin C (Prasad 1980) and vitamin E (Chinery et 
al. 1997, Prasad et al. 1980), used with standard cancer therapy may enhance the 
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growth inhibitory effect of chemotherapy agents on some cancer cells and, also 
protect normal body cells from toxicity (Prasad et al. 1999, Kumar et al. 2002, 
Prasad et al. 1994).  
 
In order to learn about antioxidants and oxidative stress in paediatric cancer patients 
at diagnosis and during therapy, and whether they have any protective or detrimental 
influence on clinical outcome, it is vital to review current evidence on this topic. 
Thus, an electronic search of the English language was performed (no restriction-
April 2014) using the Cochrane Library, MEDLINE (via EBSCOhost), CINHAL 
(via EBSCOhost) and PUBMED to identify systematic reviews, Randomised Control 
Trials (RCT) and observational studies. The reference list of all relevant articles was 
also examined. The initial search strategy identified the following keywords: 
“paediatrics”, “cancer”, “cancer treatment”, “antioxidant status”, “antioxidant 
capacity” and “oxidative stress” and, adaptations for British and American English 
were made for all searches. The eligibility criteria included studies investigating 
children and young people aged less than 18 years, diagnosed with and treated for 
cancer (diagnosis according to ICCC-3 criteria) and also investigating total 
antioxidant status (TAS), total antioxidant capacity (TAC) and/or oxidative stress in 
paediatric cancer patients.        
 
The primary search yielded 388 studies and, of these, only 23 met the eligibility 
criteria. A summary of these studies is presented in table 1.3. Four studies were 
excluded because they were performed in adults instead of children (Brackett et al. 
2012, Calautti et al. 1980, Drozda et al. 2010, Jonas et al. 2000). Most of the studies 
investigated antioxidant status and/or antioxidant capacity (n=19) and oxidative 
stress (n=14). But very few assessed whether antioxidant status, antioxidant capacity 
or oxidative stress was either predictive of clinical outcome or had any effect on 
clinical outcome (n=8). Additionally, all studies were either prospective cohort or 
cross-sectional studies and a control was used in the majority as reference values.           
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1.4.1.1 Antioxidant status and antioxidant capacity in paediatric cancer 
patients   
Evidence investigating TAS and TAC in paediatric cancer patients at different stages 
of the disease, especially after the completion of therapy, is limited as only 19 studies 
have been published to date (see table 4.1). Despite this, most studies apart from two 
(Papageorgiou et al. 2005, Pazirandeh et al. 1999)  are in agreement with the fact that 
both antioxidant status and antioxidant capacity are lowered in patients diagnosed 
with cancer in comparison to control groups at the time of diagnosis (Battisti et al. 
2008, Al-Tonbary et al. 2011, Kennedy et al. 2004a, Krawczuk-Rybak et al. 2012, 
Malvy et al. 1997, Malvy et al. 1997, Misaki et al. 2003, Neyestani et al. 2007, 
Nathan et al. 2011, Sentürker et al. 1997, Fiore et al. 1997) and as expected, TAS and 
TAC are reduced further during the course of treatment (Mazor et al. 2008, 
Neyestani et al. 2007, Papageorgiou et al. 2005, Pazirandeh et al. 1999, Pazirandeh et 
al. 1999, Protas et al. 2010). Only two studies have investigated TAS and TAC after 
the completion of therapy and they both reported no difference between survivors of 
childhood cancer and the control group (Krawczuk-Rybak et al. 2012, Papageorgiou 
et al. 2005).  
A number of limitations have been common to most studies: (i) it can be seen from 
the table that most studies investigated children diagnosed with ALL and very few 
focused on solid and brain tumours, (ii) the type of dietary and endogenous 
antioxidants measured and the techniques employed to assess antioxidant capacity 
were very variable, making once more the comparison between the different articles 
very difficult. Of note, all techniques used in the studies were validated. (iii) Dietary 
intake, the use of nutritional support and vitamin and mineral supplementation was a 
major confounding factor in most studies. (iv) None of the studies assessed treatment 
induced side-effects such as malabsorption. Despite these limitations exogenous 
antioxidant status and its antioxidant capacity as well as endogenous antioxidants 
will be described.  
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- Antioxidant status 
(i) Vitamins A, E and C 
Changes in plasma vitamin A, E and C in children diagnosed and treated for cancer 
have been described in very few studies. Three studies were found in the literature to 
investigate Vitamin A (Malvy et al. 1997, Fiore et al. 1997, Kennedy et al. 2004b, 
Kennedy et al. 2005). Of these, two assessed changes in plasma vitamin A in  
children diagnosed with any type of malignancy (Malvy et al. 1997, Fiore et al. 
1997), whilst one study examined plasma vitamin A in children diagnosed with ALL 
only (Kennedy et al. 2004b). Malvy (1997) and Fiore and co-workers (1997) 
reported significantly lower levels of vitamin A (and β-carotene) in children 
diagnosed with cancer at the time of diagnosis in comparison with matched healthy 
controls. Plasma vitamin A remained low following six months of treatment (Malvy 
et al. 1997). Only, Fiore et al (1997) assessed dietary intake using a 48-hours dietary 
recall and found that 33% of the cohort consumed less than 80% of the 
recommended daily allowances. The authors proposed that the low level of vitamin 
A seen in this population was induced by the cancer itself instead of the poor dietary 
intake (Fiore et al. 1997). Although, this might be the case, it can be argued that a 48-
hours dietary recall is not a very accurate measurement of assessing dietary intake, 
especially micronutrients, as it tends to underestimate both macronutrients and 
micronutrients (Burrows et al. 2010). Additionally, the authors reported total energy 
intake but vitamin A intake was reported in neither the cohort nor the controls. 
Finally, the cut-off value established by the authors (less than 80% of the 
recommended daily allowances for energy intake) might have underestimated their 
findings. 
 In contrast, Kennedy et al. (2004) found that children diagnosed with ALL (n=103) 
had both poor vitamin A intake and levels at diagnosis. This increased during 
treatment (at six months) despite vitamin A intake remaining below 
recommendations. There was no correlation between vitamin A intake and plasma 
vitamin A, which was attributed to the methods used to assess dietary intake: 24-hour 
dietary recall and the food frequency questionnaire. It has also been discussed that an 
42 
 
increase in plasma vitamin A in ALL patients occurs as a result of treatment with 
prednisone (Kennedy et al. 2005). In normal circumstances, 50-80% of vitamin A is 
stored in the liver and this is used in periods of deficiency while maintaining normal 
plasma vitamin A (Yu et al. 1994). For vitamin A to be transferred to target tissues it 
first needs to be de-esterified and bound to retinol binding protein (RBP). Prednisone 
is thought induce the synthesis of RBP, thus causing an increase in plasma vitamin A 
(Yu et al. 1994)      
Plasma vitamin E and α-tocopherol (organic chemical compound with vitamin E 
activity) in paediatric cancer patients has been studied by four groups (Battisti et al. 
2008, Kennedy et al. 2004a, Malvy et al. 1997, Misaki et al. 2003). Of these, three 
studies included children diagnosed with ALL only (Battisti et al. 2008, Kennedy et 
al. 2004a, Misaki et al. 2003), whilst one examined erythrocytes α-tocopherol and 
lymphocytes α-tocopherol concentration in children diagnosed with a malignancy 
included in the ICCC-3 (Malvy et al. 1997). It appears that children diagnosed with 
ALL tend to have normal vitamin E levels at the time of onset (Kennedy et al. 2004a, 
Misaki et al. 2003); however levels decrease with treatment (Battisti et al. 2008, 
Kennedy et al. 2004a, Misaki et al. 2003) and return to normal thereafter (Battisti et 
al. 2008). Similar findings have been reported in adults diagnosed and treated for 
chronic myeloid leukaemia (Ghalaut et al. 1999, Singh et al. 2000). Only, Battisti et 
al. 2008 reported low vitamin E at the time of onset, which was attributed to an 
increased in oxidative stress. Finally, Malvy et al. (1997) reported an increased risk 
of vitamin E (α-tocopherol) deficiency at diagnosis, which only continues throughout 
treatment in children diagnosed with bone tumours. Of note, neither Battisti et al. 
(2008) nor Malvy et al. (1997) measured dietary intake, which could have also been 
the reason for the low vitamin E levels as it has been reported by Kennedy et al. 
(2004), who found that 85% of children had a vitamin E intake below 
recommendations. Moreover, none of the above studies described treatment induced 
side-effects, such as vomiting or mucositis, which would reduce absorption of 
nutrients.                      
Alterations in plasma vitamin C show more consistent results. The three studies 
found in the literature investigated vitamin C in children diagnosed with ALL at 
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diagnosis (Kennedy et al. 2004a) and during treatment (Kennedy et al. 2004a, 
Neyestani et al. 2007, Kakar et al. 1975). Although plasma vitamin C was reported to 
be within the normal range at diagnosis (Kennedy et al 2004a), this was significantly 
lower in the cohort than in the controls during treatment, despite vitamin C intakes 
being higher in the cohort group (Kennedy et al. 2004a, Neyestani et al 2007). These 
findings suggest that there might be an increased use of vitamin C due to cancer 
treatment in patients treated for ALL, which in turn may increase vitamin C 
requirements.                 
(ii) Zinc, Copper and Selenium  
Zinc, copper and selenium have antioxidant properties. In healthy (non-stressed) 
individuals the plasma concentration of these micronutrients is a reliable indicator of 
the body’s status. However, they are also acute phase reactants and their plasma 
concentration may change during inflammation; zinc and selenium concentration 
may decrease, whilst copper levels may increase (Galloway et al. 2000). Despite this, 
two studies have investigated the changes in zinc and copper as a measured of 
antioxidant status in children diagnosed with ALL (Sgarbieri et al. 2006)  and a 
malignancy according to the ICCC-3 (Malvy et al. 1997). These patients were also 
treated with chemotherapy at the time of the studies. Their findings are contradictory 
(see table 3.1). Furthermore, two studies investigated plasma selenium in this 
population (Malvy et al. 1997, Pazirandeh et al. 1999). Once more, findings are 
inconsistent. Pazirandeh and co-workers (1999) investigated plasma selenium in 
children diagnosed with ALL and AML and compared this with a matched healthy 
control. At diagnosis, the authors found no differences between the ALL and the 
control group; however, the AML group had significantly lower selenium levels than 
the control group. Plasma selenium did not change in the AML group after induction 
chemotherapy, whilst this was significantly reduced in the ALL group. In contrast, 
Malvy and co-workers (1997) found no difference in plasma selenium when the 
cancer (ICCC) group was compared to the control group at the time of diagnosis. 
However, the cancer group had significantly higher selenium levels after 6 months of 
treatment in compare to healthy controls. As none of the studies reported markers of 
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inflammation, treatment induced side-effects; especially malabsorption, kidney and 
liver impairment, and only one study (Sgarbieri et al. 2006) reported dietary intake, 
the causes of these changes are still unknown. Additionally, the inconsistent findings 
could also be attributed to the differences in the cancer diagnosis and the different 
treatment regimes.  
- Total antioxidant capacity 
Total antioxidant capacity (TAC) has been assessed by measuring the endogenous 
antioxidants enzymes catalase (CAT), superoxide dismutase (SOD) and glutathione 
peroxidase (GPx) and or by measuring the scavenging strength of exogenous 
antioxidants (see table 1.3). All studies, apart two (Nathan et al. 2011, Stachowicz-
Stencel et al. 2011) included children diagnosed with ALL (Battisti et al. 2008, 
Mazor et al. 2008, Al-Tonbary et al. 2011, Neyestani et al. 2007, Sentürker et al. 
1997, Papageorgiou et al. 2005, Protas et al. 2010, Nakagawa 2000). As expected 
most studies agreed that TAC was lowered in children with cancer in compared to 
controls and that this was reduced further during cancer therapy. Additionally, those 
children treated with high risk protocols (ALL) or considered to have a poorer 
prognosis at diagnosis had lower TAC than those treated with standard risk protocols 
(ALL) or considered to have a good prognosis (Al-Tonbary et al. 2011, Stachowicz-
Stencel et al. 2011). Interestingly, only one study investigated changes in TAC 
throughout all the stages of disease (diagnosis, treatment and after therapy) and 
compared it against a control group (Papageorgiou et al. 2005). The authors reported 
that TAC in children diagnosed with ALL, AML or a CNS tumour was not 
significantly lowered than that of the cancer-free controls either at diagnosis or after 
the completion of therapy. Notably, the study did not mention whether the controls 
were healthy at the time of the study, only that they were cancer free.        
1.4.1.2 Oxidative stress 
Although the number of studies assessing oxidative stress in this population is scarce, 
all studies reported consistent findings. Oxidative stress increases at diagnosis and 
during the course of therapy (or it is higher than healthy controls) and, this is 
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regardless of the type of diagnosis and the technique employed to assess it. These 
findings are consistent regardless of the technique used to assess oxidative stress: by 
lipid peroxidation (Battisti et al. 2008, Al-Tonbary et al. 2011), DNA damage 
(Sentürker et al. 1997), oxidation of the cerebrospinal fluid (CSF) (Protas et al. 2010, 
Caron et al. 2009, Miketova et al. 2005, Stenzel et al. 2010) or protein carbonylation 
(Battisti et al. 2008, Mazor et al. 2008, Stachowicz-Stencel et al. 2011).  
As it has already been discussed oxidative stress is part of the normal body functions 
and it is induced by the cancer treatment in order to kill cancer cells; therefore, these 
findings are reassuring. The questions are whether oxidative stress causes irreversible 
damage to the body, which can be detected after treatment, whether the degree of 
oxidative stress at diagnosis and during therapy can predict clinical outcome and 
whether tissue damage can be avoided or reduced with antioxidant intake. Although, 
there is a lot of evidence reporting long term side-effects of childhood cancer 
survivors (Wallace et al. 2013), only one study has addressed the first question 
(Battisti et al. 2008). The authors found that lipid peroxidation and protein 
carbonylation not only was high during treatment but also remained high after the 
completion of therapy, suggesting irreversible damage to tissues. The second 
question will be discussed in the next section and the third question has been 
discussed previously (1.4.1.1 Antioxidant status).  
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Table 1-3 Studies measuring antioxidant status, antioxidant capacity oxidative stress 
Author Quality Patients Dx N, age years  
 
Time of measurement 
and method 
Method 
 
Results 
Design Parameters At diagnosis During 
treatment 
After 
treatment 
Al-
Tonbary 
et al. 
(2011)  
Egypt  
Weak ALL 
 
Controls 
(outpatient 
clinic of 
general 
paediatric 
surgery) 
ALL: 
N=50 
Age:  
mean±SD 
(range): 
6.84±3.73 
(1.5-12) y 
 
Controls: 
N=10 
(matched for 
age and sex) 
 
T: At diagnosis and 
after 5 weeksof 
treatment  (end of 
induction therapy) 
 
M: Measurement of 
serum TAC: Koracevic 
et al 2001 
 
Measurement of MDA 
(lipid peroxidation):  
Satoh K 1978 and 
Ohkawa et al 1979 
 
Apoptosis DeadEnd
TM
 
Fluorometric TUNEL 
System (Promega 
Corp., Madison, WI, 
USA) 
PCS TAC, MDA, 
apoptosis 
 
Controls had 
higher TAC 
(p<0.0001) 
and lower 
MDA 
(p<0.0001) 
than  ALL 
cases 
 
ALL cases: 
 
No sig 
difference 
between 
standard and 
high risk 
groups for 
MDA, TAC 
and apoptosis 
 
ALL cases: 
MDA sig ↑ from 
diagnosis 
(p<0.001) 
 
TAC sig ↓from 
diagnosis 
(p=NR) 
 
Apoptosis sig 
↑from diagnosis 
(p<0.001) 
 
TAC was sig 
lower in the 
high risk group 
than the 
standard risk 
group 
(p=0.024), but 
no difference 
was found in 
MDA between 
the groups 
 
 
Battisti et 
al. (2008) 
Brazil 
Weak ALL 
 
Controls 
(healthy 
ALL: 
N=80 
Age range: 
Just 
T:  
JD, RI, RM, OT 
 
M:  
C Oxidative 
stress: lipid 
and protein 
oxidation 
Lipid 
peroxidation 
was ↑ in the 
JD, RI in 
NA NA 
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volunteers, age 
and SES 
matched) 
diagnosed 
(JD): 3-17 y 
Remission 
induction 
(RI):  
3-19 y 
Remission 
maintenance 
(RM): 3-23 y 
Out of 
treatment 
(OT): 
 4-20 y  
 
Controls: 
N=50 
(matched for 
age and SES) 
TBARS (lipid 
peroxidation): Jentzsch 
et al1996 
 
CAT activity: Nelson 
and Kiesow 1972 
 
SOD activity Mc Cord 
and Fridovich 1969 
 
Non-protein thiols: 
Ellman GL 1959 
 
Serum vitamin E: 
Hansen and Warwick 
1969  
 
Protein carbonylation 
(protein oxidation): 
Bradford MM 1976 
 
 
 
Endogenous 
antioxidants 
(CAT, SOD) 
Exogenous 
antioxidants 
(vitamin E) 
 
 
compare to 
controls, RM 
and OT 
(p<0.001) 
 
CAT activity 
was ↓ in JD, 
RI, RM 
compared to 
controls 
(p<0.001) 
 
SOD activity ↓ 
JD, RI 
compared to 
controls 
(p<0.01). 
Controls, RM 
and OT 
(p>0.05)  
 
Non-protein 
thiols levels 
were ↓ at JD, 
RI and RM in 
compare to 
controls  
(p<0.001) 
 
Vitamin E was 
↓ JD and RI 
(p<0.001)  
 
Nodifference 
between 
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controls, RM 
and OT 
patients 
Caron et 
al. (2009) 
USA 
Moderat
e 
ALL N=88 
Mean(±SD) 
7.1(±3.1)y 
T: from diagnosis to 3 
years 
Diagnosis, post-
induction, post-
consolidation and end 
of therapy 
 
M:  
Oxidised changes in 
CSF PC: Miketova et 
al 2005 
 
Executive function 
measures: The 
Behavior Rating 
Inventory of Executive 
Function (BRIEF): 
Gioia et al 2000 higher 
scores reflect more 
pathology 
PCS Oxidised 
changes in 
CSF 
 
 
 Oxidised PC ↑ 
from diagnosis 
to post-
induction 
(p<0.001) and 
post-
consolidation 
(p<0.001)  
 
Fiore et 
al. (1997) 
Italy 
Moderat
e 
Newly 
diagnosed 
malignancy  
 
Healthy 
controls 
Cases n=54 
mean(range) 
5.6(0.7-
16.5)y 
 
Healthy 
children mean 
n=47 
mean(range) 
5.9(0.7-
15.5)y 
T: at diagnosis 
 
M: Vitamin A 
measured by high 
performance liquid 
chromatography (pump 
model 200LC, Perkin-
Elmer) 
 
Reference values: age 
and sex-specific Italian 
recommended daily 
PC Plasma 
Vitamin A 
Dietary 
vitamin A and 
total energy 
intake 
33% (18) 
consumed less 
than RDA  
 
26%(14) had 
extremely low 
levels of 
Vitamin A 
 
Vitamin A 
levels were 
significantly 
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allowances 
 
Cases’ vitamin A levels 
were compared against 
healthy controls 
 
lower in the 
cases 
compared to 
the control 
group 
(p<0.001; 95% 
CI: 288-412) 
 
Kakar et 
al. (1975) 
Ireland   
Weak ALL 
Controls 
(cancer-free): 
congenital hip 
dislocation, 
congenital 
talipes, tonsils 
and adenoids 
and fracture of 
femur 
Cases n=10 
Age range 4-
11 y 
 
Controls 
n=10 Age 
range 4-14 y 
 
 
T: during treatment 
 
M: Plasma ascorbic 
acid concentration 
measured using 
dinitrophenyl-
hydrazine (Loh and 
Wilson 1971) 
CS Plasma and 
leukocytes 
ascorbic acid 
 Ascorbic acid 
from plasma 
(p<0.001) and 
leukocytes 
(p<0.05) were 
sig lower in 
ALL than in 
controls  
 
 
Kennedy 
et al. 
(2004) 
USA 
Strong ALL N= 103 
Age mean 
(±SD)y 
Standard-risk 
protocol 
4.7(±2.6)y  
High risk 
protocol 
10.5(±4.6)y 
T: at diagnosis, 3-4 
months and 6-7 months 
post diagnosis 
 
M:  
Total ascorbate 
analysis: HPLC 
analysis (Behrens et al 
1987) 
 
Vitamin A and E: 
HPLC analysis (Bieri 
et al 1979) 
 
Total carotenoids 
Colorimetric procedure 
(Roels et al 1972) 
PCS Total 
ascorbate 
Vitamins A 
and E 
Total 
carotenoids 
HDL and LDL 
Ch and TG 
 
 
Percentage of 
children with 
TEI below 
recommendati
ons (FFQ/24-
dietary recall) 
Vitamin A 
49/54% 
Total 
carotenoid 
33% 
Β-carotenoid 
88% 
Vitamin C 
10/13% 
Vitamin E 
83/85% 
Plasma vitamin 
A : 
↑ from 
diagnosis at 3 
(p<0.001) and 4 
months 
(p<0.001) 
 
Plasma total 
carotenoids 
expressed per 
TCh  
No change 
 
Plasma vitamin 
C: 
↑ at 3 months 
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Dietary intake: 24h 
recall and FFQ 
 
Dietary analysis: 
Minnesota 
NUTRITION DATA 
SYSTEM (NDS) 
software 
 
Recommended dietary 
allowance (National 
Health and Nutrition 
Examination Survey 
2000) 
 
Plasma antioxidant cut-
off values NR   
  
 
Normal ranges 
for plasma 
antioxidants 
NR 
 
(p=0.04) and ↓ 
at 6 months 
(p=0.007) 
 
Plasma vitamin 
E/Ch: 
↓at 3 months 
and 6 months 
(p=0.02) 
 
Plasma vitamin 
E: 
↓at 3 months 
(p=0.005) and 6 
months (p=0.02) 
 
Kennedy 
et al. 
(2005)  
USA 
Strong   ALL N= 103  
Age mean 
(±SD)y 
Standard-risk 
protocol 
4.7(±2.6)y  
High risk 
protocol 
10.5(±4.6)y  
T: at diagnosis, 3-4 
months and 6-7 months 
post diagnosis 
 
M: Total ascorbate 
analysis: HPLC 
analysis (Behrens et al 
1987) 
Vitamin A and E: 
HPLC analysis (Bieri 
et al 1979) 
Total carotenoids 
Colorimetric procedure 
(Roels et al 1972) 
Antioxidant capacity 
(ORAC): Cao G and 
PCS Exogenous 
antioxidants 
(vitamins A 
and E, 
carotenoids) 
Antioxidant 
capacity 
Oxidative 
stress 
 
 
 ↓ ORAC  
 
↑8-oxo-dG  
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Prior R 1995 
Oxidative damage (8-
oxo-dG): Yarborough 
et al 1996    
Krawczu
k-Rybak 
et al. 
(2012) 
Poland 
Weak Survivors: 
ALL, AML, 
NHL, HD and 
solid tumours 
 
Healthy 
controls 
 
Newly 
diagnosed ALL 
 
 
Survivors:  
N=100 
Age 
median(IQR) 
12.7(8.68-
16.55)y 
 
Healthy 
controls  
N=22 
Age 
mean(±SD): 
12.6(±4.79)y 
 
Newly 
diagnosed 
ALL: NR 
 
T:  
Survivors: mean(±SD) 
since cessation of 
treatment  5.3(±2.99)y 
 
Newly diagnosed ALL:  
At diagnosis 
During therapy 
 
M:  
TAS: RANDOX TAs 
kit (Randox, Ardmore, 
U 
K) 
Measurements of the 
Metabolic syndrome 
(MS): 
Weight, height and 
blood pressure: 
conventional 
techniques 
Abdominal obesity: 
Waist to hip ratio 
Biochemical test: 
automated directed 
methods 
 
CC Plasma TAS  
 
  
TAS was ↓ in 
newly 
diagnosed 
ALL 
compared to 
survivors an d 
healthy 
controls  
 
 
 
 
TAS did 
not differ 
between 
survivors 
and 
healthy 
controls 
 
 
Mazor et 
al. (2008) 
Israel  
Weak  ALL 
Solid tumours 
 
Controls 
N= 13 
ALL (n=7) 
Age mean 
(±SD) NR 
T: During treatment 
 
M: 
Oxidative stress: 
CS Antioxidant 
capacity: 
Thiols, FRAP, 
TEAC and 
 Children with 
ALL:  
Thiols (p<0.01) 
and FRAP 
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(healthy adult 
controls) 
Solid tumours 
(n=6) 
Age mean 
(±SD) 
12.5(±5.6)y 
Healthy adult 
controls NR  
 
plasma total thiols: 
DTNB reduction 
method (Miao-Lin H 
1994) 
Radical scavenging 
activity: DPPH method 
(Brand-Williams et al 
1995) 
Antioxidant capacity: 
FRAP method (Benzie 
and Strain 1996) and 
TEAC method (Miller 
et al 1993) 
  
DPPH (p<0.01) were 
↓compared to 
healthy adult 
controls 
Solid tumours: 
thiols, FRAP 
and TEAC were 
normal. 
DPPH was ↓ 
compared to 
controls 
(p<0.01) 
 
Miketova 
et al. 
(2004) 
 
USA  
Moderat
e 
ALL N=21 
Mean (±SD) 
6.26(±2.1) 
Low-risk n=7 
Standard-risk 
n=7 
High risk n=7  
T: diagnosis, induction, 
consolidation and 
continuation treatment  
 
M: PC oxidation from 
the CSF (folch and 
others 1957) 
PCS CSF 
phospholipid 
oxidation  
 
 
At diagnosis; 
non-sig 
difference 
between the 3 
groups 
PC oxidation: 
 
Almost no ↑ in 
the low-risk 
group 
 
Standard risk 2-
fold ↑ 
 
High-risk 3-fold 
↑ 
 
Malvy et 
al. (1997) 
France 
Weak ICCC 
 
Controls 
(healthy 
children) 
Cases n=170 
Age range (0-
16) y  
Mean/median 
age NR 
 
Controls n= 
632 
Age range (0-
16) y 
T: at diagnosis and 6 
months 
 
M: For retinol, alpha-
tocopherol and beta-
carotene: high 
performance liquid 
chromatography assay 
(Malvy et al 1993) 
Zinc and Selenium: 
PCS Micronutrients 
with 
antioxidant 
function: 
retinol, alpha-
tocopherol, 
beta-carotene, 
zinc and 
selenium 
Mean serum 
concentrations 
of retinol, 
beta-carotene, 
alpha-
tocopherol and 
Zinc were sig 
lower in 
cancer patients 
compared to 
Retinol ↑ sig 
during treatment 
 
Zinc ↓ sig 
during treatment 
 
No other 
changes.  
 
Leukaemic  
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Mean/median 
age NR 
 
Atomic absortion 
technique by Neve et al 
1987 
 
Reference values: 
healthy French children 
(control) 
controls. 
 
No sig 
difference in 
Se  
 
 
tended to have 
higher retinol 
and Se levels 
after 6 months 
of treatment  
 
Lymphoma 
patients tended 
to have 
increased retinol 
levels 
 
Brain tumours: 
lower Zn 
 
Bone tumours: 
↓α-tocopherol 
  
Misaki et 
al. (2003) 
Japan 
Weak  ALL 
 
Controls 
(healthy 
children, acute 
infections and 
epilepsy) 
Cases 
Onset n=22 
Mean(±SD) 
5.7(±4.6) 
Remission n= 
18 Mean 
(±SD) 
6.4(±4.5)y  
 
Controls 
n= 22 Mean 
(±SD) 
4.9(±4.0)y 
 
T: at diagnosis and 
remission 
 
M:  
Plasma α-tocopherol: 
Tamai et al 1988 
 
Lipid peroxidation: 
8-isoprostane: Enzyme 
immunoassay (EIA) 
Cayman Chemical, 
Ann Arbor, MI) 
Hoffman et al 1996 
 
Acrolein: EIA 
Hoffman et al 1996 
 
CC Antioxidants: 
α-tocopherol 
(from 
erythrocytes, 
lymphocytes) 
 
Lipid 
peroxidation: 
8-isoprostane 
and acrolein 
 
α-tocopherol 
gene 
expression  
 
 
Erythrocytes 
alpha-
tocopherol did 
not differ 
between the 
three groups 
 
Leukocytes α-
tocopherol 
from untreated 
ALL children 
was sig lower 
than those in 
remission and 
controls 
 
Lipid 
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 peroxidation 
did not differ 
between 
untreated 
patients and 
controls 
 
No sig 
difference was 
found in the 
alpha-
tocopherol 
gene 
expression 
between the 
untreated and 
control 
groups.   
  
Nakagaw
a K. 
(2000) 
Japan  
Weak  ALL 
Healthy 
controls 
ALL on 
treatment n= 
57 Mean 
(±SD) 
9.7(±4.7)y 
 
ALL after 
treatment 
n=16 
Mean(±SD) 
8.7(±3.8)y 
 
Healthy 
controls n=31 
Mean(±SD) 
48(±14.7)y 
T: undergoing 
chemotherapy 
treatment and after 
treatment 
 
M: serum and CSF 
ASA and ASR 
concentrations were 
measured using a stable 
free-radical TEMPOL 
(Wisconsin, USA) 
 
EPR 
CC ASA and ASR 
from CFS and 
serum 
 ASA and ASR 
concentrations 
were higher in 
CSF than serum 
 
ASA and ASR 
in serum and 
CSF good  and 
moderate 
correlation 
(r=0.45; 
p=0.001 and r 
and p=NR): 
indicating that 
oxidation might 
be induced by 
ASA and 
ASR in 
serum and 
CSF in 
patients 
after 
treatment 
were 
similar to 
those 
receiving 
treatment.  
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treatment.  
 
Neyestan
i et al. 
(2007) 
Iran 
Moderat
e 
ALL 
Healthy 
controls 
ALL n= 28 
Range (2-
18)y 
Healthy 
controls n=30 
Range (2-
18)y 
T: undergoing 
treatment 
 
M: blood TAC 
measured using Miller 
et al 1993 method  
and serum and urinary 
vitamin C described in 
the article. Reference 
NR  
CS Blood TAC 
Blood and 
urinary 
vitamin C 
Dietary intake 
 TAC and 
vitamin C 
(serum and 
urine) were 10-
fold and 2.5-
fold higher in 
controls than in 
patients despite 
dietary intake 
being higher in 
patients  
 
Serum TAC was 
lower in patients 
than controls 
 
Nathan et 
al. (2011) 
Malaysia 
Weak  Bone and soft 
tissue sarcoma 
 
Healthy 
controls 
Cases 
N= 90 
Bone tissue 
sarcoma n=27 
Soft tissue 
sarcoma n=20 
 
Controls 
n=40 
Age range (7-
78) y 
T: diagnosis 
M:  
Lipid peroxidation:  
Plasma and urine; 
MDA TBARS 
Protein carbonyl: 
DNPH (Cayman’s kits) 
Antioxidant status: 
Enzyme antioxidants: 
Plasma CAT activity 
(Cayman’s catalase 
activity assay kit) 
PlasmaSOD activity; 
Cayman’s SOD 
activity Assay Kit 
Non-enzymatic 
antioxidants 
Total Thiols; DTNB 
C Plasma lipid 
peroxidation, 
protein 
carbonyl, 
antioxidant 
status (CAT, 
SOD, TEAC) 
Urine and 
plasma MDA 
sig higher in 
sarcoma 
patients 
compared to 
controls 
(p=0.0001) 
 
TEAC 
(p=0.0001) 
and total thiol 
(p<0.05) was 
sig lower in 
sarcoma 
patients 
compared to 
controls  
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(CALBIOChem, USA) 
TEAC: formation of 
ABTS radical (Sigma-
Aldrich Inc., USA)    
 
SOD and CAT 
were sig lower 
in sarcoma 
compared 
patients to 
controls 
(p=0.0001) 
 
Antioxidants 
and lipid and 
protein 
peroxidation: 
not difference 
was seen 
between the 
two types of 
sarcoma.  
Papageor
giou  et 
al. (2004)  
Greece 
Weak Malignant 
diseases (ALL, 
CNS, AML) 
 
Control cancer 
free children 
Cases n=20 
mean(±SD)5.
9±0.5)y 
Control 
cancer free 
children n=80 
mean(±SD) 
6.2(±0.9) 
Is the control 
healthy? 
T: at diagnosis, during 
chemotherapy and 1  
and 6 months after 
completion of therapy 
 
M: TAC and c-TAC 
TAC: TAC kit from 
Medicon SA (Gerakas, 
Greece) 
TAC and cTAC was 
calculated according to 
Kampa et al. 2003   
ROS: cytometry 
according to Rothe et 
al. 1994 
 
PCS TAC and 
cTAC 
ROS 
No sig 
difference 
were observed 
between cases 
and controls 
Sig ↓ of TAC 
(p=0.0007) and 
cTAC 
(p=0.002) 
No sig 
difference 
were 
observed 
between 
TAC and 
cTAC at 
diagnosis 
and at end 
of therapy  
Pazirande Weak  ALL ALL n=40 T: before CT and at PC Se  No sig Se sig ↓ during  
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h et al. 
(1999) 
Iran 
AML 
 
Healthy 
matched 
controls 
AML n= 20 
Age range 3-
8y 
 
Controls Age 
range 3-8y 
day 28 (during CT) 
 
M: Neutron Activation 
Analysis (reference: 
NR) 
difference 
between the 
ALL and the 
control group 
 
AML had sig 
↓ plasma Se 
than the 
control group  
treatment in 
children with 
ALL only 
 
ALL group: 
Se levels pre-
CT 
110.7(±28.3)µg/
L 
Se levels post 
CT 
80.8(±15.5)µg/L 
(p<0.001) 
 
Protas et 
al. (2010) 
Poland  
Weak ALL 
 
Controls 
(children 
diagnosed with 
cerebrospinal 
meningitis) 
Cases n= 38 
mean(range) 
7.6 (2-16) y 
 
Controls 
n=22  
mean(range) 
8.23 (3-17) y 
T: at diagnosis, after 
induction CT, during 
consolidation and 
before maintenance 
therapy 
 
M: TAC measured 
using Antioxidant 
capacity assay 
ImAnOX 
(Immundiagnostic) 
 
Oxidative stressed (8-
Isoprostane) measured 
using 8-Isoprostane 
ImmunoAssay Kit 
(Cayman) 
PC TAC of CSF 
 
Oxidative 
stressed of 
CSF  
CNS 8-
isoprostane 
level 
mean±SD) 
9.05(±1.6)pg/
mL 
 
CNS 8-
isoprostane 
did not sig 
correlate with 
leukocytes, 
organomegaly 
and 
dehydrogenase 
level 
 
TAC level 
mean(±SD) 
203.1(±6.2)μ
mol/L 
CNS 8-
isoprostane 
level sig ↑ at 
every stage: 
After induction: 
mean(±SD): 
24.8(±7.6)pg/m
L (p<0.01) 
Consolidation: 
mean(±SD) 
17.3(±2.2)pg/m
L (p<0.05) 
Before 
maintenace: 
mean(±SD) 
32.3(±7.9)pg/m
L (p<0.01) 
 
TAC level sig ↓ 
after induction: 
mean(±SD) 
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189.8(±6.2) 
μmol/L 
During 
consolidation  
Mean(±SD) 
188.3(±1.9) 
μmol/L 
 
Senturker 
et al. 
(1997) 
Turkey 
Weak  ALL 
 
Controls 
(disease-free 
children) 
Cases n=10  
Age range 3-
12 y 
 
Controls  
n=10 Age 
range 3-12 y  
T: at diagnosis (before 
treatment) 
 
M: blood samples  
CAT activity   
SOD activity 
GPx activity according 
to Beutler 1973, Paglia 
et al. 1967, 
Winterbourn et al. 
1975.  
 
DNA damage 
measured with stable-
labeled analogues and 
chromatography/mass 
spectrometry 
(Dizdaroglu 1994)     
 
CC CAT, SOD, 
and GPx 
activity in 
lymphocytes 
of children 
with ALL 
 
DNA damage 
The levels of 
all three 
enzymes from 
lymphocytes 
in ALL 
patients were 
found to be sig 
lower than 
those of the 
disease-free 
children 
group.  
 
The mean 
values of the 
modified 
DNA bases 
was sig higher 
in ALL than 
controls 
(p<0.05) 
  
Sgarbieri 
et al. 
(2006) 
Weak ALL N= 45 
Median 
(range) age 
5(1-11) y  
T: Diagnosis, 
induction, reinduction, 
and maintenance 
therapy  
 
M: Zn and Cu 
PC Plasma Zn and 
Cu 
concentration 
 
Dietary Zn 
and Cu  
Zn (±SD) 
100.8(±25)μg/
dl (within 
normal range) 
 
Cu 
Zn levels did 
not change 
during treatment 
 
Cu levels ↓ with 
the induction 
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measured using atomic 
absorption 
spectrophotometry  
206(±75)μg/dl 
sig higher than 
normal range 
(p<0.05) 
 
Zn and Cu 
intake was 
24% and 
2%below DRI 
respectively  
 
CT and 
remained stable 
during the rest 
of the treatment  
 
Dietary Zn and 
Cu ↑ during 
induction and 
re-induction 
therapy.   
 
Stachowi
cz-
Stencel et 
al. (2011) 
Poland 
Moderat
e  
STS 
NB 
 
Healthy 
controls 
N=99 
STS n= 47 
median(range
) 10.3(1.5-
21.4) y 
 
NB n=52 
median(range
) 0.9 (0.2 -
17.8) y  
 
Healthy 
controls n= 
30 
median(range
) 8.05(1.4-
17.9) y 
T: before CT and at the 
time of response 
assessment  
 
M:  
SOD in erythrocytes 
assessed according to 
Ransod (Randox, 
Crumlin, UK) 
procedure  
 
GPx assay in 
erythrocytes assessed 
according to Ransel 
(Randox) procedure  
 
Ischaemia modified 
albumin (IMA) 
assessed by 
calorimetric assay 
using dithiothreitol 
(DTT).  
 
Patients stratified 
PC Antioxidant 
enzymes: 
SOD and GPx 
 
Inflammatory 
marker: IMA 
There was not 
statistically sig 
difference in 
the SOD and 
GPx activity 
between cases 
(STS and NB) 
and controls 
 
IMA was sig 
higher in the 
cases than in 
the control 
group 
  
SOD and GSH-
Px was sig 
lower in patients 
who had a poor 
response than to 
those who had a 
good response 
to treatment 
(p=0.04) 
 
SOD and GPx 
did not 
statistically 
differ between 
healthy controls 
and cases who 
had a good 
response 
 
IMA was sig 
higher in cases 
in compared to 
controls  
(p=0.002) 
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according to: 
Good response and 
poor response  
 
Stenzel et 
al. (2010) 
USA 
Strong  ALL N= 87 
mean(±SD) 
7.0(±3.1) y 
Range 3-16 y 
T: at diagnosis, post-
induction , post-
consolidation and end 
of therapy 
 
M: CSF Sample 
phospholipids 
measured according to 
Mawatari et al. 1998 
 
Behavioral measures: 
Behavior Assessment 
System for Children 
(BASC) Reynolds et al. 
1992   
PC CSF 
phospholipids 
(oxidation) 
Sex, age at 
diagnosis, 
treatment, 
SES, IV-MTX 
dose 
 
  
 
At all 3 points 
age-adjusted 
mean T-scores 
for most of the 
individual 
BASC scales 
fell within the 
average range 
  
ALL: acute lymphoblastic leukaemia;ASA: Ascorbate; ASR: Ascorbyl Radical;  C: cohort study; CAT: Catalase; CC: Case control; Ch: Cholesterol; CNS: Central 
Nervous System;CS: cross-sectional study; CSF: Cerebrospinal fluid; CT: chemotherapy; c-TAC: Corrected Total Antioxidant Capacity; Cu: Copper; Dx: 
Diagnosis; EDI: Estimated Dietary Intake; EPR: Electron Paramagnetic Resonance; FFQ: Food Frequency Questionnaire; FRAP: Ferric Reducing Ability of 
Plasma; GPx: Glutathione Peroxidase; HD: Hodgkin’s Disease; HDL: High-density Lipoprotein; ICCC-3: International classification of Childhood Cancer, Third 
edition; LDL: Low-density Lipoprotein; M: method; MDA: Malondialdehyde; MTX: Methotrexade; NA: non-applicable (i.e. not part of study aims); NB: 
Neuroblastoma; NHL: non-Hodgkin’s lymphoma; NR: not reported and/or not clear;  ORAC: Oxygen Radical Absorbance Capacity; PCS: prospective cohort 
study; RDA: Recommended Daily Allowance; SD: standard deviation; Se: Selenium; SES: Socio-economic status; sig: Singificant; SOD: Superoxide Dismutase; 
STS: Soft Tissue Sarcoma; T: time of measurement; TAC: Total Antioxidant Capacity; TBARS: Thiobarbituric Acid Reactive Substances; TCh: Total Cholesterol; 
TEAC: Trolox Equivalent Antioxidant Capacity; TG: Triglycerides; UK: United Kingdom; USA: United States of America; y: years; Zn: Zinc; ↓: decrease; ↑: 
increase.   
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1.4.1.3 Impact of antioxidants and oxidative stress on clinical outcomes 
Table 1.4 describes the results of 8 studies investigating the impact of antioxidant 
status, TAC and oxidative stress on clinical outcomes. Although, most published 
studies agreed that high oxidative stress was associated with poorer outcomes, they 
were very heterogeneous in the outcomes measured (Al-Tonbary et al. 2011, Caron 
et al. 2009, Stenzel et al. 2010). Oxidative stress was associated with increased 
apoptosis (Al-Tonbary et al. 2011), poorer working memory and organization and, 
reduced attention at the end of therapy (Caron et al. 2009). Additionally, Stenzel and 
co-workers (2010) found that higher oxidation was significantly associated with 
increased behavioral problems at the time of treatment and at the end of therapy. 
These studies were all performed in children diagnosed and treated for ALL. 
Although, no studies have investigated oxidative stress in children diagnosed with 
other types of cancer, it is well established that the more serious the injury is the 
greater the stress response will be regardless of the diagnosis (Berger 2005).      
Evidence investigating TAS and TAC and their impact on clinical outcomes 
appeared inconclusive. Two studies found that higher TAS, whether this is intake or 
plasma concentrations, was associated with the following: reduced chemotherapy 
induced side-effects, toxicity, delays in treatment and days of hospital stay as well as 
higher quality of life scores in children diagnosed with ALL  (Kennedy et al. 2004a, 
Kennedy et al. 2005). These findings are consistent with studies performed in adults 
who are also diagnosed and treated for cancer, as reported in a systematic review 
(Ladas et al. 2004). Whilst, no correlation was found between zinc levels at any stage 
of the disease and treatment and prognosis of disease in children diagnosed with 
ALL (Sgarbieri et al. 2006). Similarly, two studies which investigated TAC, 
calculated by measuring the antioxidant enzymes SOD and GPx, found opposing 
results. Reduced TAC was associated with poorer response to therapy in children 
diagnosed and treated for soft tissue sarcoma and neuroblastoma (Stachowicz-
Stencel et al. 2011). Whilst, higher TAC did not reduce signs of the metabolic 
syndrome in children diagnosed with either haematological malignancies or solid 
tumours (Krawczuk-Rybak et al. 2012). Signs of the metabolic syndrome were 
considered when the following parameters were abnormal: BMI, total cholesterol, 
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high density lipoprotein, triglycerides, fibrinogen, fasting glucose, post-prandial 
glucose, fasting insulin and postprandial insulin. Of note, the authors did not report 
the reference values for any of the parameters measured but BMI.  
In conclusion, it appears from the published literature that children diagnosed and 
treated for cancer tend to have reduced plasma TAS, reduced endogenous and 
exogenous TAC and high oxidative stress. This is especially the case at diagnosis 
and during the first months of treatment. The reduction in TAS and TAC was mainly 
attributed to an increase in oxidative stress caused by the disease burden and the 
treatment; however, very few studies examined antioxidant intake, which might have 
been a major confounding factor. Additionally, the literature examining the impact of 
oxidative stress, TAC and TAS on clinical outcomes is heterogeneous in those 
measured, making it very difficult to establish whether these parameters have an 
impact on clinical outcome. Therefore, more research investigating these aims and 
taking into consideration both the weaknesses and strengths found in the published 
studies is warranted.      
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Table 1-4 Impact of antioxidants and oxidative stress on clinical outcomes 
Author Quality Patients Dx N, age 
years  
 
Time of measurement 
and methods 
Method 
 
 Clinical Outcomes 
Design Variables Outcomes  
Al-
Tonbary 
et al. 
(2011)  
Egypt  
Weak ALL 
 
Controls 
(outpatient 
clinic of 
general 
paediatric 
surgery) 
ALL: 
N=50 
Age:  
mean±SD 
(range): 
6.84±3.73 
(1.5-12) y 
 
Controls: 
N=10 
(matched 
for age and 
sex) 
 
T: At diagnosis and after 5 
weeksof treatment  (end of 
induction therapy) 
 
M: Measurement of serum 
TAC (total antioxidant 
capacity): Koracevic et al 
2001 
 
Measurement of MDA 
(measurement of lipid 
peroxidation i.e. oxidative 
stress); 
Satoh K 1978 and Ohkawa 
et al 1979 
 
Apoptosis DeadEnd
TM
 
Fluorometric TUNEL 
System (Promega Corp., 
Madison, WI, USA) 
PCS TAC, MDA, 
apoptosis 
 
NR Apoptosis at 5 weeks was positively 
correlated with MDA (r=0.858; 
p<0.001) and negatively correlated 
with TAC (r=-0.439; p=0.041) 
 
 
Caron et 
al. (2009) 
USA 
Moderate ALL N=88 
Mean(±SD) 
7.1(±3.1)y 
T: from diagnosis to 3 
years 
Diagnosis, post-induction, 
post-consolidation and end 
of therapy 
 
M:  
Oxidised changes in CSF 
PC: Miketova et al 2005 
 
PCS Oxidised 
changes in 
CSF 
 
 
Executive 
functions 
Scores for executive functions were 
higher in ALL patients in compare to 
normative values but did not reach 
significance (p>0.05) 
 
↑ Oxidative stress was associated 
with poorer working memory, poorer 
organization and attention problems 
at the end of therapy (p<0.05) 
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Executive function 
measures: The Behavior 
Rating Inventory of 
Executive Function 
(BRIEF): Gioia et al 2000 
higher scores reflect more 
pathology 
Oxidative stress and higher executive 
dysfunction at post-consolidation 
phase was not sig. associated 
 
Kennedy 
et al. 
(2004) 
Strong ALL N= 103 
Age mean 
(±SD)y 
Standard-
risk 
protocol 
4.7(±2.6)y  
High risk 
protocol 
10.5(±4.6)y 
T: at diagnosis, 3-4 months 
and 6-7 months post 
diagnosis 
 
M:  
Total ascorbate analysis: 
HPLC analysis (Behrens et 
al 1987) 
 
Vitamin A and E: HPLC 
analysis (Bieri et al 1979) 
 
Total carotenoids 
Colorimetric procedure 
(Roels et al 1972) 
  
Dietary intake: 24h recall 
and FFQ 
 
Dietary analysis: 
Minnesota NUTRITION 
DATA SYSTEM (NDS) 
software 
 
Recommended dietary 
allowance (National Health 
and Nutrition Examination 
Survey 2000) 
PCS Total 
ascorbate 
Vitamins A 
and E 
Total 
carotenoids 
HDL and 
LDL Ch and 
TGA 
 
 
 
Side 
effects 
Disease 
status 
 
Association between antioxidants 
intake and CT toxicity: 
↑vitamin intakes was associated with 
↓side-effects  
 
↑β-carotene at 3 months ↓risk of 
toxicity (p=0.04;OR: 0.87; 95% CI: 
0.80-0.96) 
 
↑Vitamin C at 3 months ↓ risk of 
toxicity, delays in CT treatment, days 
in hospital 
 
After Bonferroni’s adjustment for 
multiple side-effect comparisons for 
each nutrient intake only ↑mean 
intakes of β-carotene ↓ risk of 
toxicity (p=0.002) 
  
Vitamin C and E intakes were 
associated with plasma antioxidants, 
but vitamin A and total carotenoid 
were not  
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Plasma antioxidant cut-off 
values NR   
  
Kennedy 
et al. 
(2005)  
Strong   ALL N= 103  
Age mean 
(±SD)y 
Standard-
risk 
protocol 
4.7(±2.6)y  
High risk 
protocol 
10.5(±4.6)y  
T: at diagnosis, 3-4 months 
and 6-7 months post 
diagnosis 
 
M: Total ascorbate 
analysis: HPLC analysis 
(Behrens et al 1987) 
Vitamin A and E: HPLC 
analysis (Bieri et al 1979) 
Total carotenoids 
Colorimetric procedure 
(Roels et al 1972) 
Antioxidant capacity 
(ORAC): Cao G and Prior 
R 1995 
Oxidative damage (8-oxo-
dG): Yarborough et al 
1996    
PCS Exogenous 
antioxidants 
(vitamins A 
and E, 
carotenoids) 
Antioxidant 
capacity 
Oxidative 
stress 
 
 
Antioxidan
t 
concentrati
on and 
response to 
CT 
 
Antioxidan
t 
concentrati
on and CT 
toxicity 
After Bonferroni adjustment for 
multiple comparisons:  
   
↑TCar/Ch was associated with 
↓hospital stay at 3-4 months 
(p=0.001) 
 
↑ Vitamin E/Ch associated with 
↑need of NS (p=0.007) 
 
↑plasma vitamin A was associated 
with both ↑QoL score (p=0.009)) 
 
Low plasma total carotenoid 
associated with ↑ toxicity   
Krawczu
k-Rybak 
et al. 
(2012) 
Weak Survivors: 
ALL, AML, 
NHL, HD 
and solid 
tumours 
 
Healthy 
controls 
 
Newly 
diagnosed 
ALL 
 
Survivors:  
N=100 
Age 
median(IQ
R) 
12.7(8.68-
16.55)y 
 
Healthy 
controls  
N=22 
Age 
mean(±SD)
T:  
Survivors: mean(±SD) 
since cessation of 
treatment  5.3(±2.99)y 
 
Newly diagnosed ALL:  
At diagnosis 
During therapy 
 
M:  
TAS: RANDOX TAs kit 
(Randox, Ardmore, U 
K) 
CC Plasma TAS,  
 
  
Signs of 
metabolic 
syndrome 
measured 
as: BMI, 
TCh, 
HDL, TG, 
fibrinogen, 
fasting 
glucose, 
post-
prandial 
glucose, 
TAS levels did not correlate with MS 
parameters  
 
TAS and TG were positively 
correlated (p=0.02; r=0.24)  
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 : 
12.6(±4.79)
y 
 
Newly 
diagnosed 
ALL: NR 
 
Measurements of the 
Metabolic syndrome (MS): 
Weight, height and blood 
pressure: conventional 
techniques 
Abdominal obesity: Waist 
to hip ratio 
Biochemical test: 
automated directed 
methods 
 
fasting 
insulin, 
post-
prandial 
insulin 
Sgarbieri 
et al. 
(2006) 
Brazil 
Weak ALL N= 45 
Median 
(range) age 
5(1-11) y  
T: Diagnosis, induction, 
reinduction, and 
maintenance therapy  
 
M: Zn and Cu measured 
using atomic absorption 
spectrophotometry  
PC Plasma Zn 
and Cu 
concentratio
n 
 
Dietary Zn 
and Cu  
Prognosis 
of disease 
In this study Zn and Cu have been 
investigated to find out whether these 
two markers can be used as 
prognostic factor- 
 
No correlation was found.  
 
 
Stachowi
cz-
Stencel et 
al. (2011) 
Poland 
Moderate  STS 
NB 
 
Healthy 
controls 
N=99 
STS n= 47 
median(ran
ge) 
10.3(1.5-
21.4) y 
 
NB n=52 
median(ran
ge) 0.9 (0.2 
-17.8) y  
 
Healthy 
controls n= 
30 
median(ran
T: before CT and at the 
time of response 
assessment  
 
M:  
SOD in erythrocytes 
assessed according to 
Ransod (Randox, Crumlin, 
UK) procedure  
 
GPx assay in erythrocytes 
assessed according to 
Ransel (Randox) procedure  
 
Ischaemia modified 
albumin (IMA) assessed by 
PC Antioxidant 
enzymes: 
SOD and 
GPx 
 
Inflammator
y marker: 
IMA 
Response 
to 
treatment 
Authors conclude that SOD and GPx 
can be used as a marker to predict 
outcome (response).  
 
Issues with this: 
-Not sig diff between healthy controls 
and cases at diagnosis 
 
-Authors have not stratified the 
groups GR and PR at both stages 
diagnosis and after treatment, so how 
can they know that these two 
parameters are good markers if they 
only show that SOD and GSH-Px are 
lower after the response to 
treatment?  
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ALL: acute lymphoblastic leukaemia; ASA: Ascorbate; ASR: Ascorbyl radical; BMI: body mass index; C: cohort study; CAT: Catalase; CNS: central nervous 
system; CSF: cerebrospinal fluid; CS: cross-sectional study; CT: chemotherapy; DRI: dietary recommended intake; Dx: Diagnosis; EDI: estimated dietary intake; 
EPR: electron parametric resonance; FFQ: food frequency questionnaire; FRAP: Fluorescence recovery after bleaching; GPx: Glutathione peroxidase; HDL: high 
density cholesterol; ICCC: International classification of Childhood Cancer; M: method; MDA: melondialdehyde; MTX: methotrexate; NA: non-applicable; NR: 
not reported and/or not clear; ORAC: Oxygen radical absorbance capacity; PC: prospective cohort study; PCp: Phosphatidylcholine; RC: retrospective cohort 
study; ROS: reactive oxygen species; SD: standard deviation; SES: socioeconomic status; Sig: significant; SOD:Superoxide dismutase; T: time of measurement; 
TAC: total antioxidant capacity; TAS; total antioxidant status; TCh: total cholesterol; TEAC: Trolox equivalent antioxidant capacity; TG: triglycerides; Y: years; ↓: 
decrease; ↑: increase.  
 
ge) 
8.05(1.4-
17.9) y 
calorimetric assay using 
dithiothreitol (DTT).  
 
Patients stratified 
according to: 
Good response and poor 
response  
 
Stenzel et 
al. (2010) 
USA 
Strong  ALL N= 87 
mean(±SD) 
7.0(±3.1) y 
Range 3-16 
y 
T: at diagnosis, post-
induction , post-
consolidation and end of 
therapy 
 
M: CSF Sample 
phospholipids measured 
according to Mawatari et 
al. 1998 
 
Behavioral measures: 
Behavior Assessment 
System for Children 
(BASC) Reynolds et al. 
1992   
PC CSF 
phospholipid
s (oxidation) 
Sex, age at 
diagnosis, 
treatment, 
SES, IV-
MTX dose 
 
 
BASC  
 
Sig association between IV-MTX and 
behavioral pathology at post-
consolidation (p<0.01) and end of 
therapy Leadership skills (p<0.05) 
 
Younger age at diagnosis was sig 
associated with more aggression at 
the end of therapy (p<0.01) 
 
Higher PC oxidation fraction was sig 
associated with more problems in 
post-consolidation  (r= 0.42; 
p<0.01)and end of therapy  (r=0.49; 
p<0.01) 
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1.4.2 Omega-3 and omega-6 fatty acid status of paediatric cancer patients   
Like antioxidants, the health benefits of omega-3 fatty acids have extensively been 
researched in vitro, in animal and in human studies, primarily in healthy subjects 
(van der Meij et al. 2011), but a very limited number of studies have 
comprehensively investigated this in children with cancer. Long chain 
polyunsaturated omega 3 fatty acids (LC n-3 PUFA) and omega 6 fatty acid (LC n-6 
PUFA) are essential fatty acids as they are not synthesised de novo and they need to 
be supplied from the diet (Lorente-Cebrián et al. 2013). Linoleic acid, the most 
abundant n-6 LC-PUFAs in the western diet, is a precursor of arachidonic acid (AA). 
AA is a potent precursor of inflammatory markers (Lorente-Cebrián et al. 2013). 
Whereas, the main LC n-3 PUFAs are docosahexaenoic acid (DHA), 
eicosapentaenoic acid (EPA), which are found in oily fish, and α-linolenic acid, 
which is found in some vegetables oils, (Lorente-Cebrián et al. 2013). Both DHA 
and EPA are anti-inflammatory fatty acids (van der Meij et al. 2011, Lorente-Cebrián 
et al. 2013).  
In addition, DHA and EPA have a structural role in cell membranes: DHA is the 
most abundant fatty acid in neural cells and they are both incorporated in 
phospholipids of all body cell membranes. A balance between LC n-3 PUFA and LC 
n-6 PUFA is necessary for homeostasis of the immune system and optimal body and 
brain development. This is especially the case in younger children (Gleissman et al. 
2011). However, excessive LC n-6 PUFA has been associated with long term mild 
inflammation, which in turn may increase the risk of many chronic diseases, 
including CVD, cancer, rheumatoid arthritis and mental disorders (van der Meij et al. 
2004; Lorente-Cebrián et al. 2013). In contrast, recent evidence show that DHA is 
essential for neural development (Gleissman et al. 2011) and may prevent cancer 
development as DHA may act as an inhibitor of malignant cell growth in vitro 
(Larsson et al. 2004, Greene et al. 2011). Additionally, due to their anti-inflammatory 
properties, EPA and DHA are thought to protect against CVD, cancer and some 
autoimmune conditions, including rheumatoid arthritis (Lorente-Cebrián et al. 2013).  
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Although, LC n-3 PUFAs have anti-inflammatory properties and thus they are 
beneficial for healthy individuals in the prevention of cancer (Greene et al. 2011, 
Lorente-Cebrián et al. 2013), there are many factors at interplay in children treated 
for cancer that affects the immune system. Also, the degree to which DHA and EPA 
suppress inflammation in this population and whether this is beneficial is yet to be 
established. As discussed in section 1.3 the immune system is affected by the disease 
and the use of glucocorticoids, chemotherapy and radiotherapy as well as the use of 
non-steroidal anti-inflammatory drugs (NSAID). All these factors have dichotomous 
effects in the immune system; anti-inflammatory and pro-inflammatory.  
The use of immunosuppressants drugs, primarily glucocorticoids, on the one hand 
inhibits the immune system by inhibiting the transcription of genes that code for the 
up-regulation of inflammation (AP-1 and NF-κB). On the other hand, dexamethasone 
might interfere with the metabolism of PUFA by inhibiting the endogenous synthesis 
of LC n-3 PUFA to EPA and DHA (Marra et al. 1986). The ratio of AA/DHA (and 
AA/EPA) and the subsequent inflammatory markers would increase. Methotrexate, a 
folate antagonist drug, causes bone marrow toxicity, which results in a reduction in 
leukocyte synthesis and an increased susceptibility to infection. In contrast, its toxic 
effects on healthy cells induce an inflammatory response (Rang, et al. 2003). EPA 
and DHA have also been shown to inhibit NF-κB, which might further inhibit 
inflammation (Calder 2010) (see figure 1.7 for detail). In contrast, the disease itself 
and the toxic effects of the chemotherapy and radiotherapy stimulate an anti-
inflammatory response due to the destruction of normal body cells (Lorente-Cebrián 
et al. 2013, Larsson et al. 2004).  
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Figure 1.7 Effects of Corticosteroids, NSAID and DHA on inflammation 
 
Evidence regarding the protective role of LC n-3 PUFA in cancer prevention and 
treatment is emerging (Greene et al. 201, van der Meij et al. 2011). However, there is 
limited epidemiological data reporting plasma PUFA status in children with cancer 
and no studies have been published investigating the efficacy of PUFAs 
supplementation in this population. Of note, animal and human studies have 
demonstrated that PUFAs, especially DHA, can be used as vectors for anti-cancer 
agents, and consequently being more specific and target cancerous cells (Wang et al. 
2013). This has been attributed to their lipophilic nature and their readiness to be 
incorporated into cell membranes, especially from tumour cells (Gleissman et al. 
2011). Furthermore, a recent systematic review reported that there is a large body of 
evidence published investigating the efficacy of LC n-3 PUFA, DHA or EPA 
supplementation in adults diagnosed and treated for cancer (van der Meij et al. 2011). 
Evidence reporting plasma PUFA in cancer patients is contradictory. Only one 
epidemiological study found in the literature investigated the profile of PUFA in 12 
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children diagnosed with CNS, bone and abdominal tumours and having received at 
least one month of chemotherapy. Plasma PUFA was compared with a healthy 
matched control. Plasma EPA and α-linoleic acid was lowered than in the control 
group; however, plasma DHA was not significantly reduced (de la Torre Aguilar et 
al. 2012). In contrast, the plasma DHA and EPA of 47 adults diagnosed with NHL 
were found to be lowered than the healthy controls (Cvetkovic et al. 2010). Notably, 
none of the two studies reported significant differences in lipid intake (Cvetkovic et 
al. 2010; de la Torre Aguilar et al. 2012).  With regards to the efficacy of LC n-3 
PUFA supplementation in adults with cancer, the systematic review concluded that 
supplementation, given as ONS, capsules or NG-feeding, increased plasma DHA and 
EPA in most studies. It also appeared to have beneficial effects on the clinical 
outcomes body weight and quality of life. All the other clinical outcomes measured; 
morbidity, mortality and Karnofsky Performance Status, were inconsistent (van der 
Meij et al. 2011).  
In summary, it appears that supplementation of LC n-3 PUFA, especially DHA and 
EPA, might be beneficial in adults with cancer; however, there is very limited 
published evidence in children. Before supplementation is implemented in children 
with cancer, more research looking at the following is urgently warranted: 
epidemiological studies assessing plasma PUFAs status and the impact of PUFAs on 
clinical outcomes, including: morbidity, mortality, side-effects, infections and 
survival. Also, measurements of growth and development should be monitored. 
Finally, well designed RCT investigating the effectiveness of different forms of 
supplementation, in which doses of PUFAs are taken into consideration, are justified.    
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1.5 NON-ANTIOXIDANT MICRONUTRIENT STATUS OF PAEDIATRIC 
CANCER PATIENTS 
In addition to plasma vitamins and minerals with antioxidant function, there are other 
micronutrients, which reflect nutritional status and are essential to maintain healthy 
biological functions. These are also likely to be affected by the cancer and its 
associated treatment. Thus this section will review published studies of paediatric 
cancer patients reporting micronutrient status.  
1.5.1 Vitamin D   
Results from phase I of this project showed that a large percentage of children and 
adolescents diagnosed and treated for cancer in South East Scotland were classified 
as either vitamin D (25(OH)D) deficient (25(OH)D <25nmol/L) or insufficient 
(<50nmol/L). At this stage of the study, there were 16 patients with available vitamin 
D results. Of these, 5 (31%) were deficient and 7 (44%) insufficient at the time of 
diagnosis, thus a total of 75% (12/16) had 25(OH)D inadequacy (levels below 
insufficiency) at diagnosis (Paciarotti I 2013). Although these were preliminary 
results, it showed that vitamin D inadequacy in this population was much higher than 
that reported in healthy children from the UK (19%) (Department of Health 2012). 
Additionally, a pattern appeared to emerge whereby solid tumours showed higher 
levels of 25(OH)D inadequacy (44%) than children diagnosed with haematological 
malignancies (31%). However, 25(OH)D levels decreased in the solid tumours and 
increased in the haematological group during the course of treatment. This was 
attributed to the use of steroids and to the large percentage of obesity seen in children 
diagnosed with haematological malignancies, mainly ALL (Paciarotti I 2013).  
As a consequence of these findings, a systematic review was planned at the start of 
phase II. The main aims of this were to establish worldwide vitamin D levels in 
paediatric oncology patients at different stages of the disease and treatment, to 
investigate the possible causes of vitamin D inadequacy in this population and to 
finalise by comparing the findings from the systematic review and those obtained 
from paediatric oncology patients from SE Scotland. This will be fully described in 
chapter III, section 2.2.   
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1.5.2 Other micronutrients 
To date, there is not a single published study investigating the plasma concentration 
of B vitamins, vitamin K and folic acid in paediatric cancer patients. However, there 
is a paucity of evidence investigating vitamin B12 (Carmel and Eisenberg 1977, 
Carmel 1975, Coltman et al. 1975, Vlasveld LT. 2003) and folic acid in adults 
diagnosed and treated for cancer (Carmel and Eisenberg 1977, Vlasveld LT. 2003). 
In addition, no study has investigated iron status either by measuring total iron 
binding capacity in acute patients, ferritin after the completion of therapy or ferritin 
in acute patients to detect iron overload, which threshold has been set at >1000 μg/L 
(Henter et al. 2007, Schrappe & Pieters 2004).  
The few studies reporting plasma vitamin B12 (cobalamin) in adults diagnosed and 
treated for cancer have shown that although most patients have levels within the 
normal range, a significant percentage has both low and high levels. For instance, 
Carmel and Eisenberg (1977) investigated plasma vitamin B12 and transcobalamin, 
which is a vitamin B12 binding protein, in 139 patients diagnosed with solid 
tumours. Of these, 69% did not present with any vitamin B12 anomalies; however 
11% had elevated levels and 10% had low levels. Similarly, Vlasveld (2003) found 
that of the 32 patients diagnosed with multiple myeloma who had also undergone 
treatment, 66% had normal plasma vitamin B12 levels, whilst 28% and 6% had low 
and elevated levels respectively. Both studies (Carmel & Eisenberg 1977, Vlasveld 
2003) also investigated plasma folic acid, which was found to be within the normal 
range.  
In health, serum ferritin is a useful marker for the assessment of iron stores. In 
paediatric cancer patients, particularly in ALL, the interpretation of ferritin as an iron 
marker is complicated by elevation due to leukaemic synthesis of ferritin by blasts, 
acute phase response, or rare macrophage activation syndromes such as 
haemophagocytic lymphohistiocytosis (HLH), which is defined by fulfilment of five 
out of eight criteria: ferritin>500μg/L, fever, splenomegaly, cytopenias, 
hypertriglygeridemia or hypofibrinogenemia, haemophagocytosis, low NK cell 
activity and/or raised soluble CD25. Identifying iron overload accurately, especially 
in the context of ALL has clinical importance. Ferritin levels >1,000 μg/L are 
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considered indicative of iron overload, corresponding to a level at which chelation 
therapy is advised like in chronic haemolytic anaemia (Henter et al. 2007, Schrappe 
& Pieters 2004). However, no studies have assessed this in the context of nutrition.  
From this limited body of evidence two conclusions can be made. Firstly, it appears 
that plasma vitamin B12 might be affected in cancer patients. Secondly, it is clear 
that more research is urgently warranted in order to elucidate whether cancer and its 
associated treatment affects the micronutrient status of this population.             
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1.6 NUTRITIONAL MANAGEMENT IN CHILDREN AND YOUNG 
PEOPLE WITH CANCER: CURRENT PRACTICE  
The nutritional management of hospitalised children and adolescents, including those 
diagnosed with and treated for cancer, is vital to reduce the risk of malnutrition and 
allow optimal growth and development. This in turn is thought to reduce hospital 
stay and the risk of morbidity and mortality (Donaldson et al. 1981, Mejía-Arangure 
et al. 1999, Sala et al. 2004, Agostoni et al. 2005). Despite this the ESPGHAN 
committee, based on a report from the council of Europe published in 2002 (Beck et 
al. 2002), concluded that there were major issues across Europe related to the 
nutritional management of paediatric patients, including cancer patients (Agostoni et 
al. 2005b). For instance, routine nutritional risk screenings and assessments were 
often not implemented, the responsibility for food services and nutritional care was 
not clearly assigned and members of staff were not appropriately trained regarding 
clinical nutrition. Additionally, food intake was not appropriately recorded and 
allocated meal times were inflexible (Beck et al. 2002, Agostoni et al. 2005).  
Prior to the ESPGHAN report, an audit exploring the nutritional management of 
children and adolescents admitted and treated in the Haematology/Oncology ward 
from the RHSC Edinburgh, was performed. From this audit, the following issues 
were raised: (i) there was not a systematic approach to screening for malnutrition and 
the referrals were not designated to one specific team, thus this was done on an ad 
hoc basis creating confusion between members of staff; (ii) 70% of growth charts 
were incomplete or were missing and most children did not have weights and heights 
taken; (iii) the mean length of time between diagnosis and referral was 2.7 weeks and 
by that time the patients had already lost 7.6% of total body weight. Furthermore, by 
the time the patients were seen by a dietitian a further 5.9% weight loss had occurred 
(total weight loss 13.5%) (Holt 2003). These reports highlighted the need for 
introducing a systematic approach to patients screening and the need for 
multidisciplinary nutrition support teams. Thus, at present a screening tool 
specifically designed for the general paediatric population is in used in the RHSC 
Edinburgh; the Paediatric Yorkhill Malnutrition Score (PYMS). Additionally, the 
Subjective Global Assessment (SGA), originally designed by Detsky and co-authors 
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(1987), is also currently being used for the assessment of nutritional status and for 
the implementation of nutritional support; despite the publication of a recent updated 
model (see figure 1.8) advising on the nutritional management of children and adults 
(BDA 2012), which proceeds the general nutritional management pathway (Elia 
2005). Although the above changes have gradually been implemented, nutritional 
screening and management remains difficult in this population and the reasons for 
this will be discussed in this section.    
 
Figure 1.8 Model and process for Nutrition and Dietetic Practice (obtained from 
BDA 2012).  
1.6.1 Where are we with the nutritional screening tools? 
Nutritional screening is fundamental to identify patients who are malnourished or at 
risk of developing malnutrition to subsequently be referred to a nutrition specialist 
team if necessary (BDA 2012). Unlike adults, at present there is no universally 
accepted screening tool to identify the risk of malnutrition specifically designed for 
the unique paediatric oncology population (Attard-Montalto et al. 1998, Sermet-
Gaudelus et al. 2000). However, four non-disease specific nutritional screening tools 
have been developed to identify both children at risk of undernutrition and 
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undernourished and all are widely used in hospitals: the Screening tool for 
Assessment of Malnutrition in paediatrics (STAMP) developed and used in England 
(McCarthy et al. 2012); the Paediatric Yorkhill Malnutrition Score (PYMS) 
developed and used in Scottish hospitals (Gerasimidis et al. 2010); the Screening tool 
for Risk on Nutritional status and Growth (STRONG kids) developed and used in the 
Netherlands (Hulst et al. 2010). Finally, the Simple Paediatric Nutrition Risk 
(PNRS), which was developed in France and designed to be used in hospitalised 
children (Sermet-Gaudelus et al. 2000). These tools are simple and easy to use tools 
and are based on severity of disease, percentage weight loss, BMI and dietary intake 
with some variations between each screening tool. Nevertheless, a number of issues 
can be raised when these are applied to paediatric cancer patients: (i) all tools either 
included a very small sample of children with cancer (PYMS: 2.4% (38/1571); 
STRONG kids: 3% (12/296); PNRS: 4% (12/296)), or the diagnosis was not 
mentioned (STAMP: n=360 medical and surgical) making them unlikely to be 
representative and applicable to this unique population; (ii) Every child diagnosed 
with cancer and receiving any of the cancer therapies would be considered at high 
risk of undernutrition, which could increase the number of false referrals. (iii) 
Finally, all tools screen for undernutrition, whilst overnutrition is overlooked.   
Attempts have been made to either develop disease specific nutritional tools or to 
validate current ones. For instance, the Subjective Global Nutritional Assessment 
(SGNA), which is an adaptation of the SGA originally designed by Detsky and co-
authors (1987), was validated in children who were having major abdominal and 
thoracic surgery (Secker and Jeejeebhoy 2007). This tool was later proved to be too 
complicated and time consuming to use in clinical practice (Joosten & Hulst 2011). 
Additionally, the STAMP has been validated in children with a spinal cord injury 
(n=62) (Wong et al. 2012) and the STAMP, PYMS, STRONG kids and PNRS in 
children diagnosed with inflammatory bowel disease (n=46) (Wiskin et al. 2012). 
Therefore it can be seen that none of them have been validated in the paediatric 
oncology population. Of note, a few have been performed in adults with cancer 
undergoing specific treatments (Ferguson et al. 1999, Bozzetti 2009).         
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1.6.2 Nutritional assessment of paediatric cancer patients 
In section 1.2.1 both the methods of nutritional assessment and published UK 
standards to assess the nutritional status of healthy children and young people were 
discussed in depth. Thus, this section will focus on the practical aspects and current 
practice when assessing the nutritional status of paediatric cancer patients following 
the model proposed by the BDA (2012).        
 1.6.2.1 Assessment of growth and body composition  
At present, a standard measure that best determines growth in children with cancer is 
lacking; however, most physicians worldwide and in the Edinburgh RHSC rely on 
BMI, weight and linear growth patterns (Sala et al. 2004). Additionally, although 
reliable methods exist to assess the body composition in both healthy children and 
children with cancer, these are not routinely performed in paediatric cancer patients. 
Also, they all have its strengths and limitations.   
BMI is the assessment of growth most widely used in clinical practice. BMI is easy 
to calculate from weight and height, does not require high level of skills, it is 
inexpensive and internationally recognised (Cole et al. 1995; Sala et al. 2004; Cole et 
al. 2007; Brinksma et al. 2012); however, it can be misleading in many children with 
cancer (Sala et al. 2004). As it has previously been discussed the weight of a solid 
tumour in infants and younger children can account for up to 10% of total body 
weight, the effects of many chemotherapeutic agents can cause oedema and 
glucocorticoids stimulate both proteolysis and lipolysis (BNF 2009). This causes a 
reduction in FFM and an increase in abdominal FM, which can lead to protein energy 
malnutrition (Brennan 1998, Sala et al 2004, Sala, Pencharz & Barr 2004, Collins et 
al 2010). As BMI measures body surface only, none of these factors are taken into 
consideration and many malnourished paediatric cancer patients can either be 
undiagnosed or misdiagnosed (Sala et al. 2004).    
MUAC and TSF are not routinely performed in clinical practice in the RHSC, 
Edinburgh. These two measurements are inexpensive and non-invasive (Norton & 
Olds, 1996); however a high level of skill, which is achieved by training, is needed to 
reduce intra- and inter-error of measurement by the anthropometrists in order to 
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obtain accurate measurements. Despite this, these two measurements have the 
following advantages over BMI in this population; it allows for the calculation of 
FFM and FM, providing more information regarding body composition changes and, 
it is generally less affected by oedema and tumour mass (White et al. 2011, Garófolo 
et al. 2005, Oguz et al. 1999) 
Like MUAC and TSF, BIA is not used routinely to estimate the body composition of 
paediatric cancer patients from the RHSC, Edinburgh. Although it is non-invasive, 
inexpensive and painless and thus a potential practical tool in clinical practice, its use 
has been argued due to a lack of a standard TBW equation from which FFM% and 
FM% can be calculated. At present, there is only one TBW equation developed from 
a paediatric cancer cohort (Brennan et al. 1997). The authors attempted to validate a 
TBW equation by comparing measurements obtained from BIA, TSF and deuterium 
water dilution from a cohort of 40 children diagnosed with any malignancy. BIA was 
found to have a similar precision to the deuterium water dilution method; however it 
had wide limits of agreement (-2.46 to 4.06), which was attributed to the small 
sample size (Brennan et al. 1997) and perhaps due to the diversity in cancer 
diagnosis included. Dramatic changes in weight and shifts in fluid distribution also 
occurred as a result of the metabolic response to cancer and its treatment, which 
altogether may lead to inaccurate readings (Kyle et al. 2004a, Kyle et al. 2004c). 
Finally, reference values of FFM% and FM% of healthy children from which to 
compare the data are limited (Fomon et al. 1982, Laurson et al. 2011, Wells et al. 
2012) and not without limitations. The main issues identified are the following: age 
range is not always available from birth to adulthood (19-20 years) (Fomon et al. 
1982; Laurson et al.2011; Wells et al. 2012); the reference value was developed from 
only one subject (Fomon et al. 1982); FFM% and FM% were not always obtained 
from gold standard methods and some provided reference values only for FM%, but 
not for FFM% (Laurson et al. 2011). Despite these limitations, the use of BIA might 
be of value in prospective cohort studies where the aim is to investigate changes in 
body composition as a result of cancer and cancer therapy.    
Presently, none of the discussed methods taken in isolation appear to provide with an 
accurate picture of growth and body composition in paediatric cancer patients during 
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the course of treatment. However, if taken in conjunction at diagnosis, over the 
course of treatment and post-treatment, they perhaps would help to elucidate the 
nutritional status changes that occur in this population. Thus, allowing for a more 
comprehensive nutritional assessment and consequently more tailored nutritional 
support.              
1.6.2.2 Assessment of dietary intake  
The dietary intake assessment of paediatric oncology patients in clinical practice and 
in research is performed by using several methods and these vary depending on the 
objective and feasibility of the assessment. The methods most commonly used are, 
24-hour dietary recall (Delbecque-Boussard et al. 1997, Delbecque-Boussard et al. 
1997, Kennedy et al. 2004a), diet histories (Bond et al. 1992, Carter et al. 1983, 
Todorovic.& Micklewright 2007) and three to seven days diet diaries (unweight or 
weighted food records) (Brinksma et al. 2014, Burrows et al. 2010, Skolin et al. 
1997). All of these methods carry strengths and limitations with them, but the most 
common ones in children are misreporting and under-reporting (Burrows et al. 2010) 
and micronutrients inaccuracies (Kennedy et al. 2005). A 24-hour dietary recall 
involves the recording of everything a subject has eaten and drunk the day before in 
as much detailed as possible. It is considered quick, simple and tends to cause 
minimal burden to patients or carers. Also, in healthy children aged between 4-11 
years it has proved to be the most accurate when this is compared to the gold 
standard (doubly labeled water) (Burrows et al. 2010). However, its use for pre-
school children (3-4) has been questioned as it is been shown to overestimate energy 
intake (Reilly et al. 2001). Unlike healthy children, children with cancer experience 
changes on dietary habits as a result of the disease and the treatment induced side-
effects; thus, this method might not show these changes (Selwood et al. 2010). 
Nevertheless, its use becomes more reliable when it is used on alternative occasions 
to assess long term dietary patterns. Consequently, it is the preferred tool for 
population based prospective studies (Thomas & Bishop. 2009, Burrows et al. 2010, 
Jain et al. 1980). A diet history is generally the method of choice by dietitians to 
assess the dietary intake of an individual in clinical practice (Bingham 1987). The 
interviewer not only asks about the dietary intake of the previous 24 hours, but also 
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asks about usual eating patterns (Thomas & Bishop 2009, Burrows et al. 2010, Jain 
et al. 1980). This method requires high level of expertise, is time consuming and 
difficult to standardise (Bingham 1987). For that reason it is often not used for 
research purposes, yet it has been proved to be the most accurate for the assessment 
of teenagers’ energy intake (Burrows et al. 2010). Finally, unweight and weighted 
diet diaries require the child or carer to record and weight respectively everything 
that is eaten and drunk over a period of time (Bingham 1987). This method is 
popular in clinical trials involving healthy subjects and in children under the age of 4 
(Burrows et al. 2010); but, in prospective cohort studies involving children diagnosed 
and treated for cancer, this method is too troublesome and diet diaries are generally 
not returned (Paciarotti 2013).  
1.6.3 Nutritional Support: current practice  
Nutrition support aims to prevent, maintain or restore body stores to allow for 
optimal growth and development (Selwood et al. 2010, Bauer et al. 2011), yet in 
cases of severe disease and intensive treatment, the aim might be to minimise 
wasting (Bauer et al. 2011). Appropriate nutritional support also aims to improve 
tolerance of therapy by reducing treatment induced side-effects and, reduce the risk 
of infections, to ultimately improve clinical outcomes and quality of life (Bauer et al. 
2011, Selwood et al. 2010). However, the nutritional support of paediatric cancer 
patients presents many challenges due to the large spectrum of cancer diagnoses, the 
intensive treatments and the lack of specific nutritional guidelines specific to this 
population. In addition to these, the estimation of many nutrients had to be 
extrapolated from the dietary reference values from the adult population as these 
were not available for children and young people (Department of Health 1991, 
SACN 2011). Specific nutrient requirements for the paediatric oncology population 
is not available either (Bauer et al. 2011), making it difficult to estimate accurate 
energy and micronutrient requirements to provide appropriate nutritional support 
(Todorovic & Micklewright 2007, Department of Health 1991). Recently, new 
dietary reference values have been published and this includes reference data for 
healthy infants, children and young people, which were unavailable before (SACN 
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2011). These are not currently used as a reference for the calculation of nutrient 
requirements in the oncology population of SE Scotland yet.   
Nutritional support is defined as “the administration of nutrients in place of or in 
addition to that provided by normal eating” (Jones et al. 2010). The route of feeding 
is decided by either a dietitian only or the multidisciplinary team following a 
thorough clinical and nutritional assessment. There are two routes: the enteral route 
and the parenteral route, but sometimes a combination of the two might be needed 
(advanced nutritional support). The enteral route involves the alimentary tract and 
the parenteral route is the direct administration of nutrients to the blood via 
intravenous feeding, thus it bypasses the alimentary tract. Enteral nutrition includes 
oral nutrition support (ONS), but most often indicates the use of enteral tube feeding 
(ETF) like a nasogastric (NG), nasojejunal (NJ), gastrostomy (PEG) or jejunostomy 
(PEG-J) tube feeding (NICE 2006).    
A paucity of evidence has examined the use of nutritional support in paediatric 
oncology patients (Brinksma et al. 2014, Paciarotti I 2013), even though 
malnutrition, especially undernutrition, has been reported to be an issue for a long 
time (Sala et al. 2004). Also, most studies have focused on the effectiveness of 
specific nutritional treatments on the nutritional status of this population or compared 
the effectiveness of EN and PN; as described by a recent systematic review (Jones et 
al. 2010). For the purpose of this review only studies examining the use of nutritional 
support in cohort studies will be discussed. Only two were found. A retrospective 
cohort study performed in SE Scotland, in which data from 168 paediatric cancer 
patients was available, showed that this population had high needs for nutritional 
support. 44% (74/168) required any form of nutritional support. Of these 57/74 
(77%) required ETF, 40/74 (54%) ONS and 32/74 (43%) PN. Additionally, the 
diagnoses that most required nutritional support were AML and neuroblastoma 
(75%) followed by malignant bone tumours (67%) and CNS malignancies (57%). No 
significant difference in weight SD was obtained before and after nutritional support, 
indicating that nutritional support was effective; however, the author highlighted that 
these results could have been due to the large number of missing data. Similarly, 
Brinksma et al. (2014) in a prospective cohort study (1 year follow up) performed in 
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the Netherlands, in which 133 paediatric cancer patients were included, reported that 
45% of these patients required NG feeding at some point during the first year of 
treatment. Interestingly, only one child required PEG feeding and none of the 133 
children required PN (Brinksma et al. 2014). The study reported an increase in 
weight and FM% with a tendency to obesity, which was attributed to low physical 
activity rather than energy intake. Of note, neither the effectiveness of nutritional 
support nor the types of cancers requiring more nutritional support was reported; yet 
these were not part of the study’s objectives.  
The most important conclusion in regards to the use of nutritional support in 
paediatric cancer patients is the need for more UK and worldwide epidemiological 
studies that not only assess the prevalence of patients needing nutritional support, but 
also investigate its efficacy by assessing measurements of body composition, 
tolerance of nutritional therapy, quality of life and clinical outcomes (EFS, deaths, 
etc.).  
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1.7 OVERALL STUDY AIMS 
 
 To systematically review the prevalence of malnutrition in paediatric cancer and 
to establish whether there is an association between nutritional status and clinical 
outcome. 
 To systematically review the prevalence and possible causes of vitamin D 
inadequacy of paediatric cancer patients.  
 To identify patterns of change in the nutritional status of paediatric cancer 
patients throughout the course of the disease and treatment;  
 To investigate clinical and nutritional parameters that may contribute to the 
development of malnutrition.  
 To investigate the antioxidant status, oxidative stress and polyunsaturated fatty 
acid status of paediatric cancer patients.  
 The long term goal of this project is to provide the basis to perform a quality 
improvement project of the nutritional care of paediatric cancer patients in SE 
Scotland.  
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CHAPTER II 
 
 
2. SYTEMATIC REVIEWS ON NUTRITIONAL 
ISSUES IN CHILDHOOD CANCER 
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2.1 SYSTEMATIC REVIEW OF THE PREVALENCE OF MALNUTRITION 
IN PAEDIATRIC CANCER: EFFECTS OF CANCER AND ITS 
TREATMENT ON NUTRITIONAL STATUS 
2.1.1 Introduction 
Cancer is the most common disease-related cause of childhood death in the Western 
World (Cancer Research UK 2012b). Nonetheless, five-year survival rates have 
improved considerably in the last 40 years (Cancer Research UK 2012b) after the 
implementation of more intensive treatments, particularly in developed countries 
(Herbst et al. 2006). Consequently, attention is shifting to the reduction of treatment-
related sequelae during and after therapy. However, most children with cancer live in 
low- and middle-income countries accounting for 94% of all deaths in people aged 0-
14 years (Pritchard-Jones et al. 2013). New cancer therapies are not easily accessible 
in these countries, whereas attention could focus on nutritional management to raise 
standard of care in a feasible manner (Pritchard-Jones et al. 2013).       
 
Malnutrition, defined as undernutrition, overnutrition or poor growth (Brennan 1998, 
BAPEN 2010, Anon.2006b). is a major concern in paediatric cancer. It is thought to 
increase the risk of morbidity (van Eys et al. 1980), mortality (Sala et al. 2004, Lange 
et al. 2005, Reilly et al. 1994, Butturini et al. 2007), early relapse (Viana et al. 1994) 
and the number of complications during treatment (Anon.1998, van Eys 1979a). 
Additionally, a recent SIGN guideline highlighted that long-term childhood cancer 
survivors might be at higher risk of developing the metabolic syndrome, cardiac 
complications and may have a reduced peak bone mass due to related treatment side-
effects (Wallace et al. 2013). This is exacerbated by malnutrition, as obesity is an 
independent risk factor for cardiovascular disease (Hubert et al. 1983, Bauer et al. 
2011).  
 
Malnutrition in paediatric cancer has long been recognised (van Eys 1979a, 
Brinksma et al. 2012, Sala et al. 2012, Jaime-Pérez et al. 2008, Odame et al. 1994, 
Bauer et al. 2011, Reilly 2009a, Antillon et al. 2008), yet, its management remains 
variable (Sala et al. 2004, Brinksma et al. 2012, Reilly et al. 1999, Brouwer et al. 
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2007), with many malnourished children unrecognised and consequently not treated 
(Agostoni et al. 2005a, Anon.2010). To date, several narrative reviews (Sala et al. 
2004, Bauer et al. 2011, Reilly 2009a, Brouwer et al. 2007) and a systematic review 
(Brinksma et al. 2012) have investigated undernutrition in paediatric cancer. The 
narrative reviews provide a summary of the prevalence of undernutrition and 
evidence for correlations with clinical outcomes in paediatric cancer. The systematic 
review reports the prevalence of undernutrition, but not overnutrition, and explores 
the aetiology of undernutrition; the literature search finished in September 2010. The 
prevalence of undernutrition varies considerably between different studies; ranging 
from 5-10% in children with acute lymphoblastic leukaemia (Sala et al. 2004, Collins 
et al. 2010, Brinksma et al. 2012, Barr et al. 2011) to 50% in those diagnosed with 
neuroblastoma (Green et al. 2008). The associations between undernutrition and 
clinical outcomes also remain unclear; with some arguing that undernutrition is 
associated with worse outcomes (Sala et al. 2012, Donaldson et al. 1981, Lobato-
Mendizábal et al. 1989, Mejía-Aranguré et al. 1999) and others that such associations 
do not exist (Weir et al. 1998, Pedrosa et al. 2000). Finally, obesity is likely to occur 
in survivors of acute lymphoblastic leukaemia, who have been treated with 
corticosteroids (Robison and Bhatia 2003) and in children diagnosed with 
craniopharyngioma; (Iughetti and Bruzzi 2011); however, at present no systematic 
review has been published to support these findings.  
 
To reduce nutritional related side-effects, it is first essential to recognise the 
epidemiological picture of malnutrition in paediatric cancer. Thus, the study aims 
were: (i) to report the prevalence of malnutrition in paediatric cancer, (ii) to identify 
those at risk of developing both undernutrition and overnutrition during and after the 
completion of treatment, (iii) and to establish whether there are associations between 
malnutrition and clinical outcomes.  
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2.1.2 Methods 
A protocol was designed a priori. The process and reporting of this systematic review 
was performed according to the Cochrane Collaboration and following the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Moher et 
al. 2009).    
2.1.2.1 Outcome data 
The primary outcome was:  
i. The prevalence of malnutrition (undernutrition and overnutrition) in children 
diagnosed and treated for cancer; expressed as body mass index (BMI). 
 The secondary outcomes were:  
i. Studies reporting malnutrition identified with the following anthropometrical 
measurements; weight, height, mid-arm circumference (MUAC) and triceps 
skinfold (TSF).  
ii. Studies reporting prevalence of malnutrition at different stages of the 
disease; at diagnosis, during therapy and at the end of treatment.  
iii. Studies investigating the relationship between nutritional status at diagnosis 
and clinical outcome.  
2.1.2.2 Eligibility criteria and search strategy 
The eligibility criteria included: 
i. Studies investigating children and young people, aged <18 years and 
diagnosed with a first time cancer according to the International 
Classification of Childhood Cancer, third edition (ICCC-3) (Steliarova-
Foucher et al. 2005). 
ii. To minimise the risk of bias there was no restriction on follow up period, 
however we excluded studies, which only investigated the nutritional status 
of childhood cancer survivors. Additionally, studies including patients with 
second cancers or treated palliatively from diagnosis were excluded.  
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Electronic searches of the English language were performed  (January 1990-February 
2013) using the Cochrane Library, MEDLINE (via EBSCOhost), CINAHL (via 
EBSCOhost) and PUBMED to identify systematic reviews, Randomised Controlled 
Trials (RCT), observational studies, case control studies and letters to the editor. The 
reference list list of all relevant articles, narrative reviews and private collections was 
also examined. The initial search strategy identified the following keywords and 
subject heading searches (MeSH); “paediatrics”, “cancer”, “cancer treatment”, 
“malnutrition” and “nutritional assessment” and adaptations for British and 
American English were made for all searches. 
2.1.2.3 Study selection, quality assessment and data extraction 
Titles and abstracts from the combined searches were reviewed by two researchers 
independently (RRI, JMcK). In cases of disagreement, an independent advisor (DW) 
made the final decision. Evidence was critically appraised independently by two 
researchers (RRI, IP) employing a standard methodological tool; the Critical 
Appraisal Skills Programme (CASP). The CASP tool has been recommended for 
epidemiological studies, public health and evidence based practice (Sanderson et al. 
2007). The CASP comprises an assessment of: (i) Contextual information including 
the study objectives, study design and the patient’s characteristics; (ii) Potential 
selection bias including inclusion and exclusion criteria, clear patient selection and 
an assessment of validity, reliability and accuracy of techniques used; (iii) Outcome 
measures including reference values; (iv) statistical analysis employed and (v) a 
reporting of results and control for confounding factors. Each section was classified 
as “yes” if the authors covered the questions, “can’t tell” if it was not reported or 
“no” if it was not covered or considered at all. A quality rating of “strong”, 
“moderate” or “weak” was applied to each study; where “strong” was given when the 
study met all areas of the CASP criteria, “moderate” when there was one weak area 
and “weak” when ≥ two weak areas were identified. A third independent reviewer 
(DW) made the final assessment and in case of disagreement a final decision was 
made by consensus (RRI, IP, DW). A meta-analysis of selected studies investigating 
the association between malnutrition and outcome was planned to be performed a 
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priori. Finally, the median and the range percentage of the prevalence of malnutrition 
were calculated for comprehensibility of the results.     
2.1.3 Results  
2.1.3.1 Study Selection and characteristics 
46 studies met our eligibility criteria (figure 2.1). Of these, 26 were prospective 
cohort studies, 19 retrospective cohort studies and one cross-sectional study. Twenty-
nine studies investigated malnutrition in children diagnosed with haematological 
malignancies and acute lymphoblastic leukaemia was considered in all studies. 
Thirteen considered solid tumours, two brain tumours and eight studies considered 
children diagnosed with cancers included in the ICCC-3. Six studies investigated 
more than one cancer type. For differences between developed and developing 
countries, see figure 2.2.       
 
 Figure 2.1 Flow diagram of studies identified, screened and selected 
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Figure 2.2 Comparison of the total number of studies published (%), total sample 
size (%), and the prevalence of undernutrition and overnutrition. 
Total number of studies (46); number of studies published in the developing world (13); total number 
of studies published in the developed world (33); total number of subjects included in all studies 
(8734); sample size from the developing world (3411) and sample size from the developed world 
(5323) 
 
2.1.3.2 Methods used to identify malnutrition.  
Most studies used more than one method to assess nutritional status and the criteria 
used to define malnutrition was heterogeneous (table 2.1). The methods used to 
identify undernutrition were; weight measures in 23/46 studies, BMI in 16/46 and, 
MUAC and TSF in 11/46, whilst the methods used to identify overnutrition were 
measures of weight in 7/46 studies and BMI in 18/46. Studies investigating 
overnutrition did not used MUAC or TSF measurements. Finally, 13/46 studies 
explored linear growth expressed as height and/or height for age (HFA). 
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     Table 2-1 Prevalence of undernutrition by type of measurement 
 
 
 
 
 
BMI: body mass index; WFH: weight for height; MUAC: mid-upper arm circumference; TSF: triceps 
skinfold thickness. 
 
2.1.3.3 Prevalence of undernutrition and overnutrition  
Studies identified the prevalence of undernutrition employing BMI, weight loss, 
MUAC and TSF (tables 2.2, 2.3, 2.4 and 2.5). For comparative reasons, the 
prevalence of undernutrition was separated into two groups; those identified using 
weight loss, weight SD and BMI and those using MUAC and TSF. At diagnosis and 
during treatment, the prevalence of undernutrition (median %) was higher in studies 
employing MUAC and TSF than those using BMI and weight, whilst at the end of 
therapy this difference was not seen (table 2.5). Finally, the prevalence of 
overnutrition was established by selecting studies reporting BMI values (table 2.6).     
 
 
 
 
 
Stage of disease  BMI, WFH MUAC, TSF 
Range 
(%) 
Median 
(%) 
Range (%) Median 
(%) 
At diagnosis 0-50 13 0-73 29∙5 
On treatment 0-50 16 0-34 30 
End of treatment 0-46 20 0-20 19 
Overall  0-50 15 0-73 29∙5 
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Table 2-2 Studies reporting prevalence of undernutrition and overnutrition in paediatric cancer- Heamatological malignancies. 
Author Quality Patients Dx N, age 
(years) 
Method  
Time of 
measurement 
Method 
 
Results 
Design Parameters At diagnosis During 
treatment 
After treatment 
(González 
et al. 2004)  
 
Cuba
 
 
 
Weak ALL N=49 
 
Mean (6) 
Range   
 (1-15)y 
M: one 
observer 
 
T: Diagnosis 
After intensive 
phase 
End of 
Therapy 
PC Height, weight, 
BMI, TSF < 3
rd
 
centile of Cuban 
standards 
0%  NR NR 
(Antillon et 
al. 2008)  
 
Guatemala
 
Moderate ALL N=164 
 
Mean 
(±SD) 9·91  
(±4.10)y 
M: One 
observer 
 
T: Diagnosis 
3 months  
6 months 
 
 
PC  Adequate: TSF, 
MUAC >10
th
 
percentile 
Depleted: TSF, 
MUAC 5-10
th
 
percentile 
Severely 
Depleted 
MUAC, TSF 
<5
th
 percentile 
54%  
Moderately 
&/or severely 
depleted  
34%  
Moderately 
&/or severely 
depleted 
19%  
Moderately &/or 
severely 
depleted 
(Jaime-
Pérez et al. 
2008)  
 
Northern 
Mexico
 
Weak ALL N=102, 
 
Median 
(range) 6   
(2-15)y 
M: not 
mentioned 
 
T: Diagnosis  
On repeated 
occasions for 5 
years  
 
PC BMI: percentiles 
of US standards  
 
Underweight 
<10
th
  
Normal weight 
10-85
th
  
Risk of 
overweight 85-
95
th
  
Overweight 
Underweight: 
12% (12/102) 
 
Normal 
weightt: 65% 
(66/102) 
 
Risk of 
overweight: 9% 
(9/102) 
 
NR NR 
94 
 
>95
th 
  
Overwt: 
15%(15/102) 
(Gofman 
and Ducore 
2009)  
 
California, 
USA
 
 
 
Strong ALL  
NHL 
N=95 
 
≤18 years 
 
Median 
(range) ? 
M: medical 
records 
 
T: Diagnosis, 
end of therapy 
& 
2 years after 
treatment 
 
RC BMI: of US 
standards 
 
Overweight: 
Z-scores 1-
1·65SD 
Percentiles 85
th
 -
95
th
  
 
Obesity 
Ζ-scores >1·65 
Percentile >95
th
  
Overweight 6% 
 
Obese 2% 
Overweight 
20% 
 
Obese 
12% 
 
Overweight 16% 
 
Obese 24% 
(Baillargeon 
et al. 2007)  
 
Texas, USA 
Moderate B-precursor ALL N=307 
 
Median 
(range) NR 
(2-18)y 
 
 
M: medical 
records 
 
T: Diagnosis to 
30 months and 
follow up 
every 6 months 
RC Overweight 
BMI 85-95
th
 
percentile 
 
Obese 
>95
th
 percentile 
Overweight: 
10·8%  
 
Obese: 15·3% 
NA NA 
(Baillargeon 
et al. 2005)  
 
Texas, USA 
 
 
 
Weak B-precursor ALL N=141 
 
Median 
(range) NR 
(2-18)y 
M: medical 
records 
 
T: Diagnosis to 
30 months and 
follow up 
every 6 months 
 
Hispanics only 
RC Overweight 
85-95th 
percentile 
Obese 
>95th percentile 
Normal weight: 
70% (99/141) 
Overweight: 
13% (18/141) 
Obese: 17% 
(24/141) 
24 months 
Normal weight: 
71.9%(77/107) 
Overweight: 
12.1% (13/107) 
Obese: 16% 
(17/107) 
30 months 
Normal weight: 
71% (70/98) 
Overweight:13% 
(13/98) 
Obese: 15% 
(15/98) 
(Odame et 
al. 1994) 
 
 
Scotland, 
UK 
Weak Cohort: ALL 
 
Controls: Wilm’s 
tumour, non-
Hodgkin’s 
N=40 
cohort 
N=18 
controls 
 
M: medical 
records 
 
T: Diagnosis 
2 years and 4 
RC BMI z score 
Overnutrition 
criteria 
according to 
French 
Obesity in ALL 
cohort: 
Boys: 5%  
Girls: 5%  
 
Obesity in ALL 
cohort: 
Boys: 26% 
Girls: 43%  
 
Obesity in ALL 
cohort: 
Boys: 21%  
Girls: 57%  
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lymphoma, 
rhabdomyosarcoma, 
Neuroblastoma, 
LCH & yolk sac 
tumour 
Cohort: 
Mean 
boys: 3·4y 
girls 3·6y 
 
Controls: 
Mean 
boys 3·9y 
girls 3·7y  
years 
 
population 
standards 
(Rolland-
Cachera et al) 
Obesity in 
Controls: 
Boys:0% 
Girls:10% 
 
Obesity in 
Controls: 
Boys: 0% 
Girls: 20% 
Obesity in 
Controls: 
Boys: 25% 
Girls: 20% 
(Delbecque-
Boussard et 
al. 1997)   
 
France 
Weak ALL N= 15 
Mean (SD) 
6·12(±3.2)y 
 
M: NR 
 
T: day 1, 22, 
36 & 71 
PC WFH according 
to charts of 
Sempe et al 
 
MUAC: NR 
TSF: NR 
Undernourished 
2/15 (13%) 
Results were 
similar to 
diagnosis for 
day 22, 36 & 71 
NA 
(Bond et al. 
1992)
 
 
UK 
Weak ALL and Solid 
tumours 
 
Controls 
N=26  
Mean 
(±SD) 10·1 
(±0.6)y 
 
N=26 
Mean 
(±SD)10 
(±0·6)y 
M: NR 
 
T: 6 months 
from diagnosis 
and 1 week 
before CT 
 
 
PC WFH & HFA 
standards 
according to 
Waterlow et al  
 
TSF for FM not 
mentioned 
NA 4/26 (15%) 
undernourished  
1 (4%)ALL 
<90% HFA 
(stunted) 
 
3 (11.5%) solid 
tumours <80%  
WFH (wasted) 
 
NA 
(Uderzo et 
al. 1996)  
 
Italy 
Weak  Newly diagnosed 
Leukaemia 
 
 
Cohort  
N=173 
Median 
(range) 4 
(0·2-15)y 
 
Control  
N=307 
Median 
(range) 
M: two 
observers  
 
T: at diagnosis 
C Data (height, 
weight, WFH, 
MUAC & TSF) 
compared with 
the national 
center for health 
statistics in the 
USA 
Cohort v 
controls 
(p>0·05) 
 
Cohort 7% had 
WFH <90% 
Controls 8·5% 
(26) had WFH 
<90% 
 
NA NA 
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7(5-14)y MAC  
Cohort 2% 
<90% 
Controls 2% 
<90% 
 
TSF 
Cohort 18% 
Controls 11% 
 
(Reilly et al. 
1999)   
 
UK 
Strong Standard Risk ALL N=1013 
Median 
(range) 
Boys: 4·4 
(0·4-14·9)y 
Girls: 4·4 
(0·2-14·9)y 
 
M: Medical 
records 
T: at diagnosis 
RC BMI SD UK 
population 
reference data  
Undernutrition 
(-2 SD) 
Overnutrition(+2 
SD) 
Undernutrition: 
Boys: 8% 
Girls: 7% 
 
Overnutrition: 
Boys: 3% 
Girls:3% 
NA NA 
(Viana et al. 
1994)  
 
Brazil 
Moderate ALL N= 128 
Median 
(range) 5·8 
(0·7-14·7)y 
M: NR 
T:at diagnosis 
PC WHO standards  
WFA, WFH. 
HFA 
 
Undernutrition 
(Z score -2 SD) 
Undernutrition: 
WFA: 21% 
HFA: 17% 
NA   NA 
(Argüelles 
et al. 2000)
 
 
Spain 
Weak  ALL N=26 
Mean 
5·12y 
Range 
1·66-10y 
M: NR 
T: Diagnosis, 
6, 12, 18, 24, 
30 & 36 
months 
 
PC Normal BMI & 
Ht 
+1 SD to -1 SD 
according to 
Spanish 
standards  
Mean (±SEM) 
Ht SD 0.55 
(±0·19) 
 
BMI NR 
 
Prevalence NR 
 
 
Mean (±SEM) 
Ht SD 
At 6 months 
0·4(±0·19) 
At 12 months 
0·71(±0·22) 
At 18 months 
0·78(±0·2) 
At 24 months 
0·97(±0·21) 
At 30 months 
Mean (±SEM) 
Ht SD 1·03 
(±0·2) 
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1·02(±0·22) 
At 36 months 
1·03(±0·20) 
(Murphy et 
al. 2006)
 
 
UK 
Weak ALL 
 
N=29 
ALL group 
Mean(±SD) 
age 
9·6(±1·8)y 
 
Healthy 
control 
group 
Mean(±SD) 
9·6 ± 2·0y   
M: 1 observer 
T: off 
treatment 
(range 1-2y)  
Diagnosis to 5 
years 
 
 
 
PC 
 
NR 
 
NR 
 
NR 
% FM and FM 
were higher in 
ALL survivors  
 
FFM Index was 
significantly 
different 
between ALL 
and the control 
group 
 
No sig 
differences 
between Pred 
and Dexa group 
but the latter had 
a mean FM 
6%higher 
(Halton et 
al. 1998)
 
 
Canada 
Weak  ALL  
 
Study I:  
N= 116 
Study II: no 
relevant 
Study III: 
N= 19 
M: NR 
T:  
Study I 
Diagnosis  
12 months 
intervals 
during 
treatment 
12 months 
after 
completion of 
therapy 
Study II: not 
relevant 
PC Not mentioned 
All 
measurements 
are compared 
with baseline 
 
 
Study I 
 
Weight: 
Standard Risk: 
Mean SD:0·00 
Males       Mean 
SD: 0·36 
Females    
Mean SD: 0·15 
High risk:  
Mean SD: 0·2 
 
Study III 
% fat mass 
Study I 
 
Weight 
Reduction in 
weight velocity 
during 1
st
 year 
and a 
disproportionate 
↑ in weight 
thereafter  
 
At 24 months 
Standard Risk: 
Mean SD:0·16 
Catch up growth  
Study I 
 
Weight: 
Obesity 
tendency 
Standard Risk: 
Mean SD:0·47 
Males Mean SD: 
0·38 
Females mean 
SD: 0·75 
High risk:  
Mean SD: 0·35 
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Study III: 
Diagnosis and 
6 months 
intervals 
21·5±6·1 
 
   
Males Mean 
SD: 0·55 
Females mean 
SD: 0·76 
High risk:  
Mean SD: 0·4 
 
Study III 
Fat mass % 
Increase to 
25±8·9 at 12 
months 
Muscle mass  
Reduced to 
59·8±3·5 at 12 
months 
 
Study III 
% fat mass 
27·7±9·9 
 
   
 
(Ahmed et 
al. 1997)  
 
UK 
Moderate  ALL N=31  
Median 
(range) age 
at diagnosis 
4·4(1·1-
14)y 
M: one 
observer  
T: monthly 
measurements 
(range 3-
24months) 
PC  No outcomes 
measures 
NA Median Wt SD 
↑ sig over 1st  
months and by 
the end of CT 
 
Median BMI 
SD ↑ sig at 6 
and 10 months 
NA 
 (van der 
Sluis et al. 
2002)  
 
Netherlands 
Weak  ALL N=61 
Median 
(range) age 
7·1(1·6-
16·8)y 
M: not 
mentioned 
T: At 
diagnosis, 32 
weeks, 1, 2 and 
3 y 
PC Ht and BMI 
compared with 
age and sex 
matched 
reference values 
from 
Netherlands  
 
Measurements 
compared to 
baseline 
Ht: mean -0·19 
SD  
BMI: -0·31SD 
 
*values are 
approximate-
obtained from 
table with the 
use of a ruler 
32 weeks 
Height was 
decreased 
significantly to 
-0·75 SD 
BMI: sig 
increased to 
+0·65  SD 
2 year 
Ht: -0·75 SD 
BMI: +1·35 SD 
1 y after 
cessation of 
therapy sig 
increase in ht  
Ht: -0·63SD 
BMI: +1·05 
(decrease non-
sig) 
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Dx: Diagnosis; M: method; T: time of measurement; C: cohort study;  PC: prospective cohort study; RC: retrospective cohort study; CS: cross-sectional study; NR: 
not reported and/or not clear; NA: non-applicable (i.e. not part of study aims); Measurements: BMI: body mass index; Ht: height; WFH: weight for height; WFA: 
weight for age; HFA: height for age; MUAC: middle upper arm circumference; TSF: triceps skinfold thickness; FM: fat mass; FFM: free fat mass; RBW: relative 
body weight; Diagnosis: ALL: acute lymphoblastic leukaemia; HM: Heamatological malignancies; ICCC-3: International classification of Childhood Cancer, Third 
edition; NHL: non-Hodgkin’s lymphoma; Treatment: CT: chemotherapy; Dexa: Dexamethasone; Pred: Prednisolone; R: radiotherapy; ↓: decrease; ↑: increase; SD: 
standard deviation; y: years; sig: significant. Countries: UK: United Kingdom; USA: United States of America 
 
(Groot-
Loonen et 
al. 1996)  
 
Netherlands 
Weak ALL N=92 
High risk 
n=15 Mean 
age 6·7y 
Range 1·1-
15·9y 
 
Normal 
risk 
N=77 
Mean age 
5.2y 
Range0.6-
15.5y  
 
M: 
experienced 
staff 
T: diagnosis to 
2 years (8-12 
times per year) 
PC WFH 
Weight  
 
Dutch reference 
standards   
NR Patients treated 
with Dexa had 
higher WFH 
than those 
treated with 
Pred 
 
Weight did not 
differ between 
groups 
 
Weight did not 
sig differ in 
boys and girls  
 
NA 
(Koskelo et 
al. 1990)  
 
South 
Africa 
Weak  Heamatological 
malignancy 
Cohort: 
N=12  
Mean 5·9y 
Range 
(1·8-13·6)y 
 
Controls: 
N=31 
Mean: NR 
Range 
(3·6-13·9)y 
M: one 
investigator  
T: at diagnosis, 
at 2-week 
interval up to 
24 weeks 
PC  Reference 
healthy controls 
 
Weight, height, 
MUAC & TSF 
Cohort  
Median relative 
body weight  
(RBW) +2% in 
compare to 
controls  
RBW increase 
to 8% 
 
Muscle wasting 
decrease by 
27% average  
 
Increase of TSF 
NA 
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Table 2-3 Studies reporting prevalence of undernutrition and overnutrition in paediatric cancer- Solid and brain tumours    
Author Quality Patients Dx N, age Method & Time 
of measurements 
Method 
 
Results 
Design Parameters  At diagnosis During 
treatment 
After 
treatment 
(Elhasid et 
al. 1999) 
 
Israel  
Weak Solid tumours N= 50 
Median 
(range) ? 
(0·17-
17·5)y 
M: NR 
 
T: Diagnosis & 
after each course 
of CT 
 
PC Weight; weight 
loss > 5% 
 
weight loss %: 
NR 
 
Weight loss 
%: NR 
Weight loss %: 
NR 
(Schiavetti 
et al. 2002)  
 
Italy 
Weak  Solid tumours N=36 
On 
treatment 
group 
(n=19) 
mean(±SD
) 
9·7(±4·9)y 
 
Off 
treatment 
group 
(n=17) 
mean(±SD
) 
10·4(±4·6)
y 
M; One observer 
 
T: on treatment & 
off treatment (1-2 
y) 
PC RBW% according 
to Italian obesity 
consensus 
conference: 
< 90% for 
underweight  
90-110% for 
normal weight 
110-120% 
overweight 
>120 obese 
 
BMI center for 
disease control 
recommendation:  
<5
th
 underweight 
5
th
-84
th
 normal 
weight  
≥overweight 
≥95th obese 
 
NA Prevalence of 
underweight:  
On treatment 
group:  
%RBW: 26% 
BMI: 16%   
 
Prevalence of 
overweight 
and obese:  
On therapy 
group: 
%RBW: 40% 
BMI: 21% 
Off therapy: 
%RBW: 53% 
BMI: 35%    
 
Off treatment 
group 
Underweight 
0% 
Overweight and 
obese 35% 
3. Bakish et 
al 2003  
Strong  Newly diagnosed 
medulloblastoma 
N= 112 
Median 
M: hospital records 
 
RC IBW determined 
using Tanner-
Median % of 
IBW at 
46% of 
patients on 
NA 
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Canada & 
UK 
& supratentorial 
PNET 
age 
(range) 6·1 
(0·1-
15·4)y 
T:  
At diagnosis 
 
Before and after 
treatment (SG, CT, 
RT) 
 
Before, 1 & 3 
months after 
dietetic 
intervention  
Whitehouse 
growth charts 
 
Risk for 
undernutrition: 
weight < 90% of 
their IBW 
 
Significant weight 
loss/gain defined 
as change of > 5%  
Stable weight 
change < 5% 
 
diagnosis 94% 
 
31% at risk of 
undernutrition 
CT lost > 5% 
TBW 
(Barbosa-
Cortés et al. 
2007)  
 
Mexico 
Weak  Lymphoma and 
solid tumour 
N=17 
Mean 
(±SD)  
Lymphom
a (n=8): 
11·1 
(±3·2)y 
Solid 
tumour 
(n=9): 
9·5(±4·1)y 
 
M: one observer 
 
T: after 1
st
 CT 
course & 2 & 6 
months into 
treatment 
 
PC To compare 
whether there is 
differences 
between 
lymphoma & 
solid tumour 
groups in body 
composition 
4/17 (23·5%) 
children had a 
BMI Z-score <-
2 SD 
 Body weight 
↑significantly in 
the lymphoma 
group only 
(Green et 
al. 2008) 
 
Canada 
Weak  Stage IV NB N=12 
Mean 
(±SD) 3·8 
(1.5)y 
Range 
0·5* -18y 
M: one observer 
 
T: Diagnosis 
(phase 1) 
After 2 courses of 
CT (phase 2) 
2 or more weeks 
after surgical 
excision (phase 3) 
PC Undernutrition 
criteria: 
2 or more: 
WFH <85% 
TSF <5
th
 
percentile 
 
50% 
Undernourished  
30% 
Undernourish
ed 
20%  
Undernourished  
102 
 
End of therapy 
(final phase)  
 
(Oguz et al. 
1999)  
 
Turkey 
Weak  Cohort :Solid 
tumours 
 
Control: no sex 
and aged matched 
healthy children 
N= 62 
(cohort) 
Mean 
(±SD) age: 
6·5 
(±3·7)y 
Range: 
(0·08-13)y  
N= 31 
(healthy 
control) 
Mean 
(±SD) age: 
5·7 
(±4·7)y 
Range: 
0·25-15)y 
 
M: one observer 
T: at diagnosis  
PC WFH (WHO 
standards) 
MUAC & TSF 
(Frisancho 1994 
standards) 
27% 
Undernourished 
(MUAC & TSF) 
 
NA NA 
(Wessels et 
al. 1999)  
 
South 
Africa  
Weak  Wilms’ tumour N=59 
Undernour
ished 
group 
Median 
(range) 
3·0(0·5-
8·2)y 
 
Well-
nourished 
group 
Median 
(range) 2·9 
M: charts review  
T: at diagnosis, 
end of therapy 
RC WFA & WFH 
WHO standards 
 
Undernutrition 
<3
rd
 centile or 
<90
th
 centile 
 
 
35% were 
undernourished  
  NR 
103 
 
(0·5-
11·6)y* 
 
(Müller et 
al. 2001)  
 
Germany 
Strong Craniopharyngio
ma 
N=185 
Median 
(range) 8.6 
(0.1-18)y  
M: medical records 
T: At diagnosis up 
to a median 
(range) 6·6 (0·1-
34)y 
RC Rolland Cachera 
et al 1991 
BMI: 
Obesity>3SD 
Overweight 2-3 
SD 
Normal weight 
<2SD 
 
NR Normal 
weight: 43% 
Overweight: 
13% 
Obesity 44% 
NR 
(Müller et 
al. 2011)  
 
Germany   
Weak Craniopharyngio
ma 
N=120 
Median(ra
nge) 
10(1·2 -
18)y 
M: not mentioned 
T: At diagnosis, at 
36 months 
PC BMI SD to 
measure level of 
obesity 
The degree of 
obesity was 
similar in 
patients with 
different grades 
of hypothalamic 
involvement  
 
Prevalence: NR 
NA Surgical 
hypothalamic 
lesions of 
anterior and 
posterior 
hypothalamic 
areas are 
associated with 
higher ↑ in 
Mean BMI SD 
+3·22 SD in 
comparison to 
patients with no 
lesions: Mean 
BMI SD: +0·45 
and 1 anterior 
lesion Mean 
BMI SD: +0·74  
 
Prevalence NR 
 
10. Israels 
et al. 
Weak Wilm’s tumour N= 19 
Malawi 
M: NR 
T: At diagnosis 
CS HANES growth 
curve (1978) 
Malawi: 
Z-score 
NA NA 
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Dx: Diagnosis; M: method; T: time of measurement; PC: prospective cohort study; RC: retrospective cohort study; CS: cross-sectional study; NR: not reported 
and/or not clear; NA: not applicable (i.e. not part of study aims);  Measurements: BMI: body mass index; WFH:weight for height; WFA: weight for age; HFA: 
height for age; MUAC: midd upper arm circumference; TSF: triceps skinfold thickness; FM: fat mass; FFM: free fat mass; RBW:relative body weight; Diagnosis: 
ALL: acute lymphoblastic leukaemia; HM: Haematological malignancies; ICCC-3: International classification of Childhood Cancer, Third edition; NB: 
neuroblastoma; PNET: primitive neuroectodermal tumor; Treatment: CT: chemotherapy; RT: radiotherapy; SG: surgery; ↓: decrease; ↑: increase; SD: standard 
deviation; *values converted from months to years. Countries: UK: United Kingdom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(2010)(Isra
els et al. 
2010) 
 
Malawi & 
UK 
N=11 
Mean age 
(±SD) 
4·5±2·6y 
United 
Kingdom 
N=8 
Mean age 
(±SD) 
4·6±2·1y  
 corrected WFH: 
-2·3±1·3 
 
UK: 
Z-score 
corrected WFH: 
0·4±0·8 
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Table 2-4 Studies reporting prevalence of undernutrition and overnutrition in paediatric cancer- ICCC-3 and other malignancies 
Author Quality Patients Dx N, age 
(years) 
Method & 
Time of 
measurement 
Method 
 
Results    
     Design Parameters At diagnosis During 
treatment 
After 
treatment 
(Sala et al. 
2008)  
 
Guatemala 
Strong  ICCC-cancer N=472 
 
Median 
(range) 
NR 
M: one 
observer 
 
T: 48 hours 
maximum into 
treatment  
C TSF & MUAC 
Adequately 
nourished: 
>10
th
 
Depleted: 5
th
-10
th
  
Severely depleted: 
<5
th
   
 
MUAC & TSF 
(Frisancho 1981) 
57% (271/472) 
undernourished  
8% (41/472) 
severely 
undernourished  
 
Solid tumours: 
57% (112/237) 
undernourished 
10% (25/237) 
severely 
undernourished  
 
ALL 
48% (97/202) 
undernourished 
6% (13/202) 
severely 
undernourished 
 
Other leukaemias 
+ MDS 
64% (21/33) 
undernourished 
9% (3/33) 
severely 
NA NA 
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undernourished  
 
(Sala et al. 
2012) 
 
Guatemala, 
El 
Salvador, 
Nicaragua, 
Dominican 
Republic, 
Panama, 
Honduras, 
Costa Rica 
 
Strong ICCC-3 cancer N= 1787 
 
Median 
(IQR) age 
6·8y (3·8-
10·6)y 
M: one to two 
observers in 
each country 
 
T: Diagnosis 
PC BMI (WHO) 
< 15th centile 
undernourished:  
<5th centile 
severely 
undernourished  
 
MUAC & TSF 
(Frisancho 1981): 
5-10th centile 
undernourished:  
<5th severely 
depleted  
BMI: 
undernourished: 
28% 
<5th  
severely 
undernourished 
20% 
 
MUAC & TSF: 
undernourished: 
18% 
severely 
depleted:45% 
 
NA NA 
(Pietsch & 
Ford 2000)  
 
USA 
Modera
te  
Cancer diagnosis N= 133 
 
Median 
age NR 
M: medical 
records 
 
T: at diagnosis 
RC Undernutrition 
defined: 
WFH <50% 
percentile  
WFH <20% 
percentile 
WFH <80% of the 
median  
BMI <16 
BMI z-score <-
2·0 SD 
 
Reference for 
children 
BMI Z scores  
≥5y (Rosner et al 
1998)  
 
Z-scores for 
Prevalence of 
undernutrition: 
 
WFH <50
th
: 38/81 
(47%) 
 
WFH<20
th
 : 12/81 
(15%) 
 
Median WFH 
<80%: 1/81 (1%) 
 
WFH Z score: -
2·00 SD 1/81 
(1%) 
 
BMI <16 41/127 
(32%) 
 
NA NA 
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WFH, WFA & 
HFA in children 
≤10y NCHS 
growth curves 
 
BMI Z score -
2·00 SD 2/78 
(3%) 
 
 
(Smith et 
al. 1991)  
 
UK 
Modera
te 
Newly diagnosed 
malignancy 
N=100 
Median 
(range)  
5(0·3-
16·5)y 
M: one 
observer  
T: diagnosis, 
every month 
For how long? 
PC Undernutrition 
defined as  
HFA -2 SD 
(WHO) 
TSF -2 SD  
WFH 80% of 
median 
MUAC 5
th
 centile 
HFA & WFH 
normal 
MUAC & TSF 
significantly < 
than reference & 
controls  
20% had MUAC 
<5th centile  
23% had TSF >2 
SD below the 
mean 
 
NR NR 
(Collins et 
al. 2010, 
Barr et al. 
2011)  
 
Canada 
Strong   Haematological 
malignancy and 
extracranial solid 
tumour  
N=99 
Median 
(range) 
7·2 (2·1-
15·2)y* 
 
M: Registered 
dietitians 
T at diagnosis  
C BMI SD USA 
population 
reference data 
 
MUAC and  TSF 
Frisancho  
 
Undernutrition 
<5
th
 centile  
Risk of 
overweight   
85
th
-95
th
  
Overweight >95
th
  
Undernourished: 
BMI 9% 
MUAC 5% 
TSF 10% 
 
Risk of 
overweight 
BMI 18% 
MUAC 7% 
TSF 6% 
 
Overweight: 
BMI: 7% 
MUAC: 4% 
TSF:9% 
 
NA NA 
(Pedrosa et 
al. 2000) 
Modera
te 
Haematological 
malignancies and 
N=443 
Median 
M:patient’s 
records 
RC WHO standards  
WFA, WFH, 
Undernutrition: 
WFA: 23·5%  
NA 
 
NA 
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Brazil 
solid tumour (range) 
4·9 (0-
17·8)y 
T: at 
diagnosis, 1 
year 
HFA  
Undernutrition Z-
scores -2  
 
Outcome: survival 
at 1 year 
 
WFH: 16% 
HFA: 23%  
(Skolin et 
al. 1997)  
 
Sweden  
Weak Leukaemia & solid 
tumours 
N=14 
Median 
(range) 
10·0 (5·0-
16·0) y 
M: medical 
records (only 
for weight) 
T: Admission, 
1 week, 6 
weeks and 3 
months after 
diagnosis 
RC Weight compared 
with NCHS 
growth curves  
On admission 
Weight SD  
-0·09 
Weight 
reduction: 
At 1 week: 
0·19 SD   
At 6 weeks 0·10 
SD 
At 3 months 
0·37 SD 
All 
measurements 
compared to 
admission 
 
NA 
(Murphy et 
al. 2010) 
 
Australia 
Weak  Cohort 
(malignancy) 
Control (healthy 
children) 
N= 48 
(control 
and 
cohort) 
M: not 
mentioned 
T: between 1·2 
and 2 y after 
diagnosis 
CS Comparison of 
height, weight and 
BMI between 
controls and 
cohort 
 
National 
standards 
 
 No sig 
difference in 
height, weight 
and BMI 
between cohort 
and controls 
 
(Zimmerma
nn et al. 
2013)  
Strong ICCC-3 cancer N= 327 M: medical 
records 
T: from 
diagnosis until 
the end of 
therapy, 
RC Reference values: 
<4 y: WHO 
>4 y: KiGGS  
 
Undernutrition 
defined as:  
Undernutrition 
BMI or weight 
loss: 
 
Overall: 6% 
Non-
Undernutrition: 
BMI or weight 
loss: 
ALL 44 (46%)  
AML 15 (58%)  
NHL 13 (46%)  
NR 
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D: Diagnosis; M: method; T: time of measurement; C: cohort study;  PC: prospective cohort study; RC: retrospective cohort study; CS: cross-sectional; NR: not 
mentioned and/or not clear; NA: non-applicable (i.e. not part of study aims); Measurements: BMI: body mass index; WFH:weight for height; WFA: weight for age; 
HFA: height for age; MUAC: midd upper arm circumference; TSF: triceps skinfold thickness; FM: fat mass; FFM: free fat mass; RBW:relative body weight; 
Diagnosis: ALL: acute lymphoblastic leukaemia; MDS: myelodysplastic syndrome; HM: Haematological malignancies; ICCC-3: International classification of 
Childhood Cancer, Third edition;  Treatment: CT: chemotherapy; RT: radiotherapy; SG: surgery; ↓: decrease; ↑: increase; SD: standard deviation: y: years; sig: 
significance; Countries: UK: United Kingdom; USA: United States of America;  *data converted from months to years. 
 
 
 
 
relapse, death 
or continuation 
of treatment in 
a non-
participating 
hospital. 
Intervals 
between 
measurement 
between 7-90 
days 
BMI Z-score -2 
Weight loss > 
10% 
medulloblastoma 
CNS: 19% 
 
Osteosarcoma, 
medulloblastoma 
and 
neuroblastoma: 
13% 
HL 6 (24%)  
Medulloblastom
a 15 (94%)  
Other CNS 
tumor 10 (39%)  
Rhabdomyosarc
oma 8 (42%)  
Ewing sarcoma 
8 (50%)  
Osteosarcoma 
11 (73%)  
Nephroblastoma 
8 (44%)  
Neuroblastoma 
8 (50%)  
 
Other 9 (33%) 
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Table 2-5 Studies reporting the prevalence of undernutrition (from all measurement types) categorised by stage of treatment and 
diagnostic criteria 
*some studies report prevalence for more than one category 
 
 
 
 
 
 
Total 
number 
of studies 
(n) 
At diagnosis During treatment End of treatment 
n Range 
% 
Median 
% 
n Range 
% 
Median 
% 
n Range 
% 
Median 
% 
Haematological 
malignancies 
8 6 0-54 13 4 0-34 14 2 0-19 9.5 
Solid tumours 7 4 23.5-50 29.5 2 16-30 23 3 20-46 35 
ICCC-3 + 
other cancers 
5 5 3-65 20 1 50 50 none none none 
Overall 17* 14* 0-65 23.5 6* 0-50 16 5 0-46 20 
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 Table 2-6 Prevalence of undernutrition by type of measurement: prevalence of 
undernutrition obtained by BMI and weight measurements compared to those 
obtained by arm anthropometry 
% percentage; n: number of studies; BMI: body mass index; WT: weight; MUAC: middle upper arm 
circumference; TSF: triceps skinfold 
 
Table 2-7 Studies reporting prevalence of overnutrition defined by BMI and 
categorised by stage of disease and diagnostic criteria 
BMI: Body mass index; ICCC-3: International Classification of Childhood Cancer-3
rd
 edition; NR: 
not reported.  
 Overall At diagnosis On treatment End of therapy 
 BMI 
(n=16) 
WT (n=24) 
 
MUAC,T
SF 
 (n=11) 
BMI 
(n=10) 
WT ( 
n=9) 
MUAC,T
SF 
(n=7) 
BMI 
(n=2) 
WT 
(n=2) 
 
MUAC,T
SF 
(n=1) 
BMI 
(n=3) 
WT (n=1) 
 
MUAC,T
SF 
(n=1) 
Median 
% 
15 30 16 40 15 30 20 19 
Range % 0-50 0-73 0-50 0-73 0-50 0-34 0-46 0-20 
Diagnostic 
Category  
Total 
number 
of 
studies 
(n) 
At diagnosis During treatment End of treatment 
n Range 
% 
Median 
% 
n Range 
% 
Median 
% 
n Range 
% 
Median 
% 
Haematological 
malignancies 
5 5 8-30 15 3 28-69 40 3 28-78 40 
Solid tumours 1 0 none none 1 21 21 1 35 35 
Brain tumours 1 1 NR NR 1 57 57 1 NR NR 
ICCC-3 + 
other cancers 
1 1 4-9 7 none none none none none none 
Overall 8 6 8-30 15 5 21-69 30 5 28-78 38 
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2.1.3.4 Linear growth  
Thirteen out of 46 studies explored growth defined as height and HFA (table 3.8). 
Standard measures of growth were defined in 7/13 studies and 6/13 either compared 
mean height (SD) at different stages of the disease with baseline or, described a 
height pattern throughout the course of treatment. At diagnosis (7/13), five studies 
reported a normal HFA in comparison to the national average but, two reported poor 
linear growth in 17% (Viana et al. 1994) and 23% (Pedrosa et al. 2000) children. 
7/13 studies reported height SD changes during treatment. Of these, three studies 
reported normal linear growth; however, four reported a significant decrease in mean 
height SD from diagnosis or, values significantly lower than the HFA national 
averages. Finally, 5/13 studies reported height changes at the end of therapy. Of 
these, one reported normal heights in compared to the national standards, whilst four 
reported some catch up growth; however, mean height SD remained lower than the 
national average.     
2.1.3.5 Associations between malnutrition and outcome 
Nine out of 46 studies were found (see table 3.9) to explore associations between 
undernutrition and clinical outcome in children with cancer; two of these were 
preliminary data (Sala et al. 2008, Antillon et al. 2008) of a later study (Sala et al. 
2012). The outcomes measured were; relapse, mortality, abandonment of therapy, 
treatment toxicity, event free survival rates (EFS), type of tumour and age at 
diagnosis. The performance of a meta-analysis was impossible due to the 
heterogeneity of the outcomes measured, the variability found in the 
anthropometrical measurements and the heterogeneous populations. Therefore, 
evidence was described narratively. Three studies (Reilly et al. 1994, Sala et al. 
2012, Weir et al. 1998) reported data on relapse events and of these, two did not find 
that undernutrition (established with BMI SD) at diagnosis had any significant 
influence on either time of relapse (Weir et al. 1998) or relapse rates (Sala et al. 
2012); whilst one reported that children who were undernourished (established using 
WFH SD measurements) at diagnosis were more likely to relapse (Reilly et al. 1994). 
Two out 9 studies undertaken in developing countries investigated the degree of 
undernutrition and mortality rates establishing that the more undernourished the 
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children were the higher the mortality rates (Sala et al. 2012, Mejía-Aranguré et al. 
1999). One out 7 studies established that undernourished children were more likely 
to abandon therapy and this was more noticeable in children with solid tumours and 
heamatological malignancies (Sala et al. 2012). Another study found that 2-year EFS 
was significantly different between well-nourished and undernourished children, 
whereby 65% and 48% survived respectively (Sala et al. 2012). Additionally, one 
study explored factors associated with undernutrition (Zimmermann et al. 2013). 
This study found that children diagnosed with medulloblastoma, who were older than 
10 years of age at the time of diagnosis and had severe induced side effects 
(vomiting), were at higher risk of becoming undernourished (Zimmermann et al. 
2013). Finally, one cross-sectional study established that undernourished children 
from Malawi diagnosed with large Wilms tumours exhibited lower chemotherapy 
(vincristine) clearance than their well-nourished counterparts from the UK (Israels et 
al. 2010).   
One study investigated whether obesity in children diagnosed with ALL was 
associated with survival and EFS, but no significant associations were established 
(Baillargeon et al. 2006).  
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Table 2-8 Studies reporting linear growth (height and height for age) 
 
Author Quality Patients 
Dx 
N, age (years) Method & time of 
measurement 
Method 
 
Results 
Design Parameters At diagnosis During 
treatment 
After treatment 
(Argüell
es et al. 
2000) 
 
Spain 
Weak  ALL 
(HM) 
N=26 
Mean 5·12y 
Range 1·66-
10y 
M: NR 
 
T: Diagnosis, 6, 12, 
18, 24, 30 & 36 
months 
 
 
PC Normal BMI & 
Height 
±1 SD according 
to Spanish 
standards  
Mean (±SEM) 
Height SD 0·55 
(±0.19) 
 
BMI NR  
 
 
 
Mean (±SEM) 
Height SD 
At 6 months 
0·4(±0·19) 
At 12 months 
0·71(±0·22) 
At 18 months 
0·78(±0·2) 
At 24 months 
0·97(±0·21) 
At 30 months 
1·02(±0·22) 
At 36 months 
1·03(±0·20) 
Mean (±SEM) 
Height SD 1·03 
(±0·2) 
(Murphy 
et al. 
2006)  
 
UK 
Weak ALL 
(HM) 
 
N=29 
ALL group 
Mean(±SD) 
age 9.6(±1.8)y 
 
Healthy 
control group 
Mean (±SD) 
9.6 ± 2.0y  
M: one observer  
 
T: off treatment 
(range 1-2y)  
Diagnosis to 5 y 
PC NR NR NR Females with ALL 
had a tendency for 
↓height & ↑FM (FM 
60%higher than 
control group)    
(Bond et 
al. 1992)  
 
UK 
Weak ALL 
(HM) & 
Solid 
tumours 
Cohort 
N=26  
Mean (±SD) 
10·1 (±0·6)y 
M: NR 
 
T: 6 months from 
diagnosis and 1 week 
PC WFH & HFA 
according to 
Waterlow et al  
 
NA 1 (4%)ALL 
<90% HFA 
(stunted) 
 
NA 
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Controls 
 
Controls 
N=26 
Mean (±SD) 
10 (±0·6)y 
before CT 
 
TSF for FM not 
mentioned 
 
ALL group 
tended to be 
shorter  
(Halton 
et al. 
1998) 
 
Canada 
Weak  ALL 
(HM) 
Study I:  
N= 116 
Study II: no 
relevant 
Study III: 
N= 19 
Median 
(range) NR 
 
M: not mentioned 
 
T:  
Study I 
Diagnosis  
12 months intervals 
during treatment 
12 months after 
completion of therapy 
Study II: not relevant 
Study III: Diagnosis 
and 6 months 
intervals 
PC Standard 
measures not 
mentioned 
 
All measurements 
are compared 
with baseline 
 
 
Study I 
Height: 
Standard risk: 
Mean SD -0·03 
Males Mean SD -
0·18 
Females Mean SD 
0·3 
High Risk: 
Mean SD 0·28 
 
Weight: 
Standard Risk: 
Mean SD:0·0 
Males Mean SD: 
0·36 
Females mean 
SD: 0·15 
High risk:  
Mean SD: 0·2 
 
Study III 
% fat mass 
21·5±6·1 
Protein (g/l) 
65·9±11·9 
   
Study I 
Height: 
Decrease in mean 
height SD during 
treatment (12 and 
24 months) 
In the standard 
and high risk 
group  
At 24 months: 
 
Weight 
Reduction in 
weight velocity 
during 1
st
 year 
and a 
disproportionate 
increase in 
weight thereafter  
 
Study III 
Fat mass % 
Increase to 
25·0±8·9 at 12 
months 
Muscle mass  
Reduced to 
59·8±3·5 at 12 
months 
 
Catch up growth  
Study I 
Height: 
Standard risk: 
Mean SD -0·58 
Males Mean SD -
0·31 
Females Mean SD -
0·15 
High Risk: 
Mean SD -0·46 
 
Weight: 
Obesity tendency 
 
Study III 
% fat mass 
27·7±9·9 
Protein (g/l) 
57·9±2·4 (sig 
reduction from 
diagnosis) 
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(Smith et 
al. 1991) 
UK 
Moderate Newly 
diagnose
d 
malignan
cy 
(ICCC-3) 
N=100 
 
Median (range 
age 5 (0·3-
16·5)y 
 
M: one observer  
 
T: diagnosis, every 
month 
For how long? 
 
PC Undernutrition 
defined as  
HFA -2 SD 
(WHO) 
 
HFA & WFH 
normal 
 
NR NR 
(Uderzo 
et al. 
1996)  
 
Italy 
Weak  ALL 
(HM) 
Cohort  
N=173 
Median 
(range) age 4 
(0·16-15) y 
 
Control  
N=307 
Median 
(range) age 7 
(5-14)y 
M: two observers  
 
T: at diagnosis 
PC Data (height, 
weight, WFH, 
MUAC & TSF) 
compared with 
the national center 
for health 
statistics (NCHS) 
in the USA 
Height 
measurements NR 
 
NA NA 
(Pietsch 
and Ford 
2000)  
 
USA 
Moderate  Cancer 
diagnosis 
(ICCC-3 
& other) 
N= 133 
 
Median age 
NR 
M: medical records 
 
T: at diagnosis 
RC Z-scores for 
WFH, WFA & 
HFA in children 
≤10y NCHS 
growth curves 
HFA NR 
 
 
 
NA NA 
(Ahmed 
et al. 
1997)  
 
UK 
Moderate  ALL 
(HM) 
N=31  
 
Median 
(range) age at 
diagnosis 4·4 
(1·1-14)y 
M: one observer  
 
T: monthly 
measurements (range 
3-24months) 
PC  NR NA Height SD is 
lowest at 6 
months after CT 
& remains 
significantly 
depressed until 
the end of the 1st 
year 
 
Median Weight 
SD ↑ sig over 1st 
months & by the 
end of CT 
NA 
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Median BMI SD 
↑ significantly at 
6 & 10 months 
(van der 
Sluis et 
al. 2002)  
 
Netherla
nds 
Weak  ALL 
(HM) 
N=61 
Median 
(range) age 
7·1(1·6-16·8) 
y 
M: NR 
 
T: At diagnosis, 32 
weeks, 1, 2 and 3 
years after diagnosis 
PC Height and BMI 
compared with 
age & sex 
matched reference 
values from 
Netherlands  
Measurements 
compared to 
baseline 
Height: mean -
0·19 SD  
BMI: -0·31SD 
 
*values are 
approximate-
obtained from 
table 
32 weeks 
Height ↓ 
significantly to -
0·75 SD 
BMI: sig ↑ to 
+0·65  SD 
2 year 
Ht: -0·75 SD 
BMI: +1·35 SD 
1 year after 
cessation of therapy: 
sig ↑ in height 
Height: -0·63SD 
BMI: +1·05 (↓ non-
significant) 
(Tammi
nga et al. 
1992) 
 
Netherla
nds 
Weak ALL 
(HM) 
N=53 
 
Group I:  
Median 
(range) age 
4·5(2·4-10·4)y 
Group II:  
Median 
(range) age 5·3 
(1·6-14·0)y 
Group III:  
Median 
(range) age 5·6 
(2.4-12.2)y   
Group IV:  
Median 
(range)  8·3 
(4·8-13·4)y 
M: NR 
 
T: every 3 months for 
2 years 
 
Group I: ALL High 
Risk 
Group II: ALL 
irradiated 
Group III: ALL not 
irradiated  
Group IV: ALL after 
therapy 
PC Height, weight, 
WFH, MUAC, 
sitting height, arm 
span and head 
circumference 
Height SD:  
I: 1·3 SD 
II: -0·1 
III: +0·05 
IV: +1·3 
Height 
retardation was 
maximal in the 
first 6 months 
after diagnosis 
 
No sig difference 
between groups 
during treatment  
 
Sig ↑ in height in 
groups II & III 
(when NR) 
NA 
(Pedrosa 
et al. 
2000) 
 
Brazil 
Moderate HM and 
solid 
tumours 
N=443 
Median 
(range) age 4·9 
(0-17·8)y 
M:patient’s records 
T: at diagnosis, 1 
year 
RC WHO standards  
WFA, WFH, 
HFA  
Undernutrition Z-
scores -2  
Undernutrition: 
WFA: 23·5%  
WFH: 16% 
HFA: 23%  
No sig difference 
in survival rates 
between well-
nourished and 
undernourished 
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Outcome: survival 
at 1 year 
children 
 
 
(Caruso 
Nicoletti 
et al. 
1993)  
 
Italy 
Weak ALL 
CR 
Non-CR 
N= 50 
Median 
(range) age 5 
(1·6-11·9) 
M: one observer 
T: at diagnosis, every 
3 months during 
treatment and every 6 
months after 
treatment for 5 years.  
PC Height SD and 
height velocity 
Tanner’s data 
Normal height at 
diagnosis  
Both groups 
exhibited a ↓ in 
growth velocity 
during the first 6 
months  
Growth 
deprivation was 
more severe in 
the CR group 
 
During the 2
nd
 
year growth 
velocity returned 
to normal 
Catch up growth 
until almost normal 
for both groups 
(Viana et 
al. 1994)  
 
Brazil 
Moderate ALL N=128 
Median 
(range) age 5·8 
(0·75-14·75)y 
M: NR 
T: at diagnosis 
PC WHO standards 
 
Reduced HFA: 
23% 
NA NA 
D: diagnosis; M: method; T: time of measurement; PC: prospective cohort study; RC: retrospective cohort study; NR: not reported and/or not clear; NA: not 
applicable (i.e. not part of study aims); Measurements: BMI: body mass index; WFH: weight for height; WFA: weight for age; HFA: height for age; MUAC: midd-
upper arm circumference; TSF: triceps skinfold thickness; FM: fat mass; FFM: free fat mass; Diagnosis: ALL: acute lymphoblastic leukaemia; HM: 
Haematological malignancies; ICCC-3: International classification of Childhood Cancer, Third edition;  Treatment: CT: chemotherapy; R: radiotherapy; CR: 
cranial radiotherapy; ↓: decrease; ↑: increase; SD: standard deviation; y: years; sig: significant; Countries: United Kingdom; USA: United States of America. 
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Table 2-9 Associations between malnutrition and outcomes 
  
Author Quality Patients Dx N, age Time of 
measurement/method 
Method 
 
Results 
Design Variables Outcomes 
(Sala et al. 
2012) 
 
Guatemala, El 
Salvador, 
Nicaragua, 
Dominican 
Republic, 
Panama, 
Honduras, 
Costa Rica 
Strong Childhood 
cancer (ICCC-3 
criteria) 
N= 1787 
Median (IQR) 
age 6.8y (3.8-
10.6) 
T: Diagnosis 
M: one to two 
observers in each 
country 
PC Nutritional 
status assessed 
with BMI, 
MUAC & TSF 
 
 
Relapse 
Abandonment 
of treatment 
EFS 
CT 
interruptions   
No association 
between nutritional 
status and relapse 
 
Undernourished 
children abandoned 
treatment more often 
(p<0.05) 
 
Undernutrition was 
associated with 
reduced EFS and ↑ CT 
interruption. 
(Weir et al. 
1998) 
 
UK 
Strong  Standard risk 
ALL 
N=1025 M: medical records  
T: at diagnosis  
RC BMI SD UK 
national 
standards  
Undernutrition 
(-2 SD) 
Overnutrition(2 
SD)  
 
Relapse rates BMI SD at diagnosis 
did not influence 
statistically time of 
relapse 
(Reilly et al. 
1994) 
 
UK 
Moderate Standard risk 
ALL 
N=78 M: NR 
T: at diagnosis 
PC WFH SD UK 
population 
reference data  
Undernutrition 
Relapse rates Children with the 
lowest WFH SD score 
at diagnosis were at 
higher risk of early 
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(-2 SD) 
Overnutrition(2 
SD) 
relapse than their 
well-nourished 
counterparts 
(Viana et al. 
1994, Pedrosa 
et al. 2000) 
 
Brazil 
Moderate Heamatological 
malignancies 
and solid 
tumours 
N=443 
Median (range) 
4·9 (0-17·8)y 
M:patient’s records 
T: at diagnosis, 1 year 
RC WHO standards  
WFA, WFH, 
HFA  
Undernutrition 
Z-scores -2  
Survival at 1 
year  
No sig difference in 
survival rates between 
well-nourished and 
undernourished 
children 
 
(Viana et al. 
1994)  
 
Brazil 
Moderate ALL N= 128 
Median (range) 
age 5·83 (0·75-
14·75)y 
M: NR 
T:at diagnosis 
PC  WHO standards  
WFA, WFH. 
HFA 
 
Undernutrition 
defined as Z 
score -2 SD 
 
Relapse, 
remission, 
deaths, second 
tumour, EFS 
Undernutrition was an 
adverse factor 
affecting duration of 
complete remission   
(Wessels et 
al. 1999)   
 
South Africa  
Weak  Wilms’ tumour N=59 
Undernourished 
group 
Median(range) 
age 3 (0·5-
8·25)y 
 
Well-nourished 
group   
Median (range) 
age 2.91 (0·5-
11·58)y 
M: charts review  
T: at diagnosis, end of 
therapy 
RC  WFA & WFH 
WHO standards 
 
Undernutrition 
<3
rd
 centile or 
<90% 
 
 
Survival No difference in 
survival between the 
two groups  
74% of 
undernourished 
children survived in 
compare to 56% of the 
well-nourished group 
(Mejía-
Arangure et 
al. 1997) 
 
Mexico 
Strong  ALL 
High Risk (HR) 
Low risk (LR) 
N=105 
Median  NR 
M: four observers 
T:  at diagnosis, 2 and 
3 months 
PC WFH Waterlow 
classification  
MUAC 
Frisancho 
standards  
 
Undernutrition 
Risk of 
mortality 
Undernutrition was 
associated with higher 
risk of mortality 
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defined as 
≥10%  loss of 
MUAC  
(Israels et al. 
2010)  
 
Malawi, UK 
Weak Wilm’s tumour N=19 
Malawi (n=11) 
UK (n=8) 
M: NR 
T: At diagnosis 
CS Malawi: 
Z-score 
corrected 
WFH: -2·3±1·3 
UK: 
Z-score 
corrected 
WFH: 0·4±0·8 
Vincristine 
clearance 
 
 
Reduce Vincristine 
clearance was 
associated with 
undernutrition. 
(Zimmermann 
et al. 2013) 
Strong ICCC-3 N=327 M: medical records 
T: from diagnosis until 
the end of therapy, 
relapse, death or 
continuation of 
treatment in a non-
participating hospital. 
Intervals between 
measurement between 
7-90 days  
RC Undernutrition 
assessed with 
BMI Z-score (-
2) and weight 
loss % (10%) 
Patient’s 
related 
factors: age, 
gender and 
country of 
origin 
Disease 
factors: type 
of cancer, date 
of diagnosis, 
metastasis or 
CNS 
involvement  
Treatment 
related 
factors: 
emetogenicity 
Medulloblastoma, 
age >10 y and high 
emetogenicity was 
sig. associated with ↑ 
risk of undernutrition. 
Dx: Diagnosis; M: method; T: time of measurement; C: cohort study;  PC: prospective cohort study; RC: retrospective cohort study; CS: cross-sectional study; NR: 
not reported and/or not clear; NA: non-applicable; Measurements: BMI: body mass index; Ht: height; WFH: weight for height; WFA: weight for age; HFA: height 
for age; MUAC: middle upper arm circumference; TSF: triceps skinfold thickness; FM: fat mass; FFM: free fat mass; RBW: relative body weight; Diagnosis: ALL: 
acute lymphoblastic leukaemia; HM: Heamatological malignancies; ICCC-3: International classification of Childhood Cancer, Third edition; NHL: non-Hodgkin’s 
lymphoma; Treatment: CT: chemotherapy; Dexa: Dexamethasone; Pred: Prednisolone; R: radiotherapy; ↓: decrease; ↑: increase; SD: standard deviation; y: years; 
sig: significant. EFS: event free survival; Countries: UK: United Kingdom; USA: United States of America 
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2.1.3.6 Quality of body of evidence  
According to the assessment of quality of evidence by CASP methods, the evidence 
for the prevalence of malnutrition in childhood cancer was mainly of poor quality. 
The main issues identified with studies scored as “weak” were:  
(i) It was difficult to establish the precision of the results due the absence of 
confidence intervals and relative risk (n=29).  
(ii) Confounding factors were not taken into consideration in the design and in 
the analysis of the data (n=18) 
(iii) Anthropometrical data was not compared to either national or international 
standards making it very difficult to identify malnutrition in this population 
(n=10) 
(iv) Inappropriate use of statistical methods (n=7) 
Despite this, all selected studies were considered to draw some general conclusions.  
2.1.4 Discussion 
The results from this systematic review of 46 studies show that, to date, there is 
insufficient robust evidence to accurately determine the prevalence of malnutrition in 
paediatric cancer worldwide, particularly from the developing world. Moreover, 
evidence was heterogeneous with regards to the anthropometric measurements, the 
criteria and the cut-off values used to assess nutritional status. These limitations 
meant that it was impossible to perform a meta-analysis of the associations between 
malnutrition and clinical outcomes.  
2.1.4.1 Prevalence of undernutrition and overnutrition 
Evidence of the prevalence of malnutrition at different stages of the disease was 
highly variable across all types of paediatric cancer and, as expected, differences 
were observed between the developed and developing world. Three quarters of 
studies were performed in the developed world, though most cancer diagnoses occur 
in the developing world (Pritchard-Jones et al. 2013). The majority of the studies 
considered malnutrition in ALL patients, and the data for malnutrition in either solid 
123 
 
or brain tumours are limited. Moreover, most research, until now, has focused on the 
prevalence of undernutrition, whilst overnutrition has largely been overlooked. 
Finally, most studies investigated the prevalence of malnutrition at diagnosis with 
very few exploring nutritional status during or at the end of therapy.  
Children diagnosed with haematological malignancies, mainly ALL, had the lowest 
prevalence of undernutrition; consistent with previous reviews (Sala et al. 2004, 
Brouwer et al. 2007). Contrary to previous studies (Sala et al. 2004, Carter et al. 
1983), this review suggests that the prevalence of undernutrition in this group, in 
both developed and developing countries, is still significant, especially at diagnosis 
(median 13%) and during treatment (median 14%). Of note, there was more 
variability in the prevalence of undernutrition in developing countries (range 0-54%; 
median 23%) than in developed countries (range 4-15%; median 10%). 
Undernutrition in children with solid tumours was highly prevalent from diagnosis 
until the completion of therapy. The data for this subgroup, although variable, 
appeared more consistent. Nevertheless, a few cautionary notes are needed; the small 
number of studies looking at these patients (Barbosa-Cortés et al. 2007, Green et al. 
2008, Oguz et al. 1999, Schiavetti et al. 2002, Bakish et al. 2003), their small sample 
sizes (range; 12-112) and the considerable differences in disease severity of the 
subjects included in each study as well as the site of treatment (Barbosa-Cortés et al. 
2007, Green et al. 2008).  
The median prevalence of undernutrition for all paediatric cancers (ICCC-3) was 
20% at diagnosis. Although these studies were of high-quality with large sample 
sizes, the prevalence of undernutrition was extremely variable ranging from 3-65% 
(Sala et al. 2012, Sala et al. 2008, Barr et al. 2011, Pietsch and Ford 2000, Smith et 
al. 1991, Zimmermann et al. 2013). This may be due to the following: (i) cancer 
encompasses many diseases (Steliarova-Foucher et al. 2005), all treated with 
different forms, combinations and intensities of treatment by different specialised 
physicians (Chan 2007, Tobias, J, & Hochhauser, D 2010); (ii) the sample sizes of 
each type of cancer varied between the different studies; (iii) different crietria were 
used to identify undernutrition, (iv) and the standard population against which the 
studies compared their measurements was not always specified.    
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Only three studies considering overnutrition in haematological malignancies met the 
eligibility criteria (Gofman and Ducore 2009, Baillargeon et al. 2005, Odame et al. 
1994). Although, they all reported similar prevalence (median 15%) at diagnosis 
their findings during and at the end of treatment were highly variable. Nonetheless, 
there is a suggestion that the number of cases of overnutrition increases during 
treatment (median 40%); in line with two reviews (Reilly 2009a, Brouwer et al. 
2007). The available data for solid and brain tumours was even scarcer; prevalence 
of obesity during treatment was 21% (solid tumours) (Schiavetti et al. 2002) and 
57% in patients diagnosed with brain tumours, particularly craniopharyngioma 
(Müller et al. 2001). The high incidence of obesity in children diagnosed with and 
treated for craniopharyngioma has been extensively discussed in a review, where 
obesity is attributed to a disruption of the hypothalamic function (Iughetti and Bruzzi 
2011). This disruption is most commonly caused by the tumour itself or by the 
treatment (surgery or cranial radiotherapy) and can lead to abnormalities in both the 
satiety and the hunger control mechanisms, which in turn causes a dysregulation in 
energy balance (Iughetti and Bruzzi 2011). Other factors include sedentary 
behaviour, such as reduced physical activity (Iughetti and Bruzzi 2011). At the end 
of therapy, only one study reported a prevalence of obesity of 35.5% (Schiavetti et al. 
2002). Finally, one study of children diagnosed with a paediatric cancer (ICCC-3) 
reported a prevalence of 7% at diagnosis (Barr et al. 2011). Thus, with the present 
evidence, it is not possible to accurately report the prevalence of overnutrition in the 
different subpopulations of paediatric cancer. Although, studies were variable in 
terms of their quality, mainly due to methodological issues, on a positive note the 
criterion used to define obesity was described in all the studies and the methods 
employed to identify obesity were consistent; namely BMI +2SD. 
Undernutrition in paediatric cancer at the time of diagnosis was more prevalent in 
developing (median 23·5%) than in developed countries (median 13%) (figure 3.2). 
This disparity may be multifactorial as reduced health care resources might 
contribute to either late diagnosis or treatment inaccessibility (Pritchard-Jones et al. 
2013, Sala et al. 2004). Overnutrition at diagnosis was also higher in the developing 
world (15%) than in the developed world (10%). However, only one study from the 
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developing world (Mexico) reported prevalence of overnutrition (Jaime-Pérez et al. 
2008), which is unlikely to be representative of the whole developing world.      
2.1.4.2 Linear Growth 
Children with ALL tended to have normal HFA at diagnosis, but a significant 
reduction in height velocity occurred during treatment, which remained until the end 
of therapy. At this stage, there was some catch up growth, but the HFA remained 
lower than the population average (Murphy et al. 2006, Halton et al. 1998, Ahmed et 
al. 1997, van der Sluis et al. 2002, Caruso Nicoletti et al. 1993, Holm et al. 1994). 
There were only two studies investigating linear growth in children diagnosed with 
solid tumours (Bond et al. 1992, Murphy et al. 2006); one reported normal heights at 
diagnosis (Murphy et al. 2006) and the other one reported that children with ALL 
tended to be shorter than those diagnosed with solid tumours (Bond et al. 1992). 
Thus, more research is needed to investigate linear growth in children diagnosed with 
solid tumours.  
2.1.4.3 Methods used to identify malnutrition    
The methods used to identify undernutrition were heterogeneous, whilst studies were 
more consistent in their assessment of overnutrition. At present, there is not a “gold 
standard” anthropometric measurement that best assesses undernutrition in ill 
children (Anon 2006b), whereas the evidence for the use of BMI to diagnose obesity 
is more consistent (Reilly 2006). It has been suggested (Sala et al. 2004) that arm 
anthropometry should be incorporated in clinical practice as a routine measurement 
(Sala et al. 2004, Sala et al. 2012, Oguz et al. 1999, Barr et al. 2011). This systematic 
review showed that the prevalence of undernutrition was highly variable regardless 
of the method employed; however, the median prevalence of undernutrition assessed 
by arm anthropometry (MUAC and TSF) was consistently higher than that obtained 
from BMI, both at diagnosis and during treatment, but it was almost the same at the 
end of therapy. This was the case for all diagnostic categories. The discrepancy 
between BMI and arm anthropometry may reflect the limitations of BMI in our 
population, not seen as much in healthy children (Cole et al. 1995a, Cole et al. 2007). 
BMI does not account for changes in body composition, weight of tumour and 
oedema (Oguz et al. 1999, Pietsch and Ford 2000, Smith et al. 1991, Murphy et al. 
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2010). MUAC and TSF are less influenced by these complications, hence a better 
reflection of body composition (Roche et al. 1981). Thus, this review proposes the 
following (table 2.10).  
 
Table 2-10 Research recommendations to consider for the future 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research recommendations to consider for the future: 
 Different forms of cancers need to be thought of as different diseases 
requiring very different treatments, as such should be presented 
separately. 
 Measurements need to be collected at different stages of the disease and 
treatment course. 
 A standard criterion needs to be applied to the diagnosis of both under and 
overnutrition using standard cut off values.  
 Nutritional status should be assessed by weight, height (and the 
calculation of BMI), MUAC and TSF, not only for research purposes but 
also in the clinical setting. 
 The following details need to be clearly specified: the timings of when the 
measurements are taken (before the start of treatment, at diagnosis, or 
during the initiation of treatment), the socio-economic status, ethnicity, 
disease severity, treatment protocol and nutritional support. 
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2.1.4.4 Nutritional status as a prognostic factor for outcome 
There is a paucity of evidence examining associations between malnutrition at 
diagnosis and clinical outcomes and the few published studies appeared inconclusive. 
Undernutrition in paediatric cancer may be associated with higher mortality (Sala et 
al. 2012, Mejía-Aranguré et al. 1999); however, these two studies were both 
undertaken in developing countries and there may have been other factors related to 
mortality, such as increased duration of treatment (Viana et al. 1994) and, also 
toxicity (Sala et al. 2012). These findings are supported by a recent review (Sala et 
al. 2004) and evidence from the 1980s (Donaldson et al. 1981, Lobato-Mendizábal et 
al. 1989, Rickard et al. 1983). Notably, two large studies included in this review 
(Sala et al. 2012, Weir et al. 1998) did not find associations between undernutrition 
and relapse. Obesity in children with ALL was not associated with a decrease in EFS 
in comparison to their well-nourished counterparts (Baillargeon et al. 2006). In 
contrast, a large study (n=4356; age: 2-22 years), not included in the current review, 
showed that obesity at diagnosis independently predicted the likelihood of relapse in 
preteenagers and adolescents with ALL (Butturini et al. 2007). This effect was 
independent of disease severity, chemotherapy dosages and chemotherapy induced 
toxicity (Butturini et al. 2007). Although, it remains unclear if obesity is associated 
with poorer outcomes, it is vital to reduce its prevalence to minimise long-term 
obesity related disorders, which are exacerbated by the side-effects from the 
treatment (Oeffinger et al. 2006a).    
2.1.4.5 Limitations of study 
Several limitations were identified in this review. During the search process, 
potential language bias might have occurred as the authors restricted the review to 
the English language. Following the risk of bias assessment using the CASP tool, it 
became clear that the quality of studies varied considerably, which goes some way to 
explaining the great differences in reported prevalence of malnutrition in this review.  
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2.1.5 Conclusion  
This systematic review represents the first effort to date to review the 
epidemiological evidence on prevalence of malnutrition in children diagnosed with 
cancer worldwide, and to explore whether or not malnutrition is associated with 
clinical outcome. Unfortunately, these aims have been largely frustrated by both the 
absence of high-quality research and the heterogeneous nature of the existing 
outcome data. The single most important conclusion from this systematic review is 
the need for future high-quality population based longitudinal cohort studies, which 
consider the recommendations highlighted here. Nonetheless, the present evidence 
raises the possibility that children diagnosed with and treated for cancer are likely to 
be undernourished and or overnourished at different stages of the disease.   
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2.1  SYTEMATIC REVIEW: PREVALENCE AND POSSIBLE CAUSES 
OF VITAMIN D DEFICIENCY AND INSUFFICIENCY IN 
PAEDIATRIC CANCER PATIENTS  
2.2.1  Introduction  
Survival rates of pediatric cancer patients have improved considerably in the last 40 
years as a result of treatment advances (Herbst et al. 2006). Consequently, attention 
is shifting to the reduction of treatment-related sequelae during and after the 
completion of therapy. Vitamin D inadequacy is now an international recognised 
health problem (Ahmed et al. 2011); however, there is still debate about the 
definitions of deficiency, insufficiency and sufficiency (Holick 2004, RCPCH 2013, 
Holick et al. 2011, Holick 2009) and, guidelines on supplementation remain 
inconsistent (Pramyothin and Holick 2012). Worldwide, one in seven people (14%) 
are estimated to have either insufficient or deficient vitamin D status (Holick 2007), 
whilst in healthy children, the prevalence ranges from 14% to 49% (Choudhary et al. 
2013). Childhood cancer patients may be at even higher risk of vitamin D deficiency 
than the healthy population (Duncan et al. 2011), as prevalence has been reported as 
high as 80% in children diagnosed with acute lymphoblastic leukaemia (ALL) 
(Atkinson 2008). Additionally, survivors of childhood cancer have an increased risk 
of developing the metabolic syndrome, cardiac complications and have a reduced 
peak bone mass due to related treatment side-effects (Wallace et al. 2013), which 
might be exacerbated by vitamin D deficiency during and after the completion of 
therapy (Holick 2004).  
Vitamin D is primarily obtained from sunlight (endogenously synthesised from a 
zoosterol 7-dehydrocholesterol) and it can also be absorbed directly from the diet, 
however very few foods contain naturally occurring vitamin D (Holick 2006). Once 
absorbed, vitamin D2 or vitamin D3 are converted to 25-hydroxyvitamin D2 
(25(OH)D2) or 25-hydroxyvitamin D3 (25(OH)D3) metabolites in the liver, which 
may then be activated in the kidneys to 1,25-dihydroxyvitamin D (1,25(OH)2D) 
(figure 3.3) (Holick 2006). The functions of vitamin D in the body are often divided 
into musculoskeletal and non-musculoskeletal. Until now, the principal functions of 
vitamin D were held to lie in the musculoskeletal system as vitamin D is essential to 
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allow optimal calcium homeostasis, adequate growth and skeletal development in 
children. Consequently, prolonged periods of vitamin D deficiency in children 
increase the risk of bone fractures, rickets and of slow growth (Holick
 
et al. 2011), 
with the subsequence increase risk of osteoporosis in later life (Oeffinger et al. 
2006b). More evidence is emerging supporting a wider role for vitamin D beyond the 
musculoskeletal system (Holick 2010). A potential role in lowering both blood 
pressure and the risk of developing Diabetes Mellitus has been reported (Holick 
2010, Huh and Gordon 2008). Work is also ongoing exploring its anti-inflammatory 
and immunomodulatory effects, which allied with potential cell growth regulatory 
functions (Holick 2010, Huh & Gordon 2008), raises the possibility of a role in 
preventing cancer progression (Holick & Chen 2008).    
 
Figure 2.3 Absorption, metabolism and functions of vitamin D 
(Obtained with permission from http://www.presionnnutrition.com/genetics-vitamin-d)  
 
Children diagnosed with cancer may be at increased risk of vitamin D deficiency due 
to the disease itself, but also the multiple treatment induced side-effects (Duncan et 
al. 2011). In normal circumstances, vitamin D binding protein (DBP), which is 
synthesised in the liver, binds to vitamin D (25(OH)D and 1,25(OH)D) and 
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transports these to target tissues (White & Cooke 2000, Speeckaert et al. 2006). 
Recent evidence postulates that plasma concentrations of albumin and DBP are 
correlated (Speeckaert et al. 2006). The concentration of plasma DBP, like albumin, 
might be reduced during the disease process, reducing in turn the body’s ability to 
transport vitamin D to target tissues (Speeckaert et al. 2006, Speeckaert et al. 2006). 
Some cytotoxic drugs, radiotherapy and antifungals cause phototoxicity. Thus, 
children who receive these treatments are advised to avoid sunlight (Duncan et al. 
2011). Some chemotherapy agents can cause hepatotoxicity and acute and or chronic 
kidney injury, thereby interfering with the activation of vitamin D from its inactive 
(25(OH)D2 and D3) to its active form (1,25(OH)2D) (Atkinson 2008). 
Glucocorticoids stimulate vitamin D catabolism and can increase the risk of vitamin 
D deficiency (Zhou et al. 2006). Additionally, the long term use of glucocorticoids 
increase the risk of bone fractures, which in turn may be exacerbated with vitamin D 
deficiency (Holick 2006). Mucositis is a common complication of cancer therapy, 
which results in reduced absorption of essential vitamins and minerals, including 
vitamin D (Atkinson 2008). Finally, impaired growth velocity may occur during 
treatment of childhood cancer (Wallace et al. 2013), which can also be exacerbated 
by vitamin D deficiency, as this is essential to allow adequate growth and skeletal 
development in children (Holick 2006).   
Given that most children and adolescents now survive into adulthood (Wallace et al. 
2013), the emerging evidence of the importance of vitamin D on health and the 
absence of a published systematic review looking at this subject, it is now essential to 
study the epidemiological picture of vitamin D deficiency in paediatric cancer 
patients. Thus the aims were (i) to establish the prevalence of vitamin D deficiency 
and insufficiency in children and adolescents diagnosed and treated for cancer at 
different stages of the disease (diagnosis, during treatment and at the end of therapy) 
and (ii) to explore possible causes of vitamin D inadequacy in this population. 
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2.2.2 Methods  
A protocol was designed a priori (http://www.crd.york.ac.uk/PROSPERO/ 
registration number: CRD42013004371). The process and reporting of this 
systematic review was performed according to the Cochrane Collaboration and 
following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) (Moher et al. 2009).    
2.2.2.1 Outcome data 
The primary outcome was 
(i) Plasma/serum 25 hydroxyvitamin D (25(OH)D) defined as nmol/L or ng/ml.  
The secondary outcomes were: 
(i) Plasma/serum 1,25 dehydroxycholecalciferol (1,25(OH)D) defined as nmol/L 
or ng/ml.  
(ii) Studies looking at plasma parathyroid hormone as well as plasma 25(OH)D 
and 1,25(OH)D levels. 
(iii) Studies looking at possible causes of vitamin D inadequacy (deficiency and 
insufficiency). 
2.2.2.2 Eligibility criteria and search strategy 
The eligibility criteria included: 
iii. Studies investigating children and young people, aged <18 years and 
diagnosed with cancer according to the International Classification of 
Childhood Cancer, third edition (ICCC-3)  
iv. To minimise the risk of bias there was no restriction on follow up period 
 
Electronic searches with no language restrictions were performed (no restriction-
August 2013) using the Cochrane Library, MEDLINE (via EBSCOhost), CINAHL 
(via EBSCOhost), PUBMED and Google search to identify systematic reviews, 
Randomised Controlled Trials (RCT), observational studies, case control studies and 
letters to the editor. The reference list of all relevant articles, narrative reviews and 
private collections was also examined. The initial search strategy identified the 
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following keywords and subject heading searches (MeSH); “pediatrics”, “cancer”, 
“cancer treatment”, “vitamin D”. 
2.2.2.3 Study selection, quality assessment and data extraction 
Titles and abstracts from the combined searches were reviewed by two researchers 
independently (RRI, ER). In those cases of disagreement, an independent advisor 
(DW) made the final decision. Evidence was critically appraised independently by 
two researchers (RRI, IP) employing a standard methodological tool; the Critical 
Appraisal Skills Programme (CASP). In case of disagreement a third independent 
reviewer (DW) made the final assessment and a decision was made. The CASP tool 
has been recommended for epidemiological studies, public health and evidence based 
practice (Sanderson et al. 2007). The CASP comprises an assessment of: (i) 
Contextual information including the study objectives, study design and the patient’s 
characteristics; (ii) Potential selection bias including inclusion and exclusion criteria, 
clear patient selection and an assessment of validity, reliability and accuracy of 
techniques used; (iii) Outcome measures including reference values; (iv) statistical 
analysis employed and (v) a reporting of results and control for confounding factors. 
Each section was classified as “yes” if the authors covered the questions, “can’t tell” 
if it was not reported or “no” if it was not covered or considered at all. A quality 
rating of “strong”, “moderate” or “weak” was applied to each study; where “strong” 
was given when the study met all areas of the CASP criteria, “moderate” when there 
was one weak area and “weak” when ≥ two weak areas were identified.   
For those studies that did not report the prevalence of vitamin D deficiency and 
insufficiency, we contacted the corresponding author first on two occasions, giving 
two weeks in between emails to allow for some time to reply. If that failed, we then 
repeated the process by contacting the last or most senior author and then the second 
author. If no response was received after these three attempts, the article was 
included, however the data did not count towards the final prevalence results as this 
would have been unavailable. Finally, the performance of a meta-analysis of selected 
studies investigating the association between vitamin D inadequacy and vitamin D 
related treatment complications was planned a priori.  
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Studies were classified according to four diagnostic criteria: haematological 
malignancies, solid tumours, brain and benign tumours and all malignancies (ICCC-
3) when studies considered all diagnosis together. Finally, we calculated the median 
and the range percentage of the prevalence of vitamin D inadequacy using the 
reference values recommended in the Endocrine Society Clinical Practice guideline 
(Holick et al. 2011), which defines 25(OH)D levels as sufficient/optimal (>75nmol/L 
or 30ng/ml), insufficient (75-50nmol/L or 30-20ng/ml) and deficient (<50nmol/L or 
<20ng/ml).  
2.2.2.4 Meta-analysis  
A meta-analysis investigating whether age was associated with vitamin D status was 
performed. Data on correlations and odds ratio of age with vitamin D deficiency and 
insufficiency were extracted from each relevant study and converted to a common 
effect size (ES), Fisher’s Z and the associated standard error. These were combined 
in a meta-analysis using the Meta Procedure, with Stata version 9.2 to synthesise an 
overall ES and 95% Confidence Interval, and the associated Forrest plot. Statistical 
heterogeneity was assessed using the Q statistic, with p<0.05. The results of both 
fixed and random effects models were generated, with the resulting models being 
similar, hence only the fixed effects model is reported here. Variation in ES 
attributable to heterogeneity was assessed with the I-squared statistic, which is 
defined as the percentage of the study heterogeneity attributable to variability in the 
true treatment effect, rather than sampling variation. 
 
2.2.3 Results 
2.2.3.1 Study selection and study characteristics 
19 studies met the eligibility criteria (figure 2.3). Of these, eight were prospective 
cohort studies (Arikoski et al. 1999a, Atkinson et al. 1998, Bilariki et al. 2010, El-
Ziny et al. 2005, El-Ziny et al. 2007, Halton et al. 1996, Henderson et al. 1998, 
Rosen et al. 2013), six cross-sectional studies (Arikoski et al. 1999b, Atkinson et al. 
1989, El-Hajj Fuleihan et al. 2012, Halton et al. 1995, Halton et al. 1995b, Modan-
Moses et al. 2012, de Schepper et al. 1994) and three case-control studies (Frisk et al. 
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2012, Gunes et al. 2010, Sinha et al. 2011). There was also a retrospective cohort 
study (Choudhary et al. 2013) and a non-randomised control trial (Wiernikowski et 
al. 2005). Vitamin D levels in paediatric cancer patients were investigated either as a 
primary or secondary outcome. Ten studies investigated vitamin D levels in children 
diagnosed with haematological malignancies and acute lymphoblastic leukaemia was 
considered in all studies. Six studies considered children diagnosed with childhood 
cancers included in the ICCC-3, five studies considered solid tumours and two 
considered children diagnosed with either brain tumours or benign brain tumours. 
Finally, four studies investigated vitamin D status in children diagnosed with more 
than one cancer category.   
 
A total of 1235 participants were included in all 19 studies with individual sample 
sizes ranging from 10 to 426. Four studies used the same population (Atkinson et al. 
1998, Halton et al. 1996, Atkinson et al. 1989, Halton et al. 1995a). Thus, only 
subjects and data from one study (n=40) was accounted for within the total number 
of participants. The 19 studies were all written in English and eight were performed 
in North America, six in Europe and five in the Middle East.  The methods used to 
analyze vitamin D status were reported in all studies, however only five studies 
(Frisk et al. 2012, Arikoski et al. 1999a, Arikoski et al. 1999b, El-Hajj Fuleihan et al. 
2012, Sinha et al. 2011)
 reported intra assays’ coefficient of variation, which ranged 
from 3.6 to 14% (table 3.11).  
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Figure 2.4. Flow chart of the studies screened, selected, assessed for eligibility 
criteria and included in the systematic review. 
 
2.2.3.2 Prevalence of vitamin D deficiency and insufficiency  
Plasma 25(OH)D and 1,25(OH)D are presented separately as these two metabolites 
provide different clinical information: 25(OH)D is the best marker of vitamin D 
status in humans (Zerwekh 2008), whilst 1,25(OH)D is tightly regulated by calcium 
homeostasis and its concentration changes rapidly (Zerwekh 2008).  
The prevalence of plasma 25(OH)D status was reported in 13/19 studies (table 2.11; 
table 2.12). Overall, the median prevalence of vitamin D inadequacy was 37% (range 
0-83%). Of this, prevalence of vitamin D deficiency was 14% (range 0-61.5%) and 
insufficiency 23% (range 0-83%). In order to assess plasma 25(OH)D status, the 
results were separated into three different groups; those studies reporting results at 
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diagnosis, during treatment and after the completion of therapy (figure 2.5). No study 
reported prevalence at three stages of the disease; diagnosis, treatment and after the 
completion of therapy.     
Eight out of 19 studies assessed 1,25(OH)D (table 2.11) and the prevalence of 
25(OH)D was stratified according to diagnostic category (table 2.12 and figure 2.6) 
and geographical location (by continent) (table 2.13; figure 2.6). 
PTH measured alongside vitamin D is considered a more sensitive physiological 
measure of vitamin D status in the healthy population (Holick et al. 2009); therefore 
this was also assessed. Twelve out of 19 studies (Atkinson 2008, Arikoski et al. 
1999a, Bilariki et al. 2010, El-Ziny et al. 2005, El-Ziny et al. 2007, Halton et al. 
1996, Arikoski et al. 1999b, El-Hajj Fuleihan et al. 2012, Sinha et al. 2011, Halton et 
al. 1995a) investigated plasma PTH levels as well as 25(OH)D or 1,25(OH)D (table 
3.1). However, only 5 studies reported plasma PTH in relation to either 25(OH)D or 
1,25(OH)D with very heterogeneous findings: (i) Bilariki et al. (2010) reported 
hyperparathyroidism in half of patients (n=15) who were 25(OH)D deficient (n=32); 
(ii) Atkinson et al. (1989) reported normal plasma PTH and 25(OH)D in all ALL 
patients; (iii) Halton et al. (1996) stated that 9 children with low 1,25(OH)D had also 
developed hyperparathyroidism; (iv) Schepper et al. (1994) found normal plasma 
1,25(OH)D levels, however 15% (2/13) of these had hyperparathyroidism and 8% 
(1/13) hypoparathyroidism; (v) Finally, Sinha et al. (2011) did not establish any 
significant associations between plasma 25(OH)D and PTH levels in pediatric cancer 
patients (r=0.07; p=0.65); but this association was significant in the control group 
(r=-0.42; p<0.01).         
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Figure 2.5 Prevalence of vitamin D (25(OH)D) deficiency and insufficiency 
according to stage of disease (diagnosis, treatment and end of therapy) 
 
 
Figure 2.6  Prevalence of vitamin D (25(OH)D) deficiency and insufficiency 
categorised by diagnostic category   
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Figure 2.7 Prevalence of vitamin D deficiency and insufficiency categorised by 
continent 
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Table 2-11 Studies reporting prevalence of vitamin D status in paediatric cancer patients   
Author Quality Patients Dx N, age at 
diagnosis 
(years) 
Method/time of 
measurements 
Method 
 
Results 
Design Parameters/Outcome At diagnosis During 
treatment 
After treatment 
 (Arikoski et 
al. 1999a) 
Finland 
Moderate Hematological 
malignancies 
and solid tumors  
 
N= 28 
Median 
(range)  8 
(2.9-16)y 
 
HM (n=10) 
ST (n=18) 
M: Parviainen et al 1981 
Assay’s coefficient of 
variation: 8-14% 
 
PTH two-site 
immunoradiometric assay  
Assay’s coefficient of 
variation: NR 
 
T: at diagnosis, 3 months, 
6 months  and 1 year  
PC 25 (OH)D nmol/L 
1,25-(OH)2D pmol/L 
Values compared against  
Finish children  
 
PTH reference data: NR 
 
Ethnicity:  
Caucasian (n=28) 
25 (OH)D nmol/L 
Mean (±SD) 
30 (±11)* 
 
1,25-(OH)2D 
pmol/L 
Mean (±SD) 
76 (±56) 
 
Prevalence NR 
 
PTH levels were 
sig decreased 
compared to 
normal values 
Mean (±SD) and 
prevalence: NR 
 
 
1 year follow 
up 
25 (OH)D 
nmol/L 
Mean (±SD) 
25 (±12)* 
 
1,25-(OH)2D 
pmol/L 
Mean (±SD) 
73 (±44)* 
Prevalence 
NR 
 
PTH levels 
were sig 
increased at 6 
and 12 months 
compared to 
diagnosis 
Mean (±SD) 
and 
prevalence: 
NR 
 
(Arikoski et al. 
1999b) 
Finland 
Moderate Childhood 
malignancies 
 
 
N= 48 
Median 
(range) 10.2 
(3.6-17.8)y 
 
HM (n=25) 
ST (n=22) 
BT (n=1)  
 
M: Parviainen et al 1981 
Assay’s coefficient of 
variation: 8-14% 
PTH standard methods 
 
T: one month after 
treatment 
CS 25 (OH)D nmol/L 
1,25-(OH)2D pmol/L 
Values compared against  
Finish children 
 
PTH reference data: NR 
 
Ethnicity: Caucasian 
  25 (OH)D nmol/L 
Mean (±SD) 
34 (±18)** 
 
1,25-(OH)2D 
pmol/L 
Mean (±SD) 
67 (±33)** 
Prevalence NR   
 
PTH Mean (±SD) 
42.4 (±24.0) ng/L 
Prevalence:  
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1/46 (2%) low 
4/46 (9%) high                
 
(Atkinson et 
al. 1989) 
Canada 
Weak ALL  
 
 
N=16  
Mean  
(±SD) 
6.2(±1.5)y  
M: High-pressure liquid 
chromatography D3 and 
radiochemical assays  
Frayer LJ et al 1983 
Assay’s coefficient of 
variation: NR 
 
PTH two-site 
immunoradiometric assay 
(N-tact PTH IRMA 
KitINCSTAR Corp., 
Stillwater, MN, USA) 
 
T: after first remission and 
6 months after completion 
of treatment 
 
I: magnesium 
supplementation 
Time 
series-
CS 
Reference data: 
25(OH)D (5.0-50) ng/ml  
24,25-(OH)2D (0.5-5.0) pg/ml 
1,25-(OH)2D (20-65) pg/ml 
PTH <0.88 units/L 
 
Values compared against 
Frayer et al. 1983 
 
Ethnicity: NR 
 
 0% deficiency 
on 25(OH)D 
ng/ml 
 
3/16 (19%) 
elevated 
24,25(OH)D 
 
12/13 (92%) 
non-detectable 
plasma 
1,25(OH)2 D 
 
PTH normal 
range 
  
0% deficiency on 
25(OH)D ng/ml 
 
 
Elevated 24,25 
(OH) D NR 
 
 
7/14 (50%) non-
detectable plasma 
1,25(OH)2D 
 
 
PTH normal range 
 
(Atkinson et 
al. 1998)  
Canada 
Moderate ALL 
 
 
N=40 
Median 
(range) age 
3.9 (0.3-
17)y 
M: High-pressure liquid 
chromatography D3 and 
radiochemical assays 
(Fraher et al 1983)  
Assay’s coefficient of 
variation: NR 
 
PTH two-site 
immunoradiometric assay 
(N-tact PTH IRMA 
KitINCSTAR Corp., 
Stillwater, MN, USA) 
 
T: 
1st  diagnosis/pre-therapy 
(0-5 days) 
2nd post-induction steroid, 
6 months 
3rd post-initiation of 
therapy; 12 months 
4th 24 months 
 
PC Plasma 1,25-(OH)2D pmol/L 
Normal range (48-156) pmol/L 
 
PTH reference data (0.3-3.5) 
pmol/L 
 
Ethnicity: NR 
Plasma 1,25-
(OH)2D Mean 
(±SD) 33.4±26.4 
pmol/L 
Prevalence of 
25(OH)D 
deficiency: NR 
 
PTH Median 
(range) 1.4(0.8-1.7) 
 
6 months 
1,25-(OH)2D 
Mean (±SD) 
29.3±(26.4) 
64% had a 
reduction 
from baseline  
PTH: NR 
 
12 months 
Mean(±SD) 
36.2±(SD) 
Prevalence of 
vitamin D 
deficiency: 
NR 
PTH: NR 
 
PTH at 31 
days Median 
(range) 5.1 
(1.5-11.4) 
Plasma 1,25-
(OH)2D  
24 months 
Mean(±SD) 
35.0±21.6) 
 
Prevalence of 
vitamin D 
deficiency: NR 
 
PTH: NR 
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I: magnesium 
supplementation 
 
(Bilariki et al. 
2010) 
France 
Moderate Solid and brain 
tumors 
N= 52 
Median 
(range) age 
at diagnosis 
9.0 (0.7-
18.5)y 
 
ST (n=48) 
BT (n=4) 
M: 25(OH)D and 
1,25(OH)D 
radioimmunoassays 
(Diasorin, Sallugia, Italy)   
Assay’s coefficient of 
variation: NR 
 
PTH Chemiluminescence 
(Elecsys, Roche 
Diagnostics, Meylan, 
France)  
 
T:  
1st after completion of 
therapy (within 2 years 
after treatment) 
2nd 1 year following first 
measurement 
 
PC Plasma 1,25(OH)D ng/ml 
Plasma 25(OH)D ng/ml 
 
Reference: 
Cormier and Souberbielle 2006 
 
Deficiency: <20ng/ml 
Insufficiency: 20-30ng/ml 
 
PTH reference: 10-46pg/ml 
 
Ethnicity: NR 
NA NA Plasma 25 (OH)D 
ng/ml 
1st measurement: 
(48/52 patients): 
25(OH)D Mean 
(±SD) 
19.7±8.5ng/ml 
 
Below suboptimal: 
(<30ng/ml): 83% 
 
Deficiency: 
(<20ng/ml): 61.5% 
 
Severe deficiency: 
(<10ng/ml): 11.5% 
 
2nd measurement 
(20/52) 
Mean (±SD) 
20.5(±7.1)ng/ml 
 
Deficiency: 
(<20ng/ml): 55% 
Plasma 1,25(OH)D 
NR 
 
PTH Mean (±SD) 
45.5(±21) pg/ml 
Of those who were 
vitamin D deficient 
half developed 
hyperparathyroidism 
(Choudhary et 
al. 2013) 
USA 
Strong  Cancer and  
SCT patients 
 
 
 
N= 426 
cancer 
N=58 SCT 
Median 
(range) 3.9 
(0-18)y 
 
HM (n=85) 
ST (n=212) 
M: 25-OH D 
Chemiluminescent 
(Diasorin) assay 
Assay’s coefficient of 
variation NR 
 
T: Median (range) interval 
between diagnosis and 25-
OH D test 12.3 (2.05-
RC 25-OH D insufficiency 
<20ng/ml 
 
Guidelines Institute of 
Medicine (IOM) 
 
PTH: NA 
 
Ethnicity:  
NA NA Insufficient: 29%  
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BT (n=114) 
Other 
(n=15) 
 
36.4)y 
 
White (n=381) 
Black (n=59) 
Hispanic (n=3) 
Asian (n=41) 
(El-Hajj 
Fuleihan et al. 
2012) 
Lebanon 
Strong Hematological 
malignancies 
 
Patients n= 
29 
Mean(±SD) 
9 (±2.9)y 
Controls 
n=32 
Mean (±SD) 
8.8(±2.6)y 
M: 25-OH D 
Competitive protein 
binding assay RIA 
(Immuno-Diagnostic 
Systems, Boldon,UK) 
Assay’s coefficient of 
variation: 5-8.2% 
 
PTH ELSA-PTH, IRMA 
(immunoradiometric 
assay) 
Assay’s coefficient of 
variation: 1-5.5%  
 
T: Mean (range) 14 (12-
17) months from 
diagnosis   
CS 25-OH D  <10ng/ml 
 
25-OH D <20ng/ml 
 
25-OH D >25ng/ml 
 
Reference data NR 
 
PTH reference data NR 
 
Ethnicity: NR 
NA 25(OH) D  
<10ng/ml 
Patients: 
24.1% 
Controls: 
12.5% 
 
25(OH)D 
<20ng/ml 
Patients: 
79.3% 
Controls: 
62.5% 
 
25(OH) D 
>25ng/ml 
Patients: 21% 
Controls: 16% 
 
Controls v 
cases p=0.08 
 
PTH Mean 
(±SD)  
Patients 
52(±27) pg/ml 
Controls 
21(±12) pg/ml 
 
NA 
(El-Ziny et al. 
2005) 
Egypt  
Weak  AML and ALL 
 
 
 
N=43 
Mean (±SD) 
7.0(±3.9)y 
 
Vitamin D 
sample: 
Cases n=20 
Healthy 
controls 
n=12  
 
M: 25(OH)D3 
RIA-Biosource Europe 
SA, Nivelles, Belgium) 
Assay’s coefficient of 
variation: NR 
 
PTH PTH-EASIA 
(ELIZA-Biosource 
Europe S.A, Nivelles, 
Belgium)  
Assay’s coefficient of 
PC 25(OH)D3 ng/ml cases 
compared to healthy controls 
Reference data NR 
 
PTH reference data: NR 
 
 
Ethnicity: NR 
 
25(OH)D3 ng/ml 
 
Cases: 
At presentation: 
median (IQR): 11 
(5.3-29) 
 
 
Controls:  
Median (IQR) 66 
(61-69) 
25(OH) D 
ng/ml 
 
3 months: 
14.2 (5.5-
26.8) 
 
12 months: 
17.5 (10.3-
38.5) 
 
NA 
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 variation: NR 
 
T: At presentation, after 
induction CT and 12 
months after therapy 
25(OH)D3 
(ng/ml) was 
significantly 
lower in ALL 
in comparison 
to controls 
(p<0.001)  
 
Prevalence 
NR 
 
PTH normal 
levels in all 
cases and no 
sig difference 
between cases 
and controls 
(El-Ziny et al. 
2007) 
Egypt 
Weak  
 
Hodgkin and 
non-Hodgkin 
Lymphoma 
 
 
 
 
N=20 
Mean (±SD) 
8.9±(4.2)y 
 
Vitamin D 
sample: 
Cases n=20 
Healthy 
controls 
n=12 
M: 25(OH)D3 
RIA-Biosource Europe 
SA, Nivelles, Belgium) 
Assay’s coefficient of 
variation: NR 
PTH PTH-EASIA 
(ELIZA-Biosource 
Europe S.A, Nivelles, 
Belgium)  
Assay’s coefficient of 
variation: NR 
 
T: At presentation, after 
induction CT and 12 
months after therapy 
PC 25(OH)D3 ng/ml cases 
compared to healthy controls 
Reference data NR 
 
PTH reference data: NR 
 
 
Ethnicity: NR 
 
25(OH)D3 ng/ml 
 
Cases: 
At presentation: 
median (IQR): 8.5 
(6.7-21.0) 
 
 
Controls:  
Median (IQR) 66 
(61-69) 
25(OH)D3 
ng/ml 
 
3 months: 
29.0 (16.0-
49.0) 
 
12 months: 
12.0 (10.0-
29.0) 
 
25(OH)D3 
(ng/ml) was 
significantly 
lower in HL 
& NHL in 
compare to 
controls 
(p=0.001)  
 
Prevalence 
NR 
 
PTH normal 
levels in 
children with 
lymphoma  
NA 
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and no sig 
difference 
between cases 
and controls 
(Frisk et al. 
2012) 
Sweden 
Moderate ALL and 
lymphoblastic 
lymphoma and 
SCT 
N=15 
 
Cases: 
Age at 
diagnosis 
Median 
(range) 9.8 
(5.6-18.3)y 
Age at study 
Median 
(range) 
27.5(17.3-
37.1)y 
 
Controls: 
Age at study 
Median 
(range) 
27.3(18.9-
38.6)y 
M: Chemoluminiscence 
(DiaSorin, Liaison, 
Saluggia, Italy) 
Assay’s coefficient of 
variation: 3.6-7.1% 
T: 10 years after SCT 
CC 25(OH)D < 37nmol/L 
hypovitaminosis D 
 
Reference data Kananen et al. 
2002, Taskinen et al. 2006 
 
PTH: NA 
 
Ethnicity: NR 
NA NA Cases: 59%  
Controls: 22% 
 
25(OH)D was 
significantly lower 
in the cases group 
than in the control 
group p<0.05 
(Gunes et al. 
2010) 
Turkey  
Moderate ALL 
 
 
N=70 
At diagnosis 
Mean (±SD) 
5.7(±3.4)y 
At 
enrolment 
Mean (±SD) 
10.6(±3.8) y 
Age and sex 
matched 
control 
group 
M: Radioimmunoassay 
25OH-VIT.D-RIA-CT 
KIP 1961) 
Assay’s coefficients of 
variation: NR 
 
T: at the end of ALL 
therapy 
CC 25(OH)D ng/ml cases 
compared to healthy controls 
 
Reference data NR 
 
PTH: NA 
 
Ethnicity: NR 
NA NA 25(OH)D ng/ml was 
significantly lower 
in the case group 
than in the healthy 
controls (p=0.03) 
 
Prevalence NR 
(Halton et al. 
1995a)  
Canada 
Moderate ALL 
 
 
N=40 
Median 
(range) 3.9 
(0.3-17)y 
M: High-pressure liquid 
chromatography D3 and 
radiochemical assays 
(Fraher et al 1983)  
Assay coefficient of 
variation: NR 
 
PTH: PTH two-site 
CS 25(OH)D3 reference data 
(Fraher et al. 1983) 
 
1,25(OH)2D3 reference data 
(Fraher et al. 1983): 
 
Low (<48 pmol/L or <20pg/ml)  
 
25(OH)D3  normal 
status  
 
1,25(OH)2D3  
 
Low 30 (75%) 
 
Low normal 8 
NA NA 
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immunoradiometric assay 
(N-tact PTH IRMA 
KitINCSTAR Corp., 
Stillwater, MN, USA) 
  
 
T: at diagnosis 
Low- normal (48-62.4 pmol/L 
or 20-26pg/ml) 
 
Normal (91.2-139pmol/L or 
38-58pg/ml) 
 
PTH  reference data 0.5-5.0 
pmol/L  
 
Ethnicity: NR 
(20%) 
 
Normal 2(5%) 
 
PTH (2.0±1.9) 
pmol/L 
Prevalence: 
Low 14%  
High levels NR 
(Halton et al. 
1996) Canada 
Moderate ALL 
 
 
N=40 
Median 
(range) 3.9 
(0.3-17)y 
M: High-pressure liquid 
chromatography D3 and 
radiochemical assays 
(Fraher et al 1983) 
Assay’s coefficient of 
variation: NR 
 
PTH two-site 
immunoradiometric assay 
(N-tact PTH IRMA 
KitINCSTAR Corp., 
Stillwater, MN, USA) 
 
 
T: At diagnosis, 6, 12, 18 
and 24 months 
PC 25(OH) D3 reference data 
(Fraher et al. 1983) 
 
1,25(OH)2D3 reference data 
(Fraher et al 1983): 
 
Low (<48 pmol/L or <20pg/ml)  
 
Low normal (48-62.4 pmol/L 
or 20-26pg/ml) 
 
Normal (91.2-139pmol/L or 
38-58pg/ml) 
 
PTH Normal range (0.5-5.0 
pmol/L) 
 
Ethnicity: NR 
 
25(OH)D3  normal 
status 
 
 
1,25(OH)2D3 
>70% below 
normal range  
 
PTH Mean (±SD) 
2.0(±1.9) 
 
 
25(OH)D3  
normal status 
 
1,25(OH)2D3 
70% below  
normal range 
 
 
PTH did not 
vary sig 
throughout 
treatment 
 
At 24 months 
9 children 
with low 
1,25(OH)2D3 
had elevated 
plasma PTH 
NA 
(Henderson et 
al. 1998) 
USA 
Weak  Malignancy 
treated with CT 
N=37 
Mean (±SD) 
7.3(±4.5)y 
range (1.4-
16.9) y 
 
ALL (n=24) 
ST (n=13) 
 
M: Assay kit (Incstar, 
Stillwater, MN) 
Assay’s coefficient of 
variation: NR 
 
T: followed up between 
12 and 41 months  
How often NR 
PC 25(OH)D <15ng/ml low 
 
1,25(OH)D <20pg/ml low 
 
Reference data (Chesney 1981, 
Taylor et al. 1984) 
 
PTH: NA 
 
Ethnicity: NR 
25(OH)D 
deficiency 1/37 
(3%) 
 
1,25(OH)D 
0/37(0%) 
 
25(OH)D 
deficiency 
1/37(3%) 
 
1,25(OH)D 
0/37(0%) 
 
NA 
 (Modan-
Moses et al. 
2012) 
Israel 
Moderate Malignancy N=142 
Median 
(range) 
12.03 (1.1-
5.8)y 
M: DiaSorin LLAISON 
competitive two-step 
chemiluminescent 
immunoassay (DiaSorin, 
Stillwater, MN) 
CS 25(OH)D status 
(reference data Misra et al. 
2008) 
 
Optimal: >32ng/ml  
NA Optimal      10 
(7%) 
 
Sufficient    
74 (52.1%)  
NA 
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ALL (n=57) 
ST (n=53) 
BT (n=32) 
Assay’s coefficient of 
variation: NR 
 
T: one measurement at 
clinic during or soon after 
the completion of 
treatment  
Sufficiency: >20 ng/ml 
Insufficiency: 15-20 ng/ml  
Deficiency: <15 ng/ml   
 
PTH: NA 
 
Ethnicity: NR 
 
Insufficiency 
33(23.2%)  
 
Deficiency 
35(24.6%) 
(Rosen et al. 
2013) 
USA 
Moderate Benign tumor 
Malignancy 
Treated with 
combination of 
surgery, CT 
and/or RT 
 
N= 201 
Mean (±SD) 
at diagnosis 
5.6(±0.3)y 
 
Mean (±SD) 
at initial 
visit 5.4 
(±0.2)y 
M: Liquid 
chromatography/tandem 
mass spectrometry (LC-
MS/MS) by Sonora Quest 
Laboratories (Quest 
Nichols, san Juan 
Capistrano, CA)  
Assay’s coefficient of 
variation: NR 
 
T: two assessments  
1st at study entry  
 2nd  two years after 
completion of therapy   
 
PC 25(OH)D status (reference The 
Endocrine Society (Holick et 
al. 2011) 
 
Sufficient: >30 ng/ml 
Insufficiency: 20-29.9 ng/ml 
Deficiency: <20 ng/ml  
 
PTH: NA 
 
Ethnicity: 
Caucasian (n=130) 
Hispanic (n=51) 
African-American (n=5) 
Asian-American (n=3) 
Native-American (n=9) 
Other (n=3) 
NA NA 1st Evaluation 
(n=201):  
Sufficient  46.3% 
Insufficiency 39.3% 
Deficiency 14.4% 
 
2nd Evaluation 
(n=124): 
Sufficient  31.5% 
Insufficiency 52.4%  
Deficiency 16.1% 
Of the 124 patients 
that had 25(OH)D 
concentration was 
reduced by 11.4%** 
 
(de Schepper 
et al. 1994) 
Belgium 
Weak Malignancy  N=13  
Median 
(range) 
9.5(2.9-
17.4)y 
 
ALL (n=2) 
ST (n=11) 
M radioimmunoassay 
Nicholas Institute, San 
Juan Capistrano, CA, 
USA) 
Assay’s coefficient of 
variation: NR 
PTH assay method NR 
 
T: once, minimum  3 
months after CT 
CS Parameter 
1,25(OH)2 vitamin D3  
Normal range 50-150 nmol/L 
Reference data NR 
 
PTH normal range 10-35ng/L 
 
Ethnicity: NR 
NA NA 1,25(OH)D 
0% deficiency  
 
PTH  
1/13 (8%) low 
2/13 (15%) high 
(Sinha et al. 
2011) 
UK 
Moderate Pediatric cancer Cases 
N=61 
Median 
(range) 11.1 
(1.5-24.4)y 
HM (n=19) 
ST (n=21) 
Others 
(n=8) 
BT (n=13) 
M DiaSorin 25-
hydroxyvitamin D radio-
immunoassay (RIA) (Cat 
#68100E Stillwater, 
Minnesota) 
Assay’s coefficient of 
variation: 8.4-12.6% 
 
PTH Centaur 
Chemiluminometric 
CC 25(OH)D  
Reference data (Weng et al. 
2005, Vieth et al. 2007;  
Bischoff et al. 2006) 
 
Optimal: >75nmol/L 
Adequate: 50-75nmol/L  
Insufficiency: 25-50nmol/L  
Deficiency : <20 ng/ml  
 
NA Cases: 
Optimal: 
9(14.7%) 
Adequate:  
14 (22.9%)  
Insufficiency: 
25 (40.9%)     
Deficiency: 
13 (21.3%) 
 
The median 
25(OH)D 
concentration was 
sig lower in cases 
(44nmol/L) than in 
controls 
(52nmol/L)* 
 
Higher PTH levels 
were associated with 
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Controls 
N=60 
Median 
(range) 
8.4(0.2-
18.0)y 
 
immunoassay  
Assay’s coefficient of 
variation: 7.4-16.7% 
 
T: Once, median (range) 
time post diagnosis 
3.0(0.4-9.0) y  
Some patients were on 
treatment and some had 
finished 
PTH reference data NR 
 
Ethnicity (cases):  
Pigmented skin (n=3) 
Fair skin (n=58) 
 
Ethnicity (control): 
Pigmented skin (n=7) 
Fair skin (n=53) 
 
 
 
PTH: NR 
 
The 3 
pigmented 
skin children 
from the 
cohort were 
severely 
deficient 
compared to 
1/7 in the 
control group  
 
Controls: 
Optimal: 
8(13.3%) 
Adequate:  
24 (40%)  
Insufficiency: 
26 (43.3%)     
Deficiency: 
 2 (3.3%) 
sig lower 25(OH)D 
in controls (r=-0.42; 
p<0.01) but not in 
cases (r=-0.07; 
p=0.65)  
 
 
(Wiernikowski 
et al. 2005) 
Canada 
Weak  ALL and NHL 
and on 
maintenance 
phase of CT 
N= 10 
Median 
(range) 7.2 
(3.6-14.6)y 
M: Radioimmunoassay 
(DiaSorin, Stillwater, MN, 
USA) 
Assay’s coefficient of 
variation: NR 
T: week 0, 1, 4,7,10,13 
and at the end of the 
study.  
NRCT Intervention:  
Alendronate orally once a week 
for 6 months 
Dose age dependant  
<8 years: 30 mg/week 
8-10 years: 50 mg/week 
>10 years: 70 mg/week 
Parameter: 
Reference data 25(OH)D 
American adults (Bischoff-
Ferrari 2004)  
Normal 9-37ng/ml 
 
Ethnicity: NR 
0% 0% NA 
Dx: Diagnosis; M: method; T: time of measurement; C: cohort study;  PC: prospective cohort study; RC: retrospective cohort study; CS: cross-sectional study; CC: case-control 
study; CS: cross-sectional; NRCT: non-randomised clinical trial;  NR: not reported and/or not clear; NA: non-applicable (i.e. not part of study aims); M: method; T: time of 
measurement; Dx: Diagnosis; ALL: acute lymphoblastic leukaemia; HM: Haematological malignancies; NHL: non-Hodgkin’s lymphoma; Treatment: CT: chemotherapy; R: 
radiotherapy; SCT: stem cell transplant; ng: nanograms; nmol: nanomols; pmol; picomols; pg: picograms; L: litre; mL: millilitres; SD: standard deviation; y: years; Countries: UK: 
United Kingdom; USA: United States of America; *p<0.05; **p<0.0001 compared to reference values; sig: significant. 
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Table 2-12 Prevalence of plasma 25(OH)D status in paediatric cancer patients 
 
 
Table 2-13 Studies reporting the prevalence of plasma 25(OH)D deficiency and 
insufficiency stratified by location (continent) 
 
Table 2-14 Prevalence of vitamin D (25(OH)D) deficiency and insufficiency 
according to diagnostic  criteria  
 
 
 
25(OH)D Deficiency Insufficiency  
N of 
studies 
Median % Range % N of 
studies 
Median 
% 
Range 
% 
At 
diagnosis 
3 0 0-3 4 0 0-25 
During 
treatment 
5 21 0-25 5 23 0-79 
End of 
treatment 
4 16 0-61.5 4 52 39-83 
Overall 11 14 0-61.5 13 23 0-83 
25(OH)D Deficiency Insufficiency  
N of 
studies 
Median 
% 
Range % N of 
studies 
Median 
% 
Range 
% 
Europe 2 41 21-61.5 3 59 41-83 
Middle East 2 24 24-25 2 51 23-79 
North 
America 
8 15 0-16 4 46 39-52 
25(OH)D Deficiency Insufficiency  
N of 
studies 
Median % Range 
% 
N of 
studies 
Median 
% 
Range 
% 
Haematological 
malignancies 
3  24 0-75 5 39.5 0-79 
Solid tumours 1 61.5 61.5 2 71 59-83 
Brain and 
benign tumours 
2 16 16-69.5 2 52 39-83 
ICCC-3 5 25 21-29 2 32 23-41 
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2.2.3.3 Possible causes of vitamin D deficiency/insufficiency in paediatric 
cancer patients 
Six out of 19 studies were found (table 2.15) exploring possible causes of vitamin D 
inadequacy in paediatric cancer patients. The outcome measured was 25(OH)D and 
the variables measured were: (i) demographic data: ethnicity, gender, age and 
pubertal status at diagnosis; (ii) clinical data: diagnosis, leukocyte count, length of 
treatment and nutritional status; (iii) different forms of cancer treatment including, 
the use of steroids, chemotherapy, radiotherapy and stem cell transplant (SCT) (iv) 
and environmental factors included, seasonal variation, sun exposure and the use of 
sun cream. A meta-analysis was performed with the variables age and vitamin D 
status only, as there was not commonality of independent variables; therefore, this 
evidence was described narratively.  
 
The Forest plot depicting the included studies (vitamin D deficiency) is shown in 
Figure 2.7. For the vitamin D deficiency, the summary ES was -0.132 (95%CI -
0.203, -0.060). All the studies showed a significant effect of younger age with higher 
vitamin D levels, with most ESs falling in the range -0.085 to -0.245. There is no 
evidence of heterogeneity (chi-squared =2.75 (d.f. = 2) P = 0.253), with the variation 
in ES attributable to heterogeneity (I-squared) = 27.3%. This level of heterogeneity 
indicates that there is little difference between the studies which cannot be explained 
by random variation. 
 
Three studies considered whether ethnicity was associated with decreased 25(OH)D 
status. Of these, two (Choudhary et al. 2013, Sinha et al. 2011) reported associations 
between dark skin and decreased 25(OH)D status and one (Rosen et al. 2013) did not 
find such association. Seasonal variation was explored in three studies, two (Modan-
Moses et al. 2012, Sinha et al. 2011) of which found that children who had their 
25(OH)D measured in the Winter months had lower levels than those who were 
measured in the Summer months. Additionally, the use of sun cream was found to be 
associated with lower 25(OH)D status (Modan-Moses et al. 2012). Three studies 
investigated whether cancer diagnosis was associated with 25(OH)D and, of these, 
two (Rosen et al. 2013, Sinha et al. 2011) found that patients diagnosed with cancer 
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had lower 25(OH)D status than controls. The use of glucocorticoids was also 
investigated in two studies, which reported contradictory results. One (Arikoski et al. 
1999b) found that the use of glucocorticoids was associated with lower 25(OH)D 
status and the other study (Choudhary et al. 2013) did not find such an association. 
Finally, none of the other variables were found to influence 25(OH)D status.   
     
 
 
Figure 2.8 Associations between younger age and vitamin D inadequacy in 
paediatric cancer patients                                                                                                                                                 
The horizontal lines in the Forest plot represent the 95% confidence interval around the point estimate. 
The box around the point estimate is proportional to that of the study’s weight in the analysis. The 
pooled estimate diamond is centred on the pooled estimate.
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Table 2-15 Possible causes of vitamin D deficiency/insufficiency 
Studies 
 
Quality Patients Dx N, age at 
diagnosis 
(years) 
Method/time of 
measurements 
Method 
 
Results 
Design Variables Outcome Possible causes of vitamin D 
deficiency 
(Arikoski et 
al. 1999b) 
Finland 
Strong Childhood 
malignancies 
N= 48 
Median 
(range) 
10.2 (3.6-
17.8)y 
M: Parviainen et al. 
1981 
 
T: one month after 
treatment 
CS Use of steroids 
Bone turnover 
CT 
ALT 
 
Low plasma vitamin D 
status:  
25(OH)D nmol/L 
 
1,25(OH)2D pmol/L 
 
 
Correlation:      
 - steroids (r= 0.31; p= 0.04) 
 
No correlations: 
- Bone turnover 
- CT 
- ALT 
 
(Choudhary 
et al. 2013) 
USA 
Strong  Cancer and  
SCT patients 
N= 426 
cancer 
N=58 
SCT 
Median 
(range) 
3.9 (0-18) 
y 
M: 25(OH)D 
Chemiluminescent 
(Diasorin) assay 
 
T: Median (range) 
interval between 
diagnosis and 25(OH)D 
test 12.26 (2.05-36.4)y 
RC Race 
Pubertal status 
Age at diagnosis 
Gender 
Type of cancer 
diagnosis 
Endocrinopathy 
Radiation  
Glucocorticoid 
25(OH)D insufficiency 
<20ng/ml 
 
Guidelines Institute of 
Medicine (IOM) 
Correlations  (p< 0.05) 
- Race (p< 0.001) 
 (White: OR= 1.00; Black: 
OR=3.11; Others (Hispanic and 
Asian): OR= 2.08) 
- Pubertal status (p< 0.001) 
(Tanner 1-2: OR= 1; Tanner 3-5: 
OR= 2.29) 
- Age at diagnosis (OR=1.36; p= 
0.01) 
No correlations:  
- Gender  
- Cancer diagnosis 
- Endocrinopathy 
- Radiation  
- Glucocorticoid 
 
(Halton et 
al. 1995a) 
Canada 
Moderate ALL N=40 
Median 
(range) 
3.9 (0.3-
M: High-pressure liquid 
chromatography D3 and 
radiochemical assays 
(Fraher et al 1983)  
CS Age at diagnosis 
Leukocyte count 
Morphologic and 
immunologic type 
25(OH)D3 reference data 
(Fraher et al. 1983) 
 
1,25(OH)2D3 reference data 
ALL (r= NR) 
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17)y  
T: at diagnosis 
of leukaemia 
ALL 
(Fraher et al. 1983): 
 
(Modan-
Moses et al. 
2012) 
Israel 
Moderate Malignancy N=142 
Median 
(range) 
12.03 
(1.1-5.8)y 
M: DiaSorin LLAISON 
competitive two-step 
chemiluminescent 
immunoassay 
(DiaSorin, Stillwater, 
MN) 
 
T: one measurement at 
clinic during or soon 
after the completion of 
treatment  
CS Gender 
Age at diagnosis 
Cancer diagnosis 
Length of time 
from diagnosis 
Glucocorticoids  
SCT 
Seasonal 
variation 
Sun exposure 
Sun protection 
Anthropometry 
 
25(OH)D status  
(reference data Misra et al. 
2008) 
 
 
Correlations: 
- Sun exposure (r= 0.195; p= 
0.02; multilevel analysis: OR= -
0.31; p= 0.001)  
- Sun protection (r= NR; p= NR; 
multilevel analysis: OR= 1.387; 
p= 0.002) 
- Younger age (r= -0.24; p= 
0.004) 
 
Seasonal variation: 25(OH)D 
status was significantly lower in 
Winter compared to Summer (p= 
0.001) 
(Rosen et 
al. 2013) 
USA 
Moderate Benign 
tumor 
Malignancy 
Treated with 
combination 
of surgery, 
CT and/or 
RT 
 
N= 201 
Mean 
(±SD) at 
diagnosis 
5.6(±0.3)y 
 
Mean 
(±SD) at 
initial 
visit 5.4 
(±0.2)y 
M: Liquid 
chromatography/tandem 
mass spectrometry (LC-
MS/MS) by Sonora 
Quest Laboratories 
(Quest Nichols, san 
Juan Capistrano, CA)  
 
T: 2 assessments  
1
st
 at study entry (2 
years after completion 
of therapy) 
2
nd
 follow-up  
PC Gender 
Ethnicity 
BMI 
Seasonal 
variation 
Cancer diagnosis 
Length of 
treatment 
25(OH)D status (reference 
The Endocrine Society 
Holick et al 2011): 
 
Deficiency: <20ng/ml 
Insufficiency: 20-30ng/ml 
Sufficient: >30ng/ml  
  
Correlations: 
- Younger age associated with 
higher 25(OH)D levels              
(r= -0.15; p= 0.03) 
- Cancer diagnosis (r= NR; 
p=0.017) 
 
Cancer diagnosis: osteosarcoma, 
retinoblastoma, hepatoblastoma 
and myeloid leukemias exhibited 
the lowest 25(OH)D 
concentrations 
(Sinha et al. 
2011) 
UK 
Moderate Pediatric 
cancer 
Cases 
N= 61 
Median 
(range) 
11.1 (1.5-
24.4)y 
M DiaSorin 25-
hydroxyvitamin D 
radio-immunoassay 
(RIA) (Cat #68100E 
Stillwater, Minnesota) 
 
CC Age  
Sex 
Ethnicity 
Cancer diagnosis 
History of travel 
abroad 
 
25(OH)D  
Reference data (Weng et al. 
2005, Vieth et al 2007, 
Bischoff et al 2006) 
 
Correlations: 
- Cancer diagnosis (r= NR; p= 
0.012   
- Seasonal variation (r= NR; 
p=0.001) 
- Dark skin (r= NR; p= 0.001) 
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Controls  
Median 
(range) 
8.4(0.2-
18.0)y 
T: Once median (range) 
time post diagnosis 
3.0(0.4-9.0) y  
Some patients were on 
treatment and some had 
finished 
Treatment 
Seasonal 
variation 
  
 
Deficiency : <20 ng/ml  
 
 
 
 
- Younger age associated with 
higher 25(OH)D status (r= NR; 
p= 0.011) 
 
D: Diagnosis; ALL: acute lymphoblastic leukaemia; NHL: non-Hodgkin’s Lymphoma. Type of study: PC: prospective cohort study; CC: case-control study; CS: 
cross-sectional; NRCT: non-randomised clinical trial; RC: Retrospective cohort study; Treatment:  CT: chemotherapy; RT: radiotherapy; SCT: stem cell transplant; 
ALT: aminotransferase; y: years; NR: not reported; NA: non-applicable or not part of study aims.  
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2.2.3.4 Quality of evidence 
According to the assessment of quality of evidence using CASP methods, the 
evidence for the prevalence of vitamin D insufficiency and/or deficiency was highly 
variable with six (32%) studies being of weak quality, eleven (58%) of moderate 
quality and two (10.5%) studies were scored as “strong”. The main issues identified 
with studies scored as weak and moderate were:  
(i) It was difficult to establish the precision of the results due the absence of 
confidence intervals and/or relative risk (n=11).  
(ii) Confounding factors present in the design and/or analysis of the study 
(n=9)  
(iii) Lack of definition of outcome measures and normal vitamin D reference 
values (n=6).  
Despite this, all selected studies that reported prevalence were considered to draw 
some general conclusions.     
2.2.4 Discussion 
This is the first systematic review appraising international evidence of the prevalence 
of vitamin D inadequacy in paediatric cancer patients and its possible causes. As 
only 19 studies of mainly small sample sizes and highly variable in quality were 
identified, at present there is insufficient robust evidence to accurately determine 
clear prevalence rates of vitamin D deficiency and insufficiency in the pediatric 
oncology population. Moreover, owing to the considerable diversity of the variables 
investigated and the lack of results reported in most studies, a meta-analysis 
including only studies investigating associations between age and vitamin D status 
was perfomed. Nonetheless, this systematic review importantly raises the possibility 
of a high prevalence of vitamin D deficiency and insufficiency in older children 
diagnosed with cancer, which may worsen during treatment and persist beyond 
completion of therapy.  
2.2.4.1 Prevalence of vitamin D deficiency and insufficiency  
The reported prevalence of vitamin D inadequacy at different stages of the disease, 
excepting at the time of diagnosis, it was highly variable across all types of 
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childhood cancer. Also, the fact that no study assessed all three stages of the disease 
in the same population made very difficult to establish clear patterns of change. 
Additionally, variability existed between the different geographical locations; 
Europe, North America and the Middle East. No eligible studies were found from 
Central and South America, Africa and most of Asia. The majority of the studies 
considered vitamin D status in children and young people diagnosed with 
haematological malignancies and very few investigated those diagnosed with solid 
tumors, brain tumors and benign tumors. Crucially, it was found that the terms 
deficiency and insufficiency in the context of vitamin D prevalence were used 
indiscriminately and dietary intake was not controlled for in most studies.  
In agreement with Simmons et al (Simmons et al. 2011), but contrary to Atkinson 
(Atkinson 2008), this review suggests that the prevalence of 25(OH)D inadequacy in 
children diagnosed with haematological malignancies (deficiency; median 24% and 
insufficiency; median 39%) is similar to the general paediatric population (14-49%) 
(Choudhary et al. 2013); also found with the brain and benign tumor group, as the 
median prevalence for deficiency was 16% and for insufficiency 52%. Children 
diagnosed with solid tumors had a higher prevalence of 25(OH)D deficiency (median 
61.5%) and insufficiency  (median 71%) than those children diagnosed with other 
type of malignancies; consistent with one large study (n=2198) of adult oncology 
patients, which reported a prevalence of 25(OH)D deficiency of 75% (Vashi et al. 
2010). Nevertheless, a few cautionary notes should be mentioned; the small number 
of studies looking at these population (Frisk et al. 2012, Bilariki et al. 2010, El-Ziny 
et al. 2007) and their small sample sizes, the different assay methods used to identify 
25(OH)D status (Zerwekh 2008) and the geographical differences in the prevalence 
of 25(OH)D status.  
Stratification of the studies by geographical location revealed some interesting 
differences; prevalence of 25(OH)D deficiency and insufficiency was highest in 
Europe (41% and 59% respectively), then the Middle East (24% and 51% 
respectively) and then North America (15% and 46% respectively). Moreover, whilst 
these values were higher than in the general paediatric population in Europe and the 
Middle East, they were not in North America. Of note, there was great variability 
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within the American data (prevalence ranging from 0% to 68.5%); all studies from 
Canada (Atkinson et al. 1998, Atkinson et al. 1989, Halton et al. 1995a) reported 0% 
prevalence of vitamin D deficiency and/or insufficiency, whilst those published in 
the USA ranged from 3% (Henderson et al. 1998) to 68.5% (Rosen et al. 2013). This 
could be attributed to the differences in vitamin D fortification polices from each 
country. In the USA fortification is discretionary (Institute of Medicine. Food and 
Nutrition Board 2010, Janz and Pearson 2013), whilst in Canada fortification of milk, 
margarine and plant-based milk is mandatory (Janz and Pearson 2013). An important 
observation is the difference in the prevalence of vitamin D inadequacy in both 
Europe and North America between studies from the 1980s and 1990s (Atkinson et 
al. 1998, Halton et al. 1996, Henderson et al. 1998, Atkinson et al. 1989, de Schepper 
et al. 1994) and those published after 2000 (Frisk et al. 2012, Choudhary et al. 2013, 
Bilariki et al. 2010, Rosen et al. 2013, Sinha et al. 2011); with most studies published 
after 2000 reporting higher prevalence of 25(OH)D than those published before. This 
could be a reflection of either an increase in 25(OH)D inadequacy (deficiency and 
insufficiency) in the paediatric oncology population, a recent increase seen in the 
general paediatric population (Ahmed et al. 2011, Holick 2006) or as previously 
suggested (Zerwekh 2008), the new more specific assay methods, which are more 
sensitive to vitamin D metabolites, thus providing more accurate results. 
Seven studies (Atkinson 2008, Arikoski et al. 1999a, Bilariki et al. 2010, Halton et 
al. 1996, Henderson et al. 1998, Arikoski et al. 1999b, de Schepper et al. 1994, 
Halton et al. 1995a) reported 1,25(OH)D concentration and of these only one (de 
Schepper et al. 1994) did not measured 25(OH)D as well as 1,25(OH)D. As 
expected, there was a lot of variability in the reported 1,25(OH)D concentrations and 
no relationship between 25(OH)D and 1,25(OH)D (table 3.1). This may be explained 
by the vitamin D metabolism, as it is now acknowledged that 1,25(OH)D is tightly 
regulated by plasma calcium, instead of by the human vitamin D stores, with levels 
increasing when plasma calcium is reduced. 1,25(OH)D plasma levels also change 
rapidly due to the 4 hours half-life of this metabolite. Conversely, 25(OH)D is an 
accurate parameter of vitamin D body stores for the following reasons: (i) plasma 
25(OH)D levels are normally influenced by sunlight exposure and dietary intake; (ii) 
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the half-life of 25(OH)D is three weeks, representing stores, which have been 
obtained from dietary intake and sunlight over a long period of time; (iii) the 
synthesis of 25(OH)D by the liver is not significantly regulated, but dependent 
mainly on substrate concentration (Holick et al. 2011, Holick 2009, Holick 2007, 
Zerwekh 2008).     
Studies considering both plasma 25(OH)D and 1,25(OH)D levels alongside PTH 
were very heterogeneous in their findings, suggesting that in pediatric cancer patients 
there might be other factors influencing their relationship. At present, these are 
unknown, however it could be attributed to the following: type of cancer and the 
different forms of treatment, including chemotherapy and corticosteroid, which 
affects calcium homeostasis and can also cause hepatotoxicity as well as 
nephrotoxicity; thus interfering with the 25(OH)D, 1,25(OH)D and PTH metabolism 
(Atkinson 2008, Zhou et al. 2006).      
2.2.4.2 Vitamin D supplementation 
At present, there are current paediatric guidelines for supplementation of vitamin D 
(RCPCH 2013, Holick et al. 2011). However, this review did not find other studies 
meeting the eligibility criteria and also, investigating the changes in vitamin D status 
of paediatric oncology patients before and after supplementation, and assessing 
whether current guidelines are suitable for this population during and after treatment. 
Of note, a recent randomised double-blind placebo-controlled trial that did not meet 
our inclusion criteria has been published (Kaste et al. 2014). This study found no 
difference on lumbar spine bone mineral density in survivors of ALL following two 
years of either cholecalciferol and calcium supplementation or placebo (Kaste et al. 
2014). Due to the limited body of evidence, more research that assesses the effects of 
vitamin D supplementation during and after treatment in this population is warranted.   
2.2.4.3 Possible causes of vitamin D deficiency and insufficiency  
There is a paucity of evidence examining possible causes of 25(OH)D inadequacy in 
paediatric cancer patients and the few published studies produced equivocal findings 
and considered different variables making it impossible to draw meaningful 
conclusions. Nonetheless, the meta-analysis performed showed that 25(OH)D 
159 
 
inadequacy, as in the healthy paediatric population (Holick 2007, El-Rassi and 
Baliki, G and Fulheihan El-Hajj, G), may be associated with older age (Choudhary et 
al. 2013, Rosen et al. 2013, Modan-Moses et al. 2012). Darker skin was also 
associated with lower plasma 25(OH)D levels (Choudhary et al. 2013, Sinha et al. 
2011). A reduction in sunlight exposure is expected of this population if they adhere 
to the recommendations. As previously discussed, some cytotoxic drugs, 
radiotherapy treatment and the use of antifungals cause phototoxicity (Duncan et al. 
2011), whilst those who have haematopoietic stem cell transplantations have an 
increased risk of developing skin malignancies if exposed to sunlight (Simmons et al. 
2011). However, this was assessed in only two studies of moderate quality and small 
(n=61) and large (n=142) sample sizes (Modan-Moses et al. 2012, Sinha et al. 2011). 
Notably, the use of glucocorticoids showed mixed results; one large study (n=428) 
included in our review did not find associations between glucocorticoid use in 
children and adolescents diagnosed with an ICCC-3 cancer, treated with either 
chemotherapy or haematopoietic stem cell transplant and, decreased vitamin D levels 
(Choudhary et al. 2013); supported by another study not included in our review 
(Simmons et al. 2011). In contrast, a small study (n=48) of paediatric patients 
diagnosed with an ICCC-3 cancer included in this review showed correlation 
between glucocorticoid use and reduced 25(OH)D status (Arikoski et al. 1999b). 
Chemotherapy was not associated with increased 25(OH)D inadequacy (Arikoski et 
al. 1999b, Sinha et al. 2011); however both studies were small and were not stratified 
according to diagnostic criteria or chemotherapy. There were also mixed results with 
regards to associations between the different type of cancers and poor 25(OH)D 
status and only two studies specified the type of cancers that was found to correlate 
with low 25(OH)D, which was ALL (Rosen et al. 2013, Halton et al. 1995a) and the 
following: osteosarcoma, retinoblastoma, hepatoblastoma and myeloid leukaemias 
(Sinha et al. 2011). Finally, no study assessed treatment induced side-effects; 
including, hepatotoxicity and whether this had an effect on DBP concentrations and 
consequently on plasma 25(OH)D, kidney injury and mucositis, as possible causes of 
poor 25(OH)D status. 
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Taking into consideration the results of this systematic review and the limited 
number of studies available to date, this review propose for future research (table 
2.16). 
Table 2-16 Research recommendations to consider for the future 
 
 
 
 
 
 
 
 
2.2.4.4 Quality of body of evidence, strengths and limitations of 
systematic review 
Several limitations were identified in this review. Following the risk of bias 
assessment using the CASP tool, it became clear that the quality of studies varied 
considerably, which goes some way to explaining the great differences in reported 
prevalence of vitamin D deficiency and insufficiency. Potential bias might have 
occurred as this review excluded studies in which individuals younger and also older 
than 18 years of age were included in the same study and where data were analysed 
altogether. In spite of these limitations, the strength of this systematic review lies in 
its methodology. A comprehensive search of five electronic databases without 
language restrictions was conducted, experts in the field were contacted and the 
reference list of all the included studies was screened. Still, potential eligible studies 
Research recommendations to consider for the future: 
 Different forms of cancers need to be thought of as different diseases requiring 
very different treatments, as such should be presented separately. 
 To assess vitamin D status, 25(OH)D (instead of 1,25(OH)D) should be 
measured 
 Measurements of 25(OH)D need to be monitored at different stages of the 
disease and treatment course. 
 Studies should specify the reference values of vitamin D to which they 
compare their data 
 25(OH)D deficiency and insufficiency should be clearly defined according to 
standard cut-off values. 
 The following details need to be clearly specified: the timings of when the 
measurements are taken, clinical and demographic data, dietary intake, 
exposure to sunlight and specific treatment and treatment induced side-effects. 
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might have missed. Finally, the three variables included in the meta-analysis were 
not exactly identical as two were age at diagnosis and one was older age.    
2.2.5 Conclusion  
This systematic review represents the first attempt, to date, to review the 
epidemiological evidence for the prevalence of vitamin D deficiency and 
insufficiency in pediatric cancer patients worldwide, and to explore possible causes 
of vitamin D inadequacy. Unfortunately, these aims have been largely frustrated by a 
small number of eligible studies, the absence of a universal approach to measuring 
and defining 25(OH)D status, the failure of researchers to treat different types of 
cancer as different diseases and the fact that different research groups investigated 
different variables. Nonetheless, this systematic review highlights the following: the 
possibility of a high prevalence of vitamin D deficiency and insufficiency in 
paediatric cancer patients, which might also be associated with older age and darker 
skin; the need for future high-quality population based longitudinal cohort studies 
and high-quality clinical trials that assess the effect of vitamin D supplementation. 
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CHAPTER III 
 
 
3 ASSESSMENT OF RELIABILITY, VALIDITY AND 
PRECISION OF ANTHROPOMETRICAL 
MEASUREMENTS PERFORMED IN HEALTHY 
CHILDREN 
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3.1 INTRODUCTION 
It is essential to ensure that anthropometric measurements performed as part of 
research are as accurate, reliable, precise and as valid as possible (Atkinson and 
Nevill 1999, Ulijaszek and Kerr 1999, Jamaiyah et al. 2010). The prospective study 
performed to assess the determinants of nutritional risk in the paediatric oncology 
patients required regular anthropometric measurements, which were performed in 
two phases, phase-I and phase-II, by two researchers. The anthropometric methods 
being used included; weight, height or length (<2 years of age), middle upper arm 
circumference (MUAC) and triceps skin fold (TSF). In order to reduce random errors 
of measurements anthropometrists should follow standard protocols, have 
appropriate training and the equipment should be calibrated according to 
manufacturer instructions. However, even following expert training anthropometric 
measurements, especially MUAC and TSF, are subject to some degree of error 
within and between observers (Jamaiyah et al. 2010), thus these must be established 
to be able to interpret the data.  
 
There are various terms that describe the degree of anthropometric measurement 
error: (1) precision, (2) accuracy, (3) validity and (4) reliability: (1) The degree of 
precision is defined as “the variability of repeated measurements due to intra- and 
inter observer error” (Ulijaszek and Kerr 1999) and it can be calculated by 
quantifying the technical error of measurement (TEM), which is the standard 
deviation of measurements taken independently from the same subject. Intra-
observer TEM is the Standard Deviation (SD) of measurements taken by the same 
anthropometrist, whilst inter-observer TEM is the SD of the different measurements 
taken by two or more anthropometrists (Norton and Olds 1996). (2) Accuracy is the 
degree of closeness from a measurement taken to the true value of that measurement. 
As opposed to accuracy, inaccuracy is defined as systematic bias that results from the 
faults in the equipment or errors from the observer’s technique (Ulijaszek and Kerr 
1999). (3) Validity is defined as the extent to which a measurement is relevant with 
the desired characteristic/variable actually measured and, it is assessed along with 
reliability (Ulijaszek and Kerr 1999). (4) Reliability in this context is “the extent to 
which within subject variability is due to factors other than measurement error 
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variance (accuracy) and physiological variation (reproducibility)” (Ulijaszek and 
Kerr 1999). Reliability is calculated by assessing the intraclass correlation coefficient 
(ICC)  and it is generally calculated from the results of analysis of variance 
(ANOVA) where 0 is not reliable at all and 1 is highly reliable (Atkinson and Nevill 
1998, Norton and Olds 1999, Ulijaszek and Kerr 1999, Jamaiyah et al 2010). 
 
In order to establish the precision and reliability of the measurements across the two 
phases, this study attempted to assess inter- and intra-observer TEM and ICC of 
weight, height, MUAC and TSF in a group of children.  
  
3.1.2 Aims and Objectives 
The main aim of this study was to assess the precision and reliability of the 
anthropometric measurements used by the two observers involved in the ENRICC 
study across phase-I and phase-II. 
The objectives were:  
- To calculate intra- and inter-observer TEM and ICC for the following 
anthropometric measurements: weight, height, MUAC and TSF.  
 
3.2 METHODS 
3.2.1 Study design and study population  
A cross sectional study was performed. A minimum of 10 children including both 
boys and girls should be incorporated in the study for an optimal calculation of ICC 
and TEM (Ulijaszek and Kerr 1999). Therefore, the aim for the study population was 
to recruit a total of 10 children and young people through parents/carers via the 
QMU moderator email system. Additionally, TEM and ICC must be established in a 
population as similar as possible to the one to be tested in the principle study (Norton 
and Olds 1996). Therefore, the eligibility criteria were any healthy child and/or 
young people between the ages of 2 and 18 years and, the exclusion criteria included 
children younger than 2 and older than 18 years. Although children under the age of 
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2 were included in the ENRICC study, no suitable equipment was available to 
measure this in QMU.  
3.2.2 Recruitment 
This study was granted with ethical approval from the QMU Ethics Committee 
(appendix II) and volunteers were recruited through the QMU moderator email 
system. The study was explained to the parents and children who indicated an 
interest. Age-appropriate information was given to the families; children aged 6 to 11 
were assigned the children’s information sheet and those aged older than 11 years, 
the adult’s information sheet (appendix II). Parents and children were allowed some 
time to consider participation and to ask questions prior consent was given. 
Participation in the study took place only if both the parent and the child agreed to 
participate. Oral and written consent was sought from both the parent and child. Each 
child was assigned an identification number to ensure anonymity.  
3.2.3 Measurements  
Age, gender and ethnicity were recorded from each volunteer. All anthropometric 
measurements were performed using standard procedures for which both researchers 
had been trained. The following anthropometric measurements were taken: weight, 
height, MUAC and TSF in a private location accompanied by the parents/cares and 
using the same standard protocols as in phase-I and phase-II of the project. As 
recommended by the literature (Atkinson and Nevill 1999, Ulijaszek and Kerr 1999) 
each child had four series of measurements taken (two by each anthropometrist) and 
three measurements taken at each series. This method has been shown to reduce bias 
as it minimises the possibility of memorising the measurements.    
 
Weight was taken without shoes and heavy clothing using a standing SECA digital 
weight scale. Weight was measured to the nearest 0.1Kg. Height was measured using 
a wall mounted stadiometer (SECA Hamburg, Germany) to the nearest 0.1cm. 
Children were asked to stand with their heels and back in contact with an upright 
wall and, whilst the head was hold by the researchers to make sure the child was 
looking straight forward. Before the right-angle block was slide down to touch the 
head, children were asked to breathe in and out. 
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The MUAC of the non-dominant arm was measured with a measuring tape to the 
nearest 0.1cm. The volunteers were asked to stand, remove clothing that covered the 
non-dominant arm and bent their arm in a 90º position. Then the midpoint between 
the acromion (top of the shoulder) and the olecranon (tip of the elbow) was marked. 
Finally the circumference was measured from the marked point with the arm left 
loose (Frisancho 1974). The TSF was then taken using the same point reference than 
the one used for the MUAC with the arm also left loose. A Harpenden Skinfold 
caliper was used to assess TSF. The method used consisted of pulling gently with the 
thumb and the forefinger a fold of skin from the marked level (midpoint) with the 
skinfold parallel to the long axis of the arm. Then the jaws of the caliper were placed 
at the marked level, which were left for 10 seconds to allow for an optimum reading 
(Oakley et al. 1977). The caliper measured to the nearest 0.2mm.  
 
A low TEM should be achieved to obtain accurate measurements (Pederson and 
Gore 1996). Reference levels for intra- and inter-observer TEM have been proposed 
for three accreditation anthropometrists’ level, which are presented in table 3.1. 
Reliability was calculated using ICC which measured the correlation coefficient. The 
reliability ranges from 0-1 where 0 is not reliable, 0-0.2 is slightly reliable, 0-2-0.4 is 
fairly reliable, 0.6-0.8 is substantial and 0.8-1 is almost perfect reliability (Pederson 
and Gore 1996, Ulijaszek and Kerr 1999). An ICC larger than 0.95 should be 
achieved for reliable measurements (Ulijaszek and Kerr 1999).             
 
Table 3-1 Proposed target for intra- and inter-observer TEMs for the three 
accreditation levels following the training course (Gore et al 1996) 
  Level 1 Level 2 Level 3 
Intra-
observer 
Skinfolds 10.0 7.5 7.5 
 Other measurements 2.5 2.0 2.0 
Inter-
observer 
Skinfolds 12.5 10.0 10.0 
 Other measurements  2.0 1.5 1.5 
 Note:  level 2 and 3 are the same                    
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3.2.4 Statistical Analysis  
The intra-observer TEM and %TEM for the two measurements were calculated by 
firstly performing a one way ANOVA test. This test provided the error mean square, 
which was then used in the following equations to calculate both TEM and %TEM 
(Ulijaszek and Kerr 1999): TEM =√error mean square and % TEM = (TEM/mean) x 
100. The inter-observer TEM was calculated by using the following equation 
(Ulijaszek and Kerr 1999): 
 
  
 
 
 
 
 
ICC was calculated using a one way random single measures test on SPSS®.  
 
3.3 RESULTS 
Ten children were recruited between March and July 2012. Of these 50% (n=5) were 
males and 50% (n=5) were females. The median (IQR) age was 8.5 (6.5-10.7) years 
and all of them were Caucasian. Intra- and inter-observer TEM, %TEM and ICC 
were calculated for all measurements (tables 3.2, 3.3, 3.4), as there was not a 
statistically significant difference between the measurement’s means of either each 
observer and between observers.     
Table 3-2 TEM and ICC (observer I) 
 
TEM = √((Ʃn(Ʃn M2)-( Ʃn M2)/K)) 
      (k-1) 
K= number of observers 
N= number of subjects 
M= measurement  
 Height (cm) Weight (Kg) MUAC (cm) TSF (mm) 
F* 0.00 0.00 0.00 0.02 
p value 1.00 0.99 0.99 0.97 
TEM cm 0.00 0.02 0.12 0.17 
TEM±68% CI 0.00 0.02±0.03 0.12±0.17 0.17±0.24 
TEM±95% CI 0.00 0.02±0.05 0.12±0.33 0.17±0.48 
TEM% 0.06 0.02 0.60 1.30 
ICC 0.99 0.99 0.96 0.96 
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*F: Difference between the means obtained from each series of measurements 
Table 3-3 TEM and ICC (observer II) 
 Height (cm) Weight (Kg) MUAC (cm) TSF (mm) 
F* 0.00 0.00 -0.05 -0.11 
p value 0.99 0.99 0.97 0.97 
TEM cm 0.00 0.00 0.11 0.13 
TEM±68% CI 0.00 0.00 0.11±0.15 0.13±0.18 
TEM±95% CI 0.00 0.00 0.11±0.3 0.11±0.36 
TEM% 0.01 0.01 0.22 1.23 
ICC 0.99 0.99 0.98 0.96 
*F: Difference between the means obtained from each series of measurements 
 
Table 3-4 Inter-TEM and ICC (observer I v observer II) 
*F: Difference between the means obtained from each series of measurements  
 
3.4 DISCUSSION  
The intra and inter-observer TEM for all measurements, apart from inter-observer 
TEM for MUAC, was below the proposed accreditation for level 2 post-course 
anthropometrists (Gore et al 1996). However, the inter-observer TEM for MUAC 
was 2.78cm, which is slightly higher than the proposed accreditation for level 1 post-
course anthropometrist (2.5cm) (Gore et al 1996). These results indicate that the 
intra-observer TEM for weight, height, MUAC and TSF and the inter-observer TEM 
for weight, height and TSF were minimal. Thus, it is reasonable to accept that these 
measurements have reduced systematic bias and are consequently accurate (Ulijaszek 
and Kerr 1999). In contrast, more systematic bias between observer 1 and observer 2 
are luckily to occur following MUAC measurements, which agrees with published 
 Height (cm) Weight (Kg) MUAC (cm) TSF (mm) 
F* 0.10 -0.10 -0.41 -0.85 
p value 0.99 0.99 0.83 0.70 
TEM cm 0.79 0.47 2.78 2.83 
TEM±68% CI 0.79±1.12 0.47±0.66 2.78±3.93 2.83±4.00 
TEM±95% CI 0.79±2.23 0.47±1.32 2.78±7.86 2.83±8.00 
TEM% 0.83 0.68 1.67 1.69 
ICC 0.99 0.99 0.96 0.96 
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studies reporting that higher TEM are generally obtained when measuring MUAC 
and TSF (Ulijaszek and Kerr 1999, Jamaiyah et al. 2010, Geeta et al. 2009, Ulijaszek 
and Lourie 1997). 
The intra- and inter-observer ICC for all measurements were ≥ 0.95 indicating a high 
level of reliability (Pederson and Gore 1996, Ulijaszek and Kerr 1999). Although the 
inter-observer TEM for MUAC was slightly higher than the proposed accreditation 
for the level 1 anthropometrists, the reliability (ICC) was 0.96 indicating also a high 
level of reliability.                  
3.5 CONCLUSION 
In conclusion, the measurements obtained by the two researchers showed a high level 
of precision, with a small technical error for all measurements, apart from MUAC, 
and a high level of reliability for all measurements. Consequently, it is acceptable to 
assume that the two researchers were able to detect anthropometric changes with a 
high degree of precision and reliability, and that measurements of MUAC will be 
considered with caution when interpreting the results from the longitudinal study. 
Both the TEM and ICC will be considered in chapter IV, discussion section.            
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CHAPTER IV 
 
 
4. PROSPECTIVE STUDY: THE DETERMINANTS 
OF NUTRITIONAL RISK IN PAEDIATRIC 
CANCER PATIENTS 
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4.1 AIMS AND OBJECTIVES 
The aims of this study were: 
(i) to investigate the prevalence of malnutrition (undernutrition, overnutrition 
and obesity) of paediatric cancer patients; 
(ii) to identify patterns of change in the nutritional status of paediatric cancer 
patients throughout the course of the disease and treatment;  
(iii) to determine potential factors which may contribute to the development of 
malnutrition in newly diagnosed paediatric cancer patients; 
(iv) to establish whether nutritional status at diagnosis is associated with 
clinical outcomes 
(v) to identify the use of nutritional support and whether patients at high risk 
of undernutrition were treated with any type of nutritional therapy.   
The objectives of this study included: 
- To quantitatively describe demographic, clinical and nutritional 
characteristics of this population.  
- To identify patterns of change by prospectively monitoring nutritional status 
parameters, which include measurements of growth, body composition and 
vitamins and minerals, from the time of diagnosis until the end of the study 
period (3 years). 
- To prospectively monitor newly diagnosed paediatric cancer patients for a 
maximum period of 3 years to identify short-term and medium-term 
determinants that might predict the development of undernutrition and 
overnutrition. 
- To prospectively monitor plasma vitamins and minerals status to identify and 
explore potential factors that may contribute to abnormalities.     
- To prospectively monitor the use of nutritional support in the different type of 
cancers and to identify how many PEM and undernourished (established by 
BMI) patients were receiving nutritional support.            
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- To establish whether undernutrition and obesity at the time of diagnosis are 
associated with a negative event, which includes relapse, becomining 
palliative or mortality during the 3 years of the study period  
4.2 METHODS 
4.2.1 Study design and time line 
This was a prospective cohort study originally designed in 2007 by Edinburgh 
Nutritional Risk in Childhood Cancer (ENRICC) and with the initiation of data 
collection in August 2010. The project can be divided into two phases: phase-I and 
phase-II: Phase-I was commenced in August 2010 were data were collected until 
January 2012 and phase-II, which was started in February 2012 and completed in 
April 2014.   
In this study repeated measurements were performed every three months from the 
time of recruitment over a period of one year and every six months thereafter. 
Individuals recruited in phase-I were followed until the end of phase-II for a 
maximum period of three years and those recruited in January 2014 were followed 
for a minimum period of three months (figure 4.1). 
 
∆ 3 M 6 M 12 M 24 M 30 M
Points in time when measurements will be taken:
1st year ± 3 weeks
After 1st year ± 3 months
18 M 36 M
Patients recruited in phase-I (Aug 2010) and followed in 
phase-II (Apr 2014) for a period of 42months maximum  
New recruitments 
24 months maximum 
Phase-I Phase-II Stop recruiting
33M
9 M
 
         Table 4-1 Representation of the longitudinal cohort study; phase-I and phase-II 
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4.2.2 Study population 
Eligibility criteria of the study population included: 
- Children and young people under the age of 18 years who were diagnosed 
with either a cancer included in the ICCC-3 or with Multisystem 
Langerham’s Cell Histiocytosis (LCH)  
- Children diagnosed between August 2010 and January 2014 in SE Scotland 
and treated in the RHSC, Edinburgh and/or Ninewells Hospital, Dundee.   
- Children who were treated with chemotherapy and/or radiotherapy or 
combinations therapies, which could include either chemotherapy or 
radiotherapy with or without corticosteroids, proton therapy and/or surgery.   
The following children were excluded from the study: 
- Children who were treated palliatively from the time of diagnosis  
- Children who were diagnosed with a second cancer and as a consequence had 
previously been treated. 
- Children who became palliative during the study period were withdrawn from 
the study.  
- Children treated with surgery only. 
The controls used in this study were patients who met the eligibility criteria but did 
not take part in this study. This was done to establish whether the cohort 
(participants) were representative of the paediatric oncology population from SE and 
E Scotland.   
4.2.3 Recruitment 
Children and their families (or carers) were provided with written and oral 
information once a confirmed diagnosis of cancer and a plan for treatment was 
established by the Haematology/Oncology team (appendix III). Families were given 
a minimum of 24 hours to read the information and think about participating in the 
study. Only then written consent was obtained from the older children, parents or 
carers (appendix III) and assent from children. All families were informed that they 
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were not under any obligation to participate and that they could withdraw at any time 
if they wished to.  
4.2.4 Demographics and clinical parameters 
Demographics and clinical data were collected from medical notes. As a proxy 
marker for socioeconomic deprivation level of individuals, this study used individual 
residence postcodes to assess deprivation level of areas of residence using the 
Standard Index of Multiple Deprivation (SIMD) (The Scottish Government 2012). 
SIMD is presented as a quintile where “I” denotes the most deprived and “V” the 
least deprived.   
The following clinical data were collected: cancer diagnosis, date of diagnosis and 
age at diagnosis; from which decimal age was then calculated at every time point. 
The type of cancer was then classified according to ICCC-3 (Steliarova-Foucher et 
al. 2005) (appendix I) to be able to compare with other paediatric cancer populations 
and for statistical purposes; to determine the nutritional risk of this population. In 
addition, the following data were recorded: length of treatment, treatment induced 
side effects, death, and event-free survival as well as whether the patients became 
palliative. The variables were stratified into two groups: “events” and “event free 
survival” (EFS), which in cancer is defined as responding to treatment without the 
following events: relapse, death, metastasis or becoming palliative during treatment.  
The treatment was recorded in two different ways: treatment protocol and whether 
the child received chemotherapy, radiotherapy and proton therapy, and also whether 
the child had had any surgery. Any changes in treatment protocols or other treatment 
modalities were also noted during the data collection period. Intensity of treatment is 
often related to the severity of disease; as such treatment was divided into three 
groups: high risk, medium risk and low risk to establish possible associations 
between treatment intensity and nutritional risk (appendix I) (Kazak et al. 2012). 
Those children who started on low/medium risk protocols but were soon after 
diagnosis (less than two months) changed to high risk protocols were classified as 
high risk. High dose corticosteroids are used in alternative phases for prolonge 
periods of time in all ALL treatment protocols, and small doses are also used as anti-
emetics or to reduce intracranial pressure in patients with brain tumours (Davis et al. 
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2004). Although, evidence have showed that their use may lead to obesity (Davis et 
al. 2004, Dulloo et al. 2012, Reilly et al. 2001), this study did not consider their use 
in isolation owing to the prospective nature of this project. Instead they were 
considered as part of the whole therapy.       
4.2.5 Measurements of growth and body composition  
Measurements of weight and height at the time of diagnosis, prior to recruitment, 
were obtained from clinical notes as volunteers were generally recruited a few weeks 
into treatment. Weight and height measurements were obtained following standard 
procedures for infants and children (Tanner 1990b) and using the available 
equipment from outpatient’s clinics or from the hospital’s wards.  
Children under the age of 2 had their length and weight measured. Length was 
measured between two (one researcher and either a member of staff or a parent) on a 
supine position lying down on a flat surface provided by a standard length scale 
(SECA 399, Hamburg Germany) and completely naked. Whilst the child lied down, 
one person held the head in an upward position and another straightened the legs 
with one hand and placed the sliding board in contact with the child’s heels with the 
other hand, making sure that the toes were facing upwards. Infants of less than one 
year were weighted nude using an electronic baby scale (SECA 232, Hamburg, 
Germany) providing an estimated weight to the nearest 0.1g.                 
Children older than 2 had their standing height measured without shoes using a wall 
mounting stadiometer which measured height to the nearest 0.1mm (SECA 
Hamburg, Germany). Children were asked to stand with their heels and back in 
contact with an upright wall and, whilst the head was hold by the researchers to make 
sure the child was looking straight forward. Before the right-angle block was slide 
down to touch the head, children were asked to breathe in and out. Weight was taken 
without shoes and heavy clothing using a standing scale (SECA 599, Hamburg, 
Germany), which estimated weight to the nearest 0.1Kg.       
The radiale-stylion segment length (ulna length) was measured in one patient who 
was not able to stand up due to muscular dystrophy, using Harpenden Holtain 
Anthropometer. The measurements were taken by placing one arm of the caliper on 
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the radiale and the other arm on the stylon landmark according to Norton and Tim’s 
(1996). The caliper estimates the length to the nearest 0.1mm over a range of 50mm 
to 570mm. Height was then estimated with the following equation height = 4.459 x 
(length) + 1.315 x age + 31.485 (Gauld et al. 2004). Ulna length was chosen instead 
of other limbs because evidence showed to be reproducible and to predict height 
more precisely in school-age children. It also appears to be superior in patients with 
neuromuscular weakness and spinal deformities (Gauld et al. 2004).  
BMI expressed as Kg/m
2
 was then calculated using the standard equation weight 
divided by squared height. Finally, height, weight, head circumference and BMI 
centiles and standard deviations were calculated using LMS Growth programme 
(Harlow Healthcare, UK).  
Measurements of arm anthropometry, MUAC and TSF were taken using standard 
techniques as it has been described in chapter III, section 3.1.3.4. The raw 
measurements were then used to calculate UAMA and UAFA by using an equation 
proposed by Frisancho (1981).     
 
 
 
BIA was measured using a SF-BIA Quantum II RJL System at a frequency of 50 
KHz and the device was calibrated according to manufacturer’s instructions (once 
per month). The measurements were also performed using manufacturer instructions.  
Children were asked to lie down on their backs with the arms adopting a 45° position 
and their legs slightly separated. All four electrodes were placed on the right side of 
the body, unless contraindicated for clinical reasons. Two electrodes were placed on 
one hand and two on one ankle as shown in figure 4.1. For most reliable readings, it 
is recommended that individuals have their bladders empty, are not on intravenous 
fluids or treatment at the time of the reading and, infants should have their wet 
nappies removed. This was done whenever possible. The estimation of FM and FFM 
A (mm
2
) = ᴫ/ 4 x d2 
M (mm
2
) = (C - ᴫ T)2/ 4ᴫ 
F (mm
2
) = A - M 
A: Upper arm area; M: UAMA; F: UAFA; C: MUAC mm; T: TSF 
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was calculated using the TBW equation developed by Schaefer et al (1994, 2000). 
This was originally developed in 112 healthy children and adolescents (age 3.9-18) 
and then validated in a group of children diagnosed with chronic renal failure who 
were also on haemo or peritoneal dialysis (n=23) (Schaefer et al. 1994a, Schaefer et 
al. 2000). Like paediatric cancer patients, children with chronic renal failure also 
experience rapid shifts in body fluids and many are treated with corticosteroids 
(Schaefer et al. 1994a, Schaefer et al. 2000). Furthermore, the authors reported a 
coefficient of variation of 8.5%, which is significantly smaller than those reported in 
other equations developed from similar populations (Wühl et al. 1996). Thus, the 
TBW equation developed by Schaefer et al. (1994, 2000) seemed more appropriate 
than the one specifically developed for paediatric cancer patients (Brennan 1998), 
which reported large limits of agreement and it has not been validated yet.  
 
 
 
All measurements were taken three times whenever possible and a mean of the three 
values was calculated. When the three measurements were impossible to obtained, 
the mean of the two or a single one was used for data analysis.          
 
Figure 4.1 Position of the electrodes for measurements of Bioelectrical Impedance 
Analysis 
TBW = 0.65 (h
2
/I) + 0.68 x age (years) + 0.15 
FM% = W – TBW 
FFM% = FFM x BW /100 
TBW: total body water; h: height; I: impedance; W: weight 
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4.2.6 Blood collection and analysis of samples 
Blood samples were collected by the nursing or medical staff either when the 
children had all the other measurements taken or at the next routine blood test. Due 
to ethics blood was not extracted for research purposes only, but taken in conjunction 
with routine clinical blood tests. Blood samples were immediately sent to the RHSC 
laboratory where they were processed and then analysed or sent somewhere else for 
analysis. Bloods taken to assess full blood count, liver function and urea and 
electrolytes, as well as renal function were all analysed in the Edinburgh RHSC 
laboratory facilities. Standard sensitivity C-reactive protein (ss-CRP) was analysed in 
the Royal Infirmary of Edinburgh using the Abbott Architect C8000 analyser by a 
turbidimetric method (see appendix IV).  
Full nutritional screening included the assessment of vitamin and minerals. The 
vitamins measured were: vitamin B12, folate, and the fat soluble vitamins A, D and 
vitamin E/Cholesterol (E/Ch) and, the minerals measured included: ferritin (for iron 
stores), zinc, selenium, copper, magnesium and calcium. Bloods obtained for full 
nutritional screening were analysed in the Royal Infirmary laboratory of Glasgow 
(see appendix IV). All analyses were performed using standard operating procedures 
by the hospital’s own accredited laboratory. Methods of specific vitamins and 
minerals with scientific interest will be specified. Vitamins B12, folate and ferritin 
were all measured using a chemiluminescent immunoassays performed on the Abbott 
Architect i2000 Analyser. Vitamins A and E/Ch were measured by high performance 
liquid chromatography (HPLC) with UV detection. Trace metals (zinc, copper and 
selenium) were measured by Inductively Coupled Plasma Mass Spectrometry.   
4.2.7 Assessment of dietary intake and energy requirements  
In order to determine children’s macronutrient and micronutrient intakes and any 
pattern of change throughout the study period, dietary intake was obtained at every 
time point by using a 24 hour multi-pass recall method. The researcher interviewed 
the patients and/or the parents by asking to recall everything that the child had drank 
and eaten the day before, if that was a typical day. In cases where it was not a typical 
day due to treatment procedures such as fasting, families were asked to recall a 
typical day representative of that time. For completeness, further questions about 
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portion sizes, cooking methods and brands, as well as whether the child had had 
specific foods from different food groups were asked. As patients on treatment for 
cancer often experience appetite and taste changes, questions about this were also 
asked.    
To assess the prevalence of patients needing nutritional support, the reasons for 
nutritional support and the type of nutritional treatment prescribed, all this 
information was recorded. The nutritional intervention was classified following 
NICE 2006 guidelines:  
- Oral nutrition support (ONS) 
- Enteral tube feeding (ETF): nasogastric (NG), nasojejunal (NJ), gastrostomy 
(PEG), jejunostomy (PEG-J) tube feeding  
- Parenteral nutrition (PN) 
- Advanced nutritional support (ETF and PN) 
Both macronutrient (fat, protein and carbohydrates) and relevant micronutrient 
[vitamins (A, B12, C, D, E and folate) and minerals (calcium, copper, iron, 
magnesium, selenium and zinc)] intakes were analysed using WinDiets  (Univation 
Ltd 2005) programme. Estimated energy intakes from the 24 hour multi-pass 
analysis were then compared to energy requirements to assess whether the children 
were meeting requirements. If the child was on nutritional support the total energy 
intake was calculated altogether. The Scientific Advisory Committee on Nutrition 
(SACN) published in 2011 and based on updated evidence recommends the use of 
the Henry equation (2005) to estimate energy intake in infants, children and 
adolescents. Thus this equation was used for the purpose of this study. As discussed 
in chapter I, section 1.3, there is no evidence supporting an increase in REE in this 
population as a result of an increased in metabolic response. Additionally, this 
population have an increased risk of becoming obese and there is evidence reporting 
sedentary lifestyle in this population (Brinksma et al. 2014, Reilly 2009a). Thus no 
stress factor was added to the equation. Instead a physical activity level (PAL) of low 
physical activity (10
th
 centile) adjusted for growth was added: 0-3 years: 1.3; 3-10 
years: 1.35 and 10-18 years: 1.58, which was advised in the SACN (2011) document.  
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4.2.8 Reference values  
The reference data to assess growth was obtained from height, weight and BMI 
standards published by Cole et al. (1995), which were specifically developed from 
UK children from the 1990s (Cole et al. 1995a). New growth charts for children 
under the age of 4, which combined WHO standards with UK preterm and birth data 
(32-42 weeks) from the 1990s, were introduced at the end of 2010. These were not 
used as reference data in order to keep continuity from phase-I into phase-II of the 
study as the standards used here were adopted in 2007. Additionally, this standard is 
most commonly used for research purposes making the results more suitable for 
comparison with published studies.   
BMI definitions of malnutrition were obtained from the Department of Health (2012) 
and SACN as this provides with official UK national definitions. Underweight was 
defined as BMI ≤2.3th centile (-2 SD), overweight between ≥85th (≥1.05 SD) and 
<95
th
 (<1.63 SD) centile and obese ≥95th centile (≥1.63 SD). The prevalence of 
malnutrition in the paediatric oncology population was then compared with UK 
national data obtained from the Nutrition and Diet National Survey (NDNS) 
(Department of Health 2012). New data on prevalence of malnutrition in British 
children has been published, however this was only published in September 2014, 
once data analyses had already been performed (Bates et al. 2014). 
The reference centiles used for MUAC and TSF and, UAMA and UAFA were 
Frisancho (1974) and Frisancho (1981). There are other published references 
including: WHO (2011), Oguz et al. (1999), Oakley et al. (1977), Ozturk et al. 
(2009); however they all carry disadvantages with them including small sample size 
(Oguz et al. 1999), populations that are not representative of the Scottish paediatric 
oncology patients (Ozturk et al. 2009) and reference designed for infants aged less 
than 42 weeks. Therefore the reference values from Frisancho (1974 and 1981) were 
used for many reasons. Firstly, the sample population from Frisancho’s reference 
data were thought to be more representative of the Scottish paediatric oncology 
population than that of the WHO (2011). Frisancho’s references were developed 
from a large sample from the USA; population similar to that of Scotland, whilst 
reference from WHO (2011) were developed from developed and developing 
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countries. Also, WHO (2011) does not have UAMA and UAFA centiles, whilst 
Frisancho’s references does (1974 and 1981). All references are adjusted for age and 
gender and MUAC, TSF, UAMA and UAFA’s definitions of malnutrition were: 
undernutrition ≤5th centile (Frisancho 1974, Garofalo et al. 2005; Oguz et al. 1999; 
Smith et al. 1991), overnutrition between ≥85th and <95th centile and obesity ≥95th 
centile (Frisancho 1974 and Frisancho 1981). These generated categorical data, 
which were then normalised according to age and gender by calculating the 
percentage of the 50
th
 centile. Thus, allowing for statistical calculations and 
comparisons. 
FM% and FFM% values were obtained from BIA measurements. At present, there is 
no published reference representing the age range 0-18 years. Thus two were selected 
for the purpose of this study: Fomon et al. 1982 for children under the age of 10 and 
Wells et al. 2012 for children between 10-18 years of age.  All references are 
matched for age and gender.  The reference values published by Fomon et al 1982 
have been obtained from a 4 compartment model, which includes %FM and %FFM. 
The percentage of body weight from the FFM is divided into 4 further compartments: 
protein, TBW (extracellular and intracellular fluid), minerals (osseous and non-
osseous) and carbohydrates. As the BIA only allows to obtain measurements of 3 
compartments (FM, FFM and TBW), all the compartments included in the FFM were 
summed. This value was then used to estimate the 50
th
 centile of FFM.    
The reference ranges used for blood parameters were those published by NHS 
Scotland Laboratory Handbook, which are all adjusted for age.   
UK macronutrient intake recommendations for infants, children and adolescents are 
only available for protein, thus the reference nutrient intake (RNI) for protein were 
used to compare with the protein intake from this cohort (Department of Health 
1991). Additionally, fat and carbohydrate recommendations for infants (< than 1 
year) have not been described yet, thus the average proportions of energy yielding 
nutrients of infant formula were used, which are 50% (~30g per day) for fat, and 
40% of TEI (65-70g per day) for carbohydrates (Wojcik et al. 2009). The reasons for 
using this reference are firstly, it has been recommended by the UK DRVs due to the 
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low protein content of breast milk, which is described to be insufficient for formula 
fed infants (Department of Health 1991). Secondly, dietary intake for infants in this 
cohort of patients is only available for those who were formula fed or were on 
nutritional support as opposed to breast fed babies. Therefore, these values appeared 
more suitable for this population. For the percentage of macronutrient intakes for 
children older than 1 year, UK adult recommendations were used, which are 35% for 
fat and 50% for carbohydrates. The total requirements of carbohydrates and fats (in 
grams) were calculated from the total energy requirements and the percentage 
recommendations.         
4.2.9 NHS ethical approval 
This study was granted with NHS ethical approval from the NHS Scotland (NHS 
REC 06-51104-52) on the 1
st
 of June 2007 (appendix V). The researcher also had the 
relevant enhanced disclosure and honorary contract, which allow carrying out the 
data collection of this study. All patients’ data were anonymised and kept 
confidential.       
4.2.10 Statistical analyses 
Descriptive statistics were used to evaluate the prevalence of malnutrition 
(frequencies), changes in nutritional status according to growth and body 
composition measurements and blood parameters. All data were tested for normal 
distribution. Normally distributed data were presented as mean ± standard deviation 
(SD) and non-normally distributed data as median and interquartile range (IQR). 
Comparisons of different groups (diagnostic criteria, treatment risk and gender) were 
established by independent t-test, ANOVA (normally distributed data), Mann-
Whitney and Kruskal Wallis (non-normally distributed data). Correlations between 
variables were tested using Pearson’s (normally distributed data) and Spearman’s 
correlation (non-parametric) and categorical data was tested for associations using 
the χ2 test. Participants (cohort) and non-participants (controls) were compared to 
establish whether this paediatric cancer cohort was representative of SE and East 
Scotland. Results were expressed using 95% confidence intervals, odds ratios and p 
<0.05 was considered statistically significant.    
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Multilevel analyses were performed to establish the following; (i) statistical changes 
in nutritional status assessed by using growth and body composition over time and 
(ii) possible factors that may contribute to changes in both growth and body 
composition over time.  
To establish changes in nutritional status over time a multilevel growth model was 
used. Prior to perform this analysis all groups (diagnostic criteria and treatment risk 
groups) were compared to establish whether the groups were significantly different. 
There was not statistically significant difference between the groups, therefore all 
cancer patients were analysed all together. The total length of time was 18 months as 
there was not enough data at any time point from 18 months until 36 months to 
perform growth multilevel analyses. Changes in nutritional status according to both 
growth and body composition was presented at three time points 0-3 months, 0-9 
months and 0-18 months. This was decided due to the different trajectories each 
variable followed. The outcome variables analysed were divided into growth 
measurements and body composition. Growth measurements included: BMI centile, 
HFA centile, MUAC (percentage of 50
th
 centile) and TSF (percentage of 50
th
 centile) 
and body composition measurements included: FFM% and FM% obtained from both 
arm anthropometry parameters and BIA.  
To establish factors that may contribute to changes in nutritional status at each time 
point (0-3 months, 0-9 months and 0-18 months) the mixed multilevel model was 
used. The outcome variables were kept as before (growth and body composition 
parameters) and the following factors tested were diagnostic criteria, treatment risk, 
age at diagnosis, whether the patient was on any nutritional support during the 
interval period and the total estimated energy intake also from the appropriate time 
interval. The different factors were tested one at the time and only those that reached 
a relaxed significance of 0.1 were included in the conditional model. Final 
significance was established at p <0.05. All analyses were performed using The 
Statistical Package for Social Studies (IBM-SPSS for Windows Statistics, 19), whilst 
graphs were performed using IBM-SPSS 19, Excel and Graph Pad Prisma 5. 
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4.3 RESULTS 
4.3.1 Patient’s demographics 
179 patients were diagnosed with childhood cancer between the 1
st
 of August 2010 
and the 31
st
 of January 2014 in the Edinburgh Royal Hospital for Sick Children. Of 
these 78 (43%) did not meet the eligibility criteria for the reasons described in figure 
4.2 and, a total of 101 (57%) were considered eligible. 19 (19%) patients refused to 
participate for the reasons described also in figure 4.2, thus a total of 82 (81%) 
patients were studied. 
 
       Figure 4.2 Flow diagram showing patient’s accrual  
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Table 4.2 shows that this cohort of 82 patients was representative of the whole 
paediatric oncology population from SE Scotland. Childhood cancer incident rates 
according to ICCC-3 are presented in table 4.3. At the end of the data collection 
period (31st April 2014), the survival rate was 90% (n=74), the death rate was 10% 
(n=8) and the event free survival rate was 85% (n=70). Thus 15% (n=12) of patients 
had either relapsed; their cancer had metastasised or did not respond to treatment. Of 
these, 67% (8/12) died, 17% (2/12) became palliative, 17% (2/12) were receiving 
treatment by the end of the study and 8% (1/12) survived.  
Table 4-2 Characteristics of the n=82 Paediatric Oncology cohort and n=22* 
controls (non-participants) 
Patients’ 
characteristics 
Cohort Controls P 
 Median  IQR 95% CI Median  IQR 95% CI  
Age at 
diagnosis 
(years) 
 
3.88 
 
1.96-8.83 
 
4.69-6.88 
 
6.52 
 
3.91-10.65 
 
5.37-9.26 
 
0.06
1 
 N % N %  
Gender     0.5
2 
  Male 46 56 10 45.5  
  Female 36 44 12 54.5  
Diagnostic 
criteria 
    0.9
3 
  ST 35 43 10 45.5  
  HM 36 44 11 50  
  BT 7 8.5 1 4.5  
  OAD 4 5 0 5  
Deprivation
**
      0.6
2 
  I 15 18 7 32  
  II 12 15 2 9  
  III 15 18 2 9  
  IV 24 29 8 36  
  V 15 18 3 14  
Ethnicity     0.5
3 
  White 80 98 21 95.5  
  Non-white 2 2.4 1 4.5  
*
N=22: 19 (refused to participate) + 3 (met criteria but were not approached as advised by 
consultants); 
**
Deprivation I-V where I denotes the most deprived and V the economically most 
advantageous families; 
1
Mann-Whitney;
 2
Chi square test; 
3Fisher’s Exact Test 
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Table 4-3 Cancer diagnosis according to ICCC-3 of the n=82 Paediatric Oncology 
cohort and n=22* controls 
Diagnosis 
 
Cohort n=82 Control n=22 
 N % N % 
I-Leukaemias 
 
35 43 11 50 
   ALL 29 35 11 50 
   AML 3 4 0 0 
   CML  2 2 0 0 
   HLH 1 1 0 0 
II-Lymphoma 
 
10 12 3 14 
III-CNS tumours 
 
5 6 2 9 
IV-Neuroblastoma 
 
6 7 2 9 
V-Retinoblastoma 
 
2 2 0 0 
VI-Renal tumours  
 
6 7 0 0 
VII-Hepatic tumours 
 
1 1 0 0 
VIII-Malignant bone tumours 
 
4 5 3 14 
IX-Soft tissue sarcoma 
 
5 6 1 4.5 
X-Germ cell tumours 
 
1 1 0 0 
XI-Malignant epithelial 
neoplasm  
 
4 5 0 0 
XII-Others and unspecified 
malignant neoplasms 
 
0 0 0 0 
Other associated diagnoses 
 
3 4 0 0 
   LCH
**
 3 4 0 0 
 *N=22: 19 (refused to participate) + 3 (met criteria but were not approached as advised by 
consultants);  
**LCH: Langerham’s cell Histiocytosis.  
A total of 24 treatment protocols were used to treat this cohort of patients. These 
were further stratified into different treatment risks and subsequently randomised 
into different arms of the trials. Therefore, for simplification of the data, the 
treatment type was presented into five categories: (i) 56% (n=46) were treated with 
chemotherapy only; (ii) 4% (n=3) with a combination of chemotherapy and 
radiotherapy; (iii) 18% (n=15) with a combination of chemotherapy and surgery; (iv) 
19.5% (n=16) with chemotherapy, radiotherapy (or proton therapy) and surgery and, 
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(v) 4% (n=3) were treated with other forms of treatment like HSCT. Finally, the 
cohort was stratified according to risk of treatment failure (low risk, medium risk and 
high risk) to be able to perform correlation statistics. There were 22% (n=18) 
classified as low risk, 37% (n=30) as medium risk and 41.5% (n=34) as high risk.    
The number of patients and measurements available at each time point is presented in 
table 4.4.  
Table 4-4 Patient’s accrual and follow up at each time point and number of patients 
having had each type of measurement taken 
Time point Patients 
availability 
Drop 
outs* 
BMI MUAC TSF BIA Dietary 
intake 
Bloods 
Recruitment 82 0 81 79 75 60 77 77 
3 months 82 6 75 71 70 56 75 70 
6 months 73 19 54 49 49 38 54 42 
9 months 65 14 51 48 47 37 51 34 
12 months 55 14 42 41 40 30 42 25 
18 months 47 13 34 33 32 28 34 25 
24 months 35 11 24 24 24 20 24 13 
30 months 19 7 12 12 12 10 12 6 
36 months 16 9 7 7 7 6 7 3 
*
Drop outs due to: deceased patients, palliative treatment, treatment given in centres other than RHSC, 
Edinburgh and Ninewells Hospital, Dundee and patients who missed appointments. 
 
4.3.2 Prevalence of malnutrition and changes in nutritional status according to 
growth and body composition measurements   
The prevalence of malnutrition in paediatric cancer patients was investigated at each 
time point from the time of diagnosis and recruitment (baseline) up to a maximum of 
36 months and a minimum of 3 months. Prevalence and changes in nutritional status 
were presented all together (all cancers) and stratified by gender and cancer type 
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(solid tumours, haematological malignancies, brain tumours and other associated 
diagnoses). 
4.3.2.1 Measurements of growth 
(i) Prevalence of malnutrition  
The prevalence of malnutrition (undernutrition, overnutrition and obesity) where all 
cancers are presented together varied at each time point and with each measurement. 
The prevalence of well nourished paediatric cancer patients according to BMI are 
presented in figure 4.3 for comparative reasons.    
The prevalence of undernutrition was identified using BMI, MUAC and TSF 
measurements. At the time of diagnosis and baseline, the prevalence of 
undernutrition was higher than at any other time during the study period. This ranged 
between 13% and 15% depending on the type of measurement used. BMI (11/81) 
and MUAC (10/79) identified the same percentage of undernourished patients (13%), 
whilst TSF (11/75) identified a slightly higher percentage (15%). According to BMI, 
at 9, 12 and 18 months there were no undernourished patients; however MUAC and 
TSF identified between 3% and 6% of the total cohort of patients. Finally, at 30 and 
36 months none of the patients were undernourished (figure 4.4).  
The prevalence of overnutrition and obesity were established according to BMI and 
TSF. Both measurements identified similar prevalence of overnutrition at baseline, 3, 
6, 18 and 24 months; however this differed from each other at 9, 12 and especially at 
36 months (see figure 4.5). As it can be seen from the graph, the highest prevalence 
of overnutrition was at 30 months [BMI; 2/12 (17%)] and 36 months [TSF; 2/7 
(29%)], whilst the lowest was at 24 months [BMI and TSF; 2/24 (8%)]. 
BMI identified consistently higher prevalence of obesity than TSF throughout the 
study period and there were no obese patients at 36 months.  Figure 4.6 shows that 
obesity was least prevalent at diagnosis as BMI identified 15% (12/82) of patients 
and TSF only 1% (1/75); whilst obesity was most prevalent at 30 months with 33% 
of patients identified using BMI (4/12) and 25% TSF (3/12).   
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Figure 4.3 Prevalence of well nourished paediatric cancer patients at different stages 
of the disease and according to BMI centile between 2.3
rd
 -84
th
 centile.   
 
Figure 4.4 Prevalence of undernutrition at different stages of the disease and 
according to BMI (<2.3
rd
 centile), MUAC (<5
th
 centile) and TSF (<5
th
 centile) in all 
cancers. 
 1χ2 (9.65), p=0.03; 2 χ2 (5.274), p=0.025 against UK prevalence of undernutrition (DH 2012). For 
BMI, MUAC and TSF n values at different time points see table 4.4.  
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Figure 4.5 Prevalence of overnutrition at different stages of the disease and 
according to BMI (85-95
th
 centile) and TSF (85-95
th
 centile) in all cancers.              
For BMI and TSF n values at different time points see table 4.4.  
 
 
Figure 4.6  Prevalence of Obesity at different stages of the disease and according to 
BMI (>95
th
 centile) and TSF (>95
th
 centile) in all cancers.  
1χ2-test (5.274), p=0.03 against UK prevalence of obesity (DH 2012). For BMI and TSF n values at 
different time points see table 4.4.  
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Prevalence of malnutrition was also stratified by gender. A series of Mann Whitney 
test showed that there were not statistically significant differences between BMI 
centiles of males and females at any stage (p> 0.05). However, the odd ratios showed 
that both males and females diagnosed with cancer were 10 times more likely to be 
undernourished at the time of diagnosis and recruitment than healthy children from 
the UK (DH 2012). Males with a cancer diagnosis were 2.2, 2.27 and 4.28 times 
more likely to be overweight at 12, 30 and 36 months respectively than healthy 
males, whilst the likelihood of females with cancer to be overweight or obese did not 
differ from healthy female children. Finally, the odd ratio for males with cancer at 30 
months was 3.57 higher than healthy male children (see figure 4.7). 
 
 
Figure 4.7 Prevalence of malnutrition according to BMI and stratified by gender at 
different stages of the disease and treatment 
1 χ2 (13.085), p=0.001; 2 χ2 (6.664), p<0.02; 3 χ2 (8.6), p=0.005; 4 χ2 (5.007), p<0.03; 5 χ2 (5.711), 
p<0.03; 
6
 χ2 (8.882), p<0.03; 7 χ2 (14.742), p<0.001 against undernutrition, overnutrition and obesity 
UK prevalence (DH 2012) 
 
Finally, prevalence of malnutrition was stratified by type of cancer; solid tumours, 
haematological malignancies, brain tumours and other associated diagnoses (OAD), 
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and type of measurement; BMI, MUAC and TSF. At baseline, the BMI centiles from 
the different diagnostic groups did not statistically differ (figure 4.8); however, 
prevalence of undernutrition measured by BMI, MUAC and TSF was highest in the 
solid tumour group: 17% (BMI), 22% (MUAC) and 18% (TSF). Children diagnosed 
with solid tumours [χ2(1) 19.908, p<0.001; χ2(1) 13.085, p<0.001], haematological 
malignancies [χ2(1) 4.714, p=0.03; χ2(1) 6.664, p=0.01] and brain tumours [χ2(1) 
13.085, p<0.001; χ2(1) 9.783, p=0.03] had a significantly higher risk of being 
underweight than healthy children from the UK
 
at the time of diagnosis and baseline. 
In contrast, children diagnosed with OAD and brain tumours showed the highest 
prevalence of overweight and obesity also at baseline; however this was not 
significant. Following 6, 9 and 12 months of treatment no patients diagnosed with a 
solid tumour was classified as undernourished; but 4% (BMI, MUAC and TSF) of 
those diagnosed with haematological malignancies and 33% (TSF) of brain tumours 
were undernourished at 6 months. These two groups also had the highest prevalence 
of overweight and obesity at 6, 9, 12 and 24 months (see table 4.4). Prevalence of 
overweight was significantly correlated with haematological malignancies [χ2(1) 
17.887, p<0.001] at 12 months, brain tumours [χ2(1) 8.882, p=0.005] at 6, 9 and 24 
months and OAD [χ2(1) 8.882, p=0.005] at 12 months. Finally, although obesity 
prevalence were higher in all types of cancer (apart from solid tumours) than in the 
healthy UK children population (Department of Health 2012), only children with 
brain tumours had a significantly higher risk of becoming obese at 6 and 9 months 
[χ2(1) 5.274, p<0.03].         
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Figure 4.8 Baseline BMI centiles (median) stratified by diagnostic category.  
Solid tumours: n=36; Haematological malignancies: n=35; Brain tumours: n=7; OAD: n=4 
  
Overall MUAC and TSF identified more undernourished and overnourished children, 
whilst BMI identified higher obesity frequencies. Malnutrition measured as BMI is 
the primary outcome of the study, consequently the limit of agreement of MUAC and 
TSF were measured against BMI at the time of recruitment and 24 months post 
diagnosis. The Kappa limit test showed poor agreement between BMI and both 
MUAC [K 0.1, p=0.01) and TSF [K 0.3, p<0.001] at identifying nutritional status. 
(ii) Changes in nutritional status  
Changes in growth were assessed using BMI centiles, MUAC (percentage of the 50
th
 
centile) and TSF (percentage of the 50
th
 centile) throughout the course of the study 
period. Changes in nutritional status assessed by BMI were explored in each 
individual and in all paediatric cancer patients. Data was then stratified according to 
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diagnostic criteria and treatment risk to establish whether there were any differences 
in patterns of change between the groups. Multilevel analyses were then performed 
to establish (i) statistical changes in growth parameters over time; (ii) whether the 
growth trajectory differed between the diagnostic groups and (iii) possible factors 
that contribute to changes in growth over time.  
Figure 4.9 shows the high variability in BMI centiles of each individual at the time of 
diagnosis and throughout the course of treatment. It can also be seen that although 
most individuals were well-nourished at diagnosis, many changed to overnourished 
or obese during the study period. Overall, BMI centile in paediatric cancer patients 
increased throughout the course of treatment. The median (IQR) BMI centile at 
diagnosis was 50 (19-84.5) and at baseline was 49 (24-86). This increased steadily at 
every time point until it reached a peak at 18 months [median (IQR) 74 (48-96)] and 
30 months [median (IQR) 85 (39-98)] (figure 4.10). It can be seen from figure 4.11 
that children diagnosed with solid tumours had consistently lower BMI centiles than 
the haematological malignancy group. Additionally, by the end of the study period 
the median (IQR) BMI centile increased from 46 (17-78) at diagnosis to 65 (38.5-
87.5) at 3 months in children with solid tumours and from 54 (22-83) at diagnosis to 
95.5 (71.5-99) at 30 months in the haematological malignancy group.  Children 
treated with high treatment risk protocols had the lowest BMI centiles during the 
initial phases of treatment, however this increased sharply by the end of the treatment 
(figure 4.12). Also, infants (age < 2 years) had lower BMI centiles during the initial 
phases of treatment than older childre and teenages during the whole study period 
(figure 4.13). For changes in MUAC, TSF and UAMA and UAFA see figures 4.13 
and 4.14.            
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Figure 4.9 Individual changes of BMI centiles from the time of diagnosis up to 36 
months  
Horizontal lines indicate nutritional status: below bottom line (<2.3
rd
 centile: undernutrition), above 
medium line (≥85th centile: overnourished) and above top line (≥95th centile: obese)  
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Figure 4.10 Changes in median BMI centiles in paediatric cancer patients from the 
time of diagnosis up to 36 months  
Horizontal lines indicate nutritional status: below bottom line (<2.3rd centile: undernourished), above 
medium line (≥85th centile: overnourished) and above top line (≥95th centile: obese)    
 
Figure 4.11 Changes in median BMI centiles in the different diagnostic groups from 
baseline up to 36 months 
ST: solid tumours; HM: Haematological malignancies; BT: brain tumours and OAD: other associated 
diagnoses. Horizontal lines indicate nutritional status: below bottom line (<2.3rd centile: 
undernourished), above medium line (≥85th centile: overnourished) and above top line (≥95th centile: 
obese).    
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Figure 4.12 Changes in median BMI centiles with data stratified according to 
treatment risk from the time of diagnosis up to 36 months  
Horizontal lines indicate nutritional status: below bottom line (<2.3rd centile: undernutrition), above 
medium line (≥85th centile: overnourished) and above top line (≥95th centile: obese).   
 
Figure 4.13 Changes in BMI centiles with data stratified by age groups 
Horizontal lines indicate nutritional status: below bottom line (<2.3rd centile: undernutrition), above 
medium line (≥85th centile: overnourished) and above top line (≥95th centile: obese).   
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Figure 4.14 Changes in MUAC and TSF in all paediatric cancer patients from 
baseline up to 36 months 
Data has been standardised by calculating the percentage of the 50
th
 centile (Frisancho 1974). Error 
bars (±SEM). For MUAC and TSF n values at different time points see table 4.4.  
 
Figure 4.15 Changes in UAMA and UAFA in all paediatric cancer patients from 
baseline up to 36 months 
Data has been standardised by calculating the percentage of the 50
th
 centile (Frisancho 1981). Error 
bars (±SEM). For UAMA and UAFA n values at different time points see table 4.4.    
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Table 4-5 Prevalence of malnutrition according to BMI and TSF and stratified by type of cancer 
1
OAD: other associated diagnoses (N= 4; Langerham’s Cell Histiocytosis); 2 χ2-test; p<0.05 against undernutrition, overnutrition and 
obesity UK prevalence (DH 2012). 
 
 
 
Time 
Line 
Nutritional 
status 
Solid tumours Haematological 
malignancies 
Brain tumours OAD
1 
  BMI TSF BMI TSF BMI TSF BMI TSF 
  % N % N % N % N % N % N %  % N 
Baseline 
 
Undernutrition 17
2 
35 18 33 11
2 
36 12 33 14
2 
7 17 6 0 4 0 4 
 Overnutrition 0  9  5.5  9  28.5  0  0  25  
 Obesity 8.5  0  14  0  28.5  17  50
2 
 0  
6  
months 
Undernutrition 0 24 0 22 4 23 5 20 0 3 33 3 0 4 0 4 
 Overnutrition 8.3  9  17  25  33
2 
 0  0  0  
 Obesity 8.3  13  26  15  33
2 
 33  25  0  
12 
months 
Undernutrition 0 16 0 16 0 19 0 17 0 3 0 3 - 0 33 3 
 Overnutrition 6  19  42
2 
 23.5  33
2 
 33  -  0  
 Obesity 0  0  21  23.5  0    -  0  
24 
months 
Undernutrition 12.5
2 
8 0 14 0 14 0 14 - 0 - 0 - 0 - 0 
 Overnutrition 0  14  14  7  -  -  -  -  
 Obesity 12.5  28.5  28.5  26  -  -  -  -  
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4.3.2.2 Body composition 
Body composition, FFM and FM, was calculated from arm anthropometry (MUAC 
and TSF) and BIA. Measurements of arm anthropometry first generated data on 
UAMA and UAFA, from which centiles presented in a ratio-fashion are available. In 
order to assess the prevalence of PEM and undernutrition, overnutrition and obesity, 
the UAMA and UAFA centiles were used respectively for reference (Frisancho 
1981). This categorical data was then normalised according to age and gender by 
calculating the percentage of the 50
th
 centile, which allowed for statistical 
comparison. FFM% and FM% obtained from arm anthropometry was then estimated 
following Frisancho’s equation (1981). The reference values used for BIA (Fomon 
1982 (children <5 years), Wells 2012 (children >5 years)) allowed calculating the 
percentage of the 50
th
 centile for both FFM and FM. And the equation by Schaefer 
(2000) was used to estimate FFM% and FM%.  
Table 4-6 Comparison between children identified as PEM by UAMA and the 
nutritional status established by BMI 
Time 
line 
UAMA  BMI  
 PEM 
 <5
th 
C 
Undernourished 
<2.3
rd
 C 
Well-
nourished 
>2.3
rd 
<85
th
 C  
Overnourished 
≥85th ,95th C 
Obese 
≥95th C 
Baseline 3 2 1   
3 months 6 1 4  1 
6 months 4  4   
9 months 3  2 1  
12 
months 
3  3   
18 
months 
1  1   
24 
months 
3 1 1 1  
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(i) Prevalence of malnutrition 
PEM, established by using UAMA, was prevalent from the time of recruitment for a 
period of 2 years. Figure 4.16 shows that PEM was most prevalent at 3 months 
(10%) and 24 months (12.5%), whilst at 30 and 36 months no patients were 
classified as PEM. Table 4.6 describes the number of patients which were identified 
as PEM by UAMA, and those are compared against the classification established by 
BMI (undernourished, overnourished and obese). Figure 4.17 shows the prevalence 
of malnutrition identified by UAFA in all paediatric cancer patients.   
 
Figure 4.36 Prevalence (expressed as a percentage) of protein energy malnutrition in 
paediatric cancer patients at different stages of the disease 
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Figure 4.47 Prevalence of malnutrition established using UAFA in all paediatric 
cancer patients at different stages of the disease 
 
The percentage of the 50
th
 centile for UAMA and UAFA was stratified by gender 
and by diagnostic category. There were no statistically significant differences 
between males and females at any stage from baseline up to 36 months in neither the 
UAMA nor the UAFA data (U; p>0.05). UAMA and UAFA were compared between 
diagnostic categories using the Kruskal Wallis test at every stage from baseline up to 
24 months only. No comparison was performed after that due to the small sample 
size. Children with solid tumours had significantly lower values of UAMA at 3 
months in compare to the other 3 diagnostic categories [H (3) = 8.844, p<0.03]; 
however there were not statistically significant differences in the UAFA between 
groups at any stage from baseline up to 24 months.  Jonckheere’s test revealed a 
significant negative trend in both the UAMA and UAFA data at baseline [UAMA: 
J=840, z=-249, p=0.006, 95% CI 0.004-0.008; UAFA: J=766, z=-2.28, p<0.02, 95% 
CI 0.012-0.016] and 3 months [UAMA: J=792, z=-2.6, p=0.004, 95% CI 0.002-
0.005; UAFA: J=701, z=-1.86, p<0.04, 95% CI 0.29-0.36] (figures 4.18, 4.19) 
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 Figure 4.58 UAMA percentage of the 50
th
 centile at different stages of the disease 
and stratified by diagnostic category 
 
1
 Solid tumours had significantly lower UAMA than any other diagnosis (H (3); p<0.03) at 3 months. 
N values for the different diagnostic criteria and at different time points are presented in table 4.5, 
TSF values.   
 
Figure 4.69 UAFA percentage of the 50
th
 centile at different stages of the disease 
and stratified by diagnostic category 
N values for the different diagnostic criteria and at different time points are presented in table 4.5, 
TSF values.   
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(ii) Changes in body composition at different stages of the disease 
The percentage of FFM (FFM%) and FM (FM%) was calculated from both arm 
anthropometry (AA) measurements and BIA at every stage of the disease. Both 
measurements showed a gradual decrease in FFM% from baseline (FFM% AA: 69%; 
BIA: 68.5%) until the 12 month follow up (FFM% AA: 63%; BIA: 65%). This then 
remained steady for the remaining follow up period; 36 months (FFM% AA: 63; 
BIA: 64%). In contrast, the percentage of FM (FM%) increased gradually from 
baseline (FM% AA: 30%; BIA: 32%) until the end of the study period (FM% AA: 
36%; BIA 37%) (Figures 4.20 and 4.21). No significant differences were found 
between diagnostic criteria and gender in either FFM% and FM% [gender: F(0.02), 
p=0.9; diagnoses: F(1.7), p=0.2]  Figure 4.22 shows the agreement between FM% 
obtained from AA and BIA with a mean difference of 0.09% and 95% CI -1.0 to 1.2.       
 
Figure 4.20 Changes in FFM% calculated from BIA and *arm anthropometry (AA) 
N values for BIA and AA (see TSF) are presented in table 4.4 
55.0
57.0
59.0
61.0
63.0
65.0
67.0
69.0
71.0
73.0
P
er
ce
n
ta
g
e 
(%
) 
Time line 
Changes in FFM%  
FFM% BIA
FFM% AA*
205 
 
 
Figure 4.71 Changes in FM% calculated from BIA and *arm anthropometry (AA) 
N values for BIA and AA (see TSF) are presented in table 4.4 
 
Figure 4.82 Agreement between FM% obtained from AA and BIA measurements 
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4.3.3 Linear growth 
Linear growth was assessed using height for age (HFA) in centiles at every stage 
from the time of diagnosis up to 36 months. Data were presented including all 
cancers (i), stratified by gender (ii) and by diagnostic criteria (iii): (i) the median 
HFA centiles of paediatric cancer patients was above the 50
th
 centile [median 55, 
IQR 26.5-740] at the time of diagnosis and this decreased at every stage until it 
reached a nadir after 6 months of treatment [median 41, IQR 23-64]. From this point 
HFA centiles increased steadily until it reached a peak at 30 months [HFA 69.5, IQR 
47.7-93.7] (figure 4.23). (ii) A series of Mann-Whitney tests showed that there were 
no statistically significant differences between the HFA centiles of males and 
females at any stage (figure 4.24). However, the HFA centiles of females were 
consistently lower than that of the males at every stage after 3 months of treatment. 
(iii) Children diagnosed with solid tumours had the highest HFA at the time of 
diagnosis [median 62, IQR 25-76] and recruitment [median 62.5, IQR 35.5-79.7] 
(figure 2.25), whilst those diagnosed with haematological malignancies had the 
lowest HFA centiles at the time of recruitment [median 36, IQR 17.5-36]; however, 
it did not reach significance (Kruskal-Wallis test, p>0.05) (figure 4.24). This group 
remained with the lowest HFA centiles throughout the study period for 24 months; at 
which point it increased considerably reaching the 70
th
 centile (IQR 32-86.9) and 
levelling with the other cancer groups (figure 4.26).            
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Figure 4.93 Height for age in paediatric cancer patients at different stages of disease. 
Data presented in median and 95% CI 
For height for age n values at different time points see table 4.4.  
 
 
Figure 4.104 Height for age stratified by gender. Data presented in median and 95% 
CI 
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Figure 4.115 Height for age stratified by type of cancer at the time of recruitment 
Solid tumours: n=36; Haematological malignancies: n=35; Brain tumours: n=7; OAD: n=4 
 
Figure 4.126 HFA centiles at different stages of the disease and data stratified by 
diagnostic criteria  
All data are presented in median. ST: solid tumours; HM: Haematological malignancies; BT: Brain 
tumours; OAD: Other associated diagnoses (LCH). For HFA n values at different time points see table 
4.4.  
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4.3.4 Patterns of change in nutritional status 
Multilevel analyses (multilevel growth model) were performed to establish whether 
there were significant patters of change from baseline up to 18 months (table 4.7). 
No analysis was performed from 18 months onwards due to the reduced sample size 
from the later stages. Although the median BMI of the whole cohort decreased 
marginally at 3 months, multilevel analysis showed a significant increase in mean 
BMI of 1.5
th
 centiles at 3 months and of 19
th
 centiles at 18 months. BMI also 
increased significantly at 18 months (see table 4.7). For changes in FFM% and FM% 
see table 4.7.  
Table 4-7 Mean changes in nutritional status established in 3, 9 and 18 months 
intervals.    
All calculations were performed using multilevel analysis.   
 
4.3.5 Factors related to changes in nutritional status 
Multilevel analyses (mixed multilevel model) were performed (figure 4.27). Potential 
factors contributing to malnutrition, which was established by using BMI centile (the 
primary outcome), were: diagnostic criteria, treatment risk, age at diagnosis, 
nutritional support and TEI.  
 0-3 months  0-9 months  0-18 months  
Growth Change 95% CI p 
value 
Change 95% CI p 
value 
Change 95% CI p value 
BMI C 1.5 1.31-3.47 <0.00
1 
15.9 -0.1-0.2 0.6 19 1.31-3.47 <0.001 
HFA C -1.3 -5.9-0.04 0.05 -3.9 -0.4-0.02 0.07 -4.2 -0.005-
0.24 
0.06 
Body composition         
FFM% AA -0.9% -1.6-(-0.5) <0.00
1 
-4.1% -0.09-0.06 0.7 -4.87% -0.01-0.02 0.7 
FFM% BIA -1.71% -0.78-(-
0.01) 
<0.05 -2.83% -0.13-(-
0.01) 
<0.02 -3.88% -0.01-0.01 0.8 
FM% AA 1.92% -0.01-0.02 0.8 5.22% -0.06-0.08 0.7 5.98% -0.01-0.02 0.8 
FM% BIA 1.71% 0.006-
0.077 
<0.05 3.1% 0.01-0.1 <0.02 3.9% -0.01-0.01 0.4 
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Figure 4.137 Factors related to nutritional status changes at different stages of the 
disease 
Fixed models (left) and conditional model (right).   
 
4.3.6 Haematological and biochemical blood results 
The haematological blood results haemoglobin, white cell count and platelets are 
presented as mean ± SD in table 4.8. These blood parameters cannot be interpreted 
for nutritional purposes due to the nature of the treatment of these patients, as they 
are treated with continuous cycles of chemotherapy (reduce these parameters) 
followed by blood transfusions (increase again).  
Liver function was assessed by measuring alanine transaminase (ALT), alkaline 
phosphatase (ALP), G-glutamyl transferase (GGT) and bilirubin (table 4.9). ALT 
was elevated throughout the whole study period in the haematological and solid 
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tumour group in a large percentage of children, whilst those diagnosed with brain 
tumours and other associated diagnoses (OAD) had elevated levels only during the 
first 3 (OAD) and 6 months (BT) of treatment. Likewise GGT was elevated in a 
significant percentage of patients for the haematological malignancy, solid tumour 
and brain tumour group throughout the study period, whilst those diagnosed with 
OAD had elevated levels only at 6 months. As it can be seen in table 4.9 ALP levels 
were reduced in many patients throughout the study period, especially in children 
diagnosed with haematological malignancies, solid tumours and OAD. 80% (4/5) of 
children diagnosed with brain tumours had elevated ALP levels at diagnosis and all 
had normal levels thereafter. Finally bilirubin was only elevated in the 
haematological malignancy group from baseline up to 30 months.  
Kidney function was assessed by measuring plasma creatinine and urea (table 4.10). 
Both parameters were variable (elevated and reduced levels) throughout the study 
period in all diagnostic categories.       
Inflammatory markers were tested by measuring standard sensitivity C-Reactive 
protein (ssCRP), albumin (acute phase reactant) and ferritin (table 4.11). ssCRP was 
highest in the solid tumours throughout the study period, whilst both CRP and 
ferritin tended to be high in children diagnosed with haematological malignancies 
also throughout the study period. In contrast, plasma albumin tended to be below the 
reference range in the haematological malignancy, solid tumour and OAD diagnoses 
group during the first year of treatment only, whilst brain tumours had normal levels 
throughout the study period.       
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Table 4-8 Haematological blood results presented as mean ± standard deviation (SD) 
Blood 
analysis 
Time 
months 
Haematological 
malignancies 
 Solid 
tumours 
Brain tumours Other 
malignancies 
Haemoglob
in  
g/L 
 n Mean ± SD n Mean ± 
SD 
n Mean ± SD n Mean ± SD 
Birth 149-
237 
0 34 99.4±15.0 34 104.6±1
4.3 
5 105.4±12.5 4 88.2±23.6 
2 weeks 
134-198  
3  31 102.5±14.5 29 104.9±1
5.6 
4 93.8±6.8 3 96.0±7.0 
6 months 
111-141 
6  19 105.6±12.1 16 102.1±1
1.3 
2 94.0±7.1 4 98.0±6.2 
1 year 113-
141 
9 15 108.9±20.7 9 118.2±1
6.9 
3 102.3±14.6 4 101.5±7.3 
2-6 years 
115-155 
12  13 109.1±13.3 6 106.3±1
8.2 
3 96.0±4.6 2 105.0±17.0 
6-12 years 
115-155 
18  15 109.9±17.1 4 117.8±1
6.7 
1 97.0 1 103.00 
12-18 years  24 10 117.3±9.6 1 125 1 79.0 1 104.00 
Males: 130-
160 
30  5 119.0±11.7 1 116 1 96.0 0 - 
Females: 
120-160 
36 3 118.3±8.7 0 - 0 105.4 0 - 
White Cell 
Count  
0 34 2.7±2.6 34 5.6±4.2 5 2.6± 5.7 4 4.2±2.0 
5-17 x 109 
/L 
3  31 4.5±4.0 28 6.9±14.9 4 4.0±5.2 2 4.5±0.1 
 6  19 3.6±2.4 16 3.6±2.2 2 2.4±4.9 4 3.9±4.5 
 9  15 2.7±1.4 10 4.2±2.3 3 1.4±6.3 4 5.4±3.2 
 12  13 3.1±1.9 6 5.3±3.4 3 2.0±5.9 2 7.4±2.3 
 18  15 3.6±2.4 4 4.7±3.5 1 5.5 1 0.5 
 24  10 2.5±0.7 1 2.6 1 0.7 1 16.3 
 30  5 3.5±2.5 1 2.9 1 2.2 0 - 
 36  3 2.6±1.7 0 5.6 0 1.7 0 - 
 
Platelets 0 34 148.9±122.4 34 279.6±1
75.7 
5 389.80±125.
1 
4 266.5±176.8 
150-400 x 
10
9
/L 
3 31 214.4±134.8 29 224.9±1
18.1 
4 278.25±281.
8 
3 347.7±291.6 
 6  19 201.5±146.0 16 223.9±1
47.3 
2 366.00±247.
5 
4 302.2±210.3 
 9  15 188.5±97.4 10 217.0±1
26.3 
3 360.67±144.
3 
4 319.2±129.6 
 12  13 222.8±96.7 6 207.5±1
58.1 
3 366.67±105.
6 
2 306.0±209.3 
 18  15 191.4±87.6 4 127.2±8
7.1 
1 345.00 1 175.0±176.7 
 24  10 185.2±84.1 1 156.0 1 333.00 1 427.0 
 30  5 194.8±102.7 1 315.0 1 473.00 0 266.5 
 36  3 198.7±83.2 0 - 0 389.80 0 347.7 
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Table 4-9 Blood parameters showing liver function. Values are expressed as mean ± SD and stratified by diagnostic criteria 
Blood analyses Time 
months 
Haematological malignancies Solid tumours Brain tumours Other associated diagnoses 
Liver function 
test 
 n Mean ± SD Abnormal 
n(%) 
n Mean ± SD Abnormal  
n(%) 
n Mean ± SD Abnormal 
n(%)  
n Mean ± SD Abnormal 
n(%) 
Alanine  0 34 86.9±95.7 ↑14(41) 32 28.0±16.2 ↑2(6) 5 85.0±68.6 ↑3(60) 4 18.0±5.6 ↑1(25) 
transaminase  3 32 85.7±99.3 ↑16(50) 31 35.3±27.1 ↑6(19) 4 41.2±25.4 ↑1(25) 3 32.3±31.1 ↑1(33) 
(ALT) unit/L 6 19 85.0±59.1 ↑11(58) 17 42.1±30.2 ↑5(29) 2 58.0±67.9 ↑2(100) 4 31.2±25.6 0 
0-12m  <65.0 9 13 107±90.8 ↑9(69) 9 58.6±67.0 ↑3(33) 3 28.3±14.7 0 4 19.0±4.8 0 
1-16y <50.0 12 14 57.8±32.8 ↑8(57) 6 27.5±17.0 ↑1(17) 3 28.7±11.8 0 2 18.0±4.2 0 
 18 14 56.1±30.0 ↑8(57) 4 42.2±26.2 ↑2(50) 1 12.0 0 1 37.0 0 
 24 10 108±121.0 ↑8(80) 1 110.0 ↑1(100) 1 18.0 0 1 18.0 0 
 30 5 90.2±78.3 ↑3(60) 1 374.0 ↑1(100) 1 20.0  0 -  
 36 3 27.7±6.6 0 0 - 0 0 -  0 -  
Alkaline 0 34 163±99 ↑1(3) 
↓6(18) 
34 127±49.5 ↓6(18) 5 219±98 ↑4(80) 4 158±84 ↓1(25) 
Phosphatase 3 32 179±104 ↑1(3) 
↓3(9) 
31 150±57.7 ↓1(32) 4 158±32 0 3 274±202 ↑1(33) 
(ALP) unit/L 6 19 133±43 ↓3(16) 17 171±51.6  2 192±61 0 4 164±81 ↓1(25) 
0-1m 80-440 9 14 176±102 0 10 387±699.0 ↑1(10) 3 165±44 0 4 187±46 0 
1-6m 120-580 12 14 156±48 ↓1(7) 6 216±105.2 ↓1(17) 3 142±37 0 2 163±0.7 0 
6m-1y 110-430 18 15 723±2188 ↑1(7) 4 222±46.0  1 119 0 1 142 0 
1-12y 100-400 24 10 184±111 ↑1(10) 
↓1(10) 
1 88.0 ↓1(100) 1 109 0 1 155 0 
12-16y  30 5 132±59 0 1 221 0 1 112 0 0 -  
M 100-400        
F 60-400 
36 3 142±18 0 0 - 0 0   0 -  
G-glutamyl  0 34 68.6±103 ↑9(26) 32 47.5±116 ↑5(16) 5 38.8±34.9 ↑2(40) 4 24.2±14.4 0 
transferase 3 32 43.3±58 ↑6(17) 31 26.8±18 ↑5(16) 4 34.5±23.1 ↑2(50) 3 24.0±24.3 0 
(GGT) unit/L 6 19 45.0±62 ↑6(32) 17 56.1±77 ↑5(29) 2 51.0±4.2 ↑2(100) 4 19.7±15.7 ↑1(25) 
0-2m <200 9 13 86.1±215 ↑4(31) 10 75.9±198 ↑1(10) 3 25.3±22.3 ↑1(33) 4 13.7±9.1 0 
1-16y <40.0 12 14 40.8±61 ↑3(21) 6 38.5±64 ↑1(33) 3 26.3±13.6 0 2 15.5±10.7 0 
 18 14 27.0±23 ↑4(27) 4 67.0±83 ↑2(50) 1 14.0 0 1 30.0 0 
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 24 10 21.1±14 ↑1(10) 1 33.0 0 1 14.0 0 1 23.0 0 
 30 5 30.0±27 ↑1(20) 0 -  0 1 9.00 0 0 - - 
 36 3 16.7±11.8 0 0 - 0 0 -  0 - - 
Bilirubin 0 34 13.9±6.8 ↑7(21) 32 7.5±5.9 0 5 4.8±1.3 0 4 6.2±4.8 0 
µmol/L 3 32 10.8±8.4 ↑5(16) 31 7.9±4.6 0 4 9.2±3.1 0 3 4.3±2.3 0 
All ages <20.0 6 19 11.0±9.1 ↑2(10) 17 6.8±3.3 0 2 8.0±2.8 0 4 4.7±2.1 0 
 9 14 17.5±19.5 ↑4(29) 10 5.4±2.8 0 3 8.0±1.7 0 4 5.5±3.1 0 
 12 14 16.4±15.1 ↑4(29) 6 5.3±2.2 0 3 6.7±2.1 0 2 5.5±3.5 0 
 18 15 15.8±13.9 ↑3(20) 4 8.2±4.0 0 1 6.0 0 1 5.0 0 
 24 10 14.7±7.7 ↑3(30) 1 24.0 ↑1(100) 1 4.0 0 1 3.0 0 
 30 5 28.4±21.8 ↑3(60) 1 10.0 0 1 4.0 0 0 - - 
 36 3 18.3±11.3 0 0 - - 0 - - 0 - - 
M: months; y: years; ↑high levels; ↓ low levels; Reference ranges: laboratory handbook (NHS Scotland Laboratory Handbook) 
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Table 4-10 Blood parameters showing kidney function. Values are expressed as mean ± SD and stratified by diagnostic criteria 
Blood analyses Time 
months 
Haematological malignancies Solid tumours Brain tumours Other associated diagnoses 
Kidney function 
test 
 n Mean ± SD Abnormal 
n(%) 
n Mean ± SD Abnormal  
n(%) 
n Mean ± SD Abnormal 
n(%)  
n Mean ± SD Abnormal 
n(%) 
Urea mmol/L 0 34 5.7±2.6 ↑10(29) 34 5.0±8.0 ↓7(21) 
↑2(6) 
5 3.4±1.1 ↑1(20) 4 4.1±0.8 ↓1(25) 
14d-1m 0.08-0.39 3 32 4.0±1.6 ↓1(3) 
↑2(6) 
31 3.5±1.5 ↓4(13) 4 3.2±2.0 ↓1(25) 3 3.2±1.2 0 
1m-12m 1.2-5.0 6 19 3.5±1.4 ↓3(16) 17 4.2±2.4 ↓2(12) 
↑2(12) 
2 4.0±1.3 0 4 4.0±1.6 0 
1-16y 2.4-6.5 9 14 3.4±1.6 ↓2(14) 10 5.4±3.7 ↑1(10) 3 3.8±1.0 0 4 4.0±0.7 0 
 12 14 3.5±0.9 ↓1(7) 
↑1(7) 
6 5.5±4.8 ↓1(17) 3 3.2±1.1 0 2 4.6±2.3 0 
 18 15 3.4±1.5 ↓3(20) 4 6.4±5.8 ↑1(25) 1 2.2 0 1 2.5 0 
 24 10 4.7±3.1 ↓1(10) 
↑1(10) 
1 1.9 ↓1(100) 1 2.6 0 
 
1 3.8 0 
 30 5 4.4±0.5 0 1 4.1 0 1 5.5 0 0 - 0 
 36 3 3.6±0.5 0 0 5.0 0 0 - 0 0 - 0 
Creatinine 
µmol/L 
0 34 26.2±12.8 ↓4(12) 
↑1(3) 
34 27.2±11.5 ↓3(9) 5 26.2±10.3 0 4 27.2±12.9 0 
0-7d not defined 3 32 28.0±12.5 ↓1(3) 
↑1(3) 
31 35.3±17.5 ↑2(6) 4 29.7±13.3 0 3 18.7±7.1 ↓1(33) 
7-28d 15-39 6 19 28.2±12.8 ↓1(5) 
↑1(5) 
17 33.5±14.9 ↑1(6) 2 39.5±6.5 0 4 25.5±10.1 0 
1-12m 12-31 9 14 28.4±9.6 ↓2(14) 10 43.6±30.4 ↑1(10) 3 46.0±13.5 ↑1(33) 4 27.0±11.8 0 
1y 13-28 12 14 30.9±9.0 ↓1(7) 6 51.3±64.0 ↑1(17) 3 35.7±3.8 0 2 36.5±20.5 ↑1(50) 
2y 15-34            
3y 15-42 
18 15 30.7±12.1 ↓3(20) 
↑1(7) 
4 47.5±43.8 ↑1(25) 1 38.0 0 1 14.0 0 
4-6y 15-42         
7-11y 26-57     
12-14y 31-67  
24 10 32.1±13.3 ↓1(10) 
↑1(10) 
1 40.0 0 1 32.0 0 1 25.0 0 
15-18y  30 5 32.0±2.7 0 1 25.0 ↓1(100) 1 34.0 0 0 - - 
M 39-92  F 34-72 36 3 24.0±17.6 0 0 - 0 0 - 0 0 - - 
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Table 4-11 Acute phase reactant parameters. Values are expressed as mean ± SD and stratified by diagnosis criteria 
Blood analyses Time 
months 
Haematological malignancies Solid tumours Brain tumours Other associated diagnoses 
Acute phase 
reactants  
 n Mean ± SD Abnormal 
n(%) 
n Mean ± 
SD 
Abnormal  
n(%) 
n Mean ± 
SD 
Abnormal 
n(%)  
n Mean ± SD Abnormal 
n(%) 
Ferritin 0 30 708±563 ↓1(3) 
↑28(93) 
32 526±510 ↓1(3) 
↑28(87) 
7 288±270 ↑3(43) 3 45.7±53 ↓1(33) 
↑19(33) 
µg/L 3 30 1750±1596 ↑29(97) 30 1208±2199 ↑24(80) 4 438±407 ↑3(75) 1 2364 ↑1(100) 
0-5y 12-80 6 19 1981±2524 ↑17(89) 16 1688±1576 ↑14(87) 2 845±1020 ↑2(100) 4 294±448 ↓2(50) 
↑1(25) 
5-16y 15-80 9 13 4841±11029 ↑13(100) 10 1299±2284 ↑8(80) 3 325±355 ↑2(67) 4 328±614 ↓1(25) 
↑1(25) 
 12 12 3590±5636 ↓1(8) 
↑11(92) 
6 1828±2962 ↑6(100) 3 332±176 ↑3(100) 2 19±18 ↓1(50) 
 18 14 2183±2127 ↑13(93) 4 2128±2235 ↑4(100) 1 195 ↑1(100) 1 885 ↑1(100) 
 24 10 2534±4052 ↑10(100) 1 2273 ↑1(100) 1 296 ↑1(100) 1 52 0 
 30 5 1290±1385 ↑5(100) 0 - - 1 126 ↑1(100) 0 - - 
 36 3 1404±2098 ↑2(67) 0 - - 0 - - 0 - - 
Albumin 0 34 28.5±5.1 ↓16(47) 33 32.4±6.3 ↓7(21) 5 36.2±2.7 0 4 32.5±9.3 ↓1(25) 
g/L 3 32 36.1±4.5 ↑1(31) 29 34.8±5.8 ↓1(3) 4 37.0±3.6 0 3 34.0±6.9 ↓1(33) 
0-3m maturity  6 19 36.8±5.9 ↓1(5) 16 35.3±4.8 ↓1(6) 2 40.0±1.4 0 4 33.0±7.3 ↓1(25) 
dependent 9 15 36.4±5.1 ↓1(7) 10 36.5±4.8 ↓1(10) 3 39.7±2.5 0 4 37.0±3.1 0 
3-12m 27-42 12 14 36.7±5.9 ↓1(7) 6 33.7±3.9 0 3 39.3±2.3 0 2 40.5±0.7 0 
1-16y28-45 18 15 36.9±3.7 0 4 33.7±7.4 ↓1(25) 1 41.0 0 1 31.0 0 
 24 10 36.5±2.0 0 1 37.0 0 1 37.0 0 1 37.0 0 
 30 5 37.0±1.6 0 1 41.0 0 1 38.0 0 0 - 0 
 36 3 38.3±2.9 0 0 - - 0 - - 0 - - 
1
ssCRP 0 30 12.2±25.0 ↑12(40) 30 28.3±52.9 ↑13(43) 5 1.3±0.4 ↑2(40) 3 4.7±6.3 ↑1(33) 
mg/L 3 28 11.1±27.3 ↑6(21) 30 8.0±14.4 ↑10(33) 4 41.0±45.1 0 2 7.5±9.2 ↑1(50) 
All ages <5 6 18 14.6±49.3 ↑3(17) 15 15.4±27.8 ↑6(40) 2 2.5±2.1 ↑1(50) 4 6.8±8.3 ↑1(25) 
 9 13 5.1±9.1 ↑2(15) 10 4.9±6.0 ↑2(20) 3 2.7±2.9 ↑1(33) 4 1.2±0.5 0 
 12 11 19.1±53.4 ↑2(18) 6 4.8±3.2 ↑3(50) 3 6.0±5.0 ↑2(67) 2 3.5±2.1 0 
 18 14 2.5±4.5 ↑1(7) 4 4.5±3.5 ↑2(50) 1 1.0 0 1 2.0 0 
 24 10 2.6±4.4 ↑1(10) 1 1.0 0 1 1.0 0 1 1.0 0 
 30 5 8.0±12.9 ↑1(20) 0 - - 1 1.0 0 0 - - 
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 36 3 8.7±13.3 ↑1(33) 0 - - 0 - - 0 - - 
1
ssCRP: standard sensitivity C-Reactive Protein; Reference ranges: laboratory handbook (NHS Scotland Laboratory Handbook).  
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4.3.7 Full blood nutritional screening 
4.3.7.1 Antioxidant micronutrients status  
Both plasma vitamins A and E/Ch were assessed (table 4.12). Abnormal vitamin A 
levels, both elevated and reduced, were prevalent in all diagnostic groups and 
throughout the study period. There were significant but weak correlations between 
plasma vitamin A (mmol/L) and the following variables: GGT (r=0.1; p=0.04), 
albumin (r=0.2; p<0.001), BMI centiles (r=0.2; p<0.001) and total vitamin A intake 
(µg/day) (r=0.15; p=0.02). Spearman’s test showed a negative and moderate 
significant correlation between plasma vitamin A and ssCRP (r=0.3; p<0.001). 
However, no statistically significant correlation was obtained between vitamin A 
levels and ALT (r=0.03; p=0.7). In order to establish whether supplementation was 
associated with hypo and hypervitaminosis A, the data was stratified by groups 
(micronutrient supplementation only, macronutrient supplementation only and a 
combination of both). No statistical significant associations were established between 
vitamin A supplementation and neither hypervitaminosis A [Fisher Exact test (3.6); 
p=0.3] nor hypovitaminosis A status [Fisher Exact test (2.8); p=0.4].  
Plasma vitamin E/Ch was abnormal only in very few patients and results from 
plasma copper, selenium and zinc are presented in table 5.10. Plasma vitamin E/Ch 
correlated significantly with vitamin E intakes [r=0.2 (weak, positive); p=0.007].         
4.3.7.2 Non-antioxidant micronutrients status 
Plasma folate and vitamin B12 were assessed. As it can be seen from table 4.13 
serum folate was reduced, especially in the haematological malignancy group, 
throughout the study period. Finally, results from plasma vitamin B12 were variable 
as patients with haematological malignancies, solid tumours and OAD had both 
hypovitaminosis and hypervitaminosis B12.     
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Table 4-12 Blood results: antioxidant micronutrient status at different stages of disease and treatment. Values expressed as mean±SD 
Blood analyses Time 
months 
Haematological malignancies Solid tumours Brain tumours Other associated diagnoses 
Fat soluble 
vitamins 
 n Mean ± SD Abnormal 
n(%) 
n Mean ± 
SD 
Abnormal  
n(%) 
n Mean ± 
SD 
Abnormal 
n(%)  
n Mean ± SD Abnormal 
n(%) 
Vitamin A 0 27 1.3±0.7 ↓2(7) 
↑5(18) 
30 1.1±0.6 ↓5(17) 
↑3(10) 
5 1.3±0.4 ↑1(20) 2 1.2±0.0 0 
µmol/L 3 28 1.5±0.8 ↓2(7) 
↑9(32) 
28 1.4±0.6 ↓3(11) 
↑6(21) 
4 0.9±0.4 ↓1(25) 1 2.0 ↑1(100) 
0-12m 0.5-1.5 6 17 1.4±0.7 ↓2(12) 
↑4(23) 
16 1.3±0.5 ↓3(19) 
↑3(19) 
2 1.9±0.8 ↑1(50) 4 1.4±0.9 ↓1(25) 
1-7y 0.7-1.5 9 14 1.7±0.8 ↑6(43) 9 1.6±0.6 ↑4(44) 3 1.3±0.1 0 4 1.5±0.7 ↑1(25) 
7-13y 0.9-1.7 12 13 1.7±0.9 ↓1(8) 
↑5(38) 
6 1.5±0.8 ↑2(33) 3 1.3±0.2 0 2 1.6±0.1 0 
13-19y 0.9-2.5 18 14 1.6±0.8 ↓2(14) 
↑7(50) 
4 1.9±0.6 ↑3(75) 1 1.6 0 1 0.9 0 
Toxic levels  24 9 1.6±0.5 ↑4(29) 1 1.8 ↑1(100) 1 1.3 0 1 1.9 0 
>3.3 30 5 1.6±0.8 ↑2(40) 0 - - 1 1.7 0 0 0 - 
 36 3 3.1±3.2 ↑1(33) 0 - - 0 - - 0 0 - 
Vitamin E/Ch 0 26 6.0±1.9 ↓1(4) 
↑1(4) 
30 6.2±1.5 ↑1(3) 5 5.3±0.6 0 2 7.6±4.2 ↑1(50) 
µmol/L 3 26 6.1±1.5 0 26 6.2±1.5 ↑1(4) 4 5.1±1.0 0 1 6.1 0 
All ages       
0.25-2.00 
6 17 5.5±1.0 0 16 6.3±1.3 0 2 6.1±0.0 0 4 5.4±0.7 0 
 9 14 5.6±1.4 0 9 6.7±1.8 0 3 6.3±0.7 0 4 6.0±1.2 0 
 12 13 5.3±1.3 ↓1(8) 6 6.3±1.5 0 3 5.2±0.7 0 2 5.8±0.3 0 
 18 14 5.3±1.0 0 4 6.0±2.4 0 1 5.6 0 1 3.1 ↓1(100) 
 24 9 5.1±1.3 ↓1(11) 1 4.7 0 1 7.0 0 1 6.4 0 
 30 5 5.7±1.5 0 0  0 1 6.6 0 0  0 
 36 3 5.4±1.5 0 0  0 0 - - 0  0 
Minerals              
Copper  0 26 12.7±5.2 ↓15(58) 34 20.5±6.6 ↓2(6) 5 15.2±1.6 0 2 15.7±4.0 ↑1(50) 
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↑1(4) ↑14(41) 
µmol/L 3 26 17.1±4.0 ↓5(2) 
↑4(15) 
28 17.4±3.7 ↑5(18) 4 21.2±5.2 ↑1(25) 2 18.2±2.7 ↑1(50) 
 6 19 16.1±4.7 ↓6(32) 
↑2(10) 
14 21.0±5.9 ↑2(14) 2 18.3±2.3 0 4 17.0±6.4 ↓1(25) 
↑1(25) 
 9 14 17.6±4.4 ↓2(14) 
↑3(21) 
10 18.6±3.5 0 3 17.1±2.2 0 4 16.9±3.6 0 
 12 13 15.6±4.0 ↓2(15) 
↑2(15) 
6 19.6±2.9 0 3 18.9±4.2 0 2 21.6±4.2 0 
 18 14 14.3±3.5 ↓3(21) 
↑1(7) 
3 15.6±1.1 0 1 14.0 0 1 15.7 0 
 24 9 15.8±3.7 ↓2(22) 1 13.7 0 1 16.7 0 1 17.3 0 
 30 5 15.1±6.9 ↓3(60) 0   1 14.9 0 0   
 36 3 15.9±4.7 0 0   0   0   
Selenium 0 26 1.2±0.5 ↓1(4) 
↑8(31) 
34 0.9±0.3 ↓2(59) 
↑1(3) 
4 0.7±0.2 0 2 1.0±0.2 0 
µmol/L 3 26 0.9±0.2 ↓2(8) 
↑3(11) 
28 0.9±0.2 ↓3(11) 4 0.8±0.2 ↓1(25) 2 0.8±0.3 0 
0-2y 0.2-0.9 6 19 0.9±0.2 ↓1(5) 14 0.9±0.3 ↓1(7) 
↑2(14) 
2 0.7±0.0 0 4 0.9±0.2 0 
2-4y 0.5-1.3 9 14 0.9±0.2 ↓2(14) 10 1.0±0.4 ↓1(10) 
↑2(20) 
3 0.8±0.1 ↓1(33) 4 0.8±0.2 0 
4-16y 0.7-1.7 12 14 0.9±0.2 ↓9(64) 6 1.0±0.3 ↓4(67) 3 0.8±0.2 ↓1(33) 2 0.9±0.4 ↓2(100) 
 18 14 1.0±0.1 0 3 0.9±0.3 0 1 0.6 ↓1(100) 1 1.2 0 
 24 9 1.1±0.2 0 1 0.8 0 1 0.7 0 1 1.0 0 
 30 5 1.1±0.4 0 0   0   0   
 36 3 1.1±0.4 0 0   0   0   
Zinc  0 24 14.3±8.8 ↓13(54) 
↑4(17) 
32 11.0±3.6 ↓23(72) 
↑2(6) 
5 10.8±2.0 ↓4(80) 2 8.3±0.7 ↓2(100) 
µmol/L 3 24 10.4±2.1 ↓18(75) 26 11.6±2.5 ↓15(58) 4 10.7±1.9 ↓2(50) 2 11.4±0.2 ↓2(100) 
<16y 12-18 6 19 13.6±14.6 ↓14(74) 
↑1(5) 
11 12.1±5.5 ↓8(73) 
↑1(9) 
2 10.5±1.8 ↓2(100) 4 10.6±1.3 ↓4(100) 
 9 13 11.8±5.1 ↓10(77) 
↑1(8) 
9 10.6±0.7 ↓3(33) 
↑1(11) 
3 11.7±1.4 ↓2(67) 4 10.6±0.7 ↓4(100) 
 12 12 10.2±2.8 ↓9(75) 6 10.8±3.4 ↓4(67) 3 20.6±15.5 ↓2(67) 2 10.6±0.1 ↓2(100) 
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↑1(33) 
 18 14 10.6±1.9 ↓12(86) 3 11.5±3.6 ↓2(67) 1 11.3 ↓1(100) 1 8.8 ↓1(100) 
 24 8 10.3±2.5 ↓5(62) 1 12.8 0 1 11.9 ↓1(100) 1 12.3 0 
 30 4 11.1±1.9 ↓3(75) 0  - 1 11.0 ↓1(100) 0 - - 
 36 3 13.5±1.2 ↓0 0  - 0   0 - - 
Reference ranges: laboratory handbook (NHS Scotland Laboratory Handbook) 
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Table 4-13 Non-antioxidant micronutrient status. Values are expressed as mean ± SD and stratified by diagnostic criteria 
Blood analyses Time 
months 
Haematological malignancies Solid tumours Brain tumours Other associated diagnoses 
Water soluble 
vitamins 
 n Mean ± SD Abnormal 
n(%) 
n Mean ± 
SD 
Abnormal  
n(%) 
n Mean ± 
SD 
Abnormal 
n(%)  
n Mean ± SD Abnormal 
n(%) 
Vitamin B 12 0 25 729±592 ↓2(8) 
↑5(20) 
29 488±205 ↓1(3) 5 498±184 0 3 448±326 0 
ng/L 3 28 624±361 ↓1(4) 
↑2(7) 
29 740±501 ↓3(10) 
↑5(17) 
4 558±177 0 2 753±154 0 
 6 18 522±270 ↓1(5) 
↑1(5) 
15 827±581 ↑3(20) 2 530±257 0 4 456±310 ↓1(25) 
0-5y 280-1400 9 15 545±315 0 8 752±411 ↓1(12) 
↑1(12) 
3 737±398 0 4 706±452 0 
5-16y 200-1100 12 11 660±331 ↑1(9) 6 627±317 ↓1(17) 3 763±354 0 2 364±9.2 0 
 18 13 524±343 ↓1(8) 
↑1(8) 
4 836±215 0 1 671 0 1 764 0 
 24 10 474±223 ↓2(20) 1 196 ↓1(100) 1 424 0 1 527 0 
 30 5 553±136 0 0 - - 1 652 0 0  - 
 36 3 645±160 0 0 - - 0  - 0  - 
Serum folate  0 24 7.1±6.2 ↓3(12) 
↑1(4) 
25 8.7±5.3 ↓3(12) 5 9.1±2.4 0 3 6.2±4.6 ↓1(33) 
µg/L 3 28 8.3±5.8 ↓5(18) 28 9.9±4.5 ↓1(4) 4 13.1±6.8 0 2 9.0±4.7 0 
1-12m >7 6 18 7.1±5.1 ↓2(11) 16 9.3±4.1 ↓1(6) 2 4.5±1.8 0 4 9.5±4.9 0 
1-4y 4-30 9 15 6.8±3.5 ↓1(7) 8 9.2±5.4 ↓1(12) 3 8.6±6.7 ↓1(33) 4 8.3±4.0 0 
4-16y 3-20 12 11 6.0±3.0 ↓1(9) 6 9.2±4.8 0 3 7.7±5.7 ↓1(33) 2 10.9±2.1 0 
 18 13 5.1±2.6 ↓3(23) 4 7.2±4.2 0 1 4.5 0 1 13.5 0 
 24 10 6.1±5.4 ↓4(40) 1 2.4 ↓1(100) 1 3.5 0 1 4.9 0 
 30 5 7.0±3.2 0 0  - 1 9.2 0 0  - 
 36 3 7.6±6.1 ↓1(33) 0  - 0  - 0  - 
Reference ranges: laboratory handbook (NHS Scotland Laboratory Handbook)
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4.3.8 Nutrient intake and nutritional support  
4.3.8.1 Energy and macronutrient intake 
TEI were established at every stage from the time of recruitment up to 36 months and 
these were compared to the total energy requirements (TER). TER were estimated 
using the Henry equation (2005) and all data were adjusted for age, gender and 
physical activity (10
th
 centile). TEI of all paediatric cancer patients were consistently 
higher than TER at every stage of the disease apart from the 3 months follow up. 
Statistical significance was obtained from 9 months onwards (see figure 4.28). 
Protein, fat and carbohydrate intake was consistently higher than recommendations at 
every stage of the disease apart from the 3 months follow up (see figures 4.29, 4.30 
and 4.31).      
 
Figure 4.148 Energy Intake (EI) compared to total energy requirements (TER) in 
paediatric cancer patients (all diagnosis) at different stages of the disease 
Values are expressed as mean ± SD; TER was calculated using Henry’s equation (2005); *Indicates 
p<0.05 (Independent t test). 
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Figure 4.159 Protein intake (PI) compared to protein requirements (PR) in paediatric 
cancer patients (all diagnosis) at different stages of the disease 
Values are expressed as mean ± SD; protein requirements obtained from RNI (Department of Health 
1991); *Indicate p<0.05 (Independent t-test).   
 
 
Figure 4.30 Carbohydrates intake (CHO I) compared with CHO recommendations 
(CHO R) at different stages of the disease 
Recommendations presented in grams were calculated from percentage CHO recommendations of 
TEI: 40% for children <1 year and 50% for children >1year o age). Values are expressed as mean ± 
SD; *Indicate p<0.05 (Independent t-test).   
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Figure 4.161 Fat intake (Fat I) compared with fat recommendations (Fat R) at 
different stages of the disease 
Recommendations presented in grams were calculated from percentage fat recommendations of TEI: 
50% for children <1 year and 35% for children >1year o age). Values are expressed as mean ± SD; * 
Indicate p<0.05 (Independent t-test).   
 
4.3.8.2 Vitamin and mineral intakes 
Vitamin and mineral intakes were obtained from 24 hour multiple pass dietary recall 
at different stages of the disease. Overall, mean vitamin intakes were above the RNI 
and mean mineral intakes were within the references ranges; however there was high 
variability between individuals for both vitamin and mineral intakes (tables 4.14 and 
4.15).     
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Table 4-14 Vitamin intakes of paediatric cancer patients during the study period 
expressed as mean ± SD 
1
RNI: reference nutrient intake between the ages of 0-18 years (Department of Health 1991); 
2
DRVs: 
dietary reference values for Vitamin E are determined by PUFA intakes, no RNI has been established 
for vitamin E.   
 
Table 4-15 Mineral intakes of paediatric cancer patients during the study period 
expressed as mean ± SD 
1
RNI: reference nutrient intake between the ages of 0-18 years (Department of Health 1991). 
 
4.3.8.3 Nutrition Support  
A total of 55 (67%) patients were referred to the Dietitian for nutritional assessment 
during the study period. Of these, 50 (61%) were prescribed some form of nutritional 
support and 5 (6%) had general dietary advice. For further detail on specific type of 
nutritional support prescribed see table 4.16. The reasons for referral were: 
undernutrition/weight loss (16/55; 25%), reduced oral intake (10/55; 18%), 
 N Vitamin A 
µg/day 
1
RNI (350-700) 
Vitamin E 
mg/day 
No 
2
DRVs 
Vitamin B12  
µg/day 
RNI (0.3-1.5) 
Vitamin C 
mg/day 
RNI (25-40) 
Folate 
µg/day 
RNI (50-200) 
Baseline 77 395±79 6.7±5.8 4.3±2.5 104±105 143±54 
3 months 73 1659±2750 4.2±3.4 2.3±2.6 57±38 87±29 
6 months 52 708±383 6.0±1.3 3.8±2.4 43±32 145±52 
9 months 49 1470±1486 6.3±3.4 4.0±2.5 60±37 225±87 
12 months 40 775±611 8.5±5.8 2.7±2.4 98±61 219±127 
18 months 34 557±108 5.0±2.1 5.6±3.7 104±50 184±83 
24 months 23 612±450 6.2±4.9 4.7±1.2 64±45 228±69 
30 months 12 591±296 5.2±2.5 4.9±3.1 67±83 237±120 
36 months 7 518±144 7.0±2.6 5.0±2.9 76±32 242±114 
 N Copper 
mg/day 
Mean±SD 
1
RNI (0.3-2.2) 
Iron 
mg/day 
Mean±SD 
RNI (1.7-14.8) 
Zinc 
mg/day 
Mean±SD 
RNI (4.0-9.5) 
Selenium 
µg/day 
Mean±SD 
RNI (10-70) 
Baseline 77 0.78±0.73 7.33±4.20 6.03±3.93 28.31±20.05 
3 months 73 0.69±0.41 8.05±4.59 9.67±1.21 36.59±66.17 
6 months 52 0.82±0.55 9.16±4.90 6.83±3.83 38.40±74.06 
9 months 49 0.80±0.45 8.52±3.83 7.03±3.87 28.57±18.03 
12 months 40 0.79±0.59 12.89±19.32 7.03±2.58 28.04±15.75 
18 months 34 0.91±0.57 8.81±3.90 7.10±3.12 31.36±16.29 
24 months 23 0.90±0.99 8.38±4.76 5.90±2.16 24.26±15.19 
30 months 12 0.70±0.43 8.75±3.76 6.35±2.54 24.17±12.71 
36 months 7 0.73±0.36 11.13±6.01 7.45±3.22 33.71±13.30 
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temporary gut failure (10/55; 18%), to prevent weight loss (7/55; 13%), dysphagia 
(4/55; 7%), steroid induced diabetes (2/55; 4%), mucositis (1/55; 2%) and following 
parent’s request (1/55; 2%).  
Total energy intakes (kcal/day) and macronutrient intakes (grams) of patients who 
were on nutritional support and those who were not were compared at every stage. 
Although patients who were not on nutritional support had consistently higher total 
energy intakes than those who were, the difference was not statistical significant at 
any stage. Additionally, there were no statistically significant differences in the 
overall (all stages of disease) BMI and HFA centiles, FM% and FFM% (estimated 
from arm anthropometry) between those who were on nutritional support and those 
who were not during the entire study period.   
Table 4.17 describes how many undernourished children, who were identified by 
BMI and UAFA, and how many PEM children, who were identified by UAMA, 
were on nutritional support throughout the study period.   
Table 4-16 Use of nutritional support according to diagnostic criteria   
1 
Langerhams Cell Histiocytosis; 
2
Some patients received more than one type of nutritional 
support
 
 
 
 
 
Diagnostic 
criteria 
NS 
 
Percentage  Type of nutritional support 
 
N  % ONS 
N(%) 
NG 
N(%) 
PEG 
N(%) 
TPN 
N(%) 
Advanced NS 
N(%) 
Solid tumours 19/35  54% 2(6%) 9(26%) 2(6%) 0 7(20%) 
Haematological 
Malignancies 
23/36 64% 8(22%) 7(19%) 0 1(3%) 7(19%) 
Brain tumours 5/7 71% 2(29%) 1(14%) 2(29%) 0 0 
Others: LCH
1 
3/4 75% 2(50%)  0 0 0 1(25%) 
Total
2 
50/82 61% 14(17%) 17(21%) 4(5%) 1(1%) 15(18%) 
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Table 4-17 Patients identified as undernourished or PEM and on nutritional support 
at different stages of the disease 
1
NS: Nutritional support. 
4.3.9 Associations between nutritional status at diagnosis and clinical outcome 
Associations between nutritional status, which was established by using BMI centile 
(undernutrition, well-nourished and overnutrition), at diagnosis and clinical 
outcomes were assessed. Only undernutrition was statistically significantly 
associated with event, which was defined as relapse, death or becoming palliative 
[Fisher’s Exact test (19.901); p<0.001]. Additionally, patients who were 
undernourished at diagnosis were 14 times more likely to have an event (RR=14). 
However, when severity of disease was taken into consideration 67% of this group of 
patients were treated with a high risk protocol and 17% with either medium or low 
risk protocol. Finally, overnutrition (overweight and obesity) was not statistically 
significantly associated with clinical outcomes [Fisher Exact test (7.10); p=0.3].          
 
 
 
 
 Undernourished 
BMI 
1
NS 
 N      % 
PEM 
(UAMA) 
NS 
N      % 
Undernourished 
(UAFA) 
NS 
N       % 
Diagnosis 11 10 91 - - - - - - 
Baseline 11 7 64 3 3 100 9 4 44 
3 months 5 5 100 6 3 50 4 3 75 
6 months 4 1 25 4 2 50 2 2 100 
9 months 1 0 0 3 1 33 1 1 100 
12 months 0 0 0 3 2 67 2 2 100 
18 months 0 0 0 1 1 100 1 1 100 
24 months 1 1 100 3 3 100 3 3 100 
30 months 0 0 0 - 0 - 0 0 - 
36 months 0 0 0 - 0 - 0 0 - 
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4.4 DISCUSSION 
This prospective cohort study from SE and E Scotland is the first and most 
comprehensive of its type as it investigates patterns of change and factors 
contributing to changes in nutritional status of paediatric cancer patients based on its 
full definition. This not only include changes in body size and body composition, but 
also any imbalance in total energy, macronutrients and micronutrients intake as well 
as plasma micronutrients. Additionally, plasma markers of stress as well as clinical 
outcomes were studied (BAPEN 2010). 
4.4.1 Patients’ characteristics  
179 patients were diagnosed with paediatric cancer during the study period (Aug 
2010-Jan 2014) in the RHSC, Edinburgh. This is a mean of 51 diagnoses per year, 
which is below the reported 55-60 mean diagnoses per year prior to Aug 2010. The 
recruitment rate of 81% (n=82 of 101 eligible patients) is slightly higher than the 
78% reported in similar studies performed in Scotland (Reilly et al. 2001), similar to 
that reported in Central America 82% (Sala et al. 2008), but lower than that from 
other studies published in Central America (92%) (Antillon et al. 2008) and the 
Netherlands (100%) (Brinksma et al. 2014). An explanation for this could be the 
difference in the population included, such as differences in severity of disease, and 
either recruitment procedures and policies (opting out instead of opting in). The most 
common diagnoses in this study were the leukaemias (43%) with ALL being the 
most prevalent diagnosis (35%), followed by the lymphomas (10%) and then 
neuroblastoma and renal tumours equally (6%). The incidence of each type of cancer 
does not entirely reflect that of the UK (Cancer Research UK 2012a) or Scotland 
(Information Service Division Scotland 2011), which could be explained by a 
relatively small sample size and also by the fact that the National and Scottish 
records stratify the ranking of most common cancers by age groups: 0-14 years and 
15-24 years (Cancer Research UK 2012a, Information Service Division Scotland 
2011).  
This study presented all diagnoses in one group (children aged less than 18 years). 
Age at diagnosis, gender, diagnostic criteria and deprivation (SES) as well as 
ethnicity of the patient’s cohort were all representative of the population from SE 
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Scotland as shown by data from the control group. Additionally, gender ratio (boys: 
56%; girls: 44%) was representative of both the UK (boys: 55%; girls: 45%) and the 
Scottish cancer population (boys: 56%; girls: 44%) (Cancer Research UK 2012a, 
Information Service Division Scotland 2011). Finally, the severity of disease was 
established by classifying patients into treatment risk due to the large numbers of 
protocols (n=24) used for treatment in this population (n=82). Of these, 22% (n=18) 
were classified as low risk, 37% (n=30) as medium risk and 41.5% (n=34) as high 
risk. At present, this information is not available nationwide, and most authors who 
report this information have only investigated children with ALL (Argüelles et al. 
2000, Reilly et al. 2001, Antillón et al. 2008). Thus, this data can only be compared 
with findings from the Netherlands (Brinksma et al. 2014) who reported a higher 
proportion of children receiving moderate/medium (45%) and high risk treatment 
(48%), with a much smaller proportion receiving low intensity treatment than the 
population from this cohort.         
This study showed a 90% survival rate by the end of the study period, which equates 
to the 1 year survival rates from Scotland (Information Service Division Scotland 
2011). However, this study had a minimum follow up of 3 months and a maximum 
of 3 years, so comparisons with national data would not be appropriate.  
4.4.2 Nutritional status of paediatric cancer patients  
4.4.2.1 Prevalence of malnutrition and changes in nutritional status 
according to growth and body composition measurements 
The first aim of this study was to investigate the prevalence of malnutrition and to 
identify patterns of change in the nutritional status of paediatric cancer patients at 
different stages of the disease and treatment. The emphasis on using a variety of 
methods (BMI, MUAC, TSF and BIA) to assess nutritional status was based on 
evidence which suggested that this was essential for the optimal nutritional 
management of this population (Viana et al. 1994, Anon.1998, Brennan et al. 1997, 
Sala et al. 2012, Reilly et al. 1999, Sala et al. 2005, Elhasid et al. 1999, van Eys 
1979b, Donaldson et al. 1981, Garófolo et al. 2005, Carter et al. 1983, Brouwer et al. 
2007, Anon.2010, Lobato-Mendizábal et al. 1989, González et al. 2004, Halton et al. 
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1998, Schiavetti et al. 2002, Tobias & Hochhauser 2010) and that the use of these 
methods allow for a more comprehensive assessment, as at present a single “gold 
standard” technique does not exist (Sala et al. 2005). Additionally, the results from 
recent systematic reviews (Brinksma et al 2012, Revuelta Iniesta et al. 2015) 
concluded that presently there is insufficient robust evidence to accurately determine 
the prevalence of malnutrition, especially during and at the end of treatment, and that 
there is a need for future high-quality population based longitudinal studies.    
(i) Nutritional status according to growth  
The results of this study showed that the prevalence of malnutrition varies between 
different type of cancers, measurements used and at different stages of the disease. 
However, there was not a gender difference.  
Overall, undernutrition was more common at diagnosis and at baseline and ranged 
between 13-15% depending on the measurement used. This gradually reduced 
throughout treatment and by the 30 and 36 month follow up, no patient was classified 
as undernourished. Undernutrition was significantly associated with paediatric cancer 
at diagnosis, baseline and 3 months in comparison with expected prevalence of 
undernutrition from the healthy UK children and young people population 
(Department of Health 2012). However, this is lower than that reported in the 
otherwise healthy children from developing countries, which has been estimated to 
affect between 19-30% of children (Stephenson et al. 2000, de Onis et al. 2010). A 
recent systematic review reported a similar level (13%) of undernourished patients in 
other paediatric cohorts from the developed world (Revuelta Iniesta et al. 2015); 
although a lower prevalence has been reported in the Netherlands (8%) (Brinksma et 
al. 2014). As already highlighted however, until now malnutrition has not been 
investigated in a uniform or consistent way; thus making comparison of data 
problematic.  
The overall higher prevalence of undernutrition seen at diagnosis in this study is not 
surprising and is likely to be multifactorial in orgin. This is often the result of tumour 
burden and the consequent increase in TEE before treatment (Schmid et al. 2005, den 
Broeder et al. 2001, Vaisman et al. 1993, Stallings et al. 1989), anorexia with a 
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decrease in dietary intake (Falconer et al. 1994, Staal-van den Brekel et al. 1995), 
and treatment induced side-effects from the initial intensive therapies (Brinksma et 
al. 2012, Antillón et al. 2008, Koskelo et al. 1990, (Pinkerton, Plowman and Pieters 
2004, Bauer et al. 2011, Donaldson 1982, van Eys 1986, Donaldson et al. 1981).    
In contrast, overnutrition and obesity rates were lowest at baseline ranging from 8-
9% and 1-14% respectively. These are slightly lower than those reported in a recent 
systematic review (15%) (Revuelta Iniesta 2015), however this review considered 
overweight and obesity as overnutrition and reported values together. A much lower 
prevalence of obesity has been reported in the Netherlands (4.5%) in a study 
published after the systematic review was carried out (Brinksma et al 2014). This 
difference could be a reflection of the higher obesity prevalence among healthy 
children from the UK in comparison to that of the Netherlands (Bibiloni et al. 2013, 
Bates et al. 2011, Currie et al. 2012). Prevalence of both overweight and obesity 
increased steadily throughout the course of the disease reaching a peak at 36 months 
(14-28%) for overnutrition and 30 months (25-33%) for obesity. Importantly though 
only prevalence of obesity at 30 months was significantly associated with paediatric 
cancer when this was compared to expected obesity frequencies from the healthy UK 
population (Department of Health 2012). This data needs to be interpreted with 
caution owing to the small sample size at these later stages of the study (30 months, 
n=12; 36 months, n=7). Nevertheless, these finding are supported by many others 
worldwide, especially in survivors of childhood cancer (Inaba et al. 2012, Brinksma 
et al. 2014, Bibiloni et al. 2013, Oeffinger et al. 2003, Siviero-Miachon et al. 2009a, 
Reilly 2009a, Reilly 2009a, Iughetti and Bruzzi 2011, Aldhafiri et al. 2014, Showell 
et al. 2013, Taylor et al. 2013, Co-Reyes et al. 2012, Siviero-Miachon et al. 2009b).  
Prevalence of malnutrition was stratified by type of cancer. Children diagnosed with 
solid tumours (range 17-22%), haematological malignancies (3-12%) and brain 
tumours (9-17%) had a significantly higher risk of being underweight at diagnosis 
and baseline than healthy children from the UK (Department of Health 2012). The 
highest prevalence of undernutrition at baseline was seen in the solid tumour group, 
ranging from 17-22% depending on the type of measurement used, whilst no child 
diagnosed with OAD presented undernourished. Higher prevalences of 
233 
 
undernutrition in children diagnosed with solid tumours have been reported in a 
recent systematic review (29.5%) (Revuelta Iniesta et al. 2015) where most studies 
reporting this data were from developed countries, mainly the USA, Canada and 
Europe. A lot of the populations from the studies, which looked at solid tumours and 
were included in the systematic review had severe disease; stage IV Neuroblastoma 
(Green et al. 2008), Wilms’ tumour (Wessels et al. 1999), and Medulloblastoma as 
well as supratentorial PNET (Bakish et al. 2003), perhaps contributing to the higher 
prevalence in comparison to the findings from this study.  
The prevalence of undernutrition seen in the haematological malignancy group at 
baseline is corroborated by those reported worldwide (13%) (Revuelta Iniesta et al. 
2015) and in developed countries only (0-10%) (Brinksma et al. 2012). Although, 
haematological malignancies include a variety of diseases, such as ALL, AML or 
CML, most studies have either investigated children diagnosed with ALL only 
(Viana et al. 1994, Jaime-Pérez et al. 2008, Reilly et al. 1999, Gofman & Ducore 
2009, Baillargeon et al. 2006, Baillargeon et al. 2007, Delbecque-Boussard et al. 
1997, Antillon et al. 2008, González et al. 2004, Uderzo et al. 1996, Ahmed et al. 
1997) or, like in this study, most of the population consist of ALL patients; 
consequently, contributing to the more consistent findings. In contrast, solid tumours 
include a wider spectrum of diseases in its classification, which could contribute to 
the high variability of results reported here and in other studies (Revuelta Iniesta 
2015).  
Only one study investigated children diagnosed with brain tumours reporting a 
higher prevalence of undernutrition (31%) (Bakish et al. 2003) than that obtained in 
this study. This discrepancy could be attributed to the difference between the type of 
cancers included in Bakish et al. (2003) (Medulloblastoma and supratentorial PNET) 
and this study (see table 4.2 and 4.3). The prevalence of undernutrition in all types of 
cancer was reduced during the treatment phase, especially after the 9 month follow 
up, and by the end of the study no child was undernourished. These findings contrast 
with those recently reported (Revuelta Iniesta et al. 2015) where prevalence of 
undernutrition during treatment were 23% and 14% and, at the end of therapy were 
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35% and 9.5% for the solid tumours and haematological malignancy group 
respectively.       
The highest prevalence of overweight (0-25%) and obesity (0-50%) was found in 
children diagnosed with OAD, followed by those with brain tumours, in whom the 
prevalence  was 0-28.5% for overweight and 17-28.5% for obesity at baseline. 
Surprisingly, children with solid tumours had a similar prevalence of overweight to 
those with haematological malignancies at baseline ranging from 0-9% and 5.5-9% 
respectively. However, obesity prevalence was higher in the haematological group 
(0-14%) compared to the solid tumours (0-8.5%). Although, a few studies have 
investigated overnutrition in brain tumours (Müller et al. 2001, Müller et al. 2011) at 
the time of diagnosis, this is the first study to report prevalence of overnutrition and 
obesity in both brain tumours and solid tumours, and also the first to report 
prevalence of malnutrition in children diagnosed with OAD (LCH) (Revuelta Iniesta 
et al. 2015, Brinksma et al. 2012) at this stage. Therefore, these results cannot be 
compared with other published studies. Overnutrition has been investigated more 
extensively in children diagnosed with haematological malignancies, especially at 
the time of diagnosis (Jaime-Pérez et al. 2008, Reilly et al. 1999, Gofman and 
Ducore 2009, Baillargeon et al. 2005, Baillargeon et al. 2007, Odame et al. 1994) 
and in survivors of ALL (Wallace et al. 2013, Dalton et al. 2003, Reilly 2009a, 
Iughetti and Bruzzi 2011, Tylavsky et al. 2010) and, the overall overnutrition 
prevalence at diagnosis of 15% found worldwide is comparable with the results 
obtained in this study (Revuelta Iniesta et al. 2015).  
Overweight and obesity prevalence increased during the course of treatment in all 
type of cancers, especially in children diagnosed with haematological malignancies 
and brain tumours (table 4.5). Moreover, they were significantly associated with 
cancer when compared to expected overweight and obesity frequencies from healthy 
UK children and young people (Department of Health 2012). This increase in obesity 
seen in haematological malignancies is consistent with findings from a systematic 
review, which reported prevalence of overnutrition as high as 40% both during 
treatment and after the completion of therapy (Revuelta Iniesta et al. 2015). In 
contrast, those reported in the solid tumour group in this same systematic review are 
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higher than those obtained in this study: 21% during treatment and 35% after the 
completion of therapy (Revuelta Iniesta et al. 2015). Once more, caution must be 
taken at interpreting these results as sample sizes for each individual type of cancer 
were very small, especially at the later stages of treatment, and either 
underestimation or overestimations of malnutrition might have occurred.  
Prevalence of malnutrition was stratified by gender. There was not a significant 
difference between males and females at any stage of the disease, and both genders 
were significantly associated with undernutrition at baseline and 3 months when this 
was compared against expected frequencies from the healthy UK children and young 
people (Department of Health 2012). Only male gender was associated with 
overweight and obesity at the end of the study period in compared to healthy UK 
children and young people (Department of Health 2012). Comparison between these 
findings and others is difficult because this study did not stratify the gender and type 
of cancer further due small sample size, especially at the end of the study. It is worth 
noting however that in other studies the prevalence of overnutrition in boys and girls 
diagnosed with ALL did not differ at diagnosis (Odame et al. 1994 and Reilly et al. 
1999); however these and other UK (Warner et al. 1995) and USA authors 
(Oeffinger et al. 2003) reported higher frequencies of overnutrition in girls compared 
to boys at later stages of the disease and after treatment in children diagnosed with 
paediatric cancer and ALL respectively, which differs from the current study. Only 
one study from the UK reported no difference between girls and boys in 
overnutrition prevalence in survivors of ALL (Didi et al. 1995).           
Despite the small sample size, this study highlights an overall high prevalence of 
undernutrition during the initiation of treatment with an increase in overweight and 
obesity at later stages. Additionally, children with solid tumours showed the highest 
prevalence of undernutrition during the initial phases of treatment, whilst those 
diagnosed with brain tumours and haematological malignancies exhibited higher 
prevalence of obesity after the completion of therapy. Finally, this study did not 
show a gender difference in the prevalence of malnutrition during the study period. 
The importance of these findings lies in the building of an epidemiological picture of 
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the nutritional status of paediatric cancer patients, which can be used to guide the 
future nutritional management of this population.      
(ii) Nutritional status according to body composition 
Protein energy malnutrition (PEM), established by using upper arm muscle area 
(UAMA) reference data (Frisancho 1981), was more prevalent at 3 months (10%) 
and, surprisingly, at 24 months (12.5%) than at baseline (5%). However, by the end 
of the study period no child was diagnosed with PEM. Malnutrition was established 
by using upper arm fat area (UAFA) reference data (Frisancho 1981), which 
identified 13.5% of undernourished children at baseline. This gradually reduced 
throughout the study period and by the end no child was identified as 
undernourished.  
Children with solid tumours had a significantly lower UAMA when compared to 
other types of cancer; yet UAFA did not statistically differ between diagnoses at any 
stage. Likewise, UAMA and UAFA did not statistically differ between genders. 
Comparison of these findings with other studies is difficult due to the paucity of 
evidence looking specifically at PEM in this population, the different methods (and 
reference values) used to assess this, and the population being small and mainly of 
ALL children. Additionally, none of the studies investigating FFM and FM report the 
actual prevalence of PEM, but instead the patterns of change in body composition. 
Despite these drawbacks similar findings have been reported. Halton et al. (1998) 
assessed body composition using DEXA scan in 16 out of 116 ALL children 
included in the study. The author reported a decrease in FFM of 5% at 6 months and 
an increase in FM of 6% by the end of therapy (Halton et al. 1998). Similarly, 
Koskelo et al. (1990) in a prospective cohort study (controls v cohort), in which 12 
ALL and 2 acute non-lymphocytic leukaemic children were included, assessed body 
composition using ultrasound method (US) and arm as well thigh measurements 
(MUAC, TSF, thigh circumference and thigh skinfold). This study showed that 
muscle mass was lower in the cancer group compared to the control at diagnosis and 
that muscle mass decreased by 27% following 4-6 weeks of treatment (Koskelo et al. 
1990). Simultaneously, FM increased by 33% and body water also increased 
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(oedema), thus maintaining net body weight (Koskelo et al. 1990). Unfortunately, the 
initial percentage of FFM and FM was not reported. 
Contrary to our findings, Murphy et al. (2010) in a cross-sectional study 
investigating the body composition of 48 children treated for cancer or 
haemophagocytic syndrome and 48 sex-matched controls found no difference in 
FFM, assessed by air displacement plethysmography, between the groups. Of note, 
the study did not state the length of treatment, which could explain the difference 
with the other studies. Interestingly, body mass cell assessed by total body potassium 
showed lower body cell mass in the cancer group than the control reflecting lower 
body function (Murphy et al. 2010). Like in the current study, FM was also higher in 
the cancer group (Murphy et al. 2010). Finally, Delbecque Boussard et al. (1997) in a 
prospective cohort study (cohort v control) of 15 ALL children showed no difference 
between the cohort and the controls in FFM and this was regardless of the 
measurement used, BIA or TSF. However, FFM reduced from a mean±SD of 
20.8±6.8 Kg at day 1 to 15.6±5.5 Kg at day 22 of treatment (Delbecque-Boussard et 
al. 1997). The study did not report significance, probably due to the small sample 
size; however a mean reduction of 5.2Kg in FFM could reflect severe PEM. 
Reasons for the high prevalence of PEM and undernutrition (assessed by UAFA), 
especially seen in the solid tumour group from the current study, could partly be 
attributed to the inflammatory response. This is supported by the high ssCRP, 
especially in solid tumours, high ferritin and hypoalbunaemia results seen in this 
study. It is well acknowledged that inflammation induces anorexia, which in turn 
leads to a reduction of dietary intake, skeletal muscle catabolism, which leads to 
muscle wasting, and to a lesser extent lipolysis, which may lead to reduced FM 
(Picton 1998, Bauer et al. 2011). This appeared to be the case in most 
undernourished patients from this study, especially during the first year of treatment; 
however, this study did not show that all children with PEM were also 
undernourished when this was assessed using either BMI or UAFA. In fact most 
children classified as PEM were identified as either well-nourished or even 
overnourished by BMI and UAFA, indicating a higher FM percentage, which may 
have masked PEM. This combination of PEM and “high” FM could be attributed to 
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the faster repletion of lean mass in comparison with fat mass caused by the 
inflammatory process and the cancer treatment. Also, the high TEI seen in this 
population could have led to an increase in FM instead of FFM. Although this study 
failed to assess physical activity using an accelerometer due to the difficulties 
encountered by the children and their families, a recent review reported a reduction 
in physical activity during the treatment phase in paediatric cancer patients (Winter 
et al. 2010), which may have also contributed to the reduced FFM and higher FM 
seen in this cohort of paediatric cancer patients.  
In summary, this study showed a high prevalence of PEM with either undernutrition 
or overnutrition as established by BMI, especially during the initial 3 months of 
treatment. Considering the short and long term implications of PEM described in 
both healthy children and in paediatric cancer patients in chapter I (section 1.2.3) and 
in chapter III (section 3.1)  (Viana et al. 1994, Cornelio-Nieto 2007, Sala et al. 2012, 
Sala et al. 2008, Mejía-Aranguré et al. 1999, Hoorweg & Stanfield 1976), and the 
discrepancy between BMI, UAMA and UAFA at identifying undernutrition and 
PEM, this study highlights the importance of assessing body composition alongside 
measurements of body size as part of regular nutritional monitoring in clinical 
practice.            
(iii) Changes in body size and body composition during the study period   
The short and medium term changes in nutritional status were established using BMI 
centiles, arm anthropometry and BIA, which allowed a comprehensive assessment of 
body size and body composition.  
A number of findings are likely to be pertinent to both future research and clinical 
practice, and may be useful in patient’s counselling. This study showed high 
individual variability in BMI centiles from diagnosis until the end of therapy 
indicating the heterogeneity of this population, which may be due to the different 
diagnosis, treatments, age and small sample size (of each individual diagnosis). 
Nevertheless, BMI centile increased overall throughout the course of treatment. 
Children diagnosed with solid tumours had consistently the lowest median BMI 
centiles compared to other diagnoses; whilst those diagnosed with OAD, brain 
239 
 
tumours and haematological malignancies had the highest median BMI centiles. 
Recent data from the Netherlands are consistent with these findings, albeit an overall 
increase in BMI centile in all type of diagnosis (Brinksma et al. 2014). Of note, this 
study, unlike the current study, did not investigate children diagnosed with OAD and 
the follow up period was 12 months (Brinksma et al. 2014), consequently 
comparison was limited to this period of time. There is a general consensus regarding 
the increase in either BMI or weight centiles in paediatric cancer patients from the 
time of diagnosis until the end of therepay; however most evidence comes from 
retrospective studies investigating children treated for haematological malignancies 
(Reilly et al. 2001, Gofman and Ducore 2009, Baillargeon et al. 2005, Baillargeon et 
al. 2007, Odame et al. 1994, Withycombe et al. 2009, Esbenshade et al. 2011) or 
survivors of ALL (Zhang et al. 2014, Baillargeon et al. 2005, Baillargeon et al. 2006, 
Oeffinger et al. 2003, Asner et al. 2008, Chow et al. 2007, Davies et al. 1995) with 
very long intervals of follow up (>6 months). Although, these studies are very 
informative at establishing trends, prevalence and possible causes of obesity in 
haematological malignancy patients and survivors, it is difficult to establish at what 
stage of the treatment obesity occurs and thus when to start targeting these patients 
with diet and lifestyle therapy.        
The current study also revealed some interesting results when the data was stratified 
by treatment risk and age at diagnosis. Children classified as high risk, regardless of 
their diagnosis, had consistently the lowest BMI centiles, whilst those who were 
classified as low risk had the highest median BMI centiles; however by the end of the 
study period BMI centiles were similar in all treatment risk groups. Furthermore the 
BMI of children diagnosed at the age of ≥12 years increased dramatically from ~55th 
centile at diagnosis to ~95
th
 centile by the end of the study, whilst those diagnosed 
between the ages of 2-11 and 0-1.99 years only increased 5 centiles during the study 
period, from 55
th
 to 60
th
 and from 35
th
 to 40
th
 respectively.  
The lower BMI centiles from the high treatment risk group found in the current study 
is not surprising as the use of more anti-cancer treatments as well as their increased 
in intensity are likely to increase the number and severity of side-effects, such as 
mucositis, vomiting and malbsorption; consequently increasing the risk of 
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undernutrition (van Eys 1979a, Bauer et al. 2011, Donaldson 1982, van Eys 1986). 
Most of the published data are in line with the results from the current study, 
whereby children diagnosed with both advanced solid tumours (Israels et al. 2010, 
Green et al. 2008) and ALL treated with high risk protocols had lower BMI centiles, 
and thus were at higher risk of having undernutrition during the initial phases of 
treatment (Delbecque-Boussard et al. 1997, Halton et al. 1998, Mejía-Arangure et al. 
1997, Esbenshade et al. 2011, Corera Sánchez et al. 1992). For instance, a case 
control study performed in México, in which 17 ALL children with severe 
undernutrition died during the initial phases of treatment (induction-to-remission 
phase) were compared with 76 ALL controls who had survived the initial phases of 
treatment. Although, the main aim of this study was to assess whether undernutrition 
was associated with an increased risk of mortality, the study also reported that 
children treated for high risk ALL with more intensive therapies had higher rates of 
undernutrition and lower BMI centiles (Mejía-Arangure et al. 1997). Likewise, a 
prospective cohort study (with healthy controls) performed in Canada, in which the 
weight for height of 12 children diagnosed with stage IV neuroblastoma and treated 
with a high risk protocol were investigated (Green et al. 2008). A total of 50% were 
undernourished at diagnosis, 30% during phase 2 of treatment and 20% in phase 3, 
which is in line with the patterns found in the current study. Unfortunately, the 
authors did not report weight for heights from the healthy controls, thus comparisons 
between cases and controls were not established (Green et al. 2008).  
In contrast, a prospective cohort study performed in Canada, in which the weight and 
body composition of 116 ALL children were investigated reported that children 
treated for high risk ALL had higher weight centiles than those treated for standard 
risk ALL; however at 24 and 36 months of treatment their weight was the lowest 
(Halton et al. 1998). This also contrasts with the findings from the current study, as it 
was found that BMI centiles were similar by the end of therapy. These discrepancies 
could be attributed to the difference in treatment and diagnoses as the high risk group 
from the Canadian study were treated with cranial irradiation, which is associated 
with obesity (Armstrong et al. 2010, Iughetti et al. 2012), and they all had an ALL 
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diagnosis (Halton et al. 1998); whilst in the current study all type of diagnoses were 
included in the stratification of treatment risk due to the small sample size.  
Evidence regarding the relationship between age at diagnosis and BMI trends are 
inconsistent, especially with regards to obesity. In contrast to the findings from this 
study, most evidence support a higher increase in BMI in younger children diagnosed 
with craniopharyngioma (Lustig et al. 2003) and ALL (Reilly et al. 2001, Oeffinger 
et al. 2003, Didi et al. 1995, Garmey et al. 2008), which has been attributed to an 
early adiposity rebound that predisposes to obesity in later life (Reilly et al. 2001, 
Lustig et al. 2003), and unhealthy behaviours (like sedentary lifestyle and limited 
food choices)  adopted early in life as result of the long lasting treatment and their 
side-effects (Bernstein 1978, Bernstein et al. 1982, Reilly 2009a, Stolley et al. 2010, 
Winter et al. 2010, San Juan et al. 2011). In line with the findings from the current 
study, a retrospective cohort study, in which the nutritional status of 1451 survivors 
of childhood ALL and 2167 siblings were investigated in the USA (Garmey et al. 
2008). It was found that ALL survivors had a greater rate of BMI increase, which 
started during the treatment phase, than their siblings. Additionally, older children 
and young people had a higher increase in BMI than younger children. Of note, it 
was reported that younger children who were exposed to CRT had a higher increase 
of becoming obese. This suggests that one of the differences between the current 
study and the published data might be the CRT treatment. No child from the current 
study received CRT as at present it is limited to children with refractory ALL and 
with optical nerve infiltration (Sposto 2004).    
One of the most striking findings from this study is the short to medium term 
changes in body composition. MUAC remained constant throughout the study 
period; however TSF increased dramatically at 3 months, and then decreased slightly 
at 6 months, but it increased gradually thereafter. Furthermore, estimation of body 
composition using both arm anthropometry and BIA showed a gradual reduction in 
FFM% throughout the study period (from 69% to 63.5%), which is indicative of 
progressive muscle wasting due to inflammation and perhaps sedentary behaviour. In 
contrast, there was a gradual increase in FM% (from 30% to 36.5%) demonstrating 
an overall increase in fat mass. No significant changes in FFM% and FM% were 
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found at any stage of the study. Therefore, this study suggest that the body 
composition of childhood cancer patients starts changing gradually during the initial 
phases of treatment and remain until the end of therapy (3 years), which emphasises 
the need for measuring body composition alongside BMI as a routine clinical 
parameter. This would allow establishing short and long term patterns of change as 
one single measurement of body composition in this population would be clinically 
irrelevant.   
These findings are consistent with most published data investigating arm 
anthropometry and body composition of ALL patients (Siimes et al. 1991, Halton et 
al. 1998, van der Sluis et al. 2002, Koskelo et al. 1990) and solid tumours during 
treatment (Skolin et al. 1997, Murphy et al. 2010, Taskinen et al. 2007, de Graaf et 
al. 1987). The aetiology of the changes seen in body composition may relate partly to 
the effects of the initial intensive chemotherapy phases combined with an 
inflammatory response (high CRP and ferritin and reduced albumin levels) seen in 
this study, thus leading to muscle wasting. This is further corroborated by an increase 
in fat mass, as excessive energy intake in catabolic individuals lead to fat deposition 
without an increase in muscle mass (Halton et al. 1998, Murphy et al. 2010). 
Previous studies have also shown that the use of glucocorticoids (Reilly et al. 2001) 
combined with an increase in TEE and reduced physical activity also contribute to an 
increase in FM during treatment (Brinksma et al. 2014, Halton et al. 1998, Murphy et 
al. 2010), which then continues into adulthood (Inaba et al. 2012, Zhang et al. 2014, 
Taylor et al. 2013). The follow up from this study was 3 years; consequently it is not 
known whether high FM% will remain in the long term.  
It is noteworthy that the body composition is presented as a percentage of the total 
FFM and FM and that when only one is affected (reduced) the other one is 
automatically increased. However, this study showed both a decrease in FFM and an 
increase in FM as MUAC remained constant and TSF increased throughout the study 
period.    
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4.4.2.2 Linear Growth 
 The current study found that poor linear growth was prevalent in this cohort of 
paediatric cancer patients; however there appeared to be catch-up growth following 2 
years of treatment. Poor linear growth was most pronounced in the haematological 
malignancy group, who showed a median reduction of 23 centiles following 2 years 
of treatment. A consensus exists regarding the poor linear growth of haematological 
malignancy patients, especially those diagnosed with ALL (Bond et al. 1992, 
Murphy et al. 2006, Halton et al. 1998, Ahmed et al. 1997, van der Sluis et al. 2002, 
Caruso Nicoletti et al. 1993, Viana and Vilela 2008), but also in children diagnosed 
with solid tumours (Bond et al. 1992, Murphy et al. 2006, Revuelta Iniesta et al. 
2015). The factors contributing to poor linear growth have been attributed to cranial 
irradiation, poly-chemotherapy, younger age at diagnosis and growth hormone 
deficiency (Viana & Vilela 2008). Like this study Viana et al. (2008) did not find any 
statistical significant difference in the HFA of males and females. In fact, more 
evidence attribute poor linear growth to the increasing use of high dose poly-
chemotherapy protocols and the long-term treatments, particularly in haematological 
malignancies, whose average treatment is 2 years for the females and 3 years for the 
males (Mycroft 2010). Linear growth is a complex mechanism, which is affected by 
chemotherapy, radiotherapy and HSCT as well as nutritional status (van Leeuwen et 
al. 2000). Particularly, the effects of corticosteroids on bone mass density have been 
well described. Corticosteroids inhibit growth hormone, the proliferation of 
osteoblast and reduce the secretion of sex hormones in adults, which in turn leads to 
an increase in bone resorption and a reduction of bone mass density (van Leeuwen et 
al. 2000). In periods of rapid growth in children, where the incident of childhood 
cancer is highest (3-4 years and puberty), corticosteroids do not only affect bone 
mass density, but also reduce bone growth velocity, leading to poor growth (El-Hajj 
Fuleihan et al. 2012, van Leeuwen et al. 2000, Kang and Lim 2013, Al-Jaouni et al. 
2009). Additionally, the most commonly used chemotherapy agents; alkylating 
agents (cyclophosphamide) and antimetabolites (cisplatin and methotrexate) are also 
thought to inhibit longitudinal growth (Davies et al. 2005). The role of chondrocyte 
cells is essential for bone growth, however in vitro studies have found that these 
agents directly interfere in their life cycle, resulting in a decrease in bone growth and 
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consequently linear growth (van Leeuwen et al. 2000). Methotrexate has been found 
to suppress osteoblast activity and stimulate osteoclasts, resulting in bone resortion 
and poor growth (van Leeuwen et al. 2000). Finally, one of the known side-effects of 
HSCT is poor growth and reduced final HFA (Leiper 2002b, Leiper 2002a). Three 
children from this cohort received HSCT, and of these 2 had a reduction in HFA 
following HSCT and 1 did not have any further follow up.  
This study showed catch up growth 2 and half years post-treatment, especially in the 
haematological malignancies. Although, this is consistent with some published 
studies (Murphy et al. 2006, Halton et al. 1998, Ahmed et al. 1997, van der Sluis et 
al. 2002, Caruso Nicoletti et al. 1993, Holm et al. 1994), caution should be taken at 
interpreting this data as at this stage there were only 12 children measured, which is 
unlikely to represent the whole cohort and most evidence investigating the final 
height of childhood cancer survivors report this to be reduced when this is compared 
to expected final height (Dalton et al. 2003, Müller et al. 1998, Sklar et al. 1993).           
In summary, there was an overall reduction in HFA in the whole cohort of paediatric 
cancer patients, which was more prominent in haematological malignancies. This is 
likely to be the result of poly-therapy, especially chemotherapy and HSCT, as poor 
linear growth starts to become apparent soon after the start of treatment.  
4.4.3 Factors contributing to nutritional status and patterns of change of 
paediatric cancer patients 
This is the first prospective cohort study performed in Scotland, which has 
established patterns of change in body size (BMI and HFA centiles) and body 
composition (FFM and FM) in paediatric cancer patiuents following 18 months of 
treatment. Only one factor has been identified which significantly contributed to 
changes in nutritional status. This was treatment risk and it only exerted this 
influence during the first 3 months of treatment. No other factor assessed in this 
study (age at diagnosis, type of cancer, treatment risk, nutritional support and TEI) 
contributed to changes in nutritional status, established by BMI.   
BMI and fat mass, measured with arm anthropometry and BIA, increased throughout 
the 18 months and both reached significance at 3 months. Interestingly, BMI had a 
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second significant increment at 18 months, whilst FM attained significance at 9 
months instead. In contrast, FFM declined significantly at 3 and 9 months when this 
was assessed using BIA. Of note, significant changes in FM and FFM assessed using 
arm anthropometry were only established at 3 months. During this initial period of 
increase in BMI and FM, HFA centiles decreased significantly. These findings are 
analogous to a recent prospective cohort study, similar in design to the current study, 
published in the Netherlands (Brinksma et al. 2014). Like Brinksma et al. (2014), the 
current study highlights that changes in body size and body composition occurred 
early on following treatment in all paediatric cancer patients; however the current 
study also indicates that both the increasing trend of BMI and FM and the reducing 
trend in FFM remained after one year, for 18 months. Although this study was 
unable to establish trends following 18 months of treatment, there is evidence 
elsewhere which suggests that these changes continue into adulthood (Zhang et al. 
2014, Siviero-Miachon et al. 2009a, Brouwer et al. 2007, Asner et al. 2008, Iughetti 
et al. 2012, Garmey et al. 2008). The consequences of reduced FFM during treatment 
include poor linear growth (Brennan 1998) loss of muscle strength, reduced tolerance 
of therapy and increase treatment induced side-effects as well as an increase in the 
risk of infections (Sala et al. 2012, Murphy et al. 2010). Furthermore, reduced FFM 
accompanied by high BMI and FM post-treatment increases the risk of 
cardiovascular disease even in later life more in this population (Wallace et al. 2013, 
Blijdorp et al. 2012).  
Total energy intake significantly contributed to overnutrition, established by BMI, 
when this was analysed independently of all the other variables. The fact that energy 
intake exceeded energy requirements in most patients regardless of whether they 
were receiving nutritional support and that 67% patients received some form of 
nutritional support, highlights the active policies currently in place in the 
Hematology and Oncology ward from both the RHSC of Edinburgh and Ninewells in 
Dundee to both prevent and treat undernutrition as all paediatric cancer patients durin 
the treatment phase are adivised to have a high energy dense diet. This might also 
explain the rapid increase in BMI, which occurred following an initial decline in 
those patients who were undernourished. However, this study proposes that the 
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recovery in BMI is due to an increase in FM rather than FFM, thus PEM may be 
masked by high FM. 
Repeated cycles of weight loss and weight gain typically seen in dieting behaviours, 
called weight cycling, may eventually lead to obesity, especially in adelescents 
(Dulloo et al. 2012). This has been attributed to hyperpagia following a period of 
starvation, consequently leading to rapid weight gain (Dulloo et al. 2012). Therefore, 
it could be hypothesised that children receiving alternative intensive cycles of 
chemotherapy and corticosteroids experience changes in body weight as consequence 
of the side-effects and appetite respectively, which combined with sedentary 
behaviour, may eventually lead to excesive and rapid fat accumulation and obesity.    
Therefore, it appears that current nutritional practices have become very successful at 
reducing undernutrition and its risk; however overnutrition has largely been 
overlooked and at present overnutrition during the treatment phases is not tackled. 
This could be attributed to current understaffing of Dietitians, which unables the 
team to deal with the high nutritional demands of this population having to prioratise 
undernutrition, and also the inexistence of specific clinical guidelines for the 
management of paediatric cancer obesity.    
Current paediatric oncology dietetic practices in SE Scotland base their nutritional 
assessments on either weight for height or weight only (Sala et al. 2004, Paciarotti I 
2013). Although, rapid weight loss is an indicator for acute undernutrition, this 
measurement alone does not estimate FFM and FM. Consequently these early 
changes in body composition are neglected. Furthermore, the equations used in 
current paediatric oncology clinical practice to estimate energy requirements in 
children take into consideration growth and a physical activity level (PAL) of 25
th
 
centile (Department of Health 1991, Henry 2005). The current study, like others 
(Bond et al. 1992, Murphy et al. 2006, Halton et al. 1998, Ahmed et al. 1997, van der 
Sluis et al. 2002, Caruso Nicoletti et al. 1993, Viana and Vilela 2008, Revuelta 
Iniesta et al. 2015), has demonstrated that there is a stagnation of linear growth 
during treatment, especially during the first 3 months of treatment. Moreover, there is 
published evidence of a sedentary lifestyle seen both during and after treatment 
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among patients (Reilly 2009a, Stolley et al. 2010, Winter et al. 2010, San Juan et al. 
2011). These two factors might have contributed to an overestimation of TER, which 
in turn might have led to an excessive TEI through nutritional treatment and general 
nutritional advice. Based on the reduced physical activity levels of paediatric cancer 
patients reported by the literature (Reilly 2009a, Stolley et al. 2010, Winter et al. 
2010, San Juan et al. 2011), the current study used a PAL of the 10
th 
centile; however 
the TEE equations and the PAL used also accounts for linear growth, which might 
have contributed to a small  overestimation of TER during the initial 3 months of 
treatment. Despite this, TEIs were still significantly higher than TER.               
Treatment risk was the most important contributor to changes in BMI during the first 
3 months of treatment in this cohort. High risk treatment protocols contributed to an 
increased risk of undernutrition, whilst low treatment risk protocol contributed to an 
increased risk of overnutrition. These findings have also been supported by others 
(van Eys 1979a, Bauer et al. 2011, Donaldson 1982, van Eys 1986). It is also 
noteworthy, that the age at diagnosis also contributed to malnutrition when this 
variable was analysed independently. Younger children were at higher risk of 
becoming undernourished and older children were at higher risk of becoming 
overnourished. As discussed in section 4.4.2.1, iii, these findings contrast with most 
published literature (Oeffinger et al. 2003, Reilly et al. 2001, Lustig et al. 2003, Didi 
et al. 1995, Garmey et al. 2008) and reasons for this have previously been discussed.  
The findings from this study have several implications for both clinical practice and 
future research. With regards to clinical practice, this study underlines the need for 
monitoring not only growth but also body composition by using either anthropometry 
or BIA. By adopting these measures, the excessive accumulation of fat in the adipose 
tissue could be identified earlier and dietary advice including TEI could be tailored 
accordingly. Equally, the muscle wasting found to be prevalent, especially at 3 and 9 
months would be detected. Whilst some degree of muscle wasting resulting from the 
initial acute phase response is inevitable (Guadagni & Biolo 2009), attempts should 
be made to minimise it at these critical stages of the disease. It has been suggested 
that this could be achieved by increasing total protein and introducing physical 
activity (Brinksma et al. 2014). This study attempted to assess physical activity, 
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however this proved impossible as it became too laborious for the patients and their 
families. Nonetheless, evidence supports early interventions to increase physical 
activity, especially when treatment induced side-effects have started to lessen 
(Brinksma et al. 2014). Finally, the vulnerability of children treated with high risk 
protocols should be targeted to prevent or reduce the risk of undernutrition at the 
early stages (initial 3 months); whislt careful matching of TER and TEI and close 
monitoring should be aimed for to avoid overfeeding.  
4.4.4 Methods used to identify body size and body composition 
The findings from this study are based on the methods, reference values and 
thresholds used to establish nutritional status already discussed in the methods 
section. In agreement with a recent systematic review (Revuelta Iniesta et al. 2015), 
this study showed poor agreement between BMI and both MUAC and TSF at 
identifying malnutrition in paediatric cancer patients. Arm anthropometry 
measurements classified consistently more children as undernourished and 
overnourished, whilst BMI identified higher prevalence of obesity when this was 
compared to TSF during the initial phases of therapy in all diagnostic criteria. 
Inaccuracies can arise from weight, height and particularly length measurements 
(Norton and Olds 1996); nevertheless the intra- and inter-TEM of the observers was 
minimal and unlikely to have affected the results. Some bias could have been derived 
from length measurements as its intra and inter-TEM was not established. Of note, 
the recommended BMI threshold for undernutrition in children aged between 2-18 
years of ≤2.3rd centile (-2SD) used in this study (Bates et al. 2011, SACN 2011, 
SACN/RCPCH 2012) and others (Reilly et al. 1999, Pietsch and Ford 2000) could 
have contributed to this discrepancy. More rigorous thresholds of ≤5th centile (severe 
undernutrition) or even ≤15th centile (moderate undernutrition) have been suggested 
(Sala et al. 2004, Sala et al. 2012); however, further research should investigate the 
precision of this cut-off values against more sensitive measures of assessment, such 
as DEXA scan, before they are implemented in this population. It is more likely that 
the discrepancy between the measurements during the initial phases of therapy 
further reflects the limitations of using BMI as the sole method of assessment in 
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paediatric cancer patients as it does not account for changes in body composition, 
oedema and weight of tumour.     
Some limitations have been associated with arm anthropometry measurements and 
the reference values used in this study. Firstly, high TEM, particularly between 
observers (inter-TEM), has been reported by many (Ulijaszek and Kerr 1999, 
Jamaiyah et al. 2010, Geeta et al. 2009, Ulijaszek and Lourie 1997). Nevertheless, 
the intra- and inter-TEM of TSF, weight and height was found to be minimal and 
unlikely to have contributed to the discrepancies seen in this study. Interestingly, the 
inter-TEM for MUAC was slightly higher and may have contributed to some error. 
Secondly, the estimation of body composition by arm anthropometry assumes that 
FM is equally distributed throughout the body (Norton and Olds 1996). This is 
certainly not the case in adults, but fat deposition in children (between 6-18 years) 
has been reported to be more equally distributed (Roche et al. 1981). Thirdly, the 
threshold used to identify undernutrition by arm anthropometry was ≤5th centile. This 
reference value comes from a population of children from the USA in the 1970s, 
which can be assumed is different from the population in this cohort and thus 
underestimation of undernutrition and overestimation of overnutrition might have 
arisen. There is a clear urgent need to update MUAC and TSF reference values that 
includes all ages (0-18 years). Lastly, the difficulty of taking these measurements for 
research purposes in a population who is severely ill and already receiving many 
forms of invasive treatments should not be underestimated.   
The main limitations of single-frequency BIA have been previously discussed 
(chapter I, section 1.6.2.1). In addition to these limitations and as a result of clinical 
practices, it was impossible to always measure the patients in the morning or at the 
same time, fasted and after micturating. Notwithstanding the limitations of the 
single-frequency BIA, the lack of reliable and specific TBW equations and the 
difficulties encountered with the reference values to assess body composition in 
paediatric cancer patients, this study revealed good limits of agreement between BIA 
and arm anthropometry for fat mass (1.2 to -1.0). This suggests that the use of BIA 
and/or arm anthropometry should be implemented in clinical practice. Other studies 
have investigated nutritional status in paediatric cancer patients using these two 
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different methods of assessment (Brennan et al. 1997, Murphy et al. 2009, Brinksma 
et al. 2014, Delbecque-Boussard et al. 1997, Oguz et al. 1999, Smith et al. 1991); 
however only one study compared the reliability of these two methods and found that 
BIA was more reliable due to the reduced inter and intra-TEM in compare to TSF 
(Brennan et al. 1997). Of note, a study in which adults on haemodialysis were 
included investigated the agreements between a single- and a multi-frequency BIA at 
assessing body composition. Although both methods showed good agreement, the 
multi-frequency BIA was more precise (Raimann et al. 2014). Findings which can be 
attributed to the functions of both types of BIA: multi-frequency BIA evaluates TBW 
and, unlike single-frequency BIA, distinguishes between intra- and extracellular fluid 
accounting for the rapid shifts in fluids of this population (Gudivaka et al. 1999, Kyle 
et al. 2004c, Kyle et al. 2004b). This would suggest that multi-frequency BIA is 
more appropriate for a similar population like the one from this cohort, nonetheless 
more research is needed to elucidate whether this is the case.  
4.4.5 Biochemical and micronutrient blood parameters 
The third objective of this study was to longitudinally investigate micronutrient 
status at different stages of the disease and to establish possible factors that may 
contribute to abnormalities. Biochemical markers were assessed to establish liver 
function, kidney function and the levels of inflammation. Abnormalities in any of 
these factors are likely to affect micronutrient status, and thus they will be considered 
altogether when interpreting the results.  
Predictably, the current study showed compromised liver function, kidney function 
and signs of inflammation in many paediatric cancer patients. Acute liver injury was 
prevalent in all paediatric cancer patients, especially during the initial intensive 
treatment phase, and this remained throughout the study period in solid tumours and 
haematological malignancies. Overall, kidney injury was less prevalent than liver 
injury; however it was still predominant in solid tumours and haematological 
malignancies during the intial phases of treatment. Finally, there were signs of 
inflammation in all diagnostic criteria except brain tumours throughout the study 
period.      
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4.4.5.1 Antioxidant micronutrient status 
This longitudinal study provides preliminary data on antioxidant micronutrient status 
in paediatric cancer patients. Whilst serum α-tocopherol:cholesterol ratio (vitamin 
E/Ch) was within the normal range in almost all patients, hypervitaminosis and 
hypovitaminosis A was prevalent in all type of cancers during the study period. 
Possible factors contributing to abnormal vitamin A levels were then explored. It was 
found that GGT, albumin, BMI centile and total vitamin A intake positively 
correlated with vitamin A status. Additionally CRP negatively correlated with 
plasma vitamin A. However, neither vitamin A supplementation nor ALT was 
significantly associated with vitamin A status.   
Consideration of vitamin E/Ch results in view of the relevant literature is difficult 
because of the paucity of evidence. Furthermore, the few available studies have 
investigated vitamin E levels, lymphocytes or erythrocytes α-tocopherol, mainly in 
ALL patients (Battisti et al. 2008, Kennedy et al. 2004a, Misaki et al. 2003, Ghalaut 
et al. 1999, Singh et al. 2000), instead of vitamin E/Ch status in all type of paediatric 
cancers. Nevertheless, most data, unlike the current study, supports a decrease in 
vitamin E during treatment (Battisti et al. 2008, Kennedy et al. 2004a, Misaki et al. 
2003), which returns to normal at the end of therapy (Battisti et al. 2008). It appeared 
that vitamin E/Ch status was not affected in this cohort perhaps due to an appropriate 
vitamin E intake during the study period, as vitamin E/Ch status was found to 
correlate with vitamin E intakes; however this is preliminary data and further studies 
should confirm these findings.    
The findings from this study suggest that poor nutritional status, reduced vitamin A 
intake and inflammation might have contributed to plasma hypovitaminosis A. 
Hypovitaminosis A is well documented in undernourished children from developing 
countries  as a result of reduced poor intake, which includes vitamin A (Akhtar et al. 
2013, Laxmaiah et al. 2013) and, although very few studies have investigated plasma 
vitamin A in paediatric cancer patients (Kennedy et al. 2004a, Malvy et al. 1997, 
Fiore et al. 1997, Kennedy et al. 2005), consensus exists regarding a high prevalence 
of hypovitaminosis A, especially at diagnosis and during the initial phases of 
treatment, in this population. Two possible mechanisms by which hypovitaminosis A 
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occurred in this study are proposed. Firstly, vitamin A is transported in the blood by 
RBP and albumin and both of these proteins are synthesised in the liver. In an acute 
phase state, like inflammation, the synthesis of both proteins is downregulated, thus 
causing a reduction in plasma vitamin A (Blomhoff et al. 1991). Secondly, RBP is a 
small molecule, which is filtered in the kidneys (Blomhoff et al. 1991). In normall 
circumstances, it binds to transthyretin forming a complex that prevents the excretion 
of vitamin A. However, either moderate renal impairment or infection, very common 
in this group of patients, increases the permeability of the glomerulus, which may in 
turn result in significant vitamin A losses (Blomhoff et al. 1991, Penniston and 
Tanumihardjo 2006).  
In contrast, it could be hypothesised that liver damage and high vitamin A intakes 
may have contributed to hypervitaminosis A (Blomhoff et al. 1991, Smith & 
Goodman 1976). Yet, this study did not show an association between 
supplementation and hypervitaminosis A. The high prevalence of hypervitaminosis 
A seen in this study is in line with Kennedy et al. (2005). But, unlike the findings 
from the current study, the authors did not establish an association between vitamin 
A intake and plasma levels. They attributed hypervitaminosis A to prednisone and 
hypothesised that this increases the synthesis of RBP leading to hypervitaminosis A 
(Kennedy et al. 2005). The current study did not investigate this association; 
however it is postulated that liver impairment may lead to both/either a reduction in 
hepatic vitamin A uptake and/or an increase in the release of stored vitamin A into 
the bloodstream, consequently causing plasma hypervitaminosis A (Smith & 
Goodman 1976).        
The role of vitamin A in the body has extensively been studied in healthy 
individuals. As well as been an antioxidant, vitamin A participates in the process of 
vision helps protecting the skin from sunburn and it is essential for optimal growth 
and bone remodelling (Stahl & Sies 2012, Tanumihardjo 2013). More recently 
vitamin A, especially retinoic acid, has been linked with the regulation of more than 
500 genes acting as a transcriptional activator or repressor of gene expression 
(McGrane 2007); however, neither the consequences of abnormal vitamin A levels in 
253 
 
paediatric cancer patients during cancer treatment nor whether this is part of the 
cancer and treatment process have been investigated.     
4.4.5.2 Non-antioxidant micronutrient status 
Plasma vitamin B12, folate and ferriting levels were considered at different stages of 
the disease throughout the study period. The results from this study showed that both 
plasma hyper and hypovitaminosis B12 were prevalent in all type of cancers, except 
in the brain tumours. Additionally, reduced serum folate was prevalent in all types of 
cancer, especially in the haematological malignancy and the solid tumour group. 
Finally, plasma ferritin levels were extremely high in the haematological malignancy 
and in the solid tumour group. These abnormalities were seen thoughout the study 
period despite vitamin B12 and folate mean intakes being above UK RNIs 
(Department of health 1991).  
The high prevalence of hyper and hopovitaminosis B12 seen in this study is in line 
with three studies performed in adults diagnosed with solid tumours (Carmel and 
Eisenberg 1977), metastatic cancer (Carmel 1975) and multiple myeloma (Vlasveld 
2003). The reasons for these findings are unknown, but it has been hypothesised that 
hypervitaminosis B12 could be caused by either an increased synthesis of vitamin 
B12-binding protein or a reduced clearance as a result of the malignancy and the 
chemotherapy (Carmel & Eisenberg 1977). Plasma hypovitaminosis B12 has been 
attributed to malabsorption and the long term use of proton pump inhibitors (PPI) 
(Force et al. 2003). However, this study does not support the latter as most patients 
received long term PPI treatment during the study period, but had different plasma 
vitamin B12 levels.  
Contrary to the findings from this study, two studies performed in adults diagnosed 
with multiple myeloma (Vlasveld 2003) and solid tumours (Carmel & Eisenberg 
1977) who were receiving treatment, reported plasma folate to be within the normal 
range. Paediatric cancer patients, especially those diagnosed and treated for 
haematological malignancies, received high doses of intrathecal methotrexate for 
their treatment regularly. One of the mechanisms of action of methotraxade is the 
inhibition of dihydropholate reductase, which converts dihydrofolate to the active 
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form of folate (tetrahydrofolate). Although, rescue treatment with folinic acid 
(leucovorin) is then administered, it could be postulated that serum folate levels do 
not recover completely in some patients despite appropriate folate intakes. 
Nonetheless, at present folic acid supplementation is discoraged due to the possible 
interactions with the chemotherapy and the proliferation of cancer cells as shown in 
adults with advanced colorectal cancer (Byström et al. 2009) and prostate cancer 
(Tomaszewski et al. 2011).  
Certainly, more research should focus on investigating plasma vitamin B12 and 
folate and whether there are any associations with clinical outcomes. Specific 
mechanisms that affect the changes in plasma vitamins and minerals seen in this 
study are also warranted. Thus, at present, the only clinical recommendation that 
arises from this study is to continue monitoring the plasma micronutrients of 
paediatric cancer patients to provide a better epidemiological picture of this 
population and form the bases for future clinical trials.                         
The extremely high levels of serum ferritin seen particularly in the haematological 
malignancy, and also in the solid tumour group, is not only a reflection of an acute 
phase response, but also a possible suggestion of iron overload, which has been set at 
>1000 µg/L (Henter et al. 2007, Schrappe & Pieters 2004). The reasons for this have 
been attributed to an increase in the synthesis of ferritin by blast cells (cancer cells) 
and also a rare microphage activation syndrome, which is fulfilled by meeting five 
out of eight criteria (see chaper I, section 1.5.2) (Henter et al. 2007, Schrappe & 
Pieters 2004). Although, this study did not assess these parameters, it could be 
postulated that chelation iron therapy might be appropriate when ferritin levels reach 
>1000 µg/L; however intervention studies should be performed before this therapy is 
implemented.   
4.4.6 Nutritional support 
This longitudinal study aimed to identify the use of nutritional support throughout 
the study period. The results showed a high need for nutritional support (67%) in all 
type of cancers at any time point during the study period; this being most prescribed 
during the intial phases of treatment. OAD (75%; 3/4) and brain tumours (71%; 5/7) 
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had the highest prevalence of nutritional support with ONS being the most 
commonly used, which was  50% (2/4) for OAD and 29% (2/7) for brain tumours. In 
contrast, the solid tumours (54%; 19/35) and the haematological malignancies (64%; 
23/36) required less nutritional prescriptions overall; however there was a higher 
need for NG [ST (26%; 9/35) and HM (19%; 7/36)] and advanced NS [ST (20%; 
7/35) and HM (19%; 7/36)]. This indicates either a greater risk of undernutrition in 
these populations or that they had more severe disease and as a consequence had 
received more intensive treatment. Contrary to these findings, others (Brinksma et al. 
2014, Paciarotti 2013) have reported a lower percentage of nutritional support 
required in paediatric cancer patients of 45% and 44% respectively. This could be 
attributed to the smaller sample size of this study (n=82) in compared to the others 
(n=133 and n=168 respectively). Different nutritional policies could have also 
contributed to the different findings as one study was performed in the Netherlands 
(Brinksma et al. 2014) and the other was retrospective, reflecting past and less 
aggressive nutritional policies which were implemented before the current study was 
performed (Paciarotti 2013).      
Another aim of this study was to identify how many patients classified as 
undernourished or PEM were on nutritional support. Most PEM and undernourished 
patients received some form of nutritional support, however only 33% and 50% PEM 
patients (between 3 to 12 months) and 25% undernourished patients as per BMI (at 6 
months) were on nutritional support. The fact that many PEM patients were not on 
nutritional support is not surprising as these were classified as normal weight, 
overweight or obese using BMI. Furthermore, it has been postulated that standard 
nutritional practices might not be beneficial to this population due to the further 
increase in fat mass instead of the desired muscle mass. Instead, they might benefit 
from higher protein intakes, reduced fat and carbohydrates in combination with 
patient-tailored physical activity (Zhang et al. 2014, Brinksma et al. 2014, Rickard et 
al. 1983). Nonetheless, this remains to be elucidated.           
Future interventional studies investigating the efficacy of nutritional interventions on 
the nutritional status (body size and body composition) of paediatric cancer patients 
are needed. Different physical activity strategies should also be incorporated 
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alongside different amounts of macronutrients, especially protein. This combination 
would allow testing for both optimal protein intakes and different physical activity 
strategies that can either reduce or minimise muscle wasting during cancer treatment 
in this population.  
4.4.7 Nutritional status at diagnosis as a prognostic factor for clinical outcomes 
This study attempted to investigate whether nutritional status (undernutrition, 
overnutrition and obesity) at diagnosis could be used as a prognostic factor for 
clinical outcome, which was either survival or event (relapse, becoming palliative or 
death) of paediatric cancer patients. However, owing to the small sample size, it was 
impossible to perform a multivariate analysis. Instead a series of univariate analyses 
were performed as preliminary analysis of associations. The results suggested that 
undernutrition was significantly associated with an event. Moreover, this group was 
also 14 times more likely to have an event during the course of treatment. 
Interestingly, when severity of disease was also considered, it became apparent that 
most of these undernourished children were also receiving a high treatment risk 
protocol, suggesting that nutritional status is likely to be affected by severity of 
disease and treatment protocol. Therefore, children in high risk treatment protocols 
might be more likely to be undernourished at diagnosis and also to relapse, become 
palliative or to die. Most evidence from low income countries (Viana et al. 1994, 
Sala et al. 2012, Mejía-Arangure et al. 1997) and high income countries (Donaldson 
et al. 1981, Lobato-Mendizábal et al. 1989, Rickard et al. 1983) support these 
findings. Of note, Sala et al. (2012) did not find that undernourished children at 
diagnosis were more likely to relapse. Nonetheless, comparison of these results with 
the published literature needs to be interpreted with caution due to the difference in 
both the population and the available resources in each country (Pritchard-Jones et al. 
2013). For instance, diagnoses in low income countries tend to be delayed due to 
reduced resources. As consequence, children present with more advanced diseases, a 
higher prevalence of undernutrition at diagnosis, which is often accompanied by 
more severe undernutrition, especially those children diagnosed with solid tumours 
(Israels et al. 2010, Israels et al. 2010, Green et al. 2008, Wessels et al. 1999).  
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In contrast, this preliminary analysis of associations suggested that obesity was not 
associated with clinical outcome (event). Comparison of these findings with 
published literature is difficult because the two published studies have investigated 
children diagnosed with ALL only, and both studies reported contradictory results 
(Butturini et al. 2007, Baillargeon et al. 2006). Even if obesity is not associated with 
an event (relapse, becoming palliative and higher mortality), it is essential to reduce 
its prevalence as obese children tend to have higher treatment induced side-effects, 
which often leads to delays in treatment and more admissions to hospital (Butturini et 
al. 2007). Unfortunately, this study did not look at these factors. It should also be 
noted that the results from the current study might have been affected by the 
statistical simplification performed, as “event” included three different clinical 
outcomes (relapse, death or becoming palliative). Undoubtedly, more research is 
needed to clarify whether nutritional status is associated with clinical outcome. This 
would allow paediatric oncologists to have more information to provide optimal 
nutritional treatment and to improve patient’s care and their quality of life during 
treatment.     
4.4.8 Limitations of study   
Like many clinical studies, particularly involving paediatric cancer patients, there are 
some limitations which may apply to this study. Due to the nature of this longitudinal 
study, the time constrictions, and the large number of drop outs, the sample size was 
reduced during the later stages of the study. The reasons for the large number of drop 
outs were death, becoming palliative, re-allocation of treatment or missing data due 
to severe treatment induced side-effect.  As a result, a mixed multilevel model to 
identify potential factors that contributed to changes in nutritional status and a 
multilevel growth model, which would have identified statistical signifant changes in 
nutritional status over time, was limited to 18 months instead of 36 months.  
Ideally anthropometry and body composition measurements should always be taken 
at the same time to reduce patients’ individual variability (Norton and Olds 1996, 
Pederson and Gore 1996). This was impossible due to clinical reasons, as the 
resaerchers were limited to already allocated appointments or other medical 
procedures. Furthermore, inaccuracies as a result of the use of sf-BIA are likely to 
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occur because some of the recommended conditions could not be met during the data 
collection period. For instance, it is recommended that patients are fasted and that 
their bladder is emptied prior to the measurement is taken. Also, measurements 
should be taken in the morning or always at the same time to reduced patients’ 
individual variability, which was not always possible.  
The body composition predictive equation used in this study has been developed 
from a healthy children population and then validated and modified accordingly in 
paediatric renal patients (Schaefer et al. 1994a, Schaefer et al. 2000). The authors 
reported good limits of agreement and coefficient of variation (%) with 
measurements obtained from total body potassium; however FFM tended to be 
overestimated by as much as 5.8% (Schaefer et al. 1994a), which could have had 
implications in the results of this study. Nonetheless, the FM% limits of agreement 
obtained from BIA and arm anthropometry were small (+1.2 to -1.0) suggesting 
accuracy of results.  
The assessment of dietary intake using a 24 hour multiple pass recall may have 
underestimated or overestimated intakes in many patients, particularly when 
assessing micronutrient intakes in children who were not enterally or parenterally 
fed. Likewise, plasma vitamins and minerals was not always performed when the 
patients were fasted, which might have led to some unreliable results.      
The reference ranges and cut-off values used to identify malnutrition, PEM and body 
composition in this study carry limitations themselves. It has been reported that 
current UK growth charts identify less undernourished and more obese children 
(SACN/RCPCH 2012) in comparison with the one used in this study (Cole et al. 
1995a). If this were to be the case, this study would have overestimated 
undernutrition and underestimated obesity slightly; however this appears unlikely as 
measurements of TSF identified more undernourished children than BMI, especially 
during the initial phases of treatment. Furthermore, this study used the lowest 
recommended threshold of <2.3
rd
 centile (-2.0 SD) for undernutrition (SACN 2011, 
SACN/RCPCH 2012), which has been widely used in the UK (Reilly et al. 1999, 
Pietsch and Ford 2000); however others recommend more rigorous cut off values 
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(Sala et al. 2012, WHO 1995) that are also able to establish different grades of 
undernutrition (moderate undernutrition <15
th
 centile and severe undernutrition <5
th
 
centile). These thresholds might be more suitable for this paediatric cancer 
population, especially in those diagnosed with severe disease.  
The reference ranges used for arm anthropometry could be argued that are now dated 
(Frisancho 1981, Frisancho 1974); however, it is the only one that offers a full 
reference for children between the ages of 1-18 or 0-18 years (Frisancho 1981, 
Frisancho 1974), instead of only focusing on specific age groups (WHO 2011). Thus 
allowing for more consistency, especially in this longitudinal cohort study where 
measurements have been taken over a long period of time. Finally, different 
reference ranges were used for children between 0-5 years (Fomon et al. 1982) and 
between 5-18 years (Wells et al. 2012). Therefore, inconsistences might have 
occurred in those children who were monitored during this time (4-5 years). 
One of the major limitations of this study was the fact that the assessment of physical 
activity by means of an accelerometer during the treatment phase failed. This study 
showed that this was too challenging for the patients and their families. Future 
studies should attempt to use practical methods such as validated physical activity 
questionnaires, which are less accurate, but have been proved more successful for 
this paediatric oncology population (Brinksma et al. 2014).     
4.5 CONCLUSION  
This study has highlighted that children diagnosed and treated for cancer may be at 
high risk of undernutrition and PEM, particularly during the initial phases of 
treatment, and overnutrition, at later stages. It has also suggested that treatment risk 
may be an important factor contributing to undernutrition during the initial phases of 
treatment and no other clear factors assessed in this study contributed to malnutrition 
at later stages of the disease. This perhaps explains the high need for nutritional 
support seen in this population. Finally, the results emphasised the need for more 
epidemiological and mechanistic research, which investigates the plasma 
micronutrients status of paediatric cancer as many had an abnormal plasma 
micronutrient profile.  
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5.1 INTRODUCTION  
Chapter II, section 2.2 showed that the prevalence of vitamin D deficiency and 
insufficiency in European paediatric cancer patients is 41% and 50% respectively, 
which is higher than that of healthy children and paediatric cancer patients from 
North America (15% and 46%) and the Middle East (24% and 51%) (Revuelta 
Iniesta et al. 2015b). Despite vitamin D inadequacy (deficiency and insufficiency) 
being an internationally recognised health problem (Ahmed et al. 2011) and  the 
existence of vitamin D supplementation guidelines for children in the UK (RCPCH 
2013, Holick et al. 2011), their implementation remains inconsistent (Pramyothin and 
Holick 2012).    
As it has previously been discussed vitamin D is essential to allow optimal calcium 
homeostasis, and thus adequate growth and skeletal development in children (Holick 
et al. 2011). A potential role in lowering blood pressure, the risk of developing 
Diabetes Mellitus (Holick 2010) and a role in cancer prevention have also been 
reported (Holick and Chen 2008). Vitamin D is primarily absorbed from sunlight, but 
it can also be obtained from the diet. However, very few foods contain naturally 
occurring vitamin D (Holick 2006), and in the UK where fortification is 
discretionary, foods are rarely fortified with vitamin D (SACN 2007). Therefore, in 
high latitude countries, like Scotland, where UV-B rays are insufficient during the 
winter months (October to April) (SANC 2007), populations are at an increased risk 
of vitamin D deficiency and insufficiency. Other factors contributing to vitamin D 
inadequacy in healthy children have been attributed to skin pigmentation, obesity and 
age (infants and adolescents) (RCPCH 2013, Holick 2006).  
Children diagnosed and treated for cancer tend to experience multiple side-effects, 
which might affect plasma 25(OH) D. These include phototoxicity, which requires 
children to avoid direct sunlight, malabsorption and reduced dietary intake 
(Oeffinger et al. 2006a), and hepatotoxicity and nephrotoxicity both of which may 
interfere with the activation of vitamin D (Zhou et al. 2006). Prolonged periods of 
vitamin D inadequacy in children increases the risk of bone fractures, rickets and of 
slow growth (Herbst et al. 2006), with a subsequent increased risk of osteoporosis in 
later life (Oeffinger et al. 2006b). Most children and adolescents treated for cancer 
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now survive into adulthood (Wallace et al. 2013); however they have an increased 
risk of developing the metabolic syndrome, cardiac complications and have a 
reduced peak bone mass, as well as developing secondary malignancies as a 
consequences of treatment (Wallace et al. 2013). Despite the emerging evidence of 
the importance of vitamin D on health, the high reported prevalence of vitamin D 
inadequacy in Europe and the recent call for high-quality population-based 
longitudinal cohort studies, there are few published studies in the UK and none in 
Scotland, investigating plasma 25 (OH)D levels in paediatric cancer patients 
(Revuelta Iniesta et al. 2015b). To address this clinical question a study with the 
following aims was designed: 
(i) To investigate both plasma 25(OH)D and parathyroid hormone (PTH) levels 
of paediatric cancer patients at different stages of their disease 
(ii) To compare plasma 25(OH)D levels of healthy children with a paediatric 
cancer cohort from Scotland  
(iii) To explore possible factors (age, ethnicity, gender, seasonality, nutritional 
status, diagnosis, treatment and the use of nutritional support) contributing to 
plasma 25(OH) D inadequacy at baseline, 3 and 6 months. 
5.2 METHODS 
5.2.1 Study design, population and time-line 
A prospective cohort study was performed. The eligibility criteria were: (i) children 
aged <18 years; (ii) diagnosed with cancer (ICCC-3) (Steliarova-Foucher et al. 2005)  
or Langerhans Cell Histiocytosis; (iii) diagnosed between Aug-2010 to Jan-2014 (iv) 
attending the South East Scotland regional center for Haematology and Oncology at 
the Royal Hospital for Sick Children (RHSC), Edinburgh or Ninewells Hospital, 
Dundee (Paediatric Oncology Shared Care Unit). The researchers excluded children 
who were treated palliative at the time of diagnosis and stopped monitoring those 
who became palliative during the study period, out of respect for the patients and 
their families. Children were monitored for a maximum period of 3 years and 
measurements were obtained at baseline (newly diagnosed patients), 3, 6, 9 and 12 
months and every 6 months thereafter.  
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Control data were obtained from a case-control study of Vitamin D in children with 
epilepsy compared to controls performed at the same time as this study. Controls 
were randomly recruited from the RHSC Emergency Department and only healthy 
children without acute or chronic conditions were included in the study. Controls 
were seen at baseline and then asked to return six months after to obtain summer and 
winter samples in each. Where controls did not return for their follow up blood 
sampling, additional controls were recruited to obtain the needed number of samples 
for that season. No advice on vitamin D supplementation was provided until after the 
second appointment.  
5.2.2 Demographics and clinical parameters 
Clinical data (diagnosis, treatment protocol, treatment risk (low, medium and high) 
(Kazak et al. 2012) and length of treatment) and demographic data (age, gender, 
ethnicity and socio-economic deprivation) were collected from the medical notes. As 
a proxy marker for socioeconomic deprivation level of individuals, the individual 
residence postcodes was used to assess deprivation level of areas of residence using 
the Standard Index of Multiple Deprivation (SIMD) [The Scottish Government, 
2012]. SIMD is presented as a quintile where “I” denotes the most deprived and “V” 
the least deprived.   
 
The paediatric cancer cohort was grouped according to the wider definition of solid 
tumours, haematological cancers, brain tumours and other associated diagnoses. 
5.2.3 Data collection  
Plasma 25(OH) D, parathyroid hormone (PTH), calcium, phosphate and magnesium 
levels of the paediatric cancer cohort and the controls were measured. For assays 
details see appendix VII. Plasma 25(OH) D from the patients was analysed using the 
liquid chromatography tandem mass spectrometry technique by the Clinical 
Chemistry Department, Royal Infirmary of Glasgow using standard techniques. The 
intermediate coefficient of variation (%) of the latter assay was ≤8.9%. Plasma 
25(OH) D from the controls was measured in Freeman Laboratoties, Newcastle using 
a competitive immunoassay chemiluminescence technology, which had a coefficient 
of variation (%) of ≤8.1%. All 25(OH)D results were expressed as nmol/L.   
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The analysis of calcium, phosphate and magnesium were all performed in the 
Edinburgh RHSC. The methods and equipment/kits used were the following: calcium 
(Gosling 1986, Kessler and Wolfman 1964), phosphate (Daly and Ertingshausen 
1972) and magnesium (Elin 1987) and Abbott Architect C8000 was used for all of 
them. PTH was analysed in the Edinburgh Royal Infirmary accredited clinical 
laboratory. The method changed in August 2013. The first equipment used was Intact 
PTH Architect system (8K25) and PTH was expressed as pg/ml and the second and 
current one is IMMULITE 2000 Intact PTH SIEMENS (PIEL2KPP-5(19)) and 
results are expressed as pmol/L. All plasma PTH results obtained before August 
2013 were converted from pg/ml to pmol/L. For more detailed on how these 
parameters were measured see appendix VII.  
 
Plasma 25(OH) D levels were classified as summer months (1st of April-30th Sep) or 
winter months (1st Oct-31st Mar). Owing to the reduced number of healthy controls 
at follow up, the mean plasma 25(OH) D results of the summer and winter samples 
were calculated. The single winter or summer sample was used for those who missed 
the follow up appointment. This was then used for statistical analyses. Plasma 
25(OH) D was defined according to the Royal College of Paediatrics and Child 
health (2013); suboptimal (50-75nmol/L), insufficient (25-50nmol/L) and deficient 
(<25nmol/L). Inadequacy was defined as <50nmol/L. The PTH reference value used 
was 1.7-7.5pmol/L (RHSC Edinburgh Clinical Chemistry Laboratory Handbook 
2014) (appendix V). 
 
Height (or length) and weight were measured using standard procedures by two 
trained researchers (RRI, IP). BMI centile was calculated and UK BMI growth 
centiles were used. Nutritional status was classified as underweight (BMI ≤2.3th 
centile) and overweight (BMI ≥85th) (Cole et al. 1995a). Vitamin D intake was 
assessed by two trained researchers (RRI, IP) using a 24 hour multi-pass recall 
method and consequently analysed in WinDiets® (Univation Ltd 2005) (Wise 2005). 
Information on nutritional treatment and vitamin D supplementation was also 
recorded. Nutritional treatment was prescribed according to Subjective Global 
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assessment by the multidisciplinary team and consisted of enteral +/- parenteral 
nutrition (macronutrient) and micronutrient (vitamin D according to UK RCPCH 
guidelines (RCPCH 2013) or multivitamins), and a combination of macronutrients 
and micronutrients. Therapeutic vitamin D supplementation was stopped once 
patients achieved optimal plasma 25(OH) D levels.    
 
This study was granted ethical approval from NHS Scotland (NHS REC 06-51104-
52) and all patients’ data were anonymised and kept confidential. 
5.2.4 Statistical analyses 
The Statistical Package for Social Science (IBM-SPSS for Windows Statistics, 
version 19, state and country) was employed to analyse all data. Descriptive statistics 
were used to evaluate the prevalence of plasma 25(OH)D inadequacy and 
comparisons between the paediatric cancer cohort and the healthy controls at 
diagnosis were performed using the Mann-Whitney test (aim i); associations between 
plasma 25(OH)D and the following variables; calcium, PTH, BMI centile and age, 
were performed using Spearman’s correlation (aim ii and iii). Univariate associations 
between demographic data and categorical variables were established by χ2-test 
(aims ii and iii). P <0.05 was considered statistically significant. The STROBE 
guidelines for the presentation of the data was followed (www.strobe-statement.org). 
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5.3 RESULTS  
5.3.1 Demographic and clinical characteristics  
A flow diagram of the paediatric cancer cohort is presented in figure 5.1. Thirty-three 
(out of 35) healthy controls and 65 (out of 82) paediatric cancer patients had plasma 
25(OH) D samples available at baseline.  
 
Figure 5.1 Flow chart showing the sample size at different stages of the study period 
 
The demographic and clinical characteristics of the population are presented in table 
5.1 and table 5.2. Gender, ethnicity and socioeconomic status as well as age at 
diagnosis did not statistically differ between the controls and the paediatric cancer 
cohort. BMI centiles were significantly lower in the paediatric cancer cohort. 
Twenty-four treatment protocols were used to treat the paediatric cancer cohort, the 
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median (IQR) time follow up was 312 (123.5-653.2) days and 22% (n=18) were 
classified as low risk, 37% (n=30) as medium risk and 41.5% (n=34) as high risk. 
The time between diagnosis and baseline measurements was 15.5 (10.0-25.0) days. 
Baseline plasma 25(OH)D of the paediatric cancer cohort did not statistically differ 
from the healthy controls (p=0.7).       
Table 5-1 Characteristics of paediatric cancer patients and the healthy controls   
 
ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; CML: chronic myeloid 
leukaemia; HLH: haemophagocytic lymphohistiocytosis; LCH: Langerham’s cell Histiocytosis; CNS: 
central nervous system; 
1
Mann-Whitney test; 
2
chi square-test. 
Baseline characteristics Paediatric cancer 
cohort 
Controls P 
value 
Total sample (n) 82 35  
Age median (IQR) 3.9 (1.9-8.8) 6.2 (4.8-9.1) 0.1
1 
BMI centile median (IQR) 50 (19.0-84.5) 60.5 (43.7-89.5) 0.003
1 
Vitamin D median (IQR) 38.0 (21.0-61.0) 37.5 (23.0-58.0) 0.7
1 
 n % n %  
Gender      0.5
2 
   male  46 56.1 17 48.6  
   female 36 43.9 18 51.4  
Ethnicity      0.6
2 
   White  80 97.6 33 94.3  
   Non-white 2 2.4 2 5.7  
SES     0.06
2 
   I 15 18.3 3 8.6  
   II 13 15.8 8 22.9  
   III 15 18.3 5 14.3  
   IV 24 29.3 5 14.3  
   V 15 18.3 14 40.0  
Haematological malignancies 35 43 - - 
 
   ALL 29 35    
   AML 3 4    
   CML  2 2    
   HLH 1 1    
Solid tumours 39 47    
  Lymphomas 10 12    
  Neuroblastoma 6 7 - -  
  Retinoblastoma 2 2 - -  
  Renal tumours  6 7 - -  
  Hepatic tumours 1 1 - -  
  Malignant bone tumours 4 5 - -  
  Soft tissue sarcoma 5 6 - -  
  Germ cell tumours 1 1 - -  
  Malignant epithelial neoplasm  4 5 - -  
  Others unspecified malignancy 0 0 - -  
Other associated diagnoses-LCH 3 4 - -  
Brain tumours-CNS tumours 5 6    
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Table 5-2 Plasma 25(OH)D levels of the controls and the paediatric cancer cohort 
 
ST: Solid tumours; HM: Haematological malignancies; BT: Brain tumours; OAD: other associated-
diagnoses; 
1χ2-test; 2Fisher’s Exact test.   
 
5.3.2 Plasma 25(OH)D levels 
At baseline, of the 82 paediatric cancer patients, 17 (21%) did not have plasma 
25(OH)D available due to clinical reasons (figure 5.1), 34 (41%) were summer and 
31 (38%) were winter samples. There was no statistical significant difference [U 
(453); p=0.3] between the summer (median 39.0, IQR 30.0-62.0) and winter (median 
36, IQR 16.0-61.0) plasma 25(OH)D levels of the paediatric cancer cohort at 
baseline and throughout the study period, apart from the 3 month follow up (figure 
6.2). Of the 35 controls, 17 (49%) were winter only samples, 10 (28%) summer only 
samples and 6 (17%) provided repeated samples (winter and summer). Two (6%) 
samples were never returned due to laboratory issues. There was a statistically 
significant difference [U (42.5); p=0.003)] between winter (median 26.0, IQR 18.0-
46.5) and summer plasma 25(OH)D (nmol/L) (median 56.5, IQR 45.5-78.0) levels in 
the control group.  
  
N Median (IQR) Deficient 
N (%) 
Insufficient 
N (%) 
Suboptimal 
N (%) 
Optimal  
N (%) 
P 
value 
co
n
tr
o
ls
 
  
 
n=35 
 
37.5 
 (23.0-58.0) 
 
8 (22.8) 
 
14 (40.0) 
 
6 (17.1%) 
 
5 (14.3) 
 
0.06
1 
P
a
ed
ia
tr
ic
 c
a
n
ce
r 
C
a
se
s  
n=65 
 
38.0  
(21.0-61.0) 
 
19 (29.2) 
 
23 (35.4) 
 
16 (24.6) 
 
7 (10.8) 
0.01
1 
D
ia
g
n
o
st
ic
 g
ro
u
p
 ST n=32 35.0  
(16.0-60.0) 
12 (37.5) 10 (31.2) 8 (25.0) 2 (6.25) 0.02
1 
HM n=26 38.0  
(27.7-52.2) 
5 (19.2) 12 (46.1) 6 (23.1) 3 (11.5) 0.04
1 
BT n=5 69  
(14.5-75.5) 
2 (40.0) 0 2 (40.0) 1 (20.0) - 
OAD n=2 80 0 0 1 (50.0) 1 (50.0) - 
N
u
tr
it
io
n
 
S
u
p
p
o
rt
 
None n=44 34.0(20.2-
52.7) 
16 (36.4) 15 (34.1) 11 (25.0) 3 (6.9) 0.006
1 
Macronutrients 
n=14 
43.0(29.2-
75.7) 
2 (14.3) 6 (42.8) 3 (21.4) 3 (21.4) 0.8
2 
Micronutrients 
n=7 
71.0(41.0-
97.0) 
1 (14.3) 1 (14.3) 3 (42.9) 2 (28.6) 0.9
2 
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Figure 5.2. Plasma 25(OH)D with data stratified according to type of nutritional 
support (left) and by seasonal variation (right) 
 
Figure 5.3 Plasma 25(OH)D levels (left) and prevalence of 25(OH)D deficiency and 
insufficiency (right) at different stages of the study period 
 
The prevalence of plasma 25(OH)D inadequacy (deficiency and insufficiency) was 
64% (42/65) in paediatric cancer patients and 63% (22/35) in healthy children at 
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baseline. However, there was a higher prevalence of plasma 25(OH)D deficiency in 
paediatric cancer patients (n=19; 29%) in comparison with healthy children (n=8; 
22%). In the paediatric cancer cohort, the prevalence of plasma 25(OH)D inadequacy 
ranged between 33-50% throughout the study period and did not significantly change 
at any stage (figure 5.3). Stratification of the data by type of tumour showed that 
patients with solid tumours had the highest prevalence of 25(OH)D inadequacy 
(34%) followed by haematological malignancies (26%), both at baseline (table 5.2) 
and during the course of treatment (table 5.3). 
Table 5-3 Prevalence of plasma 25(OH)D inadequacy with data stratified by 
diagnostic criteria  
Deficiency: <25µmol/L; Insufficiency: 25-50µmol/L; suboptimal: 50-75µmol/L; 
1
OAD: other 
associated diagnoses. 
 
Nutritional support was prescribed to 26% (21/82) of paediatric cancer patients at 
baseline. Of those on nutritional support, 14/82 (17%) were on macronutrient (enteral 
+/- parenteral nutrition), and 7/82 (8%) were receiving both macronutrient and 
micronutrient. The median (IQR) time between the start of nutritional support and 
Time line  Plasma 
25(OH)D 
levels 
Solid 
tumours 
Haematological 
malignancies  
Brain 
tumours 
OAD
1 
  N=32  100% N=26 100% N=5 100% N=2 100% 
Baseline Deficiency  12 37.5 5 19.2 2 40.0 0 0 
 Insufficiency  10 31.3 12 46.2 0 0 0 0 
 Suboptimal  8 25.0 6 23.1 2 40.0 1 50.0 
  N=28 100% N=25 100% N=7 100% N=2 100% 
3 months Deficiency 1 3.6 5 20.0 0 0 1 33.3 
 Insufficiency  10 35.7 7 28.0 0 0 0 0 
 Suboptimal  7 25.0 9 36.0 1 14.3 0 0 
  N=14 100% N=15 100% N=2 100% N=3 100% 
6 months Deficiency 1 7.1 2 13.3 0 0 0 0 
 Insufficiency  5 35.7 1 6.7 1 50.0 0 0 
 Suboptimal  2 14.3 7 46.7 0 0 2 100 
  N=6 100% N=13 100% N=3 100% N=2 100% 
12 months Deficiency 1 16.7 2 15.4 0 0 0 0 
 Insufficiency  4 66.7 4 30.8 1 33.3 0 0 
 Suboptimal  1 16.7 3 23.1 1 33.3 2 100 
  N=4 100% N=12 100% N=1 100% N=1 100% 
18 months Deficiency 0 0 2 16.7 0 0 1 100 
 Insufficiency  2 50.0 4 33.3 0 0 0 0 
 Suboptimal  1 25.0 4 33.3 1 100 0 0 
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baseline was 8 (0-23) days. Eighty percent (66/82) of paediatric cancer patients 
received one or more forms of nutritional support for several days or weeks during 
the study period. Of these, 39/82 received macronutrient supplementation only, 
which provided between 0.7µg (28IU) vitamin D/100 Kcal to 1.9µg (76IU) vitamin 
D/100 Kcal, 48/82 (58%) received both micronutrient and macronutrient 
supplementation containing vitamin D, which provided between 10µg/day (400IU) to 
500µg (20.000IU) single dose of vitamin D, and 21/82 (26%) received macronutrient 
only and micronutrient (+/- macronutrient) supplementation at different times. The 
median (IQR) vitamin D intake from diet alone was 1.2 (0.3-2.4) µg. 
Figure 5.2 shows that paediatric cancer patients who were not supplemented had the 
lowest plasma 25(OH)D throughout the study period. The prevalence of plasma 
25(OH)D inadequacy with data stratified by type of nutritional support and at 
different stages of the disease and treatment is presented in table 5.4. This was 
highest in those children who did not receive supplementation with median (IQR) 
ranging from 32.0 (21.0-46.5) nmol/L at 18 months to 45.0 (28.0-64.5) nmol/L at 24 
months. In contrast, paediatric cancer patients supplemented with micronutrient (+/- 
macronutrient) followed by macronutrient alone had the lowest prevalence of plasma 
25(OH)D inadequacy and the highest plasma 25(OH)D at most stages of the disease; 
the median (IQR) plasma 25(OH)D ranged from 63.0 (42.7-128.5) nmol/L at 6 
months to 83.0 nmol/L at 36 months and from 43.0 (29.2-75.7) nmol/L at baseline to 
79.0 (49.0-93.0) nmol/L at 6 months. Importantly, a considerable number of patients 
in the macronutrient subgroup had already received micronutrient supplementation. 
Of the 7 patients who were on macronutrient support at 6 months, all of them had 
already received micronutrient supplementation previously. Likewise, 2/5 (40%) 
patients on macronutrient support at 12 months and 1/2 (50%) patients at 18 months 
had received micronutrient supplementation in the previous follow up. Moreover, 
micronutrient supplementation was significantly associated with lower prevalence of 
plasma 25(OH)D inadequacy (Fisher’s Exact test; p=0.04; RR 0.27; 95% CI 0.04-
1.8) at 6 months. Three patients reached plasma 25(OH)D toxicity levels (>170 
nmol/L) following high dose (500 µg/day) of vitamin D.       
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Plasma 25(OH)D did not significantly correlate with plasma calcium, phosphate, 
magnesium and PTH at any stage in the paediatric cancer cohort, however there was 
a significant correlation between PTH and plasma 25(OH)D levels [r=0.6 (strong); 
p<0.001] in the healthy controls. Table 6.5 shows PTH levels stratified by plasma 
25(OH)D status at different stages of the disease.     
5.3.3 Factors contributing to 25(OH)D inadequacy levels at baseline and during 
treatment 
Age was significantly correlated with plasma 25(OH)D levels in paediatric cancer 
patients [R=-0.46 (moderate and negative); p<0.001], only at baseline, and in healthy 
children [R=-0.42 (moderate and negative); p<0.02], whereby older children had 
lower plasma 25(OH)D levels. Although, BMI centile was not significantly 
correlated with plasma 25(OH)D levels in the paediatric cancer cohort at baseline 
[R=-0.2 (weak and negative); p=0.08], 3 months [r=-0.2 (weak and negative); p=0.2] 
and 6 months [r=-0.2 (weak and negative); p=0.3], and in the healthy control [R=-0.3 
(weak and negative); p=0.3], overnourished paediatric cancer patients were 
significantly more likely to have higher prevalence of plasma 25(OH)D inadequacy 
[χ2-test(8.3); df(1); p=0.005; RR 3.1; 95% CI 1.4-14.0] at 3 months than healthy and 
undernourished children with cancer, regardless of whether the patients were on 
nutritional supplementation. Non-supplemented children were more likely to be 
deficient or insufficient (RR 4.3; 95% CI 1.1-4.7) at 6 months (Fisher’s Exact test; 
p=0.04) in comparison with those who were supplemented with micronutrients.    
None of the following categorical variables were significantly associated with 
plasma 25(OH)D status and paediatric cancer patients at any stage; treatment risk, 
diagnostic criteria, ethnicity and gender.     
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Table 5-4 Plasma 25(OH)D levels stratified by type of nutritional support   
Deficiency:  <25nmol/L; Insufficiency: 25-50nmol/L Suboptimal: 50-75nmol/L; Optimal: >75 
<170nmol/L; 
 *
n=2 vitamin D > 170nmol/L; **n=1 vitamin D >170nmol/L 
 
Time 
line  
Nutritional 
support 
 Deficiency  Insufficiency  Suboptimal  
 
Optimal  
 
Median (IQR) 
  N N  % N % N % N %  
Baseline None 44 16 25 15 23 11 17 2 3 34.0(20.2-52.7) 
N=65 Macronutrients 14 2 3 6 9 3 5 3 5 43.0(29.2-75.7) 
 Micronutrients+/- 
macronutrients 
7 1 1 1 1 3 5 2  3 71.0(41.0-97.0) 
3 
months 
None 25 4 7 11 20 6 11 4 7 45.0(32.0-56.0) 
N=55 Macronutrients 9 1 2 1 2 4 7 3 5 67.0(48.0-76.5) 
 Micronutrients+/- 
macronutrients
* 
20 1 2 6 11 7 13 6 11 67.5(38.0-87.7) 
6 
months 
None 9 3 9 2 6 4 12 0 0 45.0(16.5-68.0) 
N=34 Macronutrients 7 0 0 2 6 1 3 4 12 79.0(49.0-93.0) 
 Micronutrients+/- 
macronutrients 
18 1 3 3 9 4 12 10 29 78.0(49.2-
134.5) 
9 
months 
None 16 1 3 7 23 6 20 2 7 45.0(31.0-61.0) 
N=30 Macronutrients 8 1 3 2 7 2 7 3 10 59.0(35.5-
84.25) 
 Micronutrients+/- 
macronutrients 
6 0 0 0  2 7 4 13 77.5(66.5-
101.0) 
12 
months 
None 11 3 12 4 17 1 4 3 12 36.0(24.5-79.0) 
N=24 Macronutrients 5 0 0 1 4 4 17 0 0 63.0(51.0-63.0 ) 
 Micronutrients+/- 
macronutrients 
8 0 0 0 0 5 21 3 12 63.0(57.0-
128.5) 
18 
months 
None 12 3 17 7 39 2 11 0 0 32.0(21-46.5) 
N=18 Macronutrients 2 0 0 0 0 1 6 1 6 67.5(56.0- ) 
 Micronutrients+/- 
macronutrients
 ** 
3 0 0 0 0 3 17 0 0 64.0(42.7-
134.0) 
24 
months 
None 5 1 8 2 17 2 17 0 0 45.0 (28.0-64.5) 
N=12 Macronutrients 0 0 0 0 0 0 0 0 0  
 Micronutrients+/- 
macronutrients 
7 2 17 1 8 0 0 4 33 67.0(23.7-
106.2) 
30 
months 
None 3 1 17 2 33 0 0 0 0 35.0(13.0- ) 
N=6 Macronutrients 1 0 0 0 0 1 17 0 0 67.0 
 Micronutrients+/- 
macronutrients 
2  0 0 0 1 17 1 17 82.0(68.0- ) 
36 
months 
None 1 0 0 0 0 1 33 0 0 72.5(59.0- ) 
N=3 Macronutrients 0 0 0 0 0 0 0 0 0  
 Micronutrients+/- 
macronutrients 
1 0 0 0 0 0 0 1 33 83.0 
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Table 5-5 Pathyroid hormone levels and status with data stratified by plasma 25(OH)D status   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PTH reference range; 1.7-7.5 pg/ml 
 
 
Time line  Plasma 
25(OH)D 
levels 
Deficiency  
<25nmol/L 
Insufficiency  
25-50nmol/L 
Suboptimal  
50-75nmol/L 
Optimal  
>75 <175nmol/L 
  N  % Median 
(IQR) 
N % Median 
(IQR) 
N % Median 
(IQR) 
N % Median 
(IQR) 
Baseline ↓PTH  1 5.9 3.2   
(2.4-7.3) 
1 5 3.3      
(2.6-4.3) 
3 17.6 4.0   
(1.9-5.1) 
1 16.7 2.6   
(2.0-4.1) N=60 Normal PTH 13  18 90 12 70.6 5 83.3 
 ↑PTH 3  1 5 2 11.8 0  
3 months ↓PTH  0 0 3.2   
(1.7-4.6) 
2 13.3 2.9       
(1.9-4.2) 
0  2.8    
(2.3-3.6) 
3 20 2.6    
(1.9-5.9) N=49 Normal PTH 6 100 12 8.0 13 100 10 66.6 
 ↑PTH 0 0 1 6.7 0  2 13.3 
6 months ↓PTH 0  2.7   
(2.7-3.5) 
0  3.2      
(2.5-4.9) 
0  2.6   
(2.0-5.3) 
4 28.6 2.1    
(1.3-4.0) N=34 Normal PTH 4 100 7 100 8 88.9 9 64.3 
 ↑PTH 0  0  1 11.1 1 7.1 
12 months ↑PTH 0  6.7   
(2.6- ) 
1 20 3.5      
(1.6-4.8) 
0  3.2   
(2.1-5.7) 
2 33.3 3.0   
(1.3-6.5) N=21 ↓PTH  2 66.7 4 80 8 80 3 50.0 
 Normal PTH 1 33.3 0  2 20 1 16.7 
18 months ↓PTH  1 33.3 5.0   
(0.9- ) 
0  7.7      
(3.5-15.3) 
0  5.3   
(1.7-6.9) 
0  2.5   
(1.7- ) N=16 Normal PTH 1 33.3 3 50.0 5 83.3 2 100 
 ↑PTH 1 33.3 3 50.0 1 16.7 0  
24 months ↓PTH  1 33.3 3.7   
(1.1-4.1) 
0  5.5       
(3.8- ) 
0 0 5.3   
(1.7-6.9) 
0  3.2    
(1.9-8.8) N=12 Normal PTH 2 66.7 2 100 3 100 3 75 
 ↑PTH 0  0  0 0 1 25 
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5.4 DISCUSSION  
This is the first prospective cohort study investigating plasma 25(OH)D levels at 
diagnosis and during treatment in paediatric cancer patients from Scotland. These 
results are novel and importantly show that this cohort had a high prevalence of 
plasma 25(OH)D inadequacy (deficiency and insufficiency) during the whole study 
period. Plasma 25(OH)D levels in paediatric cancer patients and age matched healthy 
controls were similar;  however, unlike healthy controls, the paediatric cancer cohort 
showed no seasonal variation and a higher prevalence of deficiency. Moreover, 
children diagnosed with solid tumours followed by haematological malignancies 
exhibited the lowest plasma 25(OH)D levels and the only effective method to 
achieve optimal plasma 25(OH)D levels was by supplementing with vitamin D. 
Older age was identified as the only statistically significant factor contributing to 
plasma 25(OH)D inadequacy at baseline, and overnutrition and non-supplementation 
during treatment.  
5.4.1 Prevalence of plasma 25(OH)D  
Contrary to findings from a study in neighbouring North England (Sinha et al. 2011), 
this study showed that the overall plasma 25(OH)D levels of newly diagnosed 
paediatric cancer patients and healthy children was comparable. This suggested that 
paediatric cancer patients from Scotland were not at higher risk of plasma 25(OH)D 
inadequacy than healthy children at the time of diagnosis. Nonetheless, the 
prevalence of plasma 25(OH)D deficiency was higher in newly diagnosed paediatric 
cancer patients than in healthy children (29% v 23%) as opposed to insufficiency, 
which was higher in healthy children (40% v 35%). However, these levels are lower 
than those reported in paediatric cancer patients from Europe (Revuelta Iniesta et al. 
2015b). Of note, there was a higher representation of winter samples in the healthy 
controls than the paediatric cancer cohort (30% v 43%), which might have 
contributed to the unexpectedly higher prevalence of vitamin D inadequacy in the 
healthy controls. 
Current UK guidelines on vitamin D are aimed at the healthy children population and 
stipulate that children under the age of 5 years should be supplemented with 7.5-
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10µg/day (300-400 IU) of vitamin D, and those who are receiving vitamin D fortified 
foods do not need extra vitamin D (RCPCH 2013). The current study has clearly 
established that most paediatric cancer patients who were not supplemented were 
either deficient or insufficient, or eventually became deficient as shown by the high 
prevalence of plasma 25(OH)D inadequacy (33-50%) throughout the study period. 
Furthermore, macronutrient supplementation alone prevented plasma 25(OH)D 
inadequacy but patients rarely reached optimal levels, suggesting that macronutrient 
supplementation, which is fortified with vitamin D, did not meet the requirements for 
vitamin D in this population. Finally, vitamin D supplementation taken in the form of 
multivitamins or as therapeutic supplementation was essential to achieve optimal 
25(OH)D levels in all paediatric cancer patients. Remarkably, the present study 
found that older children were at higher risk of plasma 25(OH)D inadequacy at 
baseline and therefore would also require supplementation, which is not stipulated in 
the RCPCH (2013) guidelines. However, it is important to note that three patients on 
high dose (20.000 IU) vitamin D supplementation became toxic. Therefore, this 
study recommends vitamin D supplementation for all paediatric cancer patients, but 
emphasise the need for close monitoring to avoid toxicity.        
Unlike healthy children, this paediatric cancer cohort did not show any seasonal 
variation in plasma 25(OH)D levels, at diagnosis or during treatment. These findings 
are supported by a study performed in survivors of childhood cancer from the USA 
(latitude 34ºN) (Rosen et al. 2013), but contrasts with two studies (Modan-Moses et 
al. 2012, Sinha et al. 2011); one performed in North England (latitude 54.9ºN) during 
and following cancer therapy (Sinha et al. 2011), and the other performed in Israel 
(latitude 31ºN) in paediatric cancer patients during therapy (Modan-Moses et al. 
2012). Therefore, this study hypothesises that paediatric cancer patients from 
Scotland are not exposed to enough sunlight during the summer months, probably 
due to the multiple treatment induce side-effects from the disease and treatment (Sala 
et al. 2004, Revuelta Iniesta et al. 2015a), and that diet alone is not enough to 
replenish plasma 25(OH)D stores.        
Stratification of the data by type of diagnosis revealed results consistent with a recent 
systematic review (Revuelta Iniesta et al. 2015b) and a large study (n=2198) 
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performed in the adult oncology population from USA. Patients diagnosed with solid 
tumours had prevalence of plasma 25(OH)D inadequacy of 71% and 75% 
respectively, the current study showed that children diagnosed with solid tumours 
exhibited the highest prevalence of plasma 25(OH)D inadequacy (69%) at the time 
of diagnosis. However, it also showed a high prevalence of plasma 25(OH)D 
inadequacy in children diagnosed with haematological malignancies (65%) at 
diagnosis, which contrasts with findings from elsewhere (Revuelta Iniesta et al. 
2015b, Simmons et al. 2013). Although others have reported similar prevalence of 
vitamin D inadequacy in children diagnosed with haematological malignancies in 
Canada (Atkinson et al. 1998, Halton et al. 1996), the measured vitamin D was 1,25-
dihydroxyvitamin D, which is not equivalent to plasma 25(OH)D. Children 
diagnosed with brain tumours and OAD had slightly lower prevalence of plasma 
25(OH)D inadequacy at diagnosis and during treatment than other diagnoses; 
however owing to their small sample size, these results have to be interpreted with 
caution. Despite some patients having being supplemented with macronutrients and 
micronutrients, prevalence of 25(OH)D inadequacy remained high throughout the 
course of treatment for both diagnostic criteria; solid tumours and haematological 
malignancies. Once more, this highlights the need for a more rigorous approach by 
health professionals to target patients who are deficient or insufficient and to provide 
appropriate therapeutic supplementation and monitoring at diagnosis and during the 
course of treatment.        
In line with recent evidence (Sinha et al. 2011, Revuelta Iniesta et al. 2015b), the 
present study found a relationship between PTH and plasma 25(OH)D in the healthy 
controls, but not in the paediatric cancer patients. Although, in the healthy 
population, PTH measured alongside plasma 25(OH)D is considered the most 
sensitive physiological measure of plasma 25(OH)D status and bone homeostasis 
(Holick 2009), the present study suggests that there might be other factors 
influencing their relationship. Unfortunately, this study was unable to investigate 
these factors due to the relatively small sample; however it has been attributed to the 
type of cancer and the different forms of treatment, including chemotherapy and 
corticosteroids, which can lead to nephrotoxicity and hepatotoxicity, in turn 
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interfering with the 25(OH)D, 1,25(OH)D and PTH metabolism (Atkinson 2008, 
Zhou et al. 2006). Furthermore, a stronger relationship between plasma PTH and 
25(OH)D develops with age (Greer 2009), which might have affected the results 
from this study, since the healthy controls were slightly older.           
5.4.2 Factors contributing to reduced plasma 25(OH)D levels         
Consistent with results from a recent meta-analysis (Revuelta Iniesta et al. 2015b), 
older age was associated with reduced plasma 25(OH)D levels in paediatric cancer 
patients at baseline. This association was also found in the healthy controls, in line 
with a study performed in healthy children from the USA (Kumar et al. 2009), which 
could reflect the widespread issue of vitamin D. Teenagers tend to eat less vitamin D 
rich foods, especially fortified foods, and spend less time playing outdoors than 
younger children (Rosen et al. 2013). Alongside infancy, puberty is accompanied by 
a rapid period of growth and appropriate plasma 25(OH)D levels are essential to 
allow for optimal growth (Tanner 1990a); thus this population should also be 
targeted. 
Like healthy individuals  (Holick 2006), but contrary to other studies investigating 
factors contributing to plasma 25(OH)D inadequacy in paediatric cancer patients 
(Rosen et al. 2013, Modan-Moses et al. 2012), the results from the present showed 
that overnourished children were more likely to have plasma 25(OH)D inadequacy 
during treatment and this was regardless of nutritional support. An inverse 
relationship between high BMI and plasma 25(OH)D in the healthy population is 
well established (Holick 2006), which has been attributed to a reduction in plasma 
25(OH)D availability due to the sequestration of vitamin D by adipose tissue 
(Wortsman et al. 2000).      
5.4.3 Limitations of the study and future research  
Several limitations related to the methodology of this study have been identified; 
particularly, the reduced sample size at later stages of the study, which precluded 
considering factors associated with plasma 25(OH)D at later stages of treatment. 
Some patients were already on nutritional support at baseline, which could 
potentially have affected plasma 25(OH)D levels. The higher proportion of winter 
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samples in the healthy control may have distorted the high plasma 25(OH)D 
inadequacies reported. The fact that plasma 25(OH)D from the paediatric cancer 
cohort and the controls was analysed using different techniques and in different 
laboratories facilities may have added an extra degree of variability between the 
results obtained. Finally, there were only 2 non-Caucasian patients (dark skin) in 
both groups, which could explain why lower plasma 25(OH)D levels was not 
associated with ethnicity. Future research should ideally include large multicentre 
epidemiological studies that are better able to identify factors contributing to plasma 
25(OH)D inadequacy in the different types of cancer during treatment. Also, 
randomised controls trials in which the effects of vitamin D supplementation on 
clinical outcome, particularly bone mass density, are warranted.     
 
5.5 CONCLUSION  
In conclusion, the current study has highlighted that paediatric cancer patients from 
Scotland have a high prevalence of plasma 25(OH)D inadequacy at diagnosis and 
during treatment and that older age, not being supplemented and being overnourished 
potentially contributes to deficiency and insufficiency. Importantly, this study 
recommends vitamin D supplementation to all paediatric cancer patients given that 
macronutrient supplementation alone prevented further vitamin D inadequacy, but 
rarely produced optimal levels, and high longitudinal inadequacy rates continued 
throughout the study. 
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CHAPTER VI 
 
6. ASSESSMENT OF ANTIOXIDANTS, OXIDATIVE 
STRESS AND POLYUNSATURATED FATTY 
ACIDS IN PAEDIATRIC CANCER PATIENTS: A 
PROSPECTIVE COHORT PILOT STUDY 
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6.1 INTRODUCTION 
The findings from chapter IV highlighted that children diagnosed and treated for 
cancer were at high risk of undernutrition and protein energy malnutrition during the 
initial phases of treatment; but overnutrition was more prevalent at later stages. 
Children receiving a high treatment risk protocol were at higher risk of 
undernutrition also during the initial phases of treatment and there was a high need 
for nutritional support in this cohort of patients. Moreover, chapter VI showed that 
paediatric cancer patients from Scotland had a high prevalence of plasma 25(OH)D 
inadequacy during treatment and that only vitamin D supplementation produced 
optimal levels.   
At present, there is a great deal of interest in the benefits of antioxidants and 
polyunsaturated fatty acids (PUFA), particularly docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA), in health. A protective role against cardiovascular 
diseases (CVD), neurodegenerative disorders and anti-inflammatory properties has 
been associated with antioxidant intakes (Ladas et al. 2004, Obrenovich et al. 2011), 
whilst DHA and EPA have anti-inflammatory properties, which may protect against 
CVD, cancer and some auto-immune conditions, such as rheumatoid arthritis 
(Lorente-Cebrián et al. 2013).  In clinical practice a nutritional profile consists of 
assessment of growth, routine biochemical and haematological blood tests only. 
However, plasma antioxidant status (TAS), antioxidant capacity (TAC) and markers 
of oxidative stress as well as lipid profile levels may provide a further indicator of 
nutrient adequacy and functional markers (de la Torre Aguilar et al. 2012, 
Kuliszkiewicz-Janus et al. 2008, Gleissman et al. 2011, Ladas et al. 2004).  
Emerging evidence support a protective role of TAS, TAC and PUFA against 
chronic conditions. Also, most children required nutritional support during treatment 
and now survival rates have considerably improved (Wallace et al, 2013). However, 
children with cancer are at a higher risk of developing the metabolic syndrome, 
cardiac complications and developing secondary malignancies due to cancer 
treatments (Wallace et al. 2013). Despite all of this, no study has investigated the 
profile of TAS, TAC and PUFA and whether nutritional support provides appropriate 
lipids and antioxidants in this cohort. Therefore, the aims of this study were:  
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(i) To assess the TAS, TAC and oxidative stress as well as the lipid profile of 
paediatric cancer patients at diagnosis and 6 months into treatment.  
 
(ii) To establish whether there were any differences in TAS, TAC and oxidative 
stress as well as the PUFA profile between baseline and 6 months and between 
the following groups: type of cancer, treatment risk and nutritional support also at 
baseline and 6 months. 
 
(iii) To establish whether there were any associations between antioxidant intakes 
and TAS, TAC and oxidative stress and whether this contributes to clinical 
outcome (event and event free survival). 
 
(iv) To establish whether there were any differences in TAS, TAC and oxidative 
stress as well as polyunsaturated fatty acids between children who are on 
nutritional support and those who were not.   
6.2 METHODS 
6.2.1 Study design, population and time line 
A prospective cohort pilot study was performed. The eligibility criteria were: (i) 
children aged <18 years; (ii) diagnosed with cancer (ICCC-3) (Steliarova-Foucher et 
al, 2005)  or Langerhans Cell Histiocytosis (appendix I); (iii) diagnosed between 
April-2013 to Jan-2014 (iv) attending the South East Scotland regional centre for 
Haematology and Oncology at the RHSC, Edinburgh. The authors excluded children 
who were treated palliatively at the time of diagnosis and stopped monitoring those 
who became palliative during the study period, out of respect for the patients and 
their families. Two measurements were taken at different stages of the disease; one 
in newly diagnosed paediatric cancer patients and the second over a period of 6 
months (±3 months) into treatment. All measurements were taken when the patients 
were followed up for the purpose of the main prospective study, i.e. when all the 
measurements of growth, body composition, dietary intake and plasma nutritional 
screening were performed.     
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6.2.2 Demographics and clinical parameters  
Clinical data (diagnosis, treatment protocol, treatment risk (low, medium and high) 
(Kazak et al. 2012) and length of treatment) and demographic data (age, gender, 
ethnicity and socio-economic deprivation) were collected from the medical notes. As 
a proxy marker for socioeconomic deprivation level of individuals, we used 
individual residence postcodes to assess deprivation level of areas of residence using 
the Standard Index of Multiple Deprivation (SIMD) (The Scottish Government 
2012). SIMD is presented as a quintile where “I” denotes the most deprived and “V” 
the least deprived. The paediatric cancer cohort was grouped according to the wider 
definition of solid tumours, haematological cancers, brain tumours and other 
associated diagnoses. Height (or length) and weight were measured using standard 
procedures (RRI). BMI centile was calculated and UK BMI growth centiles were 
used. Nutritional status was classified as underweight (BMI ≤2.3th centile) and 
overweight (BMI ≥85th) (Cole et al, 1995). 
6.2.3 Blood collection, procedure and analysis of samples 
Vitamins and minerals of interest to assess TAS were the following: vitamin A, E, 
zinc, copper and selenium. Blood collection for the analysis of antioxidant status was 
performed as described in chapter IV, section 4.3.6.    
For the assessment of TAC and oxidative stress left over blood from the syringe was 
placed in a 1.3 ml HEPARIN tube immediately after blood collection. This was then 
kept in a metal flask filled with ice to keep the sample both cold and protected from 
the light until this was processed in the laboratory. The length of time the samples 
remained in the flask varied between 30 minutes and 2 hours. The samples were then 
processed in the Child Life and Health, University of Edinburgh, Laboratory 
facilities. To separate plasma from serum the samples were spun at 1.600ppm and at 
a temperature of 4°C in centrifuge for 15 minutes. The plasma samples were then 
extracted using a pipette and placed into an Eppendorf tube. These were then stored 
immediately at -80°C until they were all analysed for antioxidant capacity and 
oxidative stress at the end of data collection. Antioxidant capacity and oxidative 
stress were both analysed by Foudil Smail in the QMU Biochemistry laboratory 
facilities.  
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- Oxygen Radical Absorbance Capacity (ORAC) Antioxidant Assay   
The method used to analyse TAC was the Oxygen Radical Absorbance Capacity 
(ORAC) Antioxidant Assay (Ou et al. 2001, Girard-Lalancette et al. 2009). ORAC 
assay is based on the oxidation of fluorescein, which is a fluorescent probe, by 
peroxyl radicals via a hydrogen atom mechanism activated by 2,2-azobis-2-methyl-
propanimidamide (AAPH). This oxidation results in a reduction of the fluorescence 
intensity (decay), which can be captured over time, with a fluoremeter. The 
antioxidants present in the blood delay the peroxyl radical oxidation, thus the higher 
the concentration of antioxidants the longer it will take for the decay to take place. 
The TAC is quantified by calculating the net area under the fluorescence curve 
(AUC) generated from the samples. ORAC samples are expressed in µmol of Trolox 
equivalents (TE) per gram (µmol TE/g) (Ou et al. 2001; Girard-Lalancette et al. 
2009). For further methodological details, see appendix VIII  
- Thiobarbituric Acid Reactive Substances (TBARS) assay  
Oxidative stress was analysed measuring Thiobarbituric Acid Reactive Substances 
(TBARS) with a TBARS Assay Kit (Cayman, USA). The TBARS method is used for 
screening and monitoring lipid peroxidation, which is a major indicator of cellular 
injury and, thus an indicator of oxidative stress (Armstrong et al. 1994). This method 
is based on quantification of malondialdehyde (MDA), which is a reactive carbonyl 
compound derived from the effect that unstable polyunsaturated fatty acids have on 
cells (Armstrong et al. 1994, Yaki 1998). The total lipid peroxidation is quantified in 
terms of MDA per µmol.  
At present the ORAC and TBARS assays are the most widely employed methods of 
assessing plasma antioxidant capacity and plasma lipid peroxidation respectively, 
which allowed comparison with published studies. Additionally, both methods were 
affordable and were fairly specific as the within individual runs coefficient of 
variation were 0.9-1.7% for ORAC and 1.8-3.3% for TBARS (Ou et al. 2001, 
Girard-Lalancette et al. 2009, Armstrong and Browne 1994). For full description of 
both ORAC and TBARS methods, see appendix VIII. 
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- Fatty acid methyl esters (FAME) by gas-liquid chromatography 
50µl of blood left from the syringe was dropped into a Guthrie card, which is a 
postcard-sized card with specimen collection paper and left to dry. This was then 
placed in individual foil pockets and stored at -20°C in the Child Life and Health’s 
laboratory, University of Edinburgh. Analyses of DHA, EPA and AA were then 
carried out in the University of Stirling laboratory facilities by their own research 
laboratory assistant team. Blood fatty acids profiles were determined by analysis of 
fatty acid methyl esters (FAME) by gas-liquid chromatography as described by Bell 
et al. (2011) and expressed as a percentage of the total plasma lipid profile. The 
analyses of these samples were performed by Prof Gordon Bell and his laboratory 
team in the Nutrition Analytical Service, Institute of Aquaculture, University of 
Stirling.   
The reference range of lipid peroxidation for both males and females of all ages has 
been established at 1.86-3.94 µmol and it is expressed in terms of MDA (Richard et 
al. 1992, Yagi 1998). Additionally, at present there are only DHA, EPA and AA 
reference ranges specific for Scottish/British adults (Bell et al. 2011), but not for 
children. However, a recent large cross-sectional study performed in 713 healthy 
children, aged 8-11 years from Denmark, and attending a school that was taking part 
in the healthy New Nordic Diet School Meal Study has published baseline plasma 
lipid levels data (Damsgaard et al. 2014). This Danish study used a similar assay 
method (Armstrong et al. 2008) than the one used for the current study (Bell et al. 
2011), making the plasma lipid results comparable. Thus, for the purpose of this 
study these references were used: EPA (0.45-0.77), DHA (2.22-3.76) and AA (7.91-
10.46) for both girls and boys expressed as a percentage of whole blood total fatty 
acids (Damsgaard et al. 2014). Finally, no reference ranges exist for antioxidant 
capacity (ORAC) for either adults or children.      
6.2.4 Dietary intake and nutritional support  
Vitamin A, vitamin E, zinc, copper and selenium intakes were assessed by using a 24 
hour multi-pass recall method (Reilly et al. 2001) and consequently analysed in 
WinDiets® (Univation Ltd 2005) (Wise, 2005). Information on nutritional treatment 
was recorded and this was prescribed according to Subjective Global assessment by 
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the multidisciplinary team and consisted of enteral +/- parenteral nutrition 
(macronutrient), micronutrient supplementation, and a combination of 
macronutrients and micronutrients.  
6.2.5 Statistical analyses 
The Statistical Package for Social Science (IBM-SPSS for Windows Statistics, 
version 19) was employed to analyse all data. Descriptive statistics were used to 
evaluate TAS, TAC, oxidative stress (lipid peroxidation) and lipid profiles (DHA, 
EPA and) at baseline and at 6 months and Wilcoxon-Signed Rank Test was used to 
establish changes from baseline to 6 months in these variables (aim i). Associations 
between TAS (vitamin A, vitamin E/Ch, Zinc, Copper and Selenium), TAC (ORAC) 
and oxidative stress and inflammation (TBARS, ss-CRP) were performed using 
Spearman’s correlation (aim ii); and univariate associations between treatment risk 
and whether or not the patients were on nutritional support were established by χ2-
test (aims ii and iii). Mann-Whitney test was used to establish whether there were 
any differences in TAS, TAC and oxidative stress, and also in fatty acids profiles 
between children who were on nutritional support and those who were not (aim iv). 
Finally Spearman’s correlation were used to established whether there were any 
associations between antioxidant intakes (vitamin A, vitamin E, Zinc, Copper and 
Selenium) and antioxidant status, antioxidant capacity and oxidative stress (aim iv). 
P <0.05 was considered statistically significant. The STROBE guidelines were 
followed for the presentation of the data (www.strobe-statement.org). 
6.2.6 Ethics  
This study used the same population as in “The determinants of nutritional risk in 
paediatric cancer patients”. Thus, there were not changes that impacted on the 
volunteers, but only in the processing and analysis of the blood, no additional ethical 
approval was needed. All patients’ data were anonymised and kept confidential. 
6.3 RESULTS 
6.3.1 Demographic and clinical characteristics  
Plasma samples were collected from 20 paediatric cancer patients to measure TAS, 
TAC (ORAC), oxidative stress (TBARS) and PUFA (DHA, EPA and AA) at 
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baseline. Of these, 16 were also collected at six months and the remaining 4 were not 
available for the following reasons: treatment given outside reach (n=2) and no 
routine bloods performed at the time of the measurements (n=2). The baseline 
demographic and clinical characteristics of the population are presented in table 6.1. 
Twelve different treatment protocols were used to treat this paediatric cancer cohort, 
the median (IQR) time from the time of diagnosis until baseline measurements was 
15.5 (11.0-21.5) days and from baseline to the second measurement at 6 months (+/- 
3 months) was 101 (72.2-160) days. BMI centile expressed as median (IQR) 
increased from [47.5 (18.5-71.2)] at baseline to [54.0 (23.5-73.2)] at 6 months; 
however this was not significant (p=0.7).   
Table 6-1 Demographic and clinical characteristics of the paediatric cancer cohort 
(n=20) at baseline 
 
LCH: Langerham’s cell Histiocytosis; SIMD: Standard Index of Multiple Deprivation 
presented as a quintile where “I” denotes the most deprived and “V” the least deprived.   
Paediatric cancer cohort Median  IQR 
Age at diagnosis (years) 4.2 1.5-8.5 
 n % 
Gender    
   male  10 50 
   Female 10 50 
Ethnicity    
   White  18 90 
   Non-white 2 10 
SIMD   
   I 4 20 
   II 1 5 
   III 4 20 
   IV 8 40 
   V 3 15 
Diagnostic criteria   
   Solid tumours 6 30 
   Haematological malignancies 12 60 
   Brain tumours  
   (low grade  Glioma) 
1 5 
   OAD (LCH) 1 5 
   
Treatment Risk    
   Low risk 7 35 
   Medium risk 5 25 
   High risk 8 40 
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6.3.2 Plasma antioxidants, oxidative stress and PUFA levels of paediatric cancer 
patients  
Changes from baseline to 6 months in plasma TAS, TAC and PUFA levels are 
presented in table 6.2. There were no significant changes in any of the antioxidant 
status parameters measured; vitamin A, vitamin E/Ch, copper, selenium and zinc or 
TAC (ORAC). However, the latter increased from a median (IQR) of 83.0 (71.5-
89.0) at baseline to 90.2 (74.4-97.3) µmol TE/g at 6 months. In contrast, the median 
(IQR) plasma lipid peroxidation significantly decreased from 7.4 (6.2-9.0) at baseline 
to 5.3 (4.5-6.4) µmol/MDA at 6 months (p=0.003) and ss-CRP, although non-
statistically significant, also decreased from 4.0 (1.0-8.0) at baseline to 1.0 (1.0-4.0) 
mg/L at 6 months. Finally, the median (IQR) plasma DHA and AA (expressed as a 
percentage) significantly increased from 1.3 (0.9-1.9) to 1.8 (1.3-2.1) and from 6.0 
(5.4-6.8) to 7.3 (5.5-8.1) respectively, whilst no significant changes were seen in 
either plasma DHA or AA/EPA ratio.       
Vitamin A levels were within the normal range in 76.5% (13/17) of paediatric cancer 
patients at baseline and 94% (15/16) at 6 months, whilst 12% (2/17) had 
hypovitaminosis A at baseline and 6% (1/16) at 6 months. Twelve percent (2/17) of 
patients had hypervitaminosis at baseline and none at 6 months. Vitamin E/Ch levels 
were within the normal range in 94% (16/17) of patients at baseline and in 100% 
(16/16) at 6 months, whilst 6% (1/16) had hypervitaminosis E/Ch at baseline. The 
prevalence of high lipid peroxidation was 95% (19/20) at baseline and 94% (15/16) 
at 6 months (normal range: 1.86-3.94 µmol/MDA) (Yagi 1998, Richard et al. 1992).  
Most paediatric cancer patients had plasma PUFA levels below the reference ranges 
(Damsgaard et al. 2014). The prevalence of paediatric cancer patients with low EPA 
(<0.45% of total whole blood weight) was 70% (14/20) at baseline and 60% (12/16) 
at 6 months. DHA was low (<2.22%) in 95% (19/20) at baseline and in 87.5% 
(14/16) at 6 months, and the ratio AA/EPA was high (>14.59%) in 100% (20/20) of 
patients at baseline and in 75% (12/16) at 6 months. Interestingly, AA was also low 
(<7.91%) in 60% (12/20) and 50% (8/16) of patients at baseline and 6 months 
respectively.   
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Table 6-2. Plasma antioxidants, oxidative stress and PUFA of paediatric cancer 
patients at baseline and 6 months  
AA: Arachidonic acid; CRP: C-reactive protein; DHA: Docosahexaenoic acid; EPA: 
Eicosapentaenoic acid; ORAC: Oxygen Radical Absorbance Capacity; TBARS: Thiobarbituric Acid 
Reactive Substances; 
1
Wilcoxon-Signed Rank Test; 
2
TBARS reference range for human plasma lipid 
peroxidation level is 1.86 -3.94 uM in terms of MDA.  
 
Stratification of the data by treatment risk (figure 6.1 and figure 6.2) showed that 
plasma vitamin A levels were highest in the high treatment risk group in comparison 
with both low and medium treatment risk groups (figure 6.1a), whilst plasma vitamin 
E/Ch did not differ (figure 6.1b) at either baseline or 6 months. Also, plasma lipid 
peroxidation levels (TBARS) of paediatric cancer patients on a high treatment risk 
protocol were higher than those on low and medium treatment risk protocols at both 
time points (figure 6.1c). In contrast, antioxidant capacity (ORAC) did not differ in 
any of the treatment risk groups (figure 6.1d).  
Interestingly, DHA and EPA levels were highest in children treated with high 
treatment risk groups followed by medium and low treatment (figures 6.2a and 6.2b). 
Additionally, AA levels did not differ between any of the groups at baseline and 
were highest in the low treatment group at 6 months. Finally, AA/EPA ratio was 
highest in those treated with low treatment risk protocols in comparison with high 
and medium treatment risk (figure 7.2d).  
Plasma levels  Baseline 6 months         P value
1 
 Median  IQR Median              IQR   
Vitamin A (µmol/L) 0.85 0.7-1.3 1.2 0.87-1.42 0.2 
Vitamin E/Ch (µmol/L) 6.05 4.6-7.0 5.6 4.9-6.8 0.9 
Copper (µmol/L) 16.6 10.9-21.0 16.8 14.1-18.3 1 
Selenium (µmol/L) 0.97 0.8-1.4 0.9 0.8-1.1 0.3 
Zinc (µmol/L) 10.4 8.9-20.2 10.7 9.1-13.0 0.4 
ORAC  (µmol TE/g) 83.0 71.5-89.0 90.2 74.4-97.3 0.3 
TBARS (MDA µmol)
2 7.40 6.20-9.00 5.30 4.50-6.40 0.003 
CRP mg/L 4.0 1.0-8.0 1.0 1.0-4.0 0.1 
EPA (20 5n-3) % 0.4 0.3-0.5 0.4 0.3-0.6 0.6 
DHA (22 6n-3) % 1.3 0.9-1.9 1.8 1.3-2.1 0.001 
AA (20 4n-6) % 6.0 5.4-6.8 7.3 5.5-8.1 0.05 
AA/EPA ratio (%) 17.1 10.5-22.2 18.7 13.3-25.0 0.3 
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Figure 6.1 Plasma antioxidant levels, antioxidant capacity and oxidative stress in 
paediatric cancer patients with data stratified by treatment risk.  
Figure 6.1a (top left) Plasma vitamin A levels; figure 6.1b (top right) Plasma vitamin E/Ch levels; 
figure 6.1c (bottom left) Plasma lipid peroxidation levels (TBARS); 6.1d (bottom right) Plasma 
antioxidant status (ORAC).      
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Figure 6.2 Plasma PUFA levels in paediatric cancer patients with data stratified by 
treatment risk  
Figure 6.2a (top left) Plasma eicosahexanoic acid (EPA) expressed as a percentage; figure 6.1b (top 
right) Plasma decosahexanoic acid (DHA) expressed as a percentage; figure 6.1c (bottom left) Plasma 
arachidonic acid (AA) expressed as a percentage; 6.1d (bottom right) Plasma AA/EPA ratio expressed 
as a percentage. 
 
6.3.3 Associations between plasma antioxidant status and capacity, oxidative 
stress and lipid levels 
Spearman’s correlations were performed to establish whether there were any 
associations between the following variables: TAS, TAC and oxidative stress. The 
antioxidants plasma vitamin A [r=0.04 (very weak); p=0.9 (baseline) and r=0.4 
(moderate); p=0.2 (6 months)] and vitamin E/Ch [r=0.1 (weak); p=0.8 (baseline) and 
r= 0.003 (very weak); p=1 (6 months)] were not significantly associated with 
antioxidant capacity. Likewise, no significant correlation was found between lipid 
peroxidation and antioxidant capacity at baseline [r= -0.4 (moderate); p=0.07] or 6 
months [r=0.05 (very weak); p=0.8]. However, lipid peroxidation correlated with 
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copper [r=-0.9 (very strong); p<0.001] and zinc [r= -0.4 (moderate); p=0.01] at 
baseline. 
Further Spearman’s correlation analyses were performed to establish whether 
oxidative stress was associated PUFA levels and BMI centile. Lipid peroxidation 
(TBARS) did not correlate with any of the following parameters at baseline or 6 
months: plasma DHA [r=0.3 (moderate); p=0.2 (baseline) and r=0.1 (weak); p=0.6 (6 
months)] and EPA [r=0.3; (moderate); p=0.2 (baseline) and r=0.2 (weak); p=0.5 (6 
months)], but it positively correlated with AA levels [r=0.8 (very strong); p<0.001] 
and negatively correlated with BMI centile at [r= -0.5 (moderate); p=0.04] at 
baseline. Finally, only DHA positively correlated with BMI centile [r=0.9 (very 
strong); p<0.001] at baseline.       
6.3.4 Dietary antioxidants and nutritional support  
The median (IQR) antioxidant intakes of paediatric cancer patients at baseline and 6 
months are presented in table 6.3 and Spearman’s correlation between dietary 
antioxidants and corresponding plasma TAS, TAC (ORAC) and oxidative stress 
(TBARS) are presented in table 6.4.  
Table 6-3 Antioxidant intakes of paediatric cancer patients at baseline and 6 months 
          1
Wilcoxon-Signed Rank Test 
 
At baseline, there were 8/20 (40%) patients on nutritional support. Of these, all of 
them (100%) were on macronutrient supplementation; 3/8 (37.5%) were on ONS, 3/8 
(37.5%) on NG feeding and 2/8 (25%) on TPN. At 6 months, 12/16 (75%) patients 
were on nutritional support. Of these 6/12 (50%) were on micronutrient, 4/12 (33%) 
were on macronutrient supplementation only; of which 3/4 (75%) were on either NG 
or PEG feeding and 1/4 (25%) on ONS, and 2/5 (40%) were on complex nutritional 
Antioxidant intakes  Baseline n=20 6 months n=18         P value
1 
 Median  IQR Median              IQR   
Vitamin A (µd/day) 971 971-1732 264 264-820 <0.001 
Vitamin E (mg/day) 8.6 4.0-9.2 14 5.0-13.0 0.7 
Copper (mg/day) 0.7 0.5-0.75 1.7 1.7-1.8 <0.001 
Selenium (µg/day) 41 15-41 28 21-36.5 0.6 
Zinc (mg/day) 6.1 6.1-7.7 8.0 7.5-15.6 <0.001 
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support (NG-feed and TPN). Finally, one patient was on both micronutrient and 
macronutrient supplementation. Three out of 20 (15%) patients were on nutritional 
support at both baseline and 6 months. Of these, 2/3 patients were on macronutrient 
supplementation and 1/3 was on both macronutrient (NG-feeding) and micronutrient 
supplementation. The median (IQR) time the patients were on nutritional support 
was 11.5 (2.2-17.8) days at baseline and 82.5 (55.7-100) days at 6 months.  
 Table 6-4 Correlations between dietary antioxidants and plasma antioxidant levels, 
antioxidant capacity and oxidative stress   
R: correlation coefficient; strength of the relationship: 0.0 to ±0.1 (none); ±0.1 to ±0.3 (weak); ±0.3 to 
±0.5 (moderate); ±0.5 to ±0.7 (strong); ±0.7 to ±1.0 (very strong) (Bland 2000)  
 
Table 6.5 shows that there were no statistically significant differences between 
paediatric cancer patients who were on nutritional support and those who were not at 
either baseline or 6 months in the following parameters measured: TAC (ORAC), 
TAS (vitamins: vitamin A and vitamin E/Ch; minerals: zinc, selenium and copper) 
and oxidative stress (TBARS). Likewise, EPA, DHA and AA/EPA ratio (all 
expressed as percentages) did not statistically differ between these two groups at 
baseline and 6 months.     
 
Dietary 
antioxidants 
Corresponding 
plasma antioxidant  
Antioxidant 
capacity (ORAC) 
Oxidative stress 
(TBARS) 
 Baseline 6 months Baseline 6 months Baseline 6 months 
Vitamin A 
(µg/day) 
r=0.9;  
p<0.001 
r=0.7; 
p=0.001 
r=0.5 
p=0.03 
r=0.9; 
p<0.001 
r=0.7; 
p<0.001 
r=0.5; 
p=0.01 
Vitamin E 
(mg/day) 
r=0.9; 
p<0.001 
r=0.2; 
P=0.6 
r=-0.3; 
p=0.2 
r=0.7; 
p=0.001 
r=-0.7; 
p=0.001 
r=-0.4 
p=0.1 
Copper 
(mg/day) 
r=0.7; 
p=0.01 
r=0.5; 
P=0.02 
r=0.7; 
p=0.008 
r=0.5 
p=0.03 
r=-0.8; 
p<0.001 
r=-0.1; 
p=0.6 
Selenium 
(µg/day) 
r=-0.5; 
p=0.03 
r=0.9; 
p<0.001 
r=-0.3; 
p=0.1 
r=0.8; 
p<0.001 
r=-0.8; 
p<0.001 
r=-0.9; 
p<0.001 
Zinc 
(mg/day) 
r=0.7; 
p<0.001 
r=0.9; 
p<0.001 
r=0.7; 
p<0.001 
r=0.9; 
p=0.001 
r=0.6; 
p=0.003 
r=0.9; 
p<0.001 
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Table 6-5 Plasma antioxidants, oxidative stress and PUFA levels of paediatric cancer patients at baseline and 6 months with data 
stratified by nutritional support. 
 Baseline 
 
6 months 
 NS No NS P value
1 
NS No NS P value
1 
 Median IQR Median IQR  Median IQR Median IQR  
Vitamin A 
(µmol/L) 
1.2 1.0-2.6 0.9 0.7-1.2 0.3 1.0 0.8-1.4 1.4 1.4-1.9 0.2 
Vitamin E/Ch 
(µmol/L) 
8.5 4.4-10.0 6.2 5.6-6.4 1 5.8 5.0-6.8 5.5 4.9-5.6 0.1 
Copper 
(µmol/L) 
16.8 12.9-23.4 14.5 9.4-18.6 0.4 16.8 13.7-19.5 16.3 14.5-17.7 0.9 
Selenium 
(µmol/L) 
0.8 0.6-1.2 12 0.8-1.4 0.2 0.9 0.7-0.9 1.2 0.9-1.5 0.05 
Zinc (µmol/L) 16.6 11.1-26.1 9.9 9.1-18.4 0.3 10.6 9.4-12.5 15.6 7.7-25.4 0.2 
ORAC  (µmol 
TE/g)
 
82.6 78.8-85.3 87.2 71.3-91.9 0.4 84.9 75.5-97.7 90.2 81.1-90.9 0.6 
TBARS 
(MDA µmol)
2 
8.5 6.5-11.2 6.2 5.2-8.0 0.2 5.3 4.5-6.4 5.5 4.3-6.4 1 
CRP mg/L 1.0 1.0-6.0 3 1.0-9.0 0.5 1.0 1.0-3.5 1.0 1.0-4.0 0.9 
EPA (20 5n-3) 
% 
0.4 0.3-0.6 0.4 0.3-0.5 0.9 0.4 0.3-0.6 0.3 0.2-0.5 0.3 
DHA (22 6n-
3) % 
1.4 1.1-1.9 1.3 0.9-1.8 0.8 1.9 1.4-2.2 1.7 1.0-1.9 0.3 
AA (20 4n-6) 
% 
5.8 5.3-6.7 6.2 5.2-7.1 0.5 6.9 5.5-7.9 7.5 5.5-8.9 0.6 
AA/EPA ratio 
(%) 
12.1 9.4-22.5 17.7 12.1-22.7 0.4 18.3 9.0-22.6 19.8 15.3-33.6 0.2 
AA: arachidonic acid; CRP: C-reactive protein; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; ORAC: Oxygen Radical Absorbance Capacity; NS: 
Nutrition support; TBARS: Thiobarbituric Acid Reactive Substances; 
1
Mann-Whitney test.   
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Interestingly, 6/8 paediatric cancer patients classified as high treatment risk were on 
nutritional support at baseline in comparison with 1/6 patients classified as low 
treatment risk and 1/5 as low treatment risk. There was a significant association 
between high treatment risk and whether the patients were on nutritional support at 
baseline (Fisher’s Exact test, p<0.02); however, no significant associations between 
treatment risk and nutritional support were established at 6 months.               
6.4 DISCUSSION  
This is the first prospective cohort pilot study investigating plasma TAS, TAC and 
lipid peroxidation as well as the PUFA’s profile of paediatric cancer patients from 
South East Scotland. The current study has shown that 95% and 94% of paediatric 
cancer patients had lipid peroxidation levels above the reference range at baseline 
and 6 months respectively, and that this cohort was most stressed at baseline despite 
antioxidant status remaining at similar levels. Interestingly, TAC increased slightly 
following 6 months of treatment. Moreover, there was a high percentage of 
paediatric cancer patients with low levels of EPA (70% at baseline and 60% at 6 
months) and DHA (95% at baseline and 87.5% at 6 months) and, high levels of 
AA/EPA ratio (100% at baseline and 60% at 6 months). Although, DHA levels 
improved following 6 months of treatment, AA also increased, whilst EPA remained 
the same. As a consequence the ratio between AA and EPA also increased.  
Children on high treatment risk protocols exhibited the highest lipid peroxidation and 
plasma vitamin A levels during the study period, whilst antioxidant capacity and the 
remaining antioxidants measured (Vitamin E/Ch, copper, zinc and selenium) were 
similar in all treatment risk groups. It was also found that nutritional support did not 
make any difference to plasma TAS, TAC and oxidative stress (lipid peroxidation) in 
this cohort; however vitamin E, selenium and copper intakes significantly 
contributed to higher plasma TAS, higher TAC and lower lipid peroxidation. Finally, 
as no correlations were found between plasma TAS, TAC and oxidative stress, the 
current pilot study rejects the hypothesis that the assessment of all vitamins and 
minerals with antioxidant function are a reliable marker of antioxidant capacity as 
this appears to be affected by some vitamins and minerals with antioxidant function, 
but not others and by oxidative stress instead.                     
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6.4.1 Plasma antioxidant levels, antioxidant capacity and oxidative stress 
The current study showed that none of the plasma antioxidant levels, which included 
vitamin A, vitamin E/Ch, zinc, copper and selenium, significantly changed over the 6 
months study period. The plasma vitamin A and vitamin E/Ch results are in line with 
findings from “the determinants of nutritional risk in paediatric cancer” (chapter IV) 
and have extensively been discussed in regards to other literature in section 4.5.5.1. 
In line with the current results, a study from Brazil in which 45 children diagnosed 
with and treated for ALL reported that neither zinc nor copper significantly changed 
during treatment (Sgarbieri et al. 2006). Likewise, no changes in selenium levels 
were reported in a French study, in which 170 children diagnosed with and treated 
for paediatric cancer were included (Malvy et al. 1997). However, unlike the current 
study, Malvy et al. (1997) reported a significant decrease in zinc levels and 
Pazirandeh et al. (1999) a reduction in selenium levels in children with ALL 
receiving treatment. It is well established that zinc, copper and selenium are acute 
phase reactants and their plasma concentration may change during inflammation 
(Galloway et al. 2000). Plasma zinc and selenium may decrease during inflammation 
(Shenkin 2006). The reason for a reduction in plasma zinc levels has been attributed 
to an increased uptake by the liver to allow zinc to bind to the protein 
matallothionein, which acts as an antioxidant; whilst a fall in plasma selenium 
concentration has been attributed to an increase in capillary escape of selenoprotein 
P, which is the main selenium containing protein in plasma (Shenkin 2006). The 
discrepancies seen between the current study and those published elsewhere (Malvy 
et al. 1997, Pazirandeh et al. 1999, Sgarbieri et al. 2006), could therefore be 
attributed to the timing of measurements as all baseline bloods from the current study 
were collected while the patients were receiving treatment compared with the other 
studies, which were collected at diagnosis, before the treatment had started, thus 
allowing for the changes to occur.  
Contrary to all studies published to date, which have investigated antioxidant 
capacity and oxidative stress using a variety of techniques [antioxidant capacity 
using ORAC (Kennedy et al. 2005) or different techniques (Battisti et al. 2008, 
Mazor et al. 2008, Al-Tonbary et al. 2011, Neyestani et al. 2007, Sentürker et al. 
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1997, Papageorgiou et al. 2005, Protas et al. 2010, Nakagawa 2000), and oxidative 
stress using TBARS (Battisti et al. 2008, Al-Tonbary et al. 2011) or different 
techniques (Sentürker et al. 1997, Protas et al. 2010, Stachowicz-Stencel et al. 2011, 
Caron et al. 2009, Miketova et al. 2005, Stenzel et al. 2010)], the present study found 
that paediatric cancer patients were more stressed and had lower plasma TAC levels 
at baseline, soon after the commencement of treatment, than 6 months into treatment. 
This may reflect that treatment protocols are most intensive during the first 3 months, 
especially in the ALL group, which represented 60% of the total cohort. 
Furthermore, children in the high treatment risk group had higher levels of lipid 
peroxidation, which further confirms that more intensive treatments are associated 
with higher oxidative stress.   
The current study showed that antioxidant intakes contributed to higher plasma TAS 
and TAC, but helped reduced oxidative stress (lipid peroxidation). Also, lower BMI 
centiles were associated with higher oxidative stress, which suggests that both 
undernutrition and reduced antioxidant intake may lead to more cell damage and may 
explain the higher toxicity rates seen in undernourished children as reported 
somewhere else (Sala et al. 2012, Green et al. 2008). Unfortunately, due to the small 
sample size and the short follow up period, the current study was unable to establish 
any associations between TAC, oxidative stress and clinical outcomes, and the short 
and long term implications of reduced TAC and high oxidative stress during the 
treatment phase remain to be elucidated. TAS and TAC have been associated with 
reduced chemotherapy toxicity, delays in treatment and thus days of hospital stay in 
children with ALL (Kennedy et al. 2004a, Kennedy et al. 2005) and in children with 
soft tissue sarcoma and neuroblastoma (Stachowicz-Stencel et al. 2011). However, 
plasma zinc and copper did not correlate with prognosis in children with ALL 
(Sgarbieri et al. 2006). As most evidence agreed that higher oxidative stress is 
associated with poorer clinical outcomes (Al-Tonbary et al. 2011, Caron et al. 2009, 
Stenzel et al. 2010), it is fair to assume that a higher antioxidant intake would reduce 
oxidative stress and be in turn beneficial for this cohort.  
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6.4.2 Plasma PUFA levels  
The present pilot study showed that paediatric cancer patients had low levels of EPA 
and DHA and high levels of AA/EPA ratio. Similar findings have been reported in a 
small cohort of children diagnosed with a CNS tumour (de la Torre Aguilar et al. 
2012) and in adults diagnosed and treated for NHL (Cvetkovic et al. 2010). 
Moreover, the current study showed that children with higher AA levels also had 
higher lipid peroxide levels. AA is not only a precursor of inflammatory markers 
(Lorente-Cebrián et al. 2013), but it is easily oxidised and the main precursor of 
MDA; therefore contributing further to oxidative stress (Rahal et al. 2014). 
Interestingly, plasma copper and zinc concentration negatively correlated with lipid 
peroxidation, and although only plasma copper was statistically significant, this 
study suggest that copper and zinc may have an essential role at reducing oxidative 
stress caused by MDA in this cohort of patients during cancer therapy. Copper and 
zinc are co-factors for the metalloenzyme called superoxide dismutase, which 
dismutase (deo-oxidise) the extremely toxic MDA into the less toxic hydrogen 
peroxide (Rahal et al. 2014).       
Unlike healthy individuals (Lorente-Cebrián et al. 2013, Greene et al. 2011, Calder 
2010, Rahal et al. 2014), this study did not establish that higher levels of whole blood 
EPA% and DHA% were associated with lower plasma lipid peroxide, but they were 
negatively associated with ss-CRP. No studies including paediatric cancer patients 
have investigated this relationship, however such findings have been established in 
adults with chronic conditions such as cancer (van der Meij et al. 2011, Mocellin et 
al. 2013) and cardiovascular diseases (Lorente-Cebrián et al. 2013, Bays et al. 2015). 
In line with the current studies, others have also reported a positive association 
between PUFA levels, particularly DHA, and nutritional status (Silva et al. 2012, 
Finocchiaro et al. 2012).     
6.4.3 Nutritional support  
The TAS, TAC and oxidative stress as well as the PUFA profile (DHA and EPA) of 
paediatric cancer patients on nutritional support and those who were not did not 
statistically differ. Furthermore, children on high treatment risk protocols tended to 
be more nutritionally supplemented than those in low or medium risk treatment 
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protocols. Given that the current study showed a positive relationship between 
antioxidant intakes and plasma TAS, it can be hypothesised that current nutritional 
treatment formulas may not support the needs of paediatric cancer patients, 
especially those receiving intensive treatments. Due to the lack of studies performed 
in the same population, comparison of these results is difficult. However a 
randomised-placebo control trial in which 15 children with active Crohn’s disease 
were treated with exclusively polymeric diet or antioxidant (glutamine) enriched 
polymeric diet found no differences in plasma antioxidant concentration (Akobeng et 
al. 2007), which contrasts with the results from the current study.  
6.4.4 Limitations of the study and future research  
There are several limitations related to the methodology of this study, which may 
have affected the results. An underestimation of the percentage of whole blood EPA 
and DHA as well as an overestimation of AA/EPA ratio may have occurred in this 
study as samples were stored for a period of 3 months to 1 year. A reduction of 9% 
and 4% in EPA and DHA respectively has been reported following 1 month storage 
at -20ºC; whilst AA is a more stable PUFA with no reduction of stability during this 
period of time and also stored at -20ºC (Bell et al. 2011). The reduced sample size 
precluded stratification of the data by diagnostic criteria and to establish associations 
between TAS, TAC, oxidative stress and lipid profile, and clinical outcomes; 
including survival and event. Owing to the nature of this population, the collection of 
fasted samples was impossible, which could potentially have affected both plasma 
antioxidant concentrations and total antioxidant capacity. Moreover, the type of 
nutritional support and the time the patients received it was variable, which once 
more could have affected the results. Antioxidant intake from children who were not 
receiving nutritional support was assessed using a 24-hour dietary recall, which may 
have led to some inaccuracies. Finally, the prevalence of PUFA could have been 
under or overestimated slightly as the reference range used was obtained from 
healthy Danish children aged 8-11 years old.    
Future research should ideally include: (i) larger population based epidemiological 
studies in which the TAS, TAC and oxidative stress of paediatric cancer patients are 
followed up for a longer period of time. Studies should take into consideration 
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treatment induced side-effects, response to therapy and clinical outcome, such as 
relapse, death and survival; (ii) well-designed RCT investigating the effectiveness of 
different forms of supplementation, in which doses of antioxidants are taken are also 
warranted; (iii) Owing to the paucity of evidence and that at present no specific 
micronutrient (including those with antioxidant function) and PUFA requirements 
(including EPA and DHA) have been established for paediatric cancer patients or for 
critically ill individuals (Department of Health 1991), more research is needed to set 
optimal doses for this population.    
6.5 CONCLUSION  
In conclusion, this pilot study has highlighted that paediatric cancer patients from SE 
Scotland have a high prevalence of oxidative stress, which is highest in children 
treated with high risk treatment protocols and during the initial phases of treatment. 
Importantly, nutritional support did not contribute to higher levels of antioxidants 
and did not appear to meet the needs for EPA and DHA of paediatric cancer patients 
during the study period. Nonetheless, larger high-quality population based studies 
and also clinical trials are now justified. This should investigate the effects of 
nutritional support in the short and long term clinical outcome of paediatric cancer 
patients and in order to establish optimal formulas, these should include different 
concentrations of antioxidants and PUFA. 
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7 SUMMARY, CONCLUSIONS AND FUTURE 
RESEARCH DIRECTIONS 
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7.1 SUMMARY AND GENERAL CONCLUSIONS 
The focus of this PhD has been to investigate changes in nutritional status of children 
and young people diagnosed with and treated for cancer. The principal aims have 
focused on the definition and assessment of nutritional status, which has been 
defined as the body’s state in relation to the consumption and utilisation of nutrients 
(BAPEN 2010). A comprehensive assessment of nutritional status includes 
evaluating anthropometry, body composition and biochemical parameters, including 
the assessment of micronutrients status, as well as a clinical and dietary assessment. 
Thus, these concepts have formed the basis of this project and the themes have been 
explored throughout.  
Given the stated aims of the PhD and in order to put the Scottish paediatric cancer 
population in context, the second chapter looked at the worldwide prevalence of 
malnutrition in paediatric cancer patients. It also investigated the effects of both 
under and overnutrition on clinical outcomes in a published systematic review of the 
literature.  The key findings were as follows:  
i. Robust epidemiological data is lacking; rather the heterogeneity of the data 
reporting made it impossible to accurately determine the prevalence of 
malnutrition in paediatric cancer patients.  
ii. Allied to this, the majority of data concerned both children diagnosed with 
ALL and the clinical problem of undernutrition during treatment, with little 
information available about other types of cancer and the problem of 
overnutrition. Most studies investigating obesity concentrated on survivors of 
childhood cancer many years after treatment. Looking at childhood cancer as 
a whole, patients are more likely to be undernourished at diagnosis and 
during the initial phases of treatment and to then become overnourished at the 
end of therapy.  
iii. When data was stratified by type of cancer, this systematic review found that 
children diagnosed with solid tumours exhibited a higher prevalence of 
undernutrition, whilst overnutrition was more common in the haematological 
malignancies, especially ALL.  
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iv. The paucity of evidence and the variability of outcomes measured in different 
studies meant that it was impossible to establish whether nutritional status 
could be used as a prognostic marker for clinical outcome.  
v. It was found that in terms of anthropometry there was a wide variation in the 
criteria and cut off values used by different research groups and clinicians 
when trying to assess nutritional status.  
vi. Many studies failed to make observations at different stages of the disease 
and treatment. Thus the principal recommendations of this systematic review 
are for a consensus to be reached internationally regarding the definitions and 
measurement of nutritional status and then for high-quality population based 
longitudinal cohort studies to be undertaken and better address this clinical 
problem. 
Informed by this review of the literature, this project aimed to prospectively identify 
patterns of change in growth, dietary intake and vitamin and mineral levels in 
paediatric cancer patients from SE Scotland during their course of illness and 
treatment. Alongside this, it investigated the need for nutritional support and whether 
or not clinical and nutritional factors contributed to the development of malnutrition 
in this population.  
The most important findings of this study were that the prevalence of malnutrition 
varied between different types of cancer, treatment risk and at different stages of the 
disease highlighting the complexity and diversity of this population. Firstly, a high 
prevalence of undernutrition was seen during the initial phases of treatment, 
particularly in children diagnosed with solid tumours; whilst an increase in 
overweight and obesity rates, particularly in children diagnosed with brain tumours 
and haematological malignancies, were seen at later stages of the disease and after 
the completion of treatment. Secondly, high treatment risk was the most important 
factor contributing to undernutrition (assessed by BMI) during the first three months 
of treatment, whilst children on low treatment risk protocols were at higher risk of 
becoming overnourished. However, owing to the limited sample size especially 
during the later stages of the study, these results should be interpreted with caution. 
Finally, the preliminary analysis of associations performed in this study found that 
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undernutrition at diagnosis was associated with an adverse event (relapse, becoming 
palliative or dying); however this result must be taken with caution due to the small 
sample siz. Additionally, most children who were undernourished at diagnosis also 
had more severe disease. It must be highlighted that an extra layer of complexity was 
identified in that the assessment of nutritional status differed between the different 
measurements employed. 
The current study also showed that younger children were at higher risk of becoming 
undernourished, whilst older children were at higher risk of becoming overnourished. 
However, malnutrition did not differ between males and females. Poor linear growth 
was most common in children diagnosed with haematological malignancies, which 
has been attributed to the intensive treatments and the increasing use of polytherapy. 
Although, there were signs of catch up growth at two and a half years post-diagnosis, 
the sample size was too small to represent an accurate picture of linear growth at 
later stages.  
One of the most striking findings in this study was the progressive muscle wasting 
witnessed in the initial phases of treatment, which remained until the end of the 
study. This resulted in a relatively high percentage of patients with PEM and the 
concurrent gradual increase in fat mass. As a result some paediatric cancer patients 
became PEM with low fat mass (undernutrition), others PEM with healthy fat mass 
(well-nourished) and some with  high fat mass (overnutrition), however only those 
with PEM and low fat mass were identified as undernourished by using weight (and 
BMI) as the only method of assessment.  These changes in body composition seen in 
this paediatric oncology cohort combined with some of the associated effects of 
cancer and its treatment, which includes oedema, weight of tumour and rapid shifts 
in fluids, highlights the importance of using arm anthropometry and/or BIA 
alongside BMI to assess nutritional status in this population. This would greatly help 
to identify undernutrition, PEM and early signs of obesity and ultimately implement 
appropriate nutritional and physical activity interventions early on. 
Almost 70% of paediatric cancer patients received a form of nutritional support, 
mainly during the initial phases of treatment. Although a higher proportion of 
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children diagnosed with brain tumours and OAD received nutritional support, more 
children diagnosed with solid tumours and haematological malignancies required 
aggressive nutritional treatments, including advanced nutritional support. This was a 
reflection of both greater risk of undernutrition in these populations and that they had 
more severe disease and as a consequence had received more intensive treatment. 
The current study found that total energy intake significantly contributed to 
overnutrition, established by BMI, and total energy intake exceeded total energy 
requirements from nine months onwards. The fact that energy intake exceeded 
energy requirements in most patients regardless of whether they were receiving 
nutritional support and that almost 70% patients received some form of nutritional 
support, highlights the active policies currently in place in the Haematology and 
Oncology ward from both the RHSC of Edinburgh and Ninewells in Dundee at both 
preventing and treating undernutrition. This might also explain the rapid increase in 
BMI, which occurred following an initial decline in those patients who were 
undernourished. However, this study demonstrated that in some patients the recovery 
in BMI was due to an increase in FM rather than FFM, thus masking PEM in some 
patients. Therefore, it appears that current nutritional practices have become very 
successful at reducing undernutrition and its risk. However, the current approach is 
less effective at identifying and tackling overnutrition during treatment. The reason 
for this is multifactorial; (i) understaffing, which may have prevented the team to 
deal with the high nutritional demands of this populations and (ii) clinical 
governance, including lack of protocols, systems and specific clinical guidelines for 
the management of paediatric cancer obesity.    
Even though almost 70% of patients received some form of nutritional support, this 
observational study showed abnormal plasma levels of vitamin A, vitamin B12 and 
folate in a large proportion of paediatric cancer patients during treatment. The 
reasons for hypovitaminosis A were attributed to reduced dietary intake and 
inflammation, whilst hypervitaminosis A was attributed to liver impairment and high 
vitamin A intakes. No clear factors were identified to contribute to abnormal vitamin 
B12 and folate deficiency. Although, the optimal plasma levels of paediatric cancer 
patients is unknown, it appeared that the dietary intake (with or without nutritional 
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support) of this cohort either exceeded or did not meet their vitamin requirements. 
Once more, caution should be taken at interpreting the results from the vitamin and 
mineral intakes of patients who were on diet alone due to unreliability of the 24 hour 
multiple pass method. Consequently, this study proposed that close monitoring of 
plasma micronutrient levels should be implemented in clinical practice by the 
medical and dietetic team.              
With the increasing numbers of children cared for in paediatric services, and the 
often complex medical, psycho-social and nutritional needs of paediatric cancer 
patients, the cost of managing these populations will rise in parallel, especially with 
the provision of a more specialised multidisciplinary team. Although, the provision 
of this cost should be in future agendas, at present shortages in staffing numbers, 
particularly Dietitians, is a reality and indeed the need for a screening tool should be 
a priority. This screening tool should be able to identify and predict early on children 
at risk of short and long term undernutrition and overnutrition, so those who are at 
risk are targeted by a specialist team.        
The second theme of this thesis was to investigate vitamin D levels in paediatric 
cancer patients at different stages of the disease. Firstly, a systematic review that 
investigated worldwide prevalence and possible causes of vitamin D inadequacy in 
this population was performed. The results of this review highlighted once more the 
absence of a universal approach to measuring and defining 25(OH) D status, the 
failure to treat different types of cancer as different diseases and the fact that 
different research groups investigated different variables. Thus the principal 
recommendation of this paper was the urgent need for high-quality population based 
longitudinal cohort studies. Nonetheless, this systematic review highlighted the 
possibility of a high prevalence of vitamin D inadequacy, particularly in European 
paediatric cancer patients, and a meta-analysis showed that older children may be at 
higher risk of becoming 25(OH) D deficient or insufficient.   
As part of this thesis a prospective case-control study investigating plasma 25(OH) D 
levels and factors that may contribute to inadequate levels in paediatric cancer 
patients at different stages of the disease was performed. This study showed that 
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paediatric cancer patients from Scotland are at high risk of becoming 25(OH) D 
deficient or insufficient during the course of treatment. In agreement with the 
systematic review performed as part of this thesis older children were at higher risk 
of 25(OH) D inadequacy at baseline, whilst being overweight and non-supplemented 
contributed to 25(OH) D inadequacy during treatment. Children diagnosed with solid 
tumours followed by haematological malignancies exhibited the lowest plasma 
25(OH) D levels and the only effective method to achieve optimal levels was by 
supplementing with vitamin D. Therefore, this study recommends vitamin D 
supplementation to all paediatric cancer patients given that macronutrient 
supplementation alone prevented further vitamin D inadequacy, but rarely produced 
optimal levels, and high longitudinal inadequacy rates continued throughout the 
study.          
The final chapter of the thesis was the assessment of antioxidant levels, antioxidant 
capacity and oxidative stress as well as the assessment of polyunsaturated fatty acids, 
particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) at 
baseline and following 6 months of treatment. This pilot study showed that paediatric 
cancer patients have high levels of oxidative stress, especially during the initial 
phases of treatment. Antioxidant capacity increased slightly despite antioxidant 
status remaining at similar levels. Therefore, this study rejected the hypothesis that 
the assessment of total antioxidant status was a reliable marker of antioxidant 
capacity. Instead this appeared to be affected by specific antioxidants, such as 
vitamin E, selenium and copper and by oxidative stress. Importantly, this pilot study 
showed that nutritional support did not contribute to higher plasma antioxidant, EPA 
and DHA levels as these were inadequate in most paediatric cancer patients 
throughout the study period.    
7.2 FUTURE DIRECTIONS 
The findings from this PhD have highlighted future areas of research: 
 Owing to the small incidence of paediatric cancer, the physical and 
psychological difficulties that children and their families face and the 
numerous clinical trials, in which they participate, robust multicentre or even 
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international high-quality population based prospective cohort studies in 
which paediatric cancer patients are monitored for a longer period of time are 
warranted. Ideally they should use universally agreed techniques, reference 
values and thresholds tailored to different populations. Importantly, different 
type of cancers should be treated as separate entities and the same approach 
should be applied to the severity of disease. Finally, the factors contributing 
to malnutrition considered in this study, and also physical activity, should be 
investigated. 
 
 Large multi-centre cohort studies are very expensive and often difficult to 
coordinate. Cheaper ways to perform research and ultimately improve the 
nutritional status of paediatric cancer patients is by sharing databases between 
centres. Sharing databases for nutritional research could be achieved by 
implementing appropriate nutritional practices, monitoring and record 
keeping first. However, in order to identify optimal nutritional practices, it is 
fisrt essential to perform nutritional quality improvement projects. For a 
quality improvement project of nutritional practices, nutritional standards 
tailored to paediatric oncology patients should be developed by searching the 
literature, consulting with the specialised multidisciplinary team and auditing 
the nutritional standards against practices. A series of interventions which 
focus on staff training and areas that need improvement should follow the 
audits to achieve optimal nutritional management of this population. 
 
 Future high-quality clinical trials should investigate the effects that different 
nutritional treatments have on the short and long term nutritional status of 
paediatric cancer patients. The interventions should focus on nutritional 
formulas and physical activity strategies. Particular emphasis should be 
placed on protein, PUFA (EPA and DHA) and antioxidant concentrations. 
Ideally, the measurement of nutritional status should incorporate 
measurements of growth, body composition, plasma micronutrient and PUFA 
status as well as a comprehensive clinical assessment.         
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- International Classification of Chiildhood Cancer, 3rd edition (ICCC-3)  
- Intensity of treatment rating scale: classifying the intensity of paediatric 
cancer treatment 
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International Classification of Childhood Cancer, Third 
Edition 
Site Group ICD-O-3 
Histology (Type) 
ICD-O-
2/3 Site 
Recode 
I Leukemias, 
myeloproliferative 
diseases, and 
myelodysplastic 
diseases 
      
(a) Lymphoid leukemias 9820, 9823, 9826, 
9827, 9831-9837, 
9940, 9948 
C000-
C809 
011 
(b) Acute myeloid 
leukemias 
9840, 9861, 9866, 
9867, 9870-9874, 
9891, 9895-9897, 
9910, 9920, 9931 
C000-
C809 
012 
(c) Chronic 
myeloproliferative 
diseases 
9863, 9875, 9876, 
9950, 9960-9964 
C000-
C809 
013 
(d) Myelodysplastic 
syndrome and other 
myeloproliferative 
diseases 
9945, 9946, 9975, 
9980, 9982-9987, 
9989 
C000-
C809 
014 
(e) Unspecified and other 
specified leukemias 
9800, 9801, 9805, 
9860, 9930 
C000-
C809 
015 
II Lymphomas and 
reticuloendothelial 
neoplasms 
      
(a) Hodgkin lymphomas 9650-9655, 9659, 
9661-9665, 9667 
C000-
C809 
021 
(b) Non-Hodgkin 
lymphomas (except 
Burkitt lymphoma) 
9591, 9670, 9671, 
9673, 9675, 9678-
9680, 9684, 9689-
9691, 9695, 9698-
9702, 9705, 9708, 
9709, 9714, 9716-
9719, 9727-9729, 
9731-9734, 9760-
9762, 9764-9769, 
9970 
C000-
C809 
022 
(c) Burkitt lymphoma 9687 C000-
C809 
023 
(d) Miscellaneous 
lymphoreticular 
neoplasms 
9740-9742, 9750, 
9754-9758 
C000-
C809 
024 
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(e) Unspecified 
lymphomas 
9590, 9596 C000-
C809 
025 
III CNS and 
miscellaneous 
intracranial and 
intraspinal neoplasms 
      
(a) Ependymomas and 
choroid plexus tumor 
9383, 9390-9394 C000-
C809 
031 
(b) Astrocytomas 9380 C723 032 
9384, 9400-9411, 
9420, 9421-9424, 
9440-9442 
C000-
C809 
032 
(c) Intracranial and 
intraspinal embryonal 
tumors 
9470-9474, 9480, 
9508 
C000-
C809 
033 
9501-9504 C700-
C729 
033 
(d) Other gliomas 9380 C700-
C722, 
C724-
C729, 
C751, 
C753 
034 
9381, 9382, 9430, 
9444, 9450, 9451, 
9460 
C000-
C809 
034 
(e) Other specified 
intracranial and 
intraspinal neoplasms 
8270-8281, 8300, 
9350-9352, 9360-
9362, 9412, 9413, 
9492, 9493, 9505-
9507, 9530-9539, 
9582 
C000-
C809 
035 
(f) Unspecified 
intracranial and 
intraspinal neoplasms 
8000-8005 C700-
C729, 
C751-
C753 
036 
IV Neuroblastoma and 
other peripheral 
nervous cell tumors 
      
(a) Neuroblastoma and 
ganglioneuroblastoma 
9490, 9500 C000-
C809 
041 
(b) Other peripheral 
nervous cell tumors 
8680-8683, 8690-
8693, 8700, 9520-
9523 
C000-
C809 
042 
9501-9504 C000-
C699, 
C739-
C768, 
042 
360 
 
C809 
V Retinoblastoma 9510-9514 C000-
C809 
050 
VI Renal tumors       
(a) Nephroblastoma and 
other nonepithelial renal 
tumors 
8959, 8960, 8964-
8967 
C000-
C809 
061 
8963, 9364 C649 061 
(b) Renal carcinomas 8010-8041, 8050-
8075, 8082, 8120-
8122, 8130-8141, 
8143, 8155, 8190-
8201, 8210, 8211, 
8221-8231, 8240, 
8241, 8244-8246, 
8260-8263, 8290, 
8310, 8320, 8323, 
8401, 8430, 8440, 
8480-8490, 8504, 
8510, 8550, 8560-
8576 
C649 062 
8311, 8312, 8316-
8319, 8361 
C000-
C809 
062 
(c) Unspecified 
malignant renal tumors 
8000-8005 C649 063 
VII Hepatic tumors       
(a) Hepatoblastoma 8970 C000-
C809 
071 
(b) Hepatic carcinomas 8010-8041, 8050-
8075, 8082, 8120-
8122, 8140, 8141, 
8143, 8155, 8190-
8201, 8210, 8211, 
8230, 8231, 8240, 
8241, 8244-8246, 
8260-8264, 8310, 
8320, 8323, 8401, 
8430, 8440, 8480-
8490, 8504, 8510, 
8550, 8560-8576 
C220, 
C221 
072 
8160-8180 C000-
C809 
072 
(c) Unspecified 
malignant hepatic tumors 
8000-8005 C220, 
C221 
073 
VIII Malignant bone 
tumors 
      
(a) Osteosarcomas 9180-9187, 9191-
9195, 9200 
C400-
C419, 
081 
361 
 
C760-
C768, 
C809 
(b) Chondrosarcomas 9210, 9220, 9240 C400-
C419, 
C760-
C768, 
C809 
082 
9221, 9230, 9241-
9243 
C000-
C809 
082 
(c) Ewing tumor and 
related sarcomas of bone 
9260 C400-
C419, 
C760-
C768, 
C809 
083 
9363-9365 C400-
C419 
083 
(d) Other specified 
malignant bone tumors 
8810, 8811, 8823, 
8830 
C400-
C419 
084 
8812, 9250, 9261, 
9262, 9270-9275, 
9280-9282, 9290, 
9300-9302, 9310-
9312, 9320-9322, 
9330, 9340-9342, 
9370-9372 
C000-
C809 
084 
(e) Unspecified 
malignant bone tumors  
8000-8005, 8800, 
8801, 8803-8805 
C400-
C419 
085 
IX Soft tissue and other 
extraosseous sarcomas 
      
(a)Rhabdomyosarcomas 8900-8905, 8910, 
8912, 8920, 8991 
C000-
C809 
091 
(b) Fibrosarcomas, 
peripheral nerve sheath 
tumors, and other fibrous 
neoplasms 
8810, 8811, 8813-
8815, 8821, 8823, 
8834-8835 
C000-
C399, 
C440-
C768, 
C809 
092 
8820, 8822, 8824-
8827, 9150, 9160, 
9491, 9540-9571, 
9580 
C000-
C809 
092 
(c) Kaposi sarcoma 9140 C000-
C809 
093 
(d) Other specified soft 
tissue sarcomas 
8587, 8710-8713, 
8806, 8831-8833, 
8836, 8840-8842, 
8850-8858, 8860-
C000-
C809 
094 
362 
 
8862, 8870, 8880, 
8881, 8890-8898, 
8921, 8982, 8990, 
9040-9044, 9120-
9125, 9130-9133, 
9135, 9136, 9141, 
9142, 9161, 9170-
9175, 9231, 9251, 
9252, 9373, 9581 
8830 C000-
C399, 
C440-
C768, 
C809 
094 
8963 C000-
C639, 
C659-
C699, 
C739-
C768, 
C809 
094 
9180, 9210, 9220, 
9240 
C490-
C499 
094 
9260 C000-
C399, 
C470-
C759 
094 
9364 C000-
C399, 
C470-
C639, 
C659-
C699, 
C739-
C768, 
C809 
094 
9365 C000-
C399, 
C470-
C639, 
C659-
C768, 
C809 
094 
(e) Unspecified soft 
tissue sarcomas 
8800-8805 C000-
C399, 
C440-
C768, 
095 
363 
 
C809 
X Germ cell tumors, 
trophoblastic tumors, 
and neoplasms of 
gonads 
      
(a) Intracranial and 
intraspinal germ cell 
tumors 
9060-9065, 9070-
9072, 9080-9085, 
9100, 9101 
C700-
C729, 
C751-
C753 
101 
(b) Malignant 
extracranial and 
extragonadal germ cell 
tumors 
9060-9065, 9070-
9072, 9080-9085, 
9100-9105 
C000-
C559, 
C570-
C619, 
C630-
C699, 
C739-
C750, 
C754-
C768, 
C809 
102 
(c) Malignant gonadal 
germ cell tumors 
9060-9065, 9070-
9073, 9080-9085, 
9090, 9091, 9100, 
9101 
C569, 
C620-
C629 
103 
(d) Gonadal carcinomas 8010-8041, 8050-
8075, 8082, 8120-
8122, 8130-8141, 
8143, 8190-8201, 
8210, 8211, 8221-
8241, 8244-8246, 
8260-8263, 8290, 
8310, 8313, 8320, 
8323, 8380-8384, 
8430, 8440, 8480-
8490, 8504, 8510, 
8550, 8560-8573, 
9000, 9014, 9015 
C569, 
C620-
C629 
104 
8441-8444, 8450, 
8451, 8460-8473 
C000-
C809 
104 
(e) Other and unspecified 
malignant gonadal 
tumors 
8590-8671 C000-
C809 
105 
8000-8005 C569, 
C620-
C629 
105 
XI Other malignant 
epithelial neoplasms 
and malignant 
      
364 
 
melanomas 
(a) Adrenocortical 
carcinomas 
8370-8375 C000-
C809 
111 
(b) Thyroid carcinomas 8010-8041, 8050-
8075, 8082, 8120-
8122, 8130-8141, 
8190, 8200, 8201, 
8211, 8230, 8231, 
8244-8246, 8260-
8263, 8290, 8310, 
8320, 8323, 8430, 
8440, 8480, 8481, 
8510, 8560-8573 
C739 112 
8330-8337, 8340-
8347, 8350 
C000-
C809 
112 
(c) Nasopharyngeal 
carcinomas 
8010-8041, 8050-
8075, 8082, 8083, 
8120-8122, 8130-
8141, 8190, 8200, 
8201, 8211, 8230, 
8231, 8244-8246, 
8260-8263, 8290, 
8310, 8320, 8323, 
8430, 8440, 8480, 
8481, 8500-8576 
C110-
C119 
113 
(d) Malignant melanomas 8720-8780, 8790 C000-
C809 
114 
(e) Skin carcinomas 8010-8041, 8050-
8075, 8078, 8082, 
8090-8110, 8140, 
8143, 8147, 8190, 
8200, 8240, 8246, 
8247, 8260, 8310, 
8320, 8323, 8390-
8420, 8430, 8480, 
8542, 8560, 8570-
8573, 8940, 8941 
C440-
C449 
115 
(f) Other and unspecified 
carcinomas 
8010-8084, 8120-
8157, 8190-8264, 
8290, 8310, 8313-
8315, 8320-8325, 
8360, 8380-8384, 
8430-8440, 8452-
8454, 8480-8586, 
8588-8589, 8940, 
8941, 8983, 9000, 
9010-9016, 9020, 
C000-
C109, 
C129-
C218, 
C239-
C399, 
C480-
C488, 
C500-
C559, 
116 
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9030 C570-
C619, 
C630-
C639, 
C659-
C729, 
C750-
C768, 
C809 
XII Other and 
unspecified malignant 
neoplasms 
      
(a) Other specified 
malignant tumors 
8930-8936, 8950, 
8951, 8971-8981, 
9050-9055, 9110 
C000-
C809 
121 
9363 C000-
C399, 
C470-
C759 
121 
(b) Other unspecified 
malignant tumors 
8000-8005 C000-
C218, 
C239-
C399, 
C420-
C559, 
C570-
C619, 
C630-
C639, 
C659-
C699, 
C739-
C750, 
C754-
C809 
122 
Not Classified by ICCC 
or in situ 
    999 
Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of 
Childhood Cancer, Third Edition. Cancer 2005;103:1457-67. 
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Intensity of treatment rating scale: classifying the intensity of 
paediatric cancer treatment 
 
   Intensity of Treatment Rating (ITR-3)        
Directions:  Please review carefully the criteria at the bottom of the page that lists examples 
of diseases and treatment modalities under each of the four levels of intensity. Based on the 
information regarding each patient’s disease and treatment, use the criteria at the bottom of 
this page to circle one number to indicate the intensity of treatment (1, 2, 3, 4).  Make your 
ratings based on the specified criteria, rather than your own clinical judgment.  
 
 
 
 
ID # 
ABSTRACTION INFORMATION  
INTENSITY 
RATING 
Diagnosis,  
including if 
relapsed 
Stage 
or 
Risk 
Level 
Treatment Modalities 
Surgery? Chemo? Radiation
? 
Transplant
? 
   y    n y    n y    n y    n 1      2      3      4 
   y    n y    n y    n y    n 1      2      3      4 
   y    n y    n y    n y    n 1      2      3      4 
   y    n y    n y    n y    n 1      2      3      4 
   y    n y    n y    n y    n 1      2      3      4 
   y    n y    n y    n y    n 1      2      3      4 
   y    n y    n y    n y    n 1      2      3      4 
   y    n y    n y    n y    n 1      2      3      4 
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II. Level 1: Least Intensive Treatments 
Includes the least intensive treatments, for these diseases  
or treatment modalities: 
 Surgery Only – All tumor types except brain tumors 
 Retinoblastoma - Enucleation (unilateral disease)  
    without chemotherapy 
 Wilms’ Tumor (Stages 1, 2) 
 Chronic Myeloid Leukemia - any chemotherapy, 
including tyrosine kinase inhibitors 
 LCH, surgery or steroid injection only 
III. Level 3: Very Intensive Treatments 
Includes very intensive treatments, for these diseases  
or treatment modalities: 
 Relapse Protocols for Hodgkins & Wilms’ Tumor (first relapse) Only 
 Acute Lymphoblastic Leukemia (ALL) (High Risk, Very High Risk, T-
cell) 
 Acute Myeloid Leukemia and Down Syndrome 
 Acute Promyelocytic Leukemia (APL) 
 Biphenotypic leukemia – treated like ALL 
 Brain Tumor - Two or more treatment modalities 
 Carcinoma NOS – Two or more treatment modalities 
 Ewings Sarcoma  
 Hepatoblastoma- With metastatic disease 
 Hemophagocytic lymphohistiocytosis (HLH), chemo alone 
 Hodgkin Lymphoma (Stages 3B or 4/High Risk) 
 Juvenile Mylomonocytic Leukemia (JMML) – Pretransplant/chemo 
only 
 Nasopharyngeal Carcinoma  
 Neuroblastoma/Ganglioneuroblastoma (Stages 3, 4) - Without 
transplant 
 Non-Hodgkin Lymphomas (Group C or Stage 4) 
 Osteosarcoma 
 Rhabdomyosarcoma (Stages 3, 4) 
 Soft Tissue Sarcoma – Two or more treatment modalities 
 Wilms’ Tumor (Stages 3, 4) – Three treatment modalities 
 Tumor, other – 2 or 3 treatment modalities 
IV. Level 2: Moderately Intensive Treatments 
Includes moderately intensive treatments, for these 
diseases  
or treatment modalities: 
 Acute Lymphoblastic Leukemia (Low, Standard, or 
Intermediate Risk; precursor B cell) 
 Brain Tumor - One treatment modality, not including 
biopsy 
 Germ Cell Tumors - With chemotherapy or radiation 
 Hepatoblastoma - With chemotherapy and surgical 
resection, no metastatic disease 
 Hodgkin Lymphoma (Low/Intermediate risk: all stages  
except IIIB, IVB) 
 Langerhans Cell Histiocytosis (LCH) with chemotherapy 
 Neuroblastoma/Ganglioneuroblastoma (Stages 1, 2  
w/chemotherapy and Stage 4S) 
 Non-Hodgkin Lymphoma (Stages 1, 2, 3 and Groups A, 
B) 
 Retinoblastoma - With chemotherapy 
 Rhabdomyosarcoma (Stages 1, 2) 
 Thyroid cancer 
 Tumor, other – either chemo or radiation alone  
 
 
 
 
 
 
***In case of more than one tumor, rate the 
tumor that falls into the highest level.  
V. Level 4: Most Intensive Treatments 
Includes the most intensive treatments, for these diseases  
or treatment modalities: 
 Relapsed  Disease - Excluding Hodgkin Lymphoma, first relapse  
of Wilms’ Tumor, LCH with systemic treatment, or CML with a 
different tyrosine kinase inhibitor 
 Hematopoietic Stem Cell Transplant (HSCT) - All diseases 
 Acute Myeloid Leukemia (AML)  
 Biphenotypic leukemia – treated like AML 
 Juvenile Myleomonocytic Leukemia (JMML) - With transplant 
 Brain tumor – with HSCT 
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APPENDIX II 
- Child Invitation to participate in the study 
- Consent form  
- Moderators email   
- QMU ethical approval 
- Volunteer information sheet 
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CHILD INVITATION TO PARTICIPATE 
 
“Assessment of reliability, validity and precision of anthropometrical 
measurements performed in healthy children” 
 
 
Invitation to take part in the study 
- We would like to ask you for help with our study. 
- We want to make sure that you understand what is all about before you 
decide if you would like to take part 
- Please talk it over with your mum/dad and take time to decide 
 
What is the study about?                     
 
 
 
 
 
 
 
 
 
 
 
 
We would like to measure your weight, height and the thickness of 
your arm to help us prepare for a larger project in which children with 
cancer are involved.  
I would recommend wearing short sleeves on the day to facilitate 
taking the measurements. 
The purpose of this is to help us get our techniques right to obtain better 
results with our measurements. 
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  Will taking part help me? 
 
                  
 
 
 
 
                                                                                                                 
  
 
 
 
 
 
 
 
 
 
 
 
 
Taking 
part 
will 
not 
hurt 
you 
Will it 
hurt me? 
Only the researchers 
involved in the study as 
we will not tell anyone 
else about your 
measurements 
Will anybody 
know about 
my 
measurements
? 
Taking part might not help you but you will help the 
researchers, Ilenia and Raquel, to improve their 
techniques.  
It will also help many children with cancer. 
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Do I have to take part? 
 
 
If you have questions you can speak with: 
Raquel Revuelta Iniesta                           rrevueltainiesta@qmu.ac.uk  
Ilenia Paciarotti                                       ipaciarotti@qmu.ac.uk    
Dr Jane McKenzie                                  jmckenzie@qmu.ac.uk      
Independent advisor (Dr Iain Gow)       igow@qmu.ac.uk   
 
 
 
 
 
 
 
 
 
 
 
 
No, this is up to you! 
If you don’t take part don’t worry, that is fine 
If you take part but change your mind later on. That is 
also fine. Just let us know 
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CONSENT FORM 
 
“Assessment of reliability, validity and precision of 
anthropometrical measurements performed in healthy children” 
 
 
I confirm that I have read and understood the information sheet for the above study, 
that I have had the chance to ask questions, and that I have received satisfactory 
answers to the asked questions. 
 
 
I understand that my/my child’s participation is voluntary and that I am free to 
withdraw myself/my child at any time, without giving any reason 
 
 
I agree to have my child take part in the above study 
 
 
 
 
 
Name of parent/carer                                  Date                               Signature 
 
 
 
 
Name of child/adolescent                          Date                              Signature    
(If considered appropriate) 
 
 
 
 
Name of researcher                                    Date                               Signature  
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To all parents/carers who have healthy children under the age of 18:  
Do you want to know your children’s nutritional status? 
 
We are two PhD’s students; Raquel Revuelta Iniesta and Ilenia Paciarotti, both from Queen 
Margaret University, under the supervision of Dr. Jane McKenzie currently undertaking a 
project in the Royal Hospital of Sick Children and we need your help. We are investigating 
how cancer and its treatment affect nutritional status in this population group and for that we 
need to optimise our skills on how to assess this.  
The measurements that we will take are the following: 
- Weight and height 
- Middle upper arm circumference 
- Triceps skinfold 
We are looking for healthy children and young adults aged between 2 and 18.  
If you would like to find out more, please contact: 
If you or your child wish to participate or would like more information, please contact: 
Raquel Revuelta Iniesta:  rrevueltainiesta@qmu.ac.uk  
Ilenia Paciarotti:               ipaciarotti@qmu.ac.uk  
 
This project has ethical approval. 
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Raquel Revuelta Iniesta 
PhD student 
Dietetics, Nutrition and Biological Sciences 
Queen Margaret University 
 
Sheila Adamson 
Collaborations Development Co-ordinator 
Queen Margaret University, Edinburgh  
Queen Margaret University Drive 
Musselburgh 
East Lothian EH21 6UU 
 
Direct Dial 
Tel  (0)131 474 0000  Fax (0)131 474 0001 
Email: sadamson@qmu.ac.uk 
 
 
07 June 2012 
 
 
Dear Raquel 
 
Request for Ethical Approval for a Research Project – Assessment of 
reliability, validity and precision between intra and inter observer 
anthropometrical measurements performed in children and young adults. 
 
Thank you for your response to the letter I sent you following consideration of your 
application by the Research Ethics Panel. 
 
Professor Nigel Gleeson, Vice-Convener of the Panel, has reviewed your response 
to the points you were required to address, and has confirmed that he is happy to 
take Convener’s Action to grant full ethical approval for your research.  
 
A standard condition of this ethical approval is that you are required to notify the 
Panel, in advance, of any significant proposed deviation from the original protocol. 
Reports to the University are also required once the research is underway if there 
are any unexpected results or events that raise questions about the safety of the 
research. Please find the appropriate form for this enclosed. 
 
We would like to thank you for your co-operation and wish you well with your project. 
 
Yours sincerely, 
 
 
 
 
Sheila Adamson 
Collaborations Development Co-ordinator 
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 INFORMATION SHEET FOR PARENTS 
 
 
 
“Assessment of reliability, validity and precision of anthropometrical 
measurements performed in healthy children” 
 
 
This study will be carried out by Ilenia Paciarotti and Raquel Revuelta Iniesta; we 
are both PhD students at Queen Margaret University under the supervision of Dr. 
Jane Mckenzie. The purpose of this project is to assess measurements of body 
composition in healthy children in preparation for an ongoing project at the Royal 
Hospital of Sick Children (RHSC), which aims to assess nutritional risk in children 
with cancer.  
 
We are looking for boys and girls aged between 2 and 18. 
 This study will involve: 
 Meeting with the children in a private location: QMU clinic room or 
other suitable place. 
 The following anthropometrical measurements will be taken on your 
child twice by each of the researchers: 
 Weight – measured clothed, without shoes, on standing scale 
 Height – measured clothed, without shoes, using a standing 
height measure 
 Middle upper arm circumference - this involves finding the 
middle point between the elbow and shoulder and measuring 
the circumference. Measurements are taken on the non-
dominant arm 
376 
 
 Triceps skinfold- this involves measuring the thickness of the 
skin on the triceps. For this measurement we use paediatric 
calipers which pinch the skin gently to measure the thickness 
 Wearing short sleeves will facilitate measurement of the arm. 
 Will it hurt my child? 
 Your child should not experience any pain, however the triceps skin 
fold is sometimes perceived as unpleasant by the children. 
 Benefits of taking part 
 This study will not benefit your child directly; however the 
information obtained will help the researchers to conduct the study 
performed at the RHSC   
 Confidentiality and anonymity 
 All children who take part in the project will be given an 
identification number and all data will be anonymous. 
 Withdrawal 
 You or your child will be able to withdraw from the study at any time 
without providing any explanation. 
 
 Contact details 
 Researchers’ name: 
 Raquel Revuelta Iniesta     rrevueltainiesta@qmu.ac.uk   
 Ilenia Paciarotti                  ipaciarotti@qmu.ac.uk  
 Supervisor: 
 Dr. Jane McKenzie            jmckenzie@qmu.ac.uk  
 Independent advisor: 
 If you wish to consult a person who is not involved in this 
research for independent advice, please contact: 
 Dr. Iain Gow                   igow@qmu.ac.uk  
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APPENDIX III 
- Child invitation to participate in the study 
- Consent forms  
- Parents invitation to participate in the study  
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CHILD INVITATION TO PARTICIPATE 
 
“Nutritional Risk in Childhood Cancer (prospective study)” 
 
 
Invitation to take part in the study 
- We would like to ask you for help with our study. 
- We want to make sure that you understand what is all about before you 
decide if you would like to take part 
- Please talk it over with your mum/dad and take time to decide what you want 
to do 
 
What is the study about?                     
 
 
 
 
 
What will happen if I agree to take part?                                  
 
 
 
 
                                                                                                                           
        
 
 
 
 
 
 
 
- Becoming underweight can happen if you have 
cancer. 
- Also some kids and teenagers get overweight later 
- So, we want to find out more about these problems 
- We will measure your weight and height as usual and also 
your thickness of your arm. 
- We will ask you some questions about your food intake 
- We will measure your blood vitamins and minerals  
- We will take these measurements when you come for 
appointments only. 
- Finally we will ask you and your mum/dad to tell us about 
what cancer does to your life by means of some questions on 
a form called questionnaire  
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  Will taking part help me? 
 
                  
 
 
 
 
                                                  
                                                      
  
 
Don’t worry! 
Taking part 
will not hurt 
you 
Will it 
hurt me? 
Only the 
researchers 
involved in the 
study and the 
doctors if 
necessary, 
otherwise nobody 
else 
Who will 
know I 
have 
taken 
part? 
 
Taking part might not help you but should help other 
children and teenagers in the future. 
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Do I have to take part? 
 
 
If you have questions you can speak with: 
Raquel Revuelta Iniesta      (Research Dietitian) (Tel: 0131 536 0824)                         
Dr Mark Brougham            (Consultant Oncologist)  
Kerry White                        (Staff Nurse) 
Prof. David Wilson             (Consultant Gastroenterologist) (Tel: 0131 536 0615) 
 
 
 
 
 
 
 
 
 
 
 
No, this is up to you! 
If you don’t take part don’t worry, that is fine 
If you take part but change your mind later on that is 
also fine. Just let us know 
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Study Number: 
Patient Identification Number for this trial: 
CONSENT FORM – child 8 to 12 years 
Title of Project: 
“Nutritional Risk in Childhood Cancer (prospective study)”. 
Name of Principal Researcher:  Dr David C Wilson 
Please initial box 
 
                                     
 
 
________________________ ________________             ________________  
  
 
________________________ ________________             ________________  
Name  Date Signature 
_________________________ ________________             ____________________ 
Name of Person providing information Date Signature   (if different from researcher) 
_________________________ ________________           ____________________ 
Researcher Date Signature 
(Investigator or delegated medically qualified co-investigator)  
1 for child, 1 for researcher; 1 to be kept with hospital notes 
Child Life and Health                 
Reproductive & Developmental Sciences               
Clinical Sciences and Community Health
   20 Sylvan 
Place EDINBURGH                                  
EH9 1UW                                            
Telephone: 0131 536 0801 
I have read or my family have read out to me the study information sheet, 
I have had the chance to ask questions and                                                        
I am happy with answers to the questions that I have asked.          
I understand that my taking part is up to me and that I am can  stop at any time, and the 
doctors will go on treating me in the way they think is best for me    
I agree to take part in the above study.  
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Study Number: 
Patient Identification Number for this trial: 
CONSENT FORM – child less than 8 years 
Title of Project: 
“Nutritional Risk in Childhood Cancer (prospective study)”. 
Name of Principal Researcher:  Dr David C Wilson 
         Please initial box 
 
 
 
  
 
________________________ ________________             ________________  
Name  Date Signature 
_________________________ ________________             ____________________ 
Name of Person providing information Date Signature   (if different from researcher) 
_________________________ ________________           ____________________ 
Researcher Date Signature 
(Investigator or delegated medically qualified co-investigator)  
1 for child, 1 for researcher; 1 to be kept with hospital notes 
 
 
Child Life and Health                 
Reproductive & Developmental Sciences               
Clinical Sciences and Community Health
   20 Sylvan 
Place EDINBURGH                                  
EH9 1UW                                            
Telephone: 0131 536 0801 
I have read or my family have read out to me the study information sheet 
I have had the chance to ask questions and                                                        
I am happy with answers to the questions that I have asked.          
I know that I don’t have to help unless I want to.  If I start, I can stop at any time.  The 
doctors will still try hard to make me better. 
I agree to take part in the above study.                                                 
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Study Number: 
Patient Identification Number for this trial: 
CONSENT FORM 
Title of Project: “Nutritional Risk in Childhood Cancer (prospective study)”. 
Name of Principal Researcher:  Dr David C Wilson 
Please initial box 
                                       
 
 
 
 
 
________________________ ________________             ________________  
  
Name of Parent/Carer Date Signature 
_________________________ ________________             ____________________ 
Name of Person providing information Date Signature 
(if different from researcher) 
_________________________ ________________           ____________________ 
Researcher Date Signature 
(Investigator or delegated medically qualified co-investigator)  
 
1 for parent/carer, 1 for researcher; 1 to be kept with hospital notes 
Child Life and Health                 
Reproductive & Developmental Sciences               
Clinical Sciences and Community Health
   20 Sylvan 
Place EDINBURGH                                  
EH9 1UW                                            
Telephone: 0131 536 0801 
I confirm that I have read and understand the information sheet for the above study, that I 
have had the opportunity to ask questions, and that I have received satisfactory answers to the 
questions that I have asked 
I understand that my child’s participation is voluntary and that I am free to withdraw my 
child at any time, without giving any reason, without my infant’s medical care or legal rights 
being affected. 
I agree to have my infant take part in the above study.             
If asked I agree to take part in audio-taped interviews.                                       
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PARENT INVITATION TO PARTICIPATE 
 
“Nutritional Risk in Childhood Cancer (prospective study)” 
 
This resaerch project will be carried out by the Royal Hospital for Sick Children, 
Edinburgh, The University of Edinburgh & Queen Margaret University. 
 
The study has the full support and permission of the paediatric haematology and 
oncology department in Sick Kid’s, the hospital and both Universities. 
 
What is the study about? 
 
Malnutrition (undernutrition and overnutrition) is a major concern in the treatment of 
children and young people with cancer. Undernutrition, loss of weight or failuring to 
gain weight normally, may occur during the treatment of cancer and also during 
remission, while obesity is becoming a major concern for the survivors of childhood 
cancer. Thus children and teenagers who face these issues may need additional help 
with nutrition. We realise that these nutritional problems are a source of great stress 
for families as we all wish to provide adequate nutrition to our children. 
 
 
Why do we need to do this research? 
 
The improvement in medical treatment is achieved by carrying out clinical research 
and thanks to them we have recently made huge progresses in the treatment and cure 
of cancer. In order to advance further and to improve health services for children and 
adolescents with cancer we need to continue doing research. 
If being undernoushed and overnourished is as common as we think, then we would 
be able to argue for greater provision of services (e.g. Dietitians) and care, which will 
in turn help children and families in the future.  
 
How will we do this? 
 
We will ask the parents of children who have been diagnosed with cancer and are 
followed up in SE Scotland if they are willing to take part in the research study.  
 
 
Child Life and Health 
Reproductive & Development Sciences 
Clinical Sciences & Community Health 
20 Sylvan Place 
Edinburgh 
EH9 1UW 
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What is involved for my child? 
 
Your child will not receive any extra tests, procedures or interviews, except we will 
do more frequent measurements of height, weight and some extra growth 
measurements in the ward and at follow up. 
 
We will ask you to tell us about your child’s food intake. 
 
When your child needs to have blood taken for medical reasons we would need a 
little extra to analyse your child’s blood vitamin and mineral levels. 
 
We also wish to measure your child’s quality of life and stress levels (stress levels 
only if your child is 8 years or older) by means of a questionnaire. 
 
What is involved for me? 
 
We wish to measure your thoughts on your child’s quality of life by means of the 
same quality of life (PedsQL) questionnaire. We also wish to measure the effects that 
your child’s cancer has caused you, your stress levels as well as your emotional and 
physical health by means of a second questionnaire (SF36). Although the 
questionnaires should only take about 5-10 minutes to fill in you may find that they 
are time consuming or tiresome. 
 
Where do I have to go? 
 
All the measurements will be taken at your child’s follow up visits or during 
admission to the Royal Hospital for Sick Children (RHSC). 
 
If you or your child want to opt in the study it is entirely up to you. Your child’s care 
will not be affected by whether or not you take part. 
If you/your child agree to take part but want to opt out later that is also fine and it 
will not affect your child’s care. 
 
If you have any questions or would like a more detailed explanation of the 
study, please contact: 
 
Prof. David Wilson (Consultant Gastroenterologist at the RHSC) Tel: 0131 536 0615 
Dr Mark Brougham (Consultant Oncologist at the RHSC) Ward 2 
Raquel Revuelta Iniesta (Research Dietitian at  the RHSC) Ward 2 Tel: 0131 536 
0824 
Kerry White (staff nurse) ward 2 
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APPENDIX IV 
- CRP protocol  
- Ferritin protocol 
- Folate protocol 
- Vitamin B12 protocol  
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Ferritin protocol   
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Folate protocol 
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Vitamin B12 Protocol 
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APPENDIX V 
- NHS Ethics for ENRICC study  
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APPENDIX VI 
- PTH protocol 
- Vitamin D protocol 
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Parathyroid hormone protocol  
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Vitamin D protocol  
CLINICAL BIOCHEMISTRY 
     Department of Laboratory Medicine, LUHD  
 
 
 
27th August 2012  
 
 
 
Dear Colleague 
 
VITAMIN D REQUESTS – IMPORTANT ANNOUNCEMENT 
You will recall that early last year Glasgow Royal Infirmary placed restrictions on the use of their 
Vitamin D assay service in order to cope with an ever increasing workload.  These pressures 
remain and, in order to manage a continuing increase in demand, the labour-intensive Liquid 
Chromatography–Tandem Mass Spectrometry (LC-MS/MS) assay is to be replaced by a fully 
automated Vitamin D immunoassay method for routine measurements.  
While 25OH Vitamin D3 levels obtained by immunoassay correlate well with those   measured by 
LC-MS/MS, the immunoassay method has reduced cross reactivity with 25OH Vitamin D2 
compared with 25OH Vitamin D3. Therefore when the assessment of Vitamin D status in patients 
receiving Vitamin D2 supplements is required, it will be necessary to request measurement by the 
LC-MS/MS assay which measures 25OH Vitamin D2 and 25OH Vitamin D3 separately.   
We anticipate that the LC-MS/MS assay should only be necessary for a small number of patients.  
When required, a written request form must always be submitted to the laboratory and the 
requirement for 25OH Vitamin D2 assay clearly indicated.  It will not be possible to make this 
request on TRAK or on the future GP electronic ordering system, both of which will be configured to 
request measurement by immunoassay only.  
Please note that Vitamin D assays are not indicated for patients being treated with alphacalcidol or 
calcitriol and that the restrictions on the frequency of testing already in place continue to apply 
(normally once a year in adults). 
The new assay will be introduced on Monday 3rd September 2012.  If you require further 
information about this change please contact the Duty Biochemist in your local laboratory.   
 
Yours sincerely 
 
 
 
JP Ashby 
Specialty Lead for Clinical Biochemistry     
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APPENDIX VII 
- Calcium protocol 
- Magnesium protocol 
- Phosphate protocol 
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Calcium protocol 
PRE-EXAMINATION 
Reception Procedures –  LP-REC-E-RecProc 
RHSC user Handbook   PD-GEN-A-USERHND 
SAMPLE REQUIREMENTS:   
Serum or heparinised plasma may be analysed. EDTA / fluoride oxalate tubes are 
unsuitable. 
A random ‘spot’ urine specimen is required for urine analysis. 
Minimum volume is 2.6uL [+25uL dead volume]. 
Store all samples at 4oC until analysis. 
 
EXAMINATION 
PRINCIPLE: 
Arsenazo-III dye reacts with calcium in an acid solution to form a blue-purple 
complex.   The colour developed is measured at 660 nm and is proportional to the 
calcium concentration in the sample. 
EQUIPMENT AND CONSUMABLES: 
Abbott Architect c8000 ON BOARD MANUAL 
Calcium procedure: uploaded from assay disc. LI-BIO-E-CAKI#Arch 
 
REAGENTS: 
Store manufacturer's kits at 15-30C. LI-BIO-E-CaKI#Arch 
(1) REAGENT 1   Abbott Cat no 3L79-21 
Use as supplied. Stable on c8000 analyser for 30 days. Remove air bubbles. 
(2) REAGENT 2   Abbott Cat no 3L79-21 
Use as supplied. Stable on c8000 analyser for 30 days. Remove air bubbles. 
 
CALIBRATION: 
The method must be calibrated every 30 days and when a new batch of reagent is 
used. For full details see the Abbott Architect systems operation manual and the 
protocol for calibrating the Abbott Architect ci16200. 
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 MCC Multiconstituent Calibrator, Abbott Cat No 1E65 LI-BIO-E-MCCKI 
Use as supplied. Stable for 2 weeks.  Upload values from calibration memory 
stick. 
 
QUALITY CONTROL: 
Run quality control samples for plasma calcium every 4 hours and after calibration. 
Run quality control samples for urine calcium as required and after calibration.  For 
full details see the Abbott Architect systems operation manual. 
 Bio-Rad Multiqual level 1 (Prod. No. 697)  LI-BIO-E-MultiqualKI 
  Bio-Rad Multiqual level 2 (Prod. No. 698)  LI-BIO-E-MultiqualKI 
  Level 3 Bio-Rad Multiqual level 3 (Prod. No. 699)  LI-BIO-E-MultiqualKI 
 Enter values from kit insert. Use as supplied. Stable for 2 weeks in fridge. 
 
 Liquichek Urine level 1 (Prod. No. 397)  LI-BIO-E-LiqUrineKI 
 Liquichek Urine level 2 (Prod. No. 398)  LI-BIO-E-LiqUrineKI 
 Enter values from kit insert. Use as supplied. Stable for 30 days in fridge. 
 
PROCEDURE: 
For details see the protocol for running patient samples on the Abbott Architect 
c8000 and the Architect onboard operation manual. LI-BIO-E-ArchSamp 
  
If sample appears haemolysed, icteric or lipaemic, request serum indices.   
  LP-BIO-E-INDICES#Arch 
 
CALCULATION: 
Direct down-load of results to computer. 
 
EXPECTED PERFORMANCE: 
(1) Assay is linear up to 6 mmol/L. [6.00 mmol/L for urine].   
(2) Plasma results >6 mmol/L may be manually diluted using saline. The dilution 
factor should be entered in the patient order screen to automatically correct the 
result otherwise the result must be manually multiplied.  
There is no Automated Dilution Protocol for plasma.  
Urine results >6.00 mmol/L may be diluted using Automated Dilution Protocol 
set at 1:2 [NB standard dilution for urines is 1:1] LI-BIO-E-CAKI#Arch 
(3) Limit of detection 0.125mmol/L; Limit of Quantitation 0.25mmol/L for plasma 
and urine. 
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(4) Indices interference– please refer to ‘Analytes affected by Haemolysis, 
Lipaemia, Icterus and Delay’ LI-BIO-E-HAEM#Arch  
 
UNCERTAINTY OF MEASUREMENT: 
The assay has a CV of 3% on the analyser.  
Calcium in the serum is largely protein bound.  Therefore venous stasis during 
sample collection can lead to increased calcium levels.   
Results are not significantly affected by haemolysis, icteria or lipaemia. 
 
Interference from medications and endogenous substances may affect results 
(Ref2). 
 
 
POST-EXAMINATION         
QUALITY CONTROL VERIFICATION: 
Check the Calcium [plasma and urine] QC charts on the Architect c8000. 
Action limits defined on the Architect QC charts are set at ± 2SD.          LI-BIO-E-SDLIMIT 
Refer to Acceptance Section of IQC Instruction sheet.  QI-GEN-E-IQC 
If the QC results are outside the action limits given on the chart, record action taken 
on analyser IQC log or IQC failure form  QF-GEN-E-IQCfail 
 
RESULT REPORTING AND AUTHORISATION 
Results are automatically downloaded into the computer via AMS.  LP-GEN-E-ILABS  
 LP-GEN-E-AMS 
For results above the interference limits, do not report results but add comment as 
appropriate eg HM, LP or IC. LI-BIO-E-HAEM#Arch 
Technical authorisation to level S LP-GEN-E-CHECK 
Telephone any urgent result(s) and any plasma result <1.90 mmol/L or >3.00 
mmol/L. 
 LP-GEN-E-Phone 
 LI-BIO-E-PHONE#Limits 
Urine:  calcium:creatinine ratio automatically calculated. 
All results are clinically validated  by Duty Biochemist.   
  
CLINICAL INTERPRETATION:     
Laboratory Handbook [PD-GEN-A-USERHND] 
Paediatric reference range in-house data (updated 3/7/07) and Abbott comparisons.  
LI-GEN-E-LIBRARY 
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Plasma 
  Reference range  (mmol/L) 
 Neonates <7 days 1.6 – 2.7  
 Neonates >7 days 2.3 – 3.0  
 Infants 2.3 - 2.8   
 Children 2.2 - 2.7  
 
Plasma calcium reference ranges from in-house data. 
 
Hypocalcaemia may be due to low dietary calcium, inadequate calcium absorption 
(eg vitamin D deficiency) or hypoparathyroidism. Total (but not ionised) plasma 
calcium may also be low when plasma albumin is low. 
Hypercalcaemia is much rarer in children and may be due to hyperparathyroidism, 
malignant disease, vitamin D toxicity or hypocalciuric hypercalcaemia (an inherited 
defect in the calcium-sensing receptor). 
 
Urine 
  Reference range  
  (mmol/mmol creatinine) 
 Infants <6 months <2.4 
 Infants >6 months <2.2 
 Children, 1 – 2 years <1.5 
 Children >2 years <0.6  
  [Equivocal range 0.6 – 0.8] 
 
Urine calcium reference ranges for Infants < 6months from ref (4).  Ranges for 
infants >6 months and children 1 – 2 years from ref (5). Range for children >2 years 
from ref (6), validated by in-house data collected September 2000. In children, the 
calcium:creatinine ratio in second-morning ‘spot’ urine samples accurately reflects 
24h urine calcium excretion.  
 
Urinary calcium:creatinine ratio is part of the paediatric urinary stone screen. Its 
measurement may be of value in nephrocalcinosis, stone formation and in 
diagnosing hypocalciuric hypercalcaemia. 
 
EQAS: 
Participation in UKNEQAS General Chemistry and General Urine Chemistry 
scheme.                                          LP-GEN-E-EQAS 
  
sCIENTIFIC REFERENCES: 
(1) Kessler G, Wolfman M. Automated procedure for the simultaneous 
determination of calcium and phosphorus. Clin Chem 1964 ; 10 : 686-703. 
(2) Gosling P. Analytical reviews in clinical biochemistry : calcium measurement. 
Ann Clin Biochem 1986 ; 23 : 145-156. 
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(3) Corns CM, Ludman CJ. Some observations on the nature of the calcium-
cresolphthalein complexone reaction and its relevance to the clinical 
laboratory. Ann Clin Biochem 1987 ; 24 : 345-351. 
(4) Sargent JD, Stukel TA, Kresel J, Klein RZ.  Normal values for random 
urinary calcium to creatinine ratios in infancy.  J Pediatr 1993 ; 123 : 393-
397. 
(5) Matos V, van Melle G, Boulat O, Markert M, Bauchmann C, Guignard J-P. 
Urinary phosphate/creatinine, calcium/creatinine and magnesium/creatinine 
ratios in a healthy pediatric population. J Pediatr 1997;131:252-257. 
(6) Shaw NJ, Wheeldon J, Brocklebank JT. Indices of intact serum parathyroid 
hormone and renal excretion of calcium, phosphate, and magnesium. Arch 
Dis Child 1990;65:1208-1211. 
 
(7) Effect of Drugs on Clinical Laboratory Tests. Ed DSYoung. AACC Press 4th 
edition 1995.  
 
(8) Source Data for RHSC Paediatric Reference Ranges (1999-) Vol 1 General 
Section 
 
(9) Source Data for RHSC Paediatric Reference Ranges (2011-) Vol 4 Abbott 
comparison data 
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Magnesium Protocol  
 
Procedure:  
Procedure must be carried out according to manufacturer’s instructions. 
Follow normal laboratory procedures to contain risk. 
 
Work area: 
Main Laboratory at the RHSC. 
 
 
 
PRE-EXAMINATION 
Reception Procedures  REC-E4 
RHSC user Handbook   PD-GEN-E-USERHND#RHSC 
 
SAMPLE REQUIREMENTS:   
Lithium heparin plasma or serum or random ‘spot’ urine required. EDTA blood is 
unsuitable. 
Samples delayed >12h in transit are unsuitable. [Unreferenced – historical] 
 
Minimum volume is 2.4uL [+25uL dead volume] for plasma and urine. 
Store all samples at 4oC until analysis. 
 
EXAMINATION 
PRINCIPLE: 
This method utilizes an arsenazo dye which binds preferentially with magnesium.   
The absorbance of the arsenazo magnesium complex is measured at 572 nm and is 
proportional to the concentration of magnesium present in the sample.   Calcium 
interference is prevented by incorporation of a calcium-chelating agent. 
 
EQUIPMENT AND CONSUMABLES: 
Abbott Architect c8000 ON BOARD MANUAL 
Magnesium procedure: uploaded from assay disc. KIT84 
 
REAGENTS: 
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Store manufacturer's kits at 2-8C. KIT84 
(3) REAGENT 1   Abbott Cat no 3P68-21 
Use as supplied. Remove air bubbles. Stable on c8000 analyser for 21 days.  
 
CALIBRATION: 
The method must be calibrated every 30 days, and with lot number change. For full 
details see the Abbott Architect systems operation manual and the protocol for 
calibrating the Abbott Architect c8000. 
 
MCC Multiconstituent Calibrator, Abbott Cat No 1E65 KIT85 
Use as supplied. Store at 2-8C. Stable for 1 week.   
Upload values from calibration memory stick. 
 
QUALITY CONTROL: 
Run quality control samples every 4 hours and after calibration. Run quality control 
samples for urine magnesium as required and after calibration.  For full details see 
the Abbott Architect systems operation manual. 
 Bio-Rad Multiqual level 1 (Prod. No. 697)  KIT30 
  Bio-Rad Multiqual level 2 (Prod. No. 698)  KIT30 
  Bio-Rad Multiqual level 3 (Prod. No. 699)  KIT30 
Use as supplied. Stable for 1 week in fridge. 
 
 Liquichek Urine level 1 (Prod. No. 397)  KIT105 
 Liquichek Urine level 2 (Prod. No. 398)  KIT105 
Use as supplied. Stable for 30 days in fridge. 
 
PROCEDURE: 
For details see the protocol for running patient samples on the Architect onboard 
operation manual.  
  
If sample appears haemolysed, icteric or lipaemic, request serum indices.   BIO-E-22 
 
CALCULATION: 
Direct download of results to computer. 
 
EXPECTED PERFORMANCE: 
(5) Assay is linear up to 3.90mmol/L [10.85mmol/L for urine].   
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(6) Plasma results >3.90 mmol/L may be manually diluted using saline. The 
dilution factor should be entered in the patient order screen to automatically 
correct the result otherwise the result must be manually multiplied.  
There is no Automated Dilution Protocol for plasma.  
Urine results >10.85 mmol/L may be diluted using Automated Dilution Protocol 
set at 1 in 10 [NB standard dilution for urines is 1:5] KIT84 
(7) Limit of Detection is 0.063mmol/L [0.313mmmol/L for urine]; Limit of 
Quantitation is 0.27mmol/L [0.67mmol/L for urine]. 
(8) Indices interference– please refer to ‘Analytes affected by Haemolysis, 
Lipaemia, Icterus and Delay’ BIO-E-6 
(9) Urine acidification is NOT required for random ‘spot’ urine specimens. [Ref 1] 
 
UNCERTAINTY OF MEASUREMENT: 
The assay has a CV of 4% on the analyser.  
Icterus and lipaemia have no significant affect on magnesium results. Haemolysis 
can affect results. 
Interference from medications and endogenous substances may affect results [Ref 
2]. 
 
POST-EXAMINATION         
QUALITY CONTROL VERIFICATION: 
Check the Magnesium [plasma and urine] QC charts on the Architect c8000. 
Action limits defined on the Architect QC charts are set at ± 2SD.           
The SD limit may be manufacturer or tighter than quoted manufacturer SD limits.  GEN-E21 
Refer to Acceptance Section of IQC Instruction sheet.  GEN-E21 
If the QC results are outside the action limits given on the chart, record action taken 
on analyser IQC log or IQC failure form  GEN-E20 
  
 
RESULT REPORTING AND AUTHORISATION 
Results are automatically downloaded into the computer via AMS.  GEN-E11 
 LP-GEN-E-AMS 
For results above the interference limits, do not report results but add comment as 
appropriate eg HM, LP or IC. BIO-E-6 
Technical authorisation to level S GEN-E7 
Telephone any urgent result(s) and any result >4.0 mmol/L      GEN-E14  BIO-E-7 
Samples delayed >12h in transit: Do not report result. Add ‘OLD’ in iLABS. [No Ref 
available]    BIO-330 
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Urine:  magnesium: creatinine ratio automatically calculated. All results are clinically validated by the Duty Biochemist.  GEN-E7 
  
CLINICAL INTERPRETATION:     
Laboratory Handbook [PD-GEN-A-USERHND] 
 LI-GEN-E-LIBRARY  
Reference Ranges  
Plasma magnesium (mmol/L) [Refs 3, 4]  
 All ages 0.5 – 1.0 
 
Urine magnesium (mmol/mmol creat) [Refs 4, 5, 6]   
 Birth – 6m no range available  
 6m – 1y <2.2 
 1 – 2y <1.7 
 2 – 16y 0.2 - 1.1 
  
Magnesium depletion may occur as a result of decreased input (eg dietary 
deficiency, total parenteral nutrition, intestinal resection) or increased loss, either 
renal (eg renal tubular acidosis, nephrotoxic drugs) or non-renal (eg chronic 
diarrhoea or vomiting). Magnesium depletion may cause cardiac arrhythmias and 
may have widespread effects on other electrolytes. It impairs PTH secretion and 
may lead to hypocalcaemia especially in babies. [Refs 7, 8] 
EQAS: 
Participation in UKNEQAS general chemistry and urine schemes. GEN-E31 
  
sCIENTIFIC REFERENCES: 
(1) In house study. L:\Laboratory Specialities\Combined Lab 
RHSC\LABFILES\Public\Pat\General Section\Urine acidification study - Ca 
Phos Mg 
(2) Effect of Drugs on Clinical Laboratory Tests. Ed DSYoung. AACC Press 4th 
edition 1995.  
(3) Source Data for RHSC Paediatric Reference Ranges (1999- ) Vol 1 General 
section. 
(4) Source Data for RHSC Paediatric Reference Ranges (2011- ) Vol 4 Abbott 
comparison data. 
(5) Shaw NJ, Wheeldon J, Brocklebank JT. Indices of intact serum parathyroid 
hormone and renal excretion of calcium, phosphate, and magnesium. Arch Dis 
Child 1990; 65:1208-1211. 
(6) Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard J-P. 
Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine 
ratios in a healthy paediatric population. J Pediatr 1997; 131:252-257. 
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(7) Ryan MF. The role of magnesium in clinical biochemistry: an overview. Ann 
Clin Biochem 1991; 28:19-26. 
(8) Elin RJ. Assessment of magnesium status. Clin Chem 1987; 33: 1965-70. 
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Phosphate Protocol 
Procedure:  
Procedure must be carried out according to manufacturer’s instructions. 
Follow normal laboratory procedures to contain risk. 
 
Work area: 
Main Laboratory at the RHSC. 
 
 
 
PRE-EXAMINATION 
Reception Procedures  REC-E4 
RHSC user Handbook   PD-GEN-E-USERHND#RHSC 
 
SAMPLE REQUIREMENTS:   
Serum or heparinised plasma is required.  
Samples that have been delayed more than 12h in transit are unsuitable. 
Urine should preferably be the second morning sample but urine collected at other 
times of day is acceptable.  
For calculation of TmPO4/GFR (= renal threshold for phosphate or  tubular 
maximum reabsorption rate of phosphate per litre of glomerular filtrate), paired blood 
and urine samples are required. Measure phosphate and creatinine in both plasma 
and urine. 
Minimum volume is 2.6uL [+25uL dead volume] for plasma and urine. 
Store all samples at 4oC until analysis. 
 
 
EXAMINATION 
PRINCIPLE: 
Inorganic phosphate reacts with ammonium molybdate to form a heteropolyacid 
complex.   The use of a surfactant eliminates the need to prepare a protein free 
filtrate.   The absorbance at 340 nm is directly proportional to the inorganic 
phosphorus level in the sample.  Sample blanks must be run to correct for any non-
specific absorbance in the sample. 
EQUIPMENT AND CONSUMABLES: 
Abbott Architect c8000 ON BOARD MANUAL 
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Phosphate procedure: uploaded from assay disc. KIT92 
 
REAGENTS: 
Store manufacturer's kits at 15-30C. KIT92 
(4) REAGENT 1   Abbott Cat no 7D71-22 
Use as supplied. Stable on c8000 analyser for 65 days. Remove air bubbles. 
(5) REAGENT 2   Abbott Cat no 7D71-22 
Use as supplied. Stable on c8000 analyser for 65 days. Remove air bubbles. 
 
CALIBRATION: 
The method must be calibrated every 41 days and with lot number change. For full 
details see the Abbott Architect systems operation manual and the protocol for 
calibrating the Abbott Architect c8000. 
MCC Multiconstituent Calibrator 1 and 2, Abbott Cat No 1E65 KIT85 
Use as supplied. Stable for 1 week.  Upload values from calibration memory stick  
 
QUALITY CONTROL: 
Run quality control samples every 4 hours and after calibration. Run quality control 
samples for urine calcium as required and after calibration.  For full details see the 
Abbott Architect systems operation manual. 
 Bio-Rad Multiqual level 1 (Prod. No. 697)  KIT30 
  Bio-Rad Multiqual level 2 (Prod. No. 698)  KIT30 
  Bio-Rad Multiqual level 3 (Prod. No. 699)  KIT30 
 Use as supplied. Stable for 1 week in fridge. 
 
 Liquichek Urine level 1 (Prod. No. 397)  KIT105 
 Liquichek Urine level 2 (Prod. No. 398)  KIT105 
 Use as supplied. Stable for 30 days in fridge. 
 
 
PROCEDURE: 
For details see the protocol for running patient samples on the Architect onboard 
operation manual. LI-BIO-E-ArchSamp 
  
If sample appears haemolysed, icteric or lipaemic, request serum indices.   BIO-E-22 
 
CALCULATION: 
Direct download of results to computer. 
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Duty Biochemist: Calculate TmPO4/GFR using spreadsheet (L:\Quality 
Management\CPA\Lab SOPs Stnds E,F\RHSC Laboratories\Biochemistry General 
/LF-BIO-E-TmPGFR). BIO-E-42 
If only urine received, enter assay code BUPHCR and calculate 
phosphate:creatinine ratio. 
 
EXPECTED PERFORMANCE: 
(10) Assay is linear up to 8.17mmol/L [60.14mmol/L for urine].   
(11) Plamsa results >8.17 mmol/L may be manually diluted using saline. The 
dilution factor should be entered in the patient order screen to automatically 
correct the result otherwise the result must be manually multiplies.  
There is no Automated Dilution Protocol. KIT92 
(12) Limit of Detection is 0.08mmol/L, Limit of Quantitation is 0.201mmol/L 
[1.418mmol/L for urine]. 
(13) Indices interference– please refer to ‘Analytes affected by Haemolysis, 
Lipaemia, Icterus and Delay’ BIO-E-6 
(14) Samples delayed more than 12h in transit are unsuitable owing to leakage of 
phosphate from red cells. BIO-330 
(15) It is not necessary to acidify urine samples for phosphate analysis. 
 
UNCERTAINTY OF MEASUREMENT: 
The assay has a CV of 4.6% on the analyser.  
Icterus and lipaemia have no significant affect on results. Haemolysis can affect 
results. 
Interference from medications and endogenous substances may affect results (Ref 
8). 
 
POST-EXAMINATION         
QUALITY CONTROL VERIFICATION: 
Check the Phosphate [plasma and urine] QC charts on the Architect c8000. 
Action limits defined on the Architect QC charts are set at ± 2SD.           
The SD limit may be manufacturer or tighter than quoted manufacturer SD limits.  GEN-E21 
Refer to Acceptance Section of IQC Instruction sheet.  GEN-E21 
If the QC results are outside the action limits given on the chart, record action taken 
on analyser IQC log or IQC failure form  GEN-E20  
RESULT REPORTING AND AUTHORISATION 
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Results are automatically downloaded into the computer via AMS.  GEN-E11 
 LP-GEN-E-AMS 
For results above the interference limits, do not report results but add comment as 
appropriate eg HM, LP or IC. BIO-E-6 
Plasma phosphate: Technical authorisation to S 
Urine phosphate: Technical authorisation to R GEN-E7 
Telephone any urgent result(s) GEN-E14 
 BIO-E-7 
Samples delayed >12h in transit: Do not report result. Add ‘OLD’ in iLABS. 
Urine:  phosphate:creatinine ratio automatically calculated. 
All results are clinically validated  by Duty Biochemist.  GEN-E7 
TmPO4/GFR calculation: is done by the Duty Biochemist using the calculation 
spreadsheet. 
 BIO-E-42 
If only urine has been received (no paired plasma), calculate phosphate:creatinine 
ratio instead. 
  
CLINICAL INTERPRETATION:     
Laboratory Handbook [PD-GEN-A-USERHND] 
RHSC paediatric reference range source data [LI-GEN-E-LIBRARY #MAN24] 
Plasma phosphate (mmol/L) reference ranges (from in-house data collected July 
1999):  
 Birth-1mo See SMMP Clinical Guidelines   
 1-12 mo 0.8 – 2.6   
 1-16y 1.0 – 2.1   
  
Urine phosphate:creatinine ratio and TmPO4/GFR reference ranges are from refs 5-
7. 
Reference ranges for urine phosphate:creatinine (mmol:mmol) ratio: 
 Birth-1mo 0.4 – 9.3 
 1 – 6 mo 0.5 – 11.1 
 6-12 mo 1.2 – 19.0 
 1 – 2 y 1.2 – 14.0 
 2 – 3 y 1.2 – 12.0 
 3 – 5 y 1.2 – 8.0 
 5 – 7 y 1.2 – 5.0 
 7 – 10 y 1.2 – 3.6 
 10 – 14 y 0.8 – 3.2 
 14 – 17 y 0.8 – 2.7 
 
Reference ranges for TmPO4/GFR (mmol/L): 
 Birth-1mo 1.48 – 3.43 
 1 – 6mo 1.48 – 3.30 
 6mo – 2y 1.15 – 2.60 
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 2 – 15y 1.15 – 2.44 
 >15y 0.96 – 1.44   
  
Plasma and urine phosphate show a marked circadian rhythm unrelated to meals, 
with a nadir at about 1100h and a peak at about 0300h with a mean difference of 0.4 
– 0.5 mmol/L between nadir and peak. Plasma phosphate measurements are of 
value in assessing bone and renal function and in monitoring nutritional intake in 
infants. TmPO4/GFR is of value in the investigation of the aetiology of 
hypophosphataemia, in certain disorders of phosphate metabolism and in oncology 
patients treated with chemotherapy (e.g. ifosfamide) known to cause renal 
phosphate wasting.  
 
 
EQAS: 
Participation in UKNEQAS general chemistry and urine schemes. GEN-E31  
sCIENTIFIC REFERENCES: 
(1) Daly JA, Ertingshausen G. Direct method for determining inorganic phosphate 
in serum with the “CentrifiChem”. Clin Chem 1972;18:263-265.  
(2) Kemp GJ, Blumsohn A, Morris BW. Circadian changes in plasma phosphate 
concentration, urinary phosphate excretion, and cellular phosphate shifts Clin 
Chem 1992;38:400-402. 
(3) Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications 
and interpretation. Ann Clin Biochem 1998;35:201-206. 
(4) Barth JH, Jones RG, Payne RB. Calculation of renal tubular reabsorption of 
phosphate: the algorithm performs better than the nomogram. Ann Clin 
Biochem 2000;37:79-81. 
(5) Bistarakis L, Voskaki I, Lambadaridis J, Sereti H, Sbyrakis S. Renal handling 
of phosphate in the first six months of life. Arch Dis Child 1986;61:677-681. 
(6) Shaw NJ, Wheeldon J, Brocklebank JT. Indices of intact serum parathyroid 
hormone and renal excretion of calcium, phosphate, and magnesium. Arch Dis 
Child 1990;65:1208-1211. 
(7) Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard J-P. 
Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine 
ratios in a healthy pediatric population. J Pediatr 1997;131:252-257. 
(8)  Young DS. Effects of Drugs on Clinical Laboratory tests, 4th ed. Washington, 
DC: AACC Press.  
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APPENDIX VIII 
- Oxygen Radical Absorbance Capacity (ORAC) Antioxidant Assay 
- Thiobarbituric Acid Reactive Substances (TBARS) Assay 
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Oxygen Radical Absorbance Capacity (ORAC) Antioxidant Assay 
References: 
Ou, B et al (2001) Development and validation of an improved oxygen radical 
absorbance capacity assay using fluroescein as the fluorescent probe. Journal of 
Agricultural and Food Chemistry, 49 (10), 4619-4626. 
Girard-Lalancette, K et al. (2009) Sensitive cell-based assay using DCFH oxidation 
for the determination of pro- and anti-oxidant properties of compounds and mixtures: 
Analysis of fruit and vegetable juices. Food Chemistry, 115, 720-726. 
The ORAC assay is based on the oxidation of a fluorescent probe (fluorescein) by 
peroxyl radicals via a classic hydrogen atom transfer (HAT) mechanism. Free 
radicals are generated by the water souable compound AAPH (2,2’-azobis-2-methyl-
propanimidamide). The peroxyl radicals thus generated quench the fluorescence of 
fluorescein over time. The antioxidants block the peroxyl radical mediated oxidation 
of fluorescein until all of the antioxidant activity in the sample is exhausted, after 
which AAPH-generated peroxyl radicals react with and quench the fluorescence of 
fluorescein. The area under the fluorescence decay curve (AUC) is used to quantify 
the total peroxyl radical antioxidant activity in a sample and is compared to a 
standard curve obtained using various concentrations of the water soluble vitamin E 
analogue Trolox (6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). Unlike 
other antioxidant assays, the fluorescent ORAC assay provides a direct measurement 
of antioxidant capacity against hydrophilic chain breaking peroxyl radicals. This 
procedure is performed as described by Ou et al (2001) with some modifications 
(Girard-Lalancette et al 2009). 
 
Materials and Methods 
Fluoroskan plate reader equipped with 488nm excitation and a 515nm emission 
filters, 
PC connected to plate reader (Username: datalog, Password: fluoroskan) 
96-well plates (black and white isoplates- white wells, black matrix) Wallac, Perkin 
Elmer. 
Pipettes with range 25-1000μl 
Multichannel pipette with range of 25-150μl 
Plasma samples must be obtained from Heparin tubes and diluted 1:100 in buffer 
before analysis. Can also do analysis in protein-free fraction using 0.5M perchloric 
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acid (PCA; in buffer). Add PCA and plasma in eppendorf (1:1, v/v) centrifuge at 
13000g for 10 minutes at 4C, and treat as whole plasma. 
Reagents          N.B. PREPARE ALL REAGENTS AND SAMPLES IN 
PHOSPHATE BUFFER (pH 7.4, 75mM)  
Perchloric Acid   
 2.16ml PCA made up to 50ml in buffer. 
Fluorescein MW: 376.28 
 Prepare a 40mM stock solution – weigh out 0.1505g fluorescein in 10ml 
buffer 
o This can last several months so long as stored at 5˚C covered in foil. 
 Immediately prior to use, dilute stock solution to 400nM with buffer 
o Dilute stock solution 1:100 (0.1ml stock + 9.9ml buffer) to give 
400μM solution, 
o Dilute this again 1:100 to give a 4μM solution, 
o Dilute this solution 1:10 (2ml of above + 18ml buffer) to give a 
400nM solution. 
 Protect from light by covering with foil and store at 5˚C. 
AAPH (375mM) MW: 271.20 
 Weigh 1.017g AAPH and dissolve in 10ml buffer 
 Prepare fresh daily, store at 5˚C and discard within 8 hours. 
Trolox MW: 250.29 
 Weigh 0.0250g Trolox in 10ml buffer (10mM) and vortex until dissolved. 
 Aliquot and store at -20˚C for 3 months. Defrost at room temperature. 
 On the day, dilute this solution 1:100 to give 100μM (9.9ml buffer +0.1ml 
Trolox) 
 Prepare serial dilutions for a calibration curve: 100, 50, 25, 12.5, 6.25μM. 
Procedure 
 Login to PC and enter password 
 Switch on plate reader and allow to warm up. 
 Open Fluoroskan Ascent icon 
 Open a session (must be a HI.SEF file) 
 Highlight the area of wells to be analysed and define wells. 
 Add 25μl buffer to the BLANK wells, and 25μl sample/standard to each well 
+ 150μl fluorescein (400nM) and place in fluoroskan.  
 Press start. Ignore window that pops up, this will disappear after 15mins. 
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 Incubate sample in Fluoroskan at 37˚C for 15mins. Plate will automatically 
come out after this time. 
 Add 25μl AAPH and press continue.  
 Run time of assay is ~35min. 
 Save data as an excel file. 
 The final results are calculated using the net AUC of the sample 
concentrations. ORAC values are expressed in micromoles of Trolox 
equivalents (TE) per gram (μmol TE/g). 
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Thiobarbituric Acid Reactive Substances (TBARS) Assay 
Cayman’s TBARS Assay Kit 
Sample Preparation –Plasma 
Typical human plasma has a lipid peroxide level (expressed in terms of MDA) of 
1.86-3.94 µmol. 
1. Collect blood using an anticoagulant such as heparin, EDTA, or citrate. 
2. Centrifuge the blood at 700-1000 x g for 10 minutes at 4ºC. 
3. Plasma does not need to be diluted before assaying.  
General Information  
 All reagents except samples must be equilibrated to room temperature before 
beginning the assay. The SDS Solution will take at least one hour to 
equilibrate to room temperature if stored at 2-8ºC. Briefly heating the SDS 
Solution at 37ºC will re-dissolve the precipitated SDS. The SDS Solution can 
then be stored at room temperature. 
 The final volume of the assay is 150 µL is all wells. 
 The assay is performed at room temperature. 
 It is not necessary to use all the wells on the plate at one time. 
 It is recommended that the samples and standards be assayed at least in 
duplicate. 
 It is recommended that the samples and standards be kept at 4ºC after 
preparation to increase sensitivity and reproducibility. 
 Monitor the absorbance at 530-540 nm or read fluorescence at an excitation 
wavelength of 530 nm and an emission wavelength of 550 nm. 
Reagents  
- Thiobarbituric Acid (TBA) 
- TBA Acetic Acid 
- TBA Sodium Hydroxide 
- TBA Malondialdehyde Standard  
- TBA SDS Solution 
- Colour Reagent:  
o Weigh 530 mg of TBA and add to ≥150 ml beaker containing 50 ml 
of diluted TBA Acetic Acid Solution. Add 50 mL of diluted TBA 
Sodium Hydroxide and mix until the TBA is completely dissolved. 
The solution is stable for 24h.   
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Calorimetric Standard Preparation 
Dilute 250 µL of the MDA Standard (TBA Malondialdehyde) with 750 µL of 
water to obtain a stock solution of 125 µmol. Take eight clean glass test tubes 
and label them A-H. Add the amount of 125 µmol. Add the amount of 125 µmol 
stock solution and water to each tube as described in table 1. 
Table 1. MDA calorimetric standards   
Tube MDA µmol Water 
(µL) 
MDA Concentration 
(µmol) 
A 0 1000 0 
B 5 995 0.625 
C 10 990 1.25 
D 20 980 2.5 
E 40 960 5 
F 80 920 10 
G 200 800 25 
H 400 600 50 
 
Fluorometric Standard Preparation  
Dilute 25 µL of the MDA Standard (TBA Malondialdehyde) with 975 µL of 
water to obtain a stock of 12.5 µmol. Take eight clean glass test tubes and label 
them A-H. Add the amount of 12.5 µmol MDA stock solution and water to each 
tube as described in table 2.    
Table 2. MDA fluorometric standards  
Tube MDA µmol Water 
(µL) 
MDA Concentration 
(µmol) 
A 0 1000 0 
B 5 995 0.0625 
C 10 990 0.125 
D 20 980 0.25 
E 40 960 0.5 
F 80 920 1 
G 200 800 2.5 
H 400 600 5 
 
Performing the Assay  
1. Label vial caps with standard number or sample identification number. 
2. Add 100 µL (1L was used here) of sample or standard to appropriately 
labelled 5 mL vial. 
3. Add 100 µL (1 L was used here) of SDS Solution to vial and swirl to mix. 
4. Add 4mL of Colour Reagent forcefully down side of each vial. 
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5. Cap vials (plastic caps tubes used -10 mL) and place them in foam or 
some other holder to keep the tubes upright during boiling.  
6. Samples were boiled at 85-95ºC temperature in a water bath for 1 hour 
7. After 1 hour immediately remove the vials and place in ice bath to stop 
reaction. Incubate on ice for 10 minutes 
8. After 10 minutes, centrifuge the vials for 10 minutes at 1600 x g at 4ºC. 
Vials may appear clear or cloudy. Cloudiness will clear upon warming to 
room temperature –these were placed in Eppendorf tubes to make sure 
they cleared.  
9. Vials are stable at room temperature for 30 minutes 
10. Load 150µL (1 L here) in duplicate from each vial to either the clear plate 
(calorimetric version) or to the black plate (fluorometric version) 
11. Read the absorbance at 530-540 nm or read fluorescence at an excitation 
wavelength of 530 nm and an emission wavelength of 550 nm. It was 
read in cuvettes at 532 nm. 
Calorimetric Calculations     
1. Calculate the average absorbance of each standard and sample. 
2. Subtract the absorbance value of the standard A (0 µmol) from itself and 
all other values (both standards and samples). This is the corrected 
absorbance. 
3. Plot the corrected absorbance values (from step 2 above) of each standard 
as a function of MDA concentration.  
MDA (µmol) = [(Corrected absorbance)-(y-intercept)/Slope] 
4. Calculate the values of MDA for each sample from the standard curve.  
Fluorometric Calculations 
1. Calculate the average fluorescence of each standard and sample. 
2. Subtract the fluorescence value of the standard A (0 µmol) from itself and 
all other values (both standards and samples). This is the corrected 
fluorescence. 
3. Plot the corrected fluorescence values (from step 2 above) of each 
standard as a function of MDA concentration.  
MDA (µmol) = [(Corrected fluorescence)-(y-intercept)/Slope] 
4. Calculate the values of MDA for each sample from the standard curve. 
Performance characteristics  
Precision:  
When a series of ten human plasma were assayed on the same day, the intra-assay 
coefficient of variation was 5.5% and 7.6% respectively.  
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When a series of eight human plasma were assayed on seven different days under the 
same experimental conditions, the inter-assay coefficient of variation was 5.9% and 
5.1% respectively.  
Assay Range: 
Under the standardised conditions of the assay described above, the dynamic range 
of the kit is 0-50 µmol (Calorimetric) or 0-5 µmol (Fluorometric) (µmol = µmol/L = 
nmol/mL) MDA equivalents.  
 
 
 
